U2570-1.2

INDEX

Population Reports

January 1979

The Population Information Program, Johns Hopkins University, Hampton House, 624 North Broadway, Baltimore, Maryland 21205, USA

Cumulative Index
1972–1977

This five-year Cumulative Index to **Population Reports** *covers the years 1972–1977 and supersedes the four previously published annual indexes. It is a combined subject, name, and geographic index.*

- *Subjects are listed under both broad and specific categories as appropriate.*
- *Names include names of organizations and individuals that have appeared in the text or tables of* **Population Reports**, *and authors of* **Population Reports**, *who are indicated by the word "author" preceding the page numbers.*
- *Geographic entries include regions and countries.*
- *Numbers following entries refer first to series and then to page numbers.*
- *This Cumulative Index covers the following* **Population Reports:**
  Series A, Nos. 1–4 and Supplement
  Series B, Nos. 1–2
  Series C, Nos. 1–7
  Series D, Nos. 1–3
  Series C–D, Nos. 1–2
  Series E, Nos. 1–4
  Series F, Nos. 1–6
  Series G, Nos. 1–7
  Series H, Nos. 1–4
  Series I, Nos. 1–2
  Series J, Nos. 1–17
  Series K, No. 1
  Special Topic Monographs, No. 1

This Cumulative Index was edited by Rita F. Bergman, M.S., with the assistance of Judith L. Smith. Ward Rinehart is Editor of **Population Reports.**

A

ABBAS, E.R.D., J103(table)
ABDOMINAL NEEDLE METHOD. See **LAPAROSCOPIC STERILIZATION**.
ABHAYARATNE, O.E.R.
  diaphragm
    failure, H65(table), H66(table)
    use, H60
ABORTION
  adolescents, J158, J169, J170
  age-specific fertility rate, J10(graph)
  availability of services, E38, J256
    prerequisites, E26
  cervical injuries, F86
  changing attitudes, E6
  China, F1, F2, J97
  combined with sterilization, F66
    colpotomy, C35, C41, C43
    laparoscopy, C23, C24
    tubal ligation, C74
  complications, F36
    length of amenorrhea and method, F66(figure)
  contraception, E26
  declining risk of morbidity and mortality, E26, E37
  demographic impact, J4
  early techniques, F26
  effect on birth rate in Taiwan and Korea, B28
  estimated number worldwide, J256
  first trimester
    inflatable dilators, F97
    PG analogue, F95
    safety, E25, J258
  HCG level, J110, J112(figure)
  hormonal-withdrawal pregnancy test, J114
  India, F1, F2–F3
  isoquinolone, G61
  Japan, F1, F6–F7
  laminaria, F94
  Latin America, J257
  legal status, E25–E39, F1–F8, F3(map), F7(table), F61, J239, J256. See also **ABORTION, ILLEGAL**.
    Austria, E7(table)
    Bulgaria, E6, E8(table)
    classification, E28–E29
    Czechoslovakia, E6, E8(table)
    de jure v. de facto, E32–E34, E35(table)
    Denmark, E7(table), E10
    El Salvador, E6, E7(table)
    France, J237
    Guatemala, E6, E7(table)
    Hungary, E6, E8(table)
    indications, E29
    Iran, E7(table)
    issues, E38–E39
    Japan, F25, I15
    maternal mortality, E36, E37
    parental consent, J165
    restrictions, E36, J164
    selected countries, E29(table), E30 (table), E32, E33(table)
    South Korea, E6, E7(table)
    Sweden, E6, E7(table)
    Tunisia, E7(table), E11
    US, E7(table)
    West Germany, E6, E7(table)
    worldwide (1975), E25, E28(figure), E31
  live births, E26
  long-term effects, F17
  low income women, E38
  maternal health, E25
  maternal mortality, F25
  menstrual regulation, E28
  midtrimester, F65–F83
    cervical dilatation, F86, F87
    incidence, F66
    inflatable dilators, F97
    laminaria, F94
    prostaglandins, F72–76, F95, G68–G73
    reasons for delay, F65
  mortality, E27(graph), E28, F36–F38
    US, F65, F67(figure)
  new acceptors
    Singapore, J15(table)
    Tunisia, J12(table)
  outpatient clinic, J72
  percentage of world population in countries with legal abortion, F7(table)
  physiological mechanism with PGs, G34–G35
  potential impact on fertility, E38
  prevalence, E26
  prostaglandins. See **PROSTAGLANDINS, pregnancy termination**.
  psychological aspects, J170
  selection of method, G38–G39
  sources of funding assistance, J271(table), J274–J276(table)
  timing, F10(figure), G38
  trends in percentage of women under 20 in selected countries, J171(table)
  US, H12
    Supreme Court decisions, F5–F6, F37
  USSR, F4–F5
ABORTION, BOUGIE, F67
ABORTION, GLUCOSE, F67
ABORTION, HABITUAL
  medroxyprogesterone acetate, K2
ABORTION, ILLEGAL, J125. See also **ABORTION, legal status**.
  Bolivia, J256
  complications, E26–E27
  decline with liberal legislation, E26
  Latin America, J170
  maternal mortality, E27, E28, J137–J138, J256–J257
  morbidity, E38
  prevalence, J137
  rising trend in Africa, E32
  risks, F25
ABORTION, INCOMPLETE, G11
  management, F59–F60
    uterine aspiration, F60(table)
  midtrimester, F67
  prostaglandins, G66
ABORTION, METREURYNTER
  description, F97
  disadvantages, F67
ABORTION, RIVANOL, F67
ABORTION, SALINE
  amount of saline, F70
  compared with PGs for pregnancy termination, G11, G12

Population Reports is published bimonthly at 624 North Broadway, Baltimore, Maryland 21205 by the Population Information Program of the Johns Hopkins University, and is supported by the United States Agency for International Development. Second class postage paid at Baltimore, Maryland, and additional offices.

Population Reports is designed to provide an accurate and authoritative overview of important developments in the population field. It does not represent official statements of policy by the Johns Hopkins University or the United States Agency for International Development.

Phyllis T. Piotrow, Ph.D., Director; Helen K. Kolbe, M.S., Co-Director.

    - PGF$_2\alpha$ in midtrimester, G65, G72, G73(figure)
  - complication rate by length of amenorrhea, F66(figure)
  - contraindications, F68
  - extraovular administration
    - complications, F70, F72
    - effectiveness, F70
    - technique, F70
  - history, F68
  - hospitalization period, F68
  - incidence, F67
  - instillation-abortion interval, F69, F71 (table)
  - intraamniotic instillation
    - complications, F69-F70, F71(table)
    - dosage, F71(table)
    - instillation-abortion interval, F71(table)
    - mortality, F70
    - selected studies, F71(table)
    - technique, F68-F69
  - local anesthesia, F68
  - mechanism of action, F68, G49
  - transcervical approach, F69

ABORTION, SELECTIVE
  - sex preselection, I21, I26

ABORTION, SEPTIC
  - mortality associated with IUD, B36(table)

ABORTION, SPONTANEOUS
  - adolescent pregnancy, J165(table)
  - coitus in postovulatory period, I13
  - congenital abnormalities, I13
  - menstrual regulation, F52
  - occurrence, F25
  - rate with IUDs, B17, B34
    - pelvic infection, B36
  - uterine aspiration, F36

ABRAMSON, H.
  - copper-7 IUD, B43

ABRUPTIO PLACENTAE
  - definition, J136(table)
  - obstetrical complication, J137
    - multiparas, J134-J135(table), J137
    - symptoms, J136

ABSCESS
  - colpotomy, C40(table), C42
  - culdoscopy, C67(table)
  - mini-laparotomy, C57, C58
  - postvasectomy, D28

ABSTINENCE
  - breast-feeding, J58
  - cultural aspects, I1
  - menstrual regulation, F15
  - rhythm method, I13

ABUREL, E.
  - saline abortion, F68

ACCEPTABILITY
  - factors influencing, K7-K8
  - injectable progestogens, K12
  - menstrual regulation, F62
  - mini-laparotomy in Thailand, C53-C54
  - rhythm method, I14-I16

ACCEPTORS
  - characteristics and motivation, A36
  - communications campaign in Iran, J307(table), J308(tables), J311(table)
  - effects of mass media, J290, J291, J294, J295, J296, J300, J301, J302, J306, J307, J309
  - IUDs in selected countries, B26, B27 (table), B28
  - married women under 20 in selected countries, J170(table)
  - vaginal contraceptives in selected countries, H49(table)

ACCION CULTURAL POPULAR (ACPO) (COLOMBIA), J302

ACETIC ACID
  - chemosterilant, D15

ACETYLCHOLINE, G1
  - prostaglandins, G26

ACIDS
  - vaginal contraceptives, H41(table)

ACNE
  - injectable progestogens, K6
  - oral contraceptives, A31(figure), A47

ACTH (ADRENOCORTICOTROPIC HORMONE)
  - lactation, J52(table), J59

ACTION FAMILIALE (MAURITIUS)
  - rhythm method, I16
    - drop-outs, J82(table)
    - training, J81
    - users, J82(table)

ADACHI, H.
  - Madlener method for tubal ligation, C33

ADENOMATOUS LESIONS
  - oral contraceptives, A83-A84

ADENYL CYCLASE, G47, G50, G54

ADHESIONS
  - band sterilization, C85
  - clip sterilization, C48
  - colpotomy, C42
    - contraindication, C65, C66
    - prevention, C35
  - culdoscopy, C65, C66
  - fimbriotexy, C91
  - mini-laparotomy, C57, C58
  - postvasectomy, D29
  - tubal occlusion with quinacrine, C87

ADIMEC, J171

ADIPOSE TISSUE
  - release of PGs, G26

ADNEXAL MASSES
  - colpotomy, C40

ADNEXITIS
  - postoperative complication of culdoscopy, C67

ADOLESCENT PREGNANCY
  - adverse consequences, J157-J158, J195, J254
  - comparative infant and neonatal mortality, J166(table)
  - cultural differences, J157
  - low birthweight, J162
  - medical complications, J165(table)
  - obstetrical complications, J161-J162
  - social consequences, J163-J164

ADOLESCENTS
  - abortion, J158, J169
    - psychological aspects, J170
  - age of menarche, J159-J160
  - birth rate, J159
  - cervical cancer, A80, A82
  - contraceptive practice, J158, J166-J169
    - selected countries, J170(table)
  - cultural attitudes toward sexual activity, J157, J158-J159
  - current trends in sexuality, J159-J161
  - decision table, J169(figure)
  - demographic advantages of family planning, J162-J163
  - early marriage, J160
  - family planning services, J158, J164-J166
  - infant mortality, J162, J254
  - maternal mortality, J161, J254
  - metaplasias, A83
  - percentage of total population by continent, J168(figure)
  - rhythm method contraindicated, I7
  - sexual behavior and cervical neoplasia, A80, A83, J162
  - trend in percentage of total births in selected countries, J161(table)
  - unwanted pregnancy, J158

ADRENAL GLAND
  - stress, J190

ADRENALIN, D4

ADRENOCORTICOTROPIC HORMONE. See **ACTH**.

ADVANCED TECHNIQUES FOR MANAGEMENT OF FERTILITY PROGRAM (JOHNS HOPKINS UNIVERSITY, BALTIMORE, MARYLAND)
  - address, C59
  - candidate qualifications, J42
  - goals, J41, J42
  - training centers, J43-J45
    - menstrual regulation, F20
    - mini-laparotomy, C59

ADVERTISING. See **MARKETING**.

ADVERTISING COUNCIL (US), J301

AEROSOL FOAM. See also **FOAM**.
  - active ingredients, H41(table), H43(table)
  - mode of action, H42
  - use-effectiveness in selected studies, H45(table)

AETIUS OF AMIDA
  - cervical dilatation, F88

AFARS AND ISSAS. See **DJIBOUTI**.

AFGHANISTAN
  - age-specific fertility rate, J225(graph)
  - availability of Depo-Provera, K13(figure)
  - birth rate, J29(table), J207(table), J209 (table)
  - condom sales, H5
  - condom shipments, H15(table)
  - legal status of abortion, E29, E30
  - legal status of voluntary sterilization, CD103(table)
  - new acceptors, A18(table), J13(table)
  - oral conraceptives
    - marketing, A13(table)
    - new acceptors, A18(table)
    - supplied by USAID, A21(table)
  - overgrazing, J188
  - population per hospital bed, J71(table)
  - population per physician, J71(table)

AFRICA. See also specific countries.
  - adolescent births, J161(table)
  - age of menarche, J162(table)
  - attitude toward out-of-wedlock pregnancy, J163
  - birth rate, J29(table), J207(table), J209(table), J210(table), J239, J249 (table)
    - decline, J206
  - cultural attitudes toward sexual activity among adolescents, J157, J158
  - Depo-Provera
    - availability, K13(figure)
    - use (1971-1975), K13(table)
  - desertification, J188
  - diaphragm use, H60
  - early marriage, J158, J160(figure)
  - estimated urbanization, J161
  - family planning, J206
  - famine, J244-J245
  - IUD distribution by USAID, B37, B38 (table)
  - lactation
    - duration of postpartum amenorrhea, J57(table)
    - effect of orals in selected studies, J61(table)
  - literacy rate, J178
  - marital status of female adolescents, J164(table)
  - mortality rate, J249(table)
  - number of children and risk of undernutrition, J255-J256
  - percentage of married female acceptors under 20 in selected countries, J170(table)
  - percentage of married women of reproductive age under 20 in selected countries, J170(table)
  - percentage of population under 20, J168(figure)
  - population growth, J206, J249(table)
  - population per hospital bed and per physician in selected countries, J71(table)
  - prevalence of iron deficiency anemia, J131(table)
  - tourism, J180
  - training nonphysicians, J98
    - selected countries, J94(table), J105 (table)

  urbanization, J191
  vaginal contraceptives
    distribution, H49(table), H50(table), J74
    sales, H48(table)
AGE
  cervical cancer, J133(table)
  choice of fertility control methods, J1
  contraceptive effectiveness, I9
  diabetes mellitus, J132, J133
  diaphragm use-effectiveness, H65, H66(table)
  effect of changes on birth and fertility rates, J214
  future of menstrual regulation, F55
  IUD performance, B2, B15, B16(graph, table), B33
    expulsion, B34
  postpartum amenorrhea, J56
  thromboembolic disease, A41(table), A42
  vasectomy, D34
    sexual behavior, D35
AGE-SPECIFIC FERTILITY RATE
  family planning, J222(graphs)
  reduced in Taiwan and Korea, B28
  selected countries, J3(graph), J5–J10(graphs), J24, J27(graphs), J222–J229(graphs)
    Africa, J34(graphs), J224(graphs), J225(graphs)
    America, J35–J36(graphs), J37 (graphs), J226(graphs), J227 (graphs)
    Asia, J225(graphs)
    Europe, J38–J39(graphs), J227(graphs), J228(graphs), J229(graphs)
    Oceania, J37(graph), J225(graphs), J226(graphs)
AGRICULTURAL EXTENSION WORKER
  Philippines, J79
AGURIA
  components, K2
  marketing, K2
AIR POLLUTION, J182
  government regulation, J200
  pathogenicity, J183–J184
AIRD, J.S.
  China
    estimated fertility level, J211(table), J212(table)
    estimated population, J250(table)
AIRLIE FOUNDATION, J159(photo)
AKHTER, M.S.
  colpotomy, C31(table)
    anesthetic, C32(table)
    complications, C40(table)
    failure, C39(table), C43(table)
    instruments, C36(table)
    Madlener and Pomeroy methods, C33(table)
    postoperative morbidity rate, C41
AKHTER, N.
  age of menarche, J162(table)
  medical complications of adolescent pregnancy, J165(table)
AKINGBA, J.B.
  age of menarche, J162(table)
  medical complications of adolescent pregnancy, J165(table)
AKWELL INDUSTRIES, INC., H12, H16, H19
  condom supply, H24
AKZO NV
  oral contraceptives, A4(table)
ALBANIA
  age-specific fertility rate, J227(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  legal status of abortion, E29(table)
  legal status of voluntary sterilization, CD103(table)
  marketing of orals, A13(table)
ALBERT EINSTEIN COLLEGE OF MEDICINE (NEW YORK, NEW YORK)
  intravaginal administration of PGs, H66–H67
ALBRIGHT, F.
  steroids for birth control, A32
ALEXANDER, C.
  Pomeroy tubal ligation, C77
ALEXANDER, G.D.
  arrhythmia during pneumoperitoneum, C20
ALEXANDER, N.J.
  antibody formation after vasectomy, D31
  postvasectomy spermatogenesis, D47
  sperm antibodies, D48
  sperm count following vas anastomosis, D47
ALGERIA, J194
  adolescent births, J161(table)
  age-specific fertility rate, J3(graph), J27(graph), J34(graph), J223(graph)
  birth rate, J23(figure), J29(table), J207 (table), J209(table)
  condom shipments, H14(table)
  family planning program, J26
  labor force, J197
  legal status of voluntary sterilization, CD103(table)
  oral contraceptives
    marketing, A13(table)
    supplied by SIDA, A20(table)
  out-of-wedlock births, J160(figure)
  population density, J189
  population trends, J248
  total fertility rate, J216(table)
ALGESTONE ACETOPHENIDE, K2
ALKALINE PHOSPHATASE
  prediction of ovulation, I8
ALLAMABAD AGRICULTURAL INSTITUTE, RURAL FAMILY PLANNING PROJECT (INDIA), J79
ALLBUTT, H.A.
  cervical cap, H70
  diaphragm use, H58
ALLEGRE, P.W., J104(table)
ALLEN, W.M.
  identification of progesterone, A30–A31
ALLENS SURGICAL PUMP, F88(figure), F89
ALL FLEX, H68(table)
ALLIS TISSUE FORCEPS, M26(table)
ALPHA ALUMINA
  tubal occlusion plug, C90
ALPHA-CHYMOTRYPSIN
  therapeutic use, D27
AL-RAZI
  postcoital contraception, J142
ALTMAN, M.
  vas occlusion, D27
  vasectomy technique, D6(table)
ALUM
  postcoital douching agent, J142
  spermicidal agent, H38
ALUMINUM
  world consumption, J194
ALUWIHARE, A.
  training nonphysicians in vasectomy, J97
ALVARADO, A
  quinacrine tubal occlusion, C86(table)
    via hysteroscopy, C87
ALVAREZ-BRAVO, A.
  iron requirement during pregnancy, J131(table)
ALVEOLUS
  anatomy, J53(figure)
ALZA CORP.
  IUD inserter, B29
  Progestasert, B38, B45
AMENORRHEA, A33. See also **MENSTRUATION DISORDERS**.
  discontinuation of Depo-Provera in selected studies, K8(table)
  folklore, K8
  following use of orals, J168
  incidence of pregnancy, F53(graph, table)
  injectable progestogens, K5
    continuation, K7
  menstrual regulation, F52(table)
    failure rate, F54
  minipill, A61
  pituitary dysfunction, A90
  postpartum. See **POSTPARTUM AMENORRHEA**.
  quinacrine tubal occlusion, C87
  therapeutic use of estrogens, K5
AMERICAN ASSOCIATION OF GYNECOLOGICAL LAPAROSCOPISTS (AAGL), C25, C26
  laparoscopic fulguration techniques, C79–C80
  survey on complications associated with laparoscopy, C20, C21
AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS
  IUD removal with pregnancy, B34
  pelvic inflammatory disease with IUD, B36
AMERICAN CYANAMID CO.
  address, C64
AMERICAN CYTOSCOPE MAKERS, INC. (ACMI), C46
  address, M32
  culdoscopy equipment, M24(table)
  guarantee and service of sterilization equipment, M30(table)
  laparoscopy equipment, C10, C25(figure)
    combination units, M11(table)
    electrosurgical generators, M14(table)
    fiberoptic projectors, M8–M9(table)
    insufflators, M12(table)
    laparoscopes, M4(table), M5(table)
    teaching attachments, M6(table)
AMERICAN HOME PRODUCTS
  oral contraceptives, A4(table)
AMERICAN HOSPITAL SUPPLY CORP., D11
AMERICAN MEDICAL ASSOCIATION, COMMITTEE ON MATERNAL AND CHILD CARE
  maternal death definition, J128
AMERICAN MEDICAL INSTRUMENT CORP. (AMICO)
  address, M32
  guarantee and service of sterilization equipment, M30(table)
  surgical kits, J281
AMERICAN PSYCHOLOGICAL ASSOCIATION (81st ANNUAL CONVENTION), I13
AMERICAN PUBLIC HEALTH ASSOCIATION (APHA)
  address, J283
  funding of family planning activities, J269, J271(table), J274(table)
AMERICAN SAMOA
  age-specific fertility rate, J225(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  diaphragm availability, H68(table)
AMERICAN UNIVERSITY (BEIRUT), C59
  fertility management training program, J45
    address, J42
AMINOCAPROIC ACID
  therapeutic use for bleeding with IUD, B39
AMMONIA
  condom preservative, H22
AMMONIUM SULFATE, I26
AMNIOCENTESIS
  congenital defects, J255
  fetal sex identification, I26
  saline abortion, F68
  urea abortion, F76
    selected studies, F78(table)
AMY, J.J.
  midtrimester pregnancy termination with PGE$_2$, G72(table)
ANABOLIC AGENTS, A32
  jaundice, A47
ANABOLIC ANDROGENS
  liver tumors, A90
ANACAP SILK SUTURES
  vas anastomoisis, D51
ANACYCLIN
  manufacture and marketing A4(table)
ANAGESTONE ACETATE
  breast neoplasia, A78(table), A79(table)
  liver tumors, A89(table)
ANALGESIA. See also **ANESTHESIA**; **NARCOTICS**.
  after colpotomy, C35
  cervical dilatation with PGs, G68
  culdoscopy, C61, C62
    complications, C66
    postoperative care, C64, C67
  IUD insertion, B7, B15
  menstrual regulation with PGs, G58
  spring-clip sterilization, C84
ANAXAGORAS
  sex preselection theory, I22
ANCHOVIES, J179, J180(figure)

ANDERSON, E.T.
- laparoscopic sterilization, C3
- tubal occlusion, C79

ANDERSON, G.
- disadvantages of oxytocin during abortion, F72

ANDERSON, G.G.
- PGs for induction of labor, G10(table), G50, G54
- PGs for pregnancy termination, G7(table), G8(table)
- umbilical cord PGF levels, G49

ANDERSON, I.
- Latex leaf, B39, B46

ANDERSSON, G.G.
- midtrimester pregnancy termination with PGF$_2\alpha$, G72(table)

ANDOLSEK, L.
- anesthesia for menstrual regulation, F51
- IUD performance, B33
  - termination rate, B23(table)

ANDORRA
- birth rate, J29(table), J207(table)

ANDREWS, B.F.
- medical complications of adolescent pregnancy, J165(table)

ANDRIESSE, R.
- postcoital estrogens
  - side effects, J147, J148(table)
  - use-effectiveness, J145(table)

ANDROGENS
- breast cancer, A79

ANEMIA. See also **FOLATE DEFICIENCY ANEMIA; IRON DEFICIENCY ANEMIA**.
- adolescent pregnancy, J165(table)
- birth interval, J126, J129
- clip sterilization, C49
- complications, J131
- contraindication for postpartum laparoscopic sterilization, C23
- etiology, J129, J130-J131
- IUD users, B35
- maternal mortality, J130
- menstrual regulation, F11
- nutrition, J129-J132
- obstetrical complication in multiparas, J134-J135(table)
- oral contraceptives, J258
- prevalence in pregnant women, J129-J130
- prevention, J131-J132
- types, J130

ANENCEPHALY
- management, G50
- PGF level in umbilical cord, G49

ANESTHESIA. See also **ANALGESIA; NARCOTICS**; specific types.
- colpotomy, C30
- combined methods, C32(table), C33
- developed and developing countries, C30, C33
- IUD insertion, B7
- uterine aspiration, F60(table)

ANESTHESIA, EPIDURAL, C32(table)
- culdoscopy, C63

ANESTHESIA, GENERAL
- colpotomy, C32(table), C33
- culdoscopy, C63
- disadvantages, D4, F28
- laparoscopic sterilization, C3(table), C4
  - complications, C4, C18
- menstrual regulation, F12, F13(table), F51(table)
  - failure rate, F54(table)
- mini-laparotomy, C54, C55
- uterine aspiration, F29(table)
- vas anastomosis, D42, D48, D51
- vas contractility, D15
- vasectomy, D7
  - indications, D4

ANESTHESIA, LOCAL
- cervical dilatation, F91, F92
- clip sterilization, C47
  - administration, C45
- colpotomy, C31, C32(table)
- culdoscopy C61, C62
  - complications, C66
- laparoscopic sterilization, C4-C5, C11
  - compared in 1- and 2-incision techniques, C4(table)
  - El Salvador, C2, C13
  - Nepal, C1, C13
  - Thailand, C2, C13
- menstrual regulation, F12, F50-F51
- mini-laparotomy, C53, C54-C55
- saline abortion, F68
- spring-clip sterilization, C84
- uterine aspiration, F30(table)
- vas anastomosis, D48
- vasectomy, D26
  - administration, D3, D4, D6-D7(table)
  - advantages, D3
- Yoon band application, C85

ANESTHESIA, PARACERVICAL
- postcoital copper IUD insertion, J151

ANESTHESIA, SPINAL
- colpotomy, C31, C32(table)
  - side effects, C42
- culdoscopy, C63
- vas anastomosis, D48

ANFERTIL
- manufacture and marketing, A4(table)

ANGIOLINI (WARNER-LAMBERT)
- marketing of minipill, A64(table)

ANGOLA
- birth rate, J29(table), J207(table), J210(table)
- marketing of orals, A13(table)
- out-of-wedlock births, J160(figure)

ANIMAL STUDIES
- advantages, A72
- artificial vas deferens, D56
- breast neoplasia with orals, A78-A79(table)
- cervical neoplasia with orals, A84(table), A85(table)
- compared with clinical studies, A37, A43, K10
- endometrial neoplasia with orals, A87(table), A88
- fimbriotexy reversal, C91
- limitations, A72
- liver tumors with orals, A89(table)
- tubal occlusion, C73
  - chemical, C87, C88
  - clips, C82
  - laser, C91
  - plugs, C90, C91
- vas anastomosis, D46, D47
- vas occlusion devices, D52, D53, D56-D57

ANKER, H.
- metal expansion dilator, F96

ANKLESARIA, S.B.
- sterilization by colpotomy, C31(table)
  - dyspareunia, C42
  - Pomeroy method, C33(table)

ANOVULAR
- manufacture and marketing, A4(table)
- patent information, A5(table)

ANOVULATION
- contraindication for BBT rhythm method, I6

ANSARI, A.H.
- morbidity following laparotomy and colpotomy, C41
- postpartum abortion and colpotomy, C43

ANSBACHER, R.
- postvasectomy antibodies, D31(table), D32, D48

ANTEBY, S.O.
- midtrimester abortion with urea, F78(table)

ANTEMIN
- active ingredients, H41(table)

ANTIBION
- active ingredients, H41(table)

ANTIBIOTICS
- after culdoscopy, C64, C68

ANTI-D IMMUNOGLOBULIN
- postabortion, F36

ANTIGON-F, B46(figure)
- description, B46
- distribution, B46
- insertion technique, B30
- use-effectiveness, B32(table)

ANTIGUA
- birth rate, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- distribution of contraceptives, H10
  - community-based, J70, J76
  - government support, H10
  - pricing system, H10
  - retail outlets, H10
- oral contraceptives
  - nonprescription, J74
  - policy, E2, E4(table)

ANTIGUA PLANNED PARENTHOOD ASSOCIATION
- subsidized community-based distribution, J76

ANTONIOU, D.
- spermagglutinating antibodies, D31

ANXIETY
- lactation, J54

APELO, R.A., J102(table)
- comparative contraceptive continuation rates, K8(graph)
- Depo-Provera
  - continuation rate, K7(table)
  - use-effectiveness, K4(table)
- injectable progestogens and body weight, K6
- menstrual pattern changes with d-norgestrel minipill, A57, A59(table)
- mini-laparotomy, C54
  - obese women, C57
- side effects of orals, A38

APLIC. See **ASSOCIATION FOR POPULATION/FAMILY PLANNING LIBRARIES AND INFORMATION CENTERS-INTERNATIONAL**.

APNEA
- culdoscopy, C66(table)

APOTEKSBOLAGET CENTRALLABORATORIET (ACL) (SWEDEN)
- diaphragm testing, H68(photo), H69(photo, table)

APOTHEKERNES
- oral contraceptives, A4(table)

APOTKENS CONTROLLABORATORIUM (SWEDEN)
- condom testing, H28(figure)

APPENDECTOMY
- barefoot doctors, J97
- mortality, E27(graph)

APPLEZWEIG, N.
- worldwide condom use, H3-H4

APTE, J.S.
- vasectomy
  - general health, D34(table)
  - sexual behavior, D35(table)

ARACHIDONIC ACID
- PG synthesis, G49

ARANDAM, C., J106(table)

ARCING SPRING DIAPHRAGM, H68(table)
- description, H61
- indications, H61

AREEPAK, A.
- training in laparoscopic sterilization in Thailand, C14

ARGENTINA, J194
- age-specific fertility rate, J35(graph), J226(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- infant and neonatal mortality, J166(table)
- injectable contraceptives, K2
- legal status of abortion, E29(table), F61
- legal status of voluntary sterilization, CD103(table)
- marketing of minipill, A64(table)
- new acceptors, A18(table), J16(table)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A13(table)
  - new acceptors, A18(table)
  - sales, A8(table)
- PG research, G19, G20, G21, G22
- population policy, E1, E2, E35

ARISTOTLE
- sex preselection, I22
- vaginal contraceptives, H38

ARMED FORCES INSTITUTE OF PATHOLOGY (WASHINGTON, D.C.)
- hepatic adenoma, A90

ARMSTRONG, D.T.
- PGF$_2\alpha$ role in ovulation, G53

ARRHYTHMIA
- culdoscopy, C66
- laparoscopic sterilization, C4, C18, C20, C23(table)

ARSENIC, A30
ARTHES, F.G.
  orals and breast disease, A44(table), A76(table)
ARTIFICIAL INSEMINATION
  BBT changes, I24(chart)
  option of vasectomy reversibility, D55(chart)
  postvasectomy, D52
  sex preselection, I24
ASAYAMA, S.
  age of menarche, J162(table)
ASCHHEIM, S.
  biologic pregnancy test, J110
ASCORBIC ACID, I26
ASIA. See also specific countries.
  adolescent births, J161(table)
  birth rate, J29(table), J207(table), J209 (table), J210(table), J249(table)
  cultural attitudes toward sexual activity among adolescents, J157, J158
  Depo-Provera
    availability, K13(figure)
    use (1971-1975), K13(table)
  distribution of vaginal contraceptives
    IPPF, H50(table)
    retail sales, H48(table)
    USAID, 49(table)
  early marriage, J158, J160(figure)
  economic incentives and disincentives, E42
  fertility control, F49
  IUD distribution by USAID, B37, B38 (table)
  lactation
    duration of postpartum amenorrhea, J57(table)
    effect of orals in selected studies, J60(table)
  marital status of female adolescents in selected countries, J164(table)
  mortality rates, J249(table)
  number of children and risk of undernutrition, J255-J256
  percentage of married female acceptors under 20 in selected countries, J170 (table)
  percentage of married women of reproductive age under 20 in selected countries, J170(table)
  percentage of population under 20, J168(figure)
  population per hospital bed and per physician in selected countries, J71(table)
  population trends, J239, J249(table)
  prevalence of iron deficiency anemia, J131(table)
  training nonphysicians, J98
    selected countries, J94(table), J101-J103(table)
  urbanization, J161, J191
ASIA FOUNDATION
  address, J283
  funding of family planning activities, J274(table)
ASPARAGINASE, I26
ASPIRATOR. See **VACUUM PUMP**.
ASPIRIN, F12, F13(table), F29(table), F40
  effect on gestation, G50
  inhibition of PG synthesis, G50
  postvasectomy, D27
ASOCIACION CHILENA DE PROTECCION DE LA FAMILIA
  address, J107(table)
  training nonphysicians, J95(table), J106(table)
ASOCIACION DEMOGRAFICA SALVADOREÑA
  address, J106(table)
  training nonphysicians, J95(table), J106(table)
ASOCIACION HONDUREÑA DE PLANIFICACION DE FAMILIA
  address, J106(table)
  training nonphysicians, J95(table), J106(table)
ASOCIACION PRO-BIENESTAR DE LA FAMILIA COLOMBIANA (PROFAMILIA)
  address, J106(table)
  community-based distribution, J80, J91
  rural program, J324
  training nonphysicians, J95(table), J98, J106(table)
ASOCIACION PRO-BIENESTAR DE LA FAMILIA DE GUATEMALA
  training nonphysicians, J95(table)
ASSENZO, J.R.
  Depo-Provera
    conception rates after discontinuation, K9(graph)
    continuation rate, K7(table)
    use-effectiveness, K4(table), K5(table)
  side effects of injectable and oral contraceptives, K7
ASSOCIATION FILMS, J171
ASSOCIATION FOR POPULATION/FAMILY PLANNING LIBRARIES AND INFORMATION CENTERS-INTERNATIONAL (APLIC)
  address, J283
  funding of family planning activities, J269, J274(table)
ASSOCIATION FOR SEX EDUCATION (SWEDEN), H11
ASSOCIATION TUNISIENNE DU PLANNING FAMILIAL
  training nonphysicians, J94(table)
ASSOCIATION FOR VOLUNTARY STERILIZATION-INTERNATIONAL PROJECT, C39
  address, C58, C69, J283
  culdoscopic equipment, C69
  funding of family planning activities, J266, J268, J270-J271(table), J274 (table)
  sterilization equipment, M2, M3
  training in mini-laparotomy, C59
ASTHMA
  potential PG treatment, G1
ATLAN-TOL INDUSTRIES, INC., D12
ATOM, INC. MEDICAL APPLIANCES, F40
ATRAUMATIC FORCEPS
  mini-laparotomy, C56
  tubal ligation, C34
ATRAUMATIC MIDAMPULLARY STERILIZATION. See **WOOD TECHNIQUE**.
ATRAUMATIC PREGNANCY TERMINATION. See **MENSTRUAL REGULATION**.
ATROPINE, C47(table), C49, F29(table)
  culdoscopy, C63(table)
  induced abortion with PGs, G35, G38
  laparoscopic sterilization, C3(table)
  menstrual regulation with PGs, G58
  prevention of bradycardia, C4
    during pneumoperitoneum, C20
  tubal occlusion with quinacrine, C86(table)
ATROPINE SULFATE, C32(table)
  tubal occlusion, C87
AUSTIN, K.
  training in laparoscopic sterilization in Panama, C13
AUSTRALIA
  adolescent births, J161(table)
  age-specific fertility rate, J3(graph), J9(graph), J37(graph), J225(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219 (figure)
  contraceptive usage, H4(table)
  copper IUDs
    experimental study, B18
    legal restriction, B18
  Development Assistance Agency (ADAA)
    address, J284
    funding of family planning activities, J274(table), J277, J278(table)
  diaphragm
    availability, H68(table)
    use, H59
  folk methods for postcoital contraception, J142
  legal status of abortion, E29(table), E34-E35
  legal status of voluntary sterilization, CD83, CD103(table)
  marital status of female adolescents, J164(table)
  marketing of minipill, A64(table)
  oral contraceptives, A1
    commercial supply, A9(table), A10(graph)
    discontinuation, A11
    marketing, A13(table)
    use, A7, J4
  out-of-wedlock births, J160(figure)
  percentage of legal abortions to women under 20, J171(table)
  PG research, G11, G19, G20, G21, G22
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population policy, E2, E41, E42, E43(table)
  population trends, J240
  postcoital estrogens, J141
  premarital sex among adolescents, J159
  rhythm method, I7, I14(table), I15(table)
  subsidy for foreign community-based distribution, J77
  training nonphysicians, J94(table), J101(table)
  tubal ligation, C75
  uterine aspiration, F27
  vaginal contraceptives, H47
  vasectomy
    complications, D28(table)
    performed by nonphysicians, J98
    sexual behavior, D35(table)
    technique, D35(table)
  voluntary sterilization, E6
AUSTRALIAN FEDERATION OF FAMILY PLANNING ASSOCIATIONS
  address, J101(table)
  training nonphysicians, J94(table), J101(table)
AUSTRIA
  age-specific fertility rate, J38(graph), J227(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure), J241(table)
  change in number of births, J219(figure)
  condom distribution and promotion, H12
    mail-order system, H13
  diaphragm availability, H68(table)
  folk methods for sex preselection, I22
  legal restriction of copper IUDs, B18
  legal status of abortion, E2, E7(table), E30 (table)
  marketing of minipill, A64(table)
  mortality rate, J241(table)
  oral contraceptives
    commercial supply, A9(table), A10(graph)
    marketing, A13(table)
    sales, A8(table)
  out-of-wedlock births, J160(figure)
  population growth, J240, J241(table)
  sympto-thermal rhythm method 17
  voluntary sterilization, E2, E6(table)
    legal status, CD80, CD103(table), E45 (table), E48
AUTOCLAVING, C42
  Karman cannula, F18
  sterilization equipment, M28-M29
AUTOIMMUNE RESPONSE. See also **SPERM ANTIBODIES**.
  postvasectomy, D32
AUTONOMIC TRANSMISSION
  effect of PGs, G25, G26, G27-G28
AUXILIARY PERSONNEL. See also **BAREFOOT DOCTORS**; **MIDWIVES**; **NURSING PERSONNEL**; **PARAMEDICAL PERSONNEL**.
  administration of injectable contraceptives, J92
  classification, J90(figure)
  definition, J89
  distribution of orals, J92
  functions, J91(figure)
  IUD insertions, J93, J96
  training in fertility control, J98
  tubal ligation, J97
AVENDANO, S.
  continuation rate of megestrol acetate minipill, A62(table)
AXELRAD, S.D.
  vasectomy
    complications, D28(table), D29
    technique, D28(table)
AYURVEDIC DOCTORS. See **INDIGENOUS MEDICAL PRACTITIONERS**.
AZTEC INTERNATIONAL
  address, C70
  culdoscopic equipment, C70(figure)

B

BABCOCK, W.W.
  colpotomy preferred to laparotomy, C30
BABCOCK FORCEPS
  menstrual regulation, F12
  mini-laparotomy, C56, C57(figure), M20
  tubal ligation, C34, C36(table)
BACKHAUS CLAMP, M26(table)
BACTERICIDES
  modes of action, H42
  vaginal contraceptives, H41(table)
BAERREIS, D.
  monsoon pattern changes, J187
BAHAMAS
  age-specific fertility rate, J226(graph)
  birth rate, J29(table), J207(table), J218(figure)
  change in number of births, J219(figure)
  marketing of oral contraceptives, A13 (table)
BAHRAIN
  birth rate, J29(table), J207(table), J209(table)
  legal status of abortion, E30
  marketing of minipill, A64(table)
  marketing of oral contraceptives, A13 (table)
BAILEY, J.
  radio campaign in Colombia, J301
BAILEY, R.E.
  fitting of cervical cap, H70(figure)
  fitting of diaphragm, H58(figure)
BAKER, J.R.
  spermicidal potency, H44
BALAKRISHNAN, T.R.
  film campaign in India, J298
BALEN, H.
  duration of postpartum amenorrhea, J57 (table)
BALI
  birth rate, J216
  family planning, J239
BALLARD, C.A.
  coagulopathy with saline abortion, F70
  intraamniotic instillation of $PGF_2\alpha$ for abortion, G71(table), G72(table)
  intraamniotic saline abortion, F71(table)
  intramuscular injection of PGE_2 methylanalogue, F77(table)
BALTIC SEA
  pollution, J181
BAND STERILIZATION, C76(table), C84-C86. See also **YOON BAND**.
  mode of action, C85
BANG, S.
  menstrual regulation research, F61
BANGLADESH
  abortion
    legal status, E35(table), E36(table), F7(table)
    practice, E35(table)
  age of menarche, J162(table)
  age-specific fertility rate, J223(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J29(table), J207(table), J209 (table)
  condom
    retail sale, E41, E42
    shipments, H14(table)
  contraceptive distribution program, E41, E42, E44(table), J72, J90
    over-the-counter sales, J72
  culdoscopy, C89
  duration of postpartum amenorrhea, J50, J56, J57(table)
  early marriage, J158
  economic growth, J190
  estimated population, E36(table), J206
  family planning
    program, J206
    promotion, J300, J324
  famine, J242–J243
  IUD continuation rate, B33(table)
  maternal mortality, J127, J255(table)
    causes, J128
  medical complications of adolescent pregnancy, J165(table)
  menstrual regulation, F51
  mortality rate, J243, J244(tables)
  new acceptors of vaginal contraceptives, H49(table)
  nonphysicians
    training, J94(table), J101(table)
    tubal ligation, J97
  oral contraceptives, A17
    marketing, A13(table)
    new acceptors, A18(table)
    nonprescription, J69, J74
    supplied by USAID, A21(table)
  population, F7(table)
  population policy, E2, E34
  sexual behavior after vasectomy, D35 (table)
  son preference and family size, I27
  sterilization, D1, D2
  total fertility rate, J216(table)
  unemployment, J197
BANK, A.H.
  culdoscopy
    local anesthesia, C64
    postoperative complications, C67 (table)
    preoperative medication, C63(table)
    tubal occlusion, C65(table), C68 (table)
BANNERMAN, R.H.O., E21(photo)
BANTU
  folklore about amenorrhea, K8
BARABBA, V.
  estimated fertility levels in China, J211 (table)
BARATZ, R.A.
  controlled ventilation during laparoscopy, C20
BARBADOS
  age-specific fertility rate, J3(graph), J7(graph), J35(graph), J222(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure), J239
  change in number of births, J219(figure)
  condom shipments, H15(table)
  diaphragm availability, H68(table)
  fertility decline, J216
  IUD insertion by nonphysicians, B28, J93
  legal status of abortion, E34
  legal status of voluntary sterilization, CD103(table)
  marketing of minipill, A64(table)
  new acceptors, J16(table)
    orals, A18(table)
    vaginal contraceptives, H49(table)
  oral contraceptives
    marketing, A13(table)
    prescription, E44
    supplied by USAID, A21(table)
  out-of-wedlock births, J160(figure)
  population policy, J247
  total fertility rate, J215(table), J216, J217 (table)
BARBASCO ROOT
  source of diosgenin, A32
BARBITURATES
  decreased effectiveness of orals, A48
BARD-PARKER KNIFE
  vaso-epididymal anastomosis, D50
BAREFOOT DOCTORS, J72, J89. See also **AUXILIARY PERSONNEL**; **MIDWIVES**; **PARAMEDICAL PERSONNEL**.
  household distribution, J83
  instruction manual, J97
  pregnancy termination, J97
  training in vasectomy, J98
  tubal ligation, J97
BARKAY, J.
  bilateral vas anastomosis, D42
  sperm cryofreezer, D52
BARLOW, P.W.
  Y-chromosome identification, I26(photo)
BARNES, A.C., J41
  tubal occlusion via laparoscopy, C79
BARNETT, R.N.
  biologic test for pregnancy, J115(table)
BARR, M.M.
  intraamniotic saline abortion, F71(table)
  PGs for induction of labor, G10(table)
BARRIER METHODS, H1–H19
BARSIVALA, V.
  lactation
    effect of orals, J60(table)
    effect of progestogen-only contraceptives, J63(table)
BARTZEN, P.J.
  use-effectiveness of temperature rhythm method, I11(table)
BASAL BODY TEMPERATURE (BBT). See **RHYTHM METHOD, TEMPERATURE**.
BATTELLE MEMORIAL INSTITUTE
  condom use in the US, H17
  electrocautery, D13
  intrauterine membrane, B46
  male sterilization workshop, D63
  measuring force of cervical dilation instruments, F87
  menstrual regulation conference, F49
  metal expansion dilator, F96
  Population Study Center, B39
  reversible vas occlusive valves, D56
  uterine aspirator, F44, F55(photo)
    advantages and disadvantages, F55
    nonelectrical, F56
  Workshop in Advances in IUD Contraception for Developing Countries, B18
  workshop on female sterilization, C47
BAXI, P.C.
  duration of postpartum amenorrhea, J57 (table)
BAYTINAL, F29(table)
BBC PUBLICATIONS, A33(figure)
BDH-2700
  breast neoplasia in rats, A78(table)
  endometrial tumors in rats, A87(table)
  pituitary tumors in animal studies, A90 (table)
BEATE UHSE ORGANIZATION, H12
BEAZLEY, J.M.
  PGs for induction of labor, G10(table)
BECK, W.W.
  sperm motility of frozen semen, D52
BEDFORD, M.
  sympathetic nervous system injury following vasectomy, D47–D48
BEEBE, G.W.
  diaphragm failure, H65(table)
BEGUIN, F.
  PGs for pregnancy termination, G8(table), G9(table)
BEHIARS (IRAN). See **MIDWIVES**.
BEHRMAN, H.R.
  luteolytic effects of $PGF_2\alpha$, G57, G60-G61
BELFORT, P.
  abortion in Brazil, E26
BELGIUM
  abortion
    legal status, E28, E30, E34, E35(table)
    practice, E35(table)
  Administration Général de la Coopération au Developpement (AGCD)
    address, J284
    funding of family planning activities, J274(table), J277, J278(table)
  age-specific fertility rate, J38(graph), J227(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  Depo-Provera
    availability, K13(figure)
    incidence of cervical cancer, K10
    use-effectiveness, K4(table)
  diaphragm availability, H68(table)
  legal status of voluntary sterilization, CD80, CD104(table)
  marital status of female adolescents, J164 (table)
  marketing of minipill, A64(table)
  maternal mortality, J128(figure)
  National Commission on Ethical Problems, E34
  oral contraceptives
    commercial supply, A9(table), A10(graph)
    marketing, A13(table)
    sales, A8(table)
  out-of-wedlock births, J160(figure)
  population policy, E41, E42, E43(table)
    contraception, E4(table)
    voluntary sterilization, E48
  population trends, J240, J241(table)
  progestogen-only contraceptives and lactation, J63(table)

- rhythm method, I14(table)

BELIZE
- age-specific fertility rate, J223(graph)
- birth rate, J29(table), J207(table), J209 (table)
- total fertility rate, J216(table)

BELSKY, R.L., author, H37-H51
- condom
    - estimated commercial distribution, H5
    - worldwide use, H3-H4
- distribution of contraceptives, H5, J70

BELT, E.
- effectiveness of vas anastomosis, D49 (table), D51

BEMFAM (BRAZIL). See **SOCIEDAD CIVIL DE BEM-ESTAR FAMILIAR NO BRASIL**.

BEN CHEIKH, T.B.
- sterilization by colpotomy, C31(table)
    - anesthetic, C32(table)
    - complications, C40(table)
    - cystocele repair, C35

BENELUX
- marketing of minipill, A64(table)

BENGAL TIGERS
- threatened extinction, J198

BENIGN BREAST NEOPLASIA. See also **BREAST NEOPLASIA**.
- oral contraceptive use, A74-A75, A78-A79(table)
    - selected studies, A73-A74(table)
- relationship to subsequent breast cancer, A75

BENIN
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- condom sales, H6
- legal status of abortion, E33(table)
- marketing or oral contraceptives, A13 (table)

BENOIT, A.
- quinacrine tubal occlusion, C86(table), C87

BENTOV, I.
- Bentov device, F96, F97(figure)

BENTOV DEVICE
- description, F96, F97(figure)

BENTSI-ENCHILL, K.K.
- training in laparoscopic sterilization in Ghana, C13

BENZALKONIUM CHLORIDE, F27, F39

BENZETHONIUM CHLORIDE, H40, H41 (table), H43(table)

BEOSPIR
- termination rate, B23(table)

BERCI, G.
- insufflation of the abdomen, M10

BERELSON, B.
- effect of mass media on family planning, J306

BERG, A.
- breast-feeding
    - comparative costs of substitutes, J55 (table)
    - rural and urban women, J54

BERG, O.
- birth rate in Greenland, J307

BERGER, G.S.
- intraamniotic saline abortion, F71(table)
    - complications, F69

BERGET, A.
- orals and cervical neoplasia, A81(table)

BERGSJO, P.
- continuation rate of chlormadinone acetate minipill, A62(table)
- ectopic pregnancy rate with minipill, A57 (table)

BERGSTROM, H.
- Rh immunization, F36

BERGSTROM, S., author, G65-G75
- chemical structure of PGs, G2, G65
- PG research, G17

BERIC, B.
- cannula and retroflexed uteri, F18
- menstrual regulation, F13(table)
    - procedure and equipment, F14(table)
- uterine aspiration, F28(table)
    - anesthesia, F29(table), F30(table)
    - blood loss, F34(table)
    - compared with curettage, F42
    - complications, F33(table)
    - equipment, F32(table), F41(table)
    - incidence and management of perforation, F35(table)
    - perforation rate compared with dilatation and curettage, F36
    - preoperative medication, F29(table)
    - pressure used, F41(table)
    - time required, F32(table), F34(table)

BERKELEY BIO-ENGINEERING, INC.
- plastic cannula, F40(figure)
- vacurette F cannula, F19(figure)
- vacuum apparatus, F19, F41(table), F51 (table)

BERLINER, V.R.
- orals and breast neoplasia in animals, A78, A79(table)

BERMAN, M.L.
- duration of postpartum amenorrhea, J57 (table)

BERMAN, R.L.
- biologic pregnancy test, J111

BERMUDA
- age-specific fertility rate, J226(graph)
- birth rate, J23(figure), J29(table), J207 (table), J210(table)
- diaphragm availability, H68(table)
- marketing of oral contraceptives, A13 (table)

BERNARD, R.P.
- maternity care monitoring, J338, J339 (figure)

BERNSTEIN, G.S.
- expulsion, pregnancy, removal, and continuation rates of IUDs in nulliparas, B15(table)
- use-effectiveness of contraceptive aerosol foam, H45(table)

BESANT, A.
- vaginal contraception, H39

BETADINE. See **POVIDONE-IODINE**.

BEUSELINCK, A.
- progestogen-only contraceptives and lactation, J63(table)

BHARDWAJ, K.S.
- sexual behavior after vasectomy, D35 (table)

BHASHTI, M.H.
- sexual sterilization and Islam, CD86

BHIRALEUS, P.
- effect of orals on lactation, J60(table)
- treatment for infection after culdoscopy, C68

BHUTAN
- birth rate, J29(table), J207(table), J210 (table)

BIDANS (MALAYSIA). See also **MIDWIVES**; **PARAMEDICAL PERSONNEL**.
- distribution of orals, J92
- effectiveness, J92
- training, J92

BIENIARZ, J.
- advantages of laminaria prior to PG abortion, F72

BIERER MARK II CANNULA, F40(figure)

BIGAZZI, P.E.
- postvasectomy antibody formation, D32

BILLINGS, E.L.
- cervical mucus rhythm method, I7
    - use-effectiveness, I11(table)

BILLINGS, J.J.
- cervical mucus rhythm method, I7
    - use-effectiveness, I11(table)

BING, O.K., J102(table)

BIONYX CONTROL (PHASER)
- reversible vas occlusion, D56

BIRK, S.A.
- orals and blood pressure, A42

BIRNBERG BOW
- comparative IUD study, B25
- surface area related to pregnancy and removal rates, B34(figure)

BIRTCHER CORP.
- address, M32
- electrosurgical generators, M14(table)
- guarantee and service of sterilization equipment, M30(table)
- vasectomy equipment, D13(photo), M27 (table), M28(figure)

BIRTH CONTROL. See **CONTRACEPTION**.

BIRTH INTERVAL
- anemia, J130
- infant mortality, J256
- lactation, J56
- maternal health, J64, J126, J131
    - nutrition, J129, J256
- optimal length, J126
- oral contraceptives, A34

BIRTH ORDER
- sex ratio, I23

BIRTH RATE. See also specific countries, **birth rate**.
- adolescents, J159
- decline in Africa, J206
- developed countries, J206, J212
- factors affecting, J214
- related to breast-feeding, J58
- selected countries, J23(figure), J29(table), J129(table), J207(table), J209(table), J210(table), J218(figure)
- socioeconomic factors, J22
- worldwide, J21, J205, J208(table), J212 (table), J220-J221(map), J237
    - affected by China, J211, J212

BIRTH REGISTRATION
- criterion, J206
- Cuba, J208
- developed countries, J206
- developing countries, J206
- methods, J206

BISCHOFF, T.L.W.
- fertile period identification, I3(table)
- fertility and menstruation, I2

BISECURIN
- manufacture and marketing, A4(table)

BITEK, INC.
- address, C90
- Proplast plugs for tubal occlusion, C90

BLACK, D.
- sperm separation by electrophoresis, I25

BLACK, T.R.L., J76(table)
- promotion of contraceptives in Africa, H49

BLACK, W.P.
- laparoscopic sterilization, C2(table)
    - complications, C19(table)
    - electrocoagulation, C8(table)
    - failure, C22(table)

BLACK JACK, H12

BLACKER, C.P.
- rhythm method in India, I15

BLACKWELDER, J., J211(table)

BLADDER INJURY
- colpotomy, C40(table)
- mini-laparotomy, C58

BLANDY, J.
- vasectomy technique, D6(table)

BLASTOCYST
- development, J146

BLAZAR, L.S.
- obstetrical complications with multiparity, J134(table)

BLEEDING
- cervical dilatation, G67
    - selected studies, G68(table)
- clip sterilization, C50, C83
- colpotomy, C49, C41
- copper IUDs, B5, B11, B18
- culdoscopy
    - operative complication, C66(table)
    - postoperative complication, C67(table)
- discontinuation of Depo-Provera in selected studies, K8(table)
- hormonal-withdrawal test, J116
- IUD removal, B11, B21, B26
    - rate, B6(table), B7(graph), B11(table), B15(table)
    - related to age and parity, B16(graph, table)
    - surface area, B34(figure)
- laparoscopic sterilization, C11, C12, C18, C19(table), C23(table)
    - fulguration, C79, C80
- menstrual regulation, F15, F16(table), F51, F52
    - mean amount, F17(table)
- midtrimester abortion
    - prostaglandin, F73(table), F74, F75 (table), F77(table)
    - saline, F69, F71(table), F72
    - urea, F78(table), F79
    - vacuum aspiration, F67

- mini-laparotomy, C58
- obstetrical complication, J126, J136(table)
  - anemia, J131
  - multiparas, J134-J135(table)
- PG administration
  - impact, G35(figures), G36(table), G37(table), G38(figure)
  - induction of labor, G60
  - menstrual regulation, G58, G59(table)
  - vaginal route, G11, G66
- postcoital norgestrel, J148
- postcoital quingestanol acetate, J148
- stem pessaries, B24
- tantalum clip sterilization, C83
- therapeutic use of estrogens, K5
- tubal ligation, C75
- tubal occlusion, C73
  - uterine aspiration, F33(table)
  - rate, F35
- vasectomy, D4, D8
  - hemostasis, D8
- Yoon band application, C85

BLEIER, W.
- plastic clip sterilization, C84

BLISS VASECTOMY PROSTHESIS, D12

BLOCH, B.
- use-effectiveness of Depo-Provera, K4 (table)

BLOOD DISORDERS (SYSTEMIC)
- contraindication to vasectomy, D26

BLOOD PLATELETS
- prostaglandins, G1

BLOOD PRESSURE
- clip sterilization, C46 C49
- culdoscopy, C66
- minipill, A62
- oral contraceptives, A42-A43
- prostaglandins, G1, G2

BLOOD VESSELS
- prostaglandins, G25

BLUE LADY, A23-A24(figure)

BOARD, J.A.
- menstrual pattern changes with norethindrone minipill, A58(table)

BODY WEIGHT
- change with Depo-Provera, K6
- pseudopregnancy, A36

BOER, C.H. de
- laparoscopic sterilization, C8
  - electrocoagulation with division, C8 (table)
  - failure, C22(table)

BOETTCHER, B.
- effect of progestogens on sperm, A55

BOGUE, D.J.
- communication of family planning with mailings, J293

BOLIVIA
- adolescent births, J161(table)
- age-specific fertility rate, J223(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J208, J209(table)
- illegal abortion, J256
- legal status of voluntary sterilization, CD104(table)
- marketing of oral contraceptives, A13 (table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- training in culdoscopy, C70

BOLOGNESE, R.J.
- menstrual regulation with PGs, G59(table)
- midtrimester abortion with laminaria and $PGF_2\alpha$, F94

BONTE, M.
- duration of postpartum amenorrhea, J57 (table)

BOOHENE, A.G., E20, E21(photo)

BORDEAUX STERILISATEURS, CD80

BORELL, U.
- cervical dilatation with $PGF_2\alpha$ analogue, G68(table)

BORGLIN, N.
- effect of orals on lactation, J61(table)

BORIC ACID, H41(table)

BOSMIN, C32(table)

BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM
- estrogen use and breast cancer in postmenopause, A77(table)
- orals and breast disease, A44(table), A45, A73(table), A76(table)
  - protective effect, A46
- orals and gallbladder disease, A47
- orals and thromboembolic disease, A41 (table)

BOTSWANA
- age-specific fertility rate, J224(graph)
- availability of Depo-Provera, K13(figure), K14
- birth rate, J29(table), J207(table), J209 (table)
- condom shipments, H15(table)
- cost of injectable progestogens, K14
- diaphragm availability, H68(table)
- oral contraceptives,
  - marketing, A13(table)
  - supplied by USAID, A21(table)
- overgrazing, J188
- tribal attitude toward premarital sex, J159

BOTTLE FEEDING
- attitude, J55
- cost, J55
- disadvantages, J55

BOURGUIBA, H., E11(photo)
- sterilization and Moslem law, E6

BOVIE ELECTRIC KNIFE
- tubal occlusion, C34

BOWBENT DIAPHRAGM. See **MATRISALUS DIAPHRAGM**.

BOWEL INJURY
- colpotomy, C40(table)
  - causes, C42
- complications of culdoscopy
  - operative, C66(table)
  - prevention, C66
  - rate, C66
- laparoscopic sterilization, CD18, CD20, CD21

BOYCE, J.G.
- orals and cervical neoplasia, A44(table), A81(table)

BOYES, D.A.
- orals and cervical neoplasia, A83(table)

BOYSEN, H.
- morbidity with colpotomy, C30

BOZORGI, N.
- ketamine hydrochloride in laparoscopic sterilization, C4

BRACKETT, J.W., author, J1-J20, J205-J234
- fertility silhouette technique, J206

BRADBURY, J.T.
- estrogen use and endometrial cancer in postmenopause, A86(table)

BRADBURY, W.W.
- posterior colpotomy, C30

BRADFIELD, G.F.
- laparoscopic sterilization, C2(table)
  - complications, C19(table)
  - electrocoagulation with division, C8 (table)
  - failure, C22(table)

BRADSHAW, F.R.
- menstrual pattern changes with norethindrone minipill, A59(table)

BRADSHAW, L.E., author, D41-D59, J265-J285

BRADYCARDIA
- anesthesia, C62
- inhibited by PG, G26
- $PGF_2\alpha$, F72
- prevention during laparoscopic sterilization, C4, C20
- spring-clip sterilization, C84

BRANCH, B.
- counseling with menstrual regulation, F12
- prototype aspirator, F44

BRASS, W.
- estimated fertility levels in China, J211 (table)

BRASS TECHNIQUE, J214

BRAT, T.M.
- use-effectiveness of Depo-Provera, K4 (table)

BRAUNSTEIN, G.D.
- measurement of HCG, F53

BRAZIL, J194
- abortion, E26
  - legal status, E29(table), E36(table), F61
- age-specific fertility rate, J27(graph), J35(graph), J223(graph)
- availability of Depo-Provera, K13(figure)
- average births per woman, J129(table)
- birth rate, J29(table), J207(table), J209 (table)
  - economic growth, J22
- contraceptive advertising, E44
- diaphragm availability, H68(table)
- economic growth, J22, J190
- estimated population, E36(table)
- family planning program, J26, J206, J217
  - distribution of contraceptives, J70, J80-J81, J84(table)
  - education, J80
  - organization, J80
  - service statistics system, J333-J335
- infant and neonatal mortality, J166(table), J254(table)
- legal status of voluntary sterilization, CD104(table)
- marital status of female adolescents, J164(table)
- marketing of minipill, A64(table)
- new acceptors, A17, A18(table), J16(table)
- oral contraceptives,
  - commercial supply, A9(table)
  - marketing, A13(table)
  - new acceptors, A17, A18(table)
  - sales, A8(table)
- PG research, G21, G22
- population, F7(table), J206
- population per hospital bed, J71(table)
- population per physician, J71(table)
- population policy, E14, J239
- total fertility rate, J216(table)
- training nonphysicians, J95(table), J105(table)
  - distribution of orals, J92

BRAZIL, RIO DE JANEIRO.
- population policy, E41, E42, E43(table)

BREAKTHROUGH BLEEDING
- minipill, A57
  - selected studies, A58-A70(tables)
- progestogens, K3

BREAST
- anatomy, J51(figure), J53(figure)

BREAST CANCER. See also **BREAST NEOPLASIA**.
- animal studies, A79-A80
- etiology, A45-A46
- incidence among women
  - Connecticut, A113(chart)
  - Denmark, A115(chart)
  - Puerto Rico, A114(chart)
  - selected countries, A70(table)
  - US, A43(figure)
- mortality, A43
  - US women, A112(chart)
- oral contraceptives, A2, A43, A45-A46, A75, A76(table)
  - incidence among users and nonusers compared, A31(graph), A46(graph)
  - selected studies, A44(table)
- related to age of first birth, A46, A79
- use of estrogens, A75
  - postmenopause, A77(table)

BREAST DISEASE. See **BENIGN BREAST NEOPLASIA**; **BREAST CANCER**; **BREAST NEOPLASIA**.

BREAST ENGORGEMENT
- etiology and treatment, J53

BREAST-FEEDING, A34, J49-J67. See also **LACTATION**.
- advantages, J49, J54, J62
- attitude of health personnel, J55
- compared with cost of substitutes, J55 (table)
- contraception during, J50, J58-J59, J62, J64
- couple-years protection, J58
  - developing countries, J59(table)
- decline in practice, J49, J54
- duration, J338(figure)
- factors hindering, J53
- family planning programs, J50, J64
- immunological benefits, J54
- indication for diaphragm use, H57
- infant mortality, J62
- let-down reflex, J51, J53(figure)
- nutritional requirements, J54
- ovulation, J56-J57
- psychological factors, J51

- smoking, J54
- techniques, J52-J53
- urban and rural mothers, J54-J55

BREAST NEOPLASIA. See also **BENIGN BREAST NEOPLASIA**; **BREAST CANCER**.
- anagestone acetate, A78(table), A79(table)
- cystic disease, A74-A75
- fibroadenoma, A74-A75
- incidence, A74
- oral contraceptives, A74-A76(table)
  - animal studies, A78-A79(table), A80
  - selected studies, A73-A74(table)

BREAST TENDERNESS
- postcoital estrogen-progestin combination, J150
- side effect of estrogens, J148(table), K3
- side effect of orals, A34, A36

BRENNER, P.H.
- uterine aspiration, F28(table)
  - complications, F33(table)
  - equipment, F32(table)
  - general anesthesia, F29(table)
  - incidence and management of perforation, F35(table)

BRENNER, W.E.
- comparison of sterilization techniques, C85(table)
- complication rates with abortion by length of amenorrhea, F66(figure)
- laparoscopic fulguration procedure, C81(photo)
- length of amenorrhea and pregnancy, F53(table)
- menstrual regulation, F13(table)
  - pregnancy test, F12
  - procedure and equipment, F14(table)
  - vaginal cleansing, F12
- midtrimester abortion
  - complications, F67
  - intraamniotic instillation of $PGF_2\alpha$, F73(table)
  - intramuscular injection of PGE_2 methyl analogue, F77(table)
  - methods, F66
- PG administration for cervical dilatation, F95
- $PGF_2\alpha$
  - cervical dilatation of nulliparas, G67, G68(table)
  - midtrimester abortion, F73, G71, G72(table)
- PGs for pregnancy termination, G7(table), G8(table)
  - compared with saline method and hysterotomy, G12
  - preferred route of administration and timing, G11
- safeguards for uterine manipulation instruments, M23
- Yoon band application, C85(photo)

BREVICON
- formulation and dose, A37(table)
  - manufacturer, A37(table)

BREVITAL SODIUM. See **SODIUM METHOHEXITAL**.

BRIANZA, C., A5(table)

BRIDGMAN, H.
- prototype aspirator, F44

BRINTON, L.A.
- uterine aspiration, F28(table)
  - complications, F33(table)

BRISTOL-MYERS CO.
- oral contraceptives, A4(table)

BRITISH COMMITTEE ON THE SAFETY OF DRUGS. See **BRITISH COMMITTEE ON SAFETY OF MEDICINES**.

BRITISH COMMITTEE ON SAFETY OF MEDICINES
- animal studies with orals
  - breast neoplasia, A78(table)
  - cervical tumors, A85(table)
  - endometrial tumors, A87(table)
  - liver tumors, A89(table)
  - ovarian tumors, A91(table)
  - pituitary tumors, A90(table)
- approval of copper IUD, B4, B18
- licensing of PGs, G13
- oral contraceptives, A12, A37
  - thrombosis, A41

BRITISH DRUG HOUSES (BDH), A5(table)
- worldwide marketing of oral contraceptives, A13-A15(table)

BRITISH FAMILY PLANNING ASSOCIATION
- clinical use of C-film, H46
- condom distribution, H12

BRITISH HONDURAS
- diaphragm availability, H68(table)
- marketing of oral contraceptives, A13 (table)

BRITISH SOLOMON ISLANDS
- birth rate, J29(table), J207(table), J210 (table)

BRITISH STANDARD SPECIFICATION 4028
- diaphragm quality control, H67(photo)

BRITISH STANDARDS INSTITUTE
- condom shelf-life, H30

BRITISH VIRGIN ISLANDS
- birth rate, J29(table), J207(table), J210 (table)

BRODIE, N.
- reversible intravas device, D14

BRODIE R-IVD
- vas occlusion, D53

BRODSKY, S.A.
- vasectomy technique, D6(table)

BRODY, S.
- HCG detection in pregnant women, J111

BRONCHITIS
- air pollution, J184

BRONCHOSPASM
- side effect of PG administration, F72, G3

BROTHERTON, J.
- abortion and hormonal-withdrawal test, J114

BROWN, L.R., author, J177-J202, J237-J251
- estimated birth and death rates for China, J211

BROWN, R.L.
- spermicidal potency, H44

BRUCE, P.T.
- vasectomy
  - complications, D28(table)
  - sexual behavior, D35(table)
  - technique, D6(table), D28(table)

BRUESCHKE, E.E.
- artificial vas deferens, D56
- reversible vas occlusive valves, D56(photo)

BRUMMER, H.C.
- seminal plasma, D30

BRUNEAU, P.
- rhythm method in Mauritius, J82(table)

BRUNEI
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- marketing of oral contraceptives, A13(table)

BRUNK, U.
- saline abortion mechanism, G49

BRUSILOW, M.
- instruments for colpotomy, C36(table)

BRYSON, R.
- monsoon pattern changes, J187

BUCALO, L.
- Phaser valve, D14-D15

BUCART, R., A5(table)

BUCHANAN, R., author, J49-J68, J125-139

BUCKLE, A.E.
- uterine aspiration, F28(table)
  - anesthesia, F29(table)
  - blood loss, F34(table)
  - complications, F33(table)
  - equipment, F32(table), F41(table)
  - incidence and management of perforation, F35(table)
  - postoperative medication, F29(table)
  - preoperative medication, F29(table)
  - pressure used, F41(table)
  - time required, F32(table), F34(table)

BULGARIA
- age-specific fertility rate, J10(graph), J38(graph), J227(graph)
- birth rate, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- estimated population, E30(table)
- legal status of abortion, E6, E8(table), E30 (table), E32, E33(table), J165
- legal status of voluntary sterilization, CD104(table)
- marketing of oral contraceptives, A13(table)
  - population, F7(table)
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - population policy, E1
  - uterine aspiration, F27
    - equipment, F41

BUNGE, R.G.
- reversible vas occlusion, D53

BURCH, J.C.
- estrogen use and breast cancer in postmenopause, A77(table)

BURDICK, C.L.
- Shamrock IUD, B47
  - use-effectiveness, B32(table)

BURKMAN, R.T., J43(photo)
- midtrimester abortion with urea, F78(table)

BURMA
- birth rate, J29(table), J207(table), J210 (table)
- legal status of abortion, E30
- legal status of voluntary sterilization, CD78, CD104(table)
- marketing of oral contraceptives, A13(table)
- water pollution, J181

BURNETT, L.S.
- midtrimester abortion with urea, F78(table)

BURNETT INSTRUMENTS
- menstrual regulation kit, F57(figure)

BURNHILL, M.
- forceps for cervical dilatation, F38

BURNIGHT, R.G.
- vasectomy
  - general health, D34(table)
  - sexual behavior, D35(table)

BURNS
- laparoscopic sterilization, C18, C19(table), C45, C79, C80
  - prevention, C80

BURUNDI
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J209 (table)
- legal status of voluntary sterilization, CD104(table)
- marital status of female adolescents, J164(table)
- marketing of oral contraceptives, A13 (table)

BUSFIELD, J.
- age of marriage and family size, J163

BUSHNELL, L.F.
- use-effectiveness of contraceptive aerosol foam, H45(table)

BUTENANDT, A.
- identification of estrone, A31

BUTLER, J.
- pressure for electrical aspirator, F42

BUTTS, H.E.
- condoms as prophylactics, H29

BYGDEMAN, M., author, G65-G75
- menstrual regulation with PGs, G57, G58, G66(table)
- midtrimester abortion with $PGF_2\alpha$, G8(table), G9(table)
  - extraamniotic route, G70(table)
  - intraamniotic route, G71(table)
  - methyl analogue, F74, F76, F77(table)
  - side effects, G70(figure)
  - time required, G69(figure)
- research with PGs, G17

BYKOV, S.G.
- induction of menstruation, F27
- vacuum aspiration, F11

C

CABRERA, H.A.
- pregnancy tests
  - biologic, J115(table)
  - immunologic, J118(table), J119(table)

CAIRD, F.
- diabetes mellitus and parity, J132(table)

CALCIUM
- myometrial activity, G47

CALDER, I.M.
- immunologic slide test for pregnancy, J119(table)

CALHOUN, J.
- population density and social behavior, J189

CALIFORNIA
- clinical testing of orals, A32
- deaths from illegal abortion, J257
- lung cancer and air pollution, J184
- septic abortion, E38

CALIFORNIA, UNIVERSITY OF, BERKELEY, J284
- orals and breast disease, A45
- population program assistance, J276 (table)

CALIFORNIA, UNIVERSITY OF, IRVINE.
- outpatient vas anastomosis, D48
- vasectomy reversal, D46

CALIFORNIA, UNIVERSITY OF, SAN FRANCISCO.
- vas anastomosis, D48

CALIFORNIA, UNIVERSITY OF, SANTA CRUZ.
- address, J108(table)
- training nonphysicians, J108(table)

CALLAWAY, H.
- women and literacy, J178

CAMBODIA. See **KHMER REPUBLIC**.

CAMERON, C.S.
- bilateral vas anastomosis, D43

CAMERON, I.D.
- factors influencing cervical cancer, J133(table)

CAMERON-MILLER, INC.
- address, M32
- electrosurgical generator, M14(table), M17(photo)
- guarantee and service of sterilization equipment, M30(table)

CAMEROON
- age-specific fertility rate, J34(graph)
- birth rate, J29(table), J207(table), J212 (table)
- legal status of abortion, E29(table)
- legal status of voluntary sterilization, CD104(table)
- marketing of oral contraceptives, A13(table)

CAMPOS, A.
- menstrual pattern changes with norethindrone minipill, A59(table)

CANADA
- abortion
  - legal status, E29(table), E32, E34
  - maternal mortality, E36, E37
- adolescents
  - abortion, J169
  - births, J161(table)
  - marital status, J164(table)
- age-specific fertility rate, J3(graph), J9(graph), J35(graph), J226(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J21, J23(figure), J29(table),
- bleeding with IUD in situ, B11
- change in number of births, J219(figure)
- chemical tubal occlusion, D87
- colpotomy, C31(table)
- copper IUD, B10, B18
  - legal aspects, B18
- diaphragm availability, H68(table)
- effects of population growth on environment, J246
- incidence of cancer in women, A70(table)
- infant and neonatal mortality, A36, J166 (table)
- legal status of voluntary sterilization, CD83, CD105(table)
- marketing of minipill, A64(table)
- maternal mortality, A36, J128(figure)
- obstetrical complications with multiparity, J134(table)
- oral contraceptives, A1, A9(table), A36, J4
  - carcinogenic effects, A44(table)
  - commercial supply, A10(graph)
  - marketing, A13(table)
  - sales, A8(table)
- out-of-wedlock births, J160(figure)
- PG research, G11, G20, G22
- population assistance. See **CANADIAN INTERNATIONAL DEVELOPMENT AGENCY (CIDA)**.
- population per hospital bed, J71(table)
- population per physician, J71(table)
- population trends, J240
- postcoital estrogen-progestin combination, J141, J150
- Province of Ontario
  - contraceptive distribution program, E41, E42, E44(table)
- rhythm method, I7, J74
  - use-effectiveness, I12(table)

CANADIAN INTERNATIONAL DEVELOPMENT AGENCY (CIDA)
- address, J284
- funding of family planning activities, J273, J274(table), J278(table)

CANARY ISLANDS
- tourism, J180

CANCER. See also specific types, e.g., **BREAST CANCER**; **CERVICAL CANCER**; etc.
- incidence in female genitalia, A70(table)
- mortality in the US (1955–1975), A109(chart), A110(chart), A111(chart)
- related to environment, J183

CANDELL, A., J244

CANNULA. See also **KARMAN CANNULA**.
- advantages of plastic over metal, F18
- description, F18
- diagnostic use, F59
- first trimester abortion, F96
- fitted with syringe, F18
- measuring uterine depth, F31
- menstrual regulation, F12, F50, F51(table), F54, F58
- size, F12, F14(table), F17
- tubal sterilization, C73
  - chemical occlusion, C87, C88
  - plugs, C90
- uterine aspiration, F31, F32(table), F60 (table)
- uterine perforation, F36

CANNULA, METAL, F55(figure)
- advantages, F40, F55
- description, F40
- diagnostic use, F59

CANNULA, PLASTIC, F40(figures)
- advantage, F26, F40, F55
- description, F40
- diagnostic use, F59
- menstrual regulation, F51

CANNULA, SEMM
- mini-laparotomy, C54

CANNULA ADAPTORS, F41(figure)
- size, F41
- use, F41

CANON LAW
- influence on contraceptive sterilization, CD87

CANTOR, B.
- PGs for pregnancy termination, G8(table)

CANTRELLE, P.
- duration of postpartum amenorrhea, J57 (table)

CAPE VERDE ISLANDS
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- marketing of oral contraceptives, A13 (table)

CAPELLMANN, C.F.N.
- fertile period identification, I3(table)

CAPILLARY TEST, J122(photo). See also **PREGNANCY TESTS, IMMUNOLOGIC**; **PREGNANCY TESTS, RADIOIMMUNOASSAY**.
- advantages, J122
- cost, J122
- development, J110
- sensitivity, J122
- storage, J122

CARAWAY, A.F.
- Sat-T-Coil insertion, B30

CARBIA, E.
- orals and cervical neoplasia, A44(table)
- orals and squamous metaplasia, A84(table)

CARBON, G1

CARBON DIOXIDE
- abdominal insufflation, C47
  - side effects, C47
- climatic effects, J187
- laser for tubal occlusion, C91
- uterine distension, C89

CARBONIC ACID, C47

CARBONIC ANHYDRASE, J146

CARDIAC DISEASE
- contraindication for laparoscopic sterilization, C18

CARDIORESPIRATORY DISEASE
- contraindication to culdoscopy, C65

CARIBBEAN. See also specific countries.
- adolescents
  - births, J161(table)
  - marital status, J164(table)
- attitude toward out-of-wedlock pregnancy, J163
- birth rate, J209(table), J210(table)
- training nonphysicians, J98
  - selected countries, J95(table), J105–J107(table)

CARL XVI GUSTAF (SWEDEN), E19

CARLSON, B.D.
- promotion of family planning in Ghana, J308

CARLSTROM, G.
- HCG detection in pregnant women, J111

CARMICHAEL, D.E.
- prevention of cardiac complications
  - general anesthesia, C4
  - pneumoperitoneum, C20

CARNETT, J.B.
- sperm count with epididymitis, D42

CAROLINA POPULATION CENTER, UNIVERSITY OF NORTH CAROLINA. See **NORTH CAROLINA, UNIVERSITY OF, CAROLINA POPULATION CENTER.**

CARPENTER, G.
- ineffectiveness of aerosol foam, H45(table)

CARRILLO-FLORES, A., E16(figure)

CARRUTHERS, G.B.
- spermicidal potency, H44

CARSTEN, M.E.
- uterine contractility, G47

CARTER, J.P., J107(table)

CASAGRANDE, J.
- estrogen use and breast cancer in postmenopause, A77(table)

CASANOVA, H3, H58

CASAVILLA, F.
- continuation rate of megestrol acetate minipill, A62(table)

CASEY, D.
- equipment for uterine aspiration, F38, F41

CASTI CONNUBI, I3

CASTRATION, CD86
- differentiated from vasectomy, D2
- sexual sterilization, CD63, CD86

CASTRO, F.
- economic growth in Cuba, J190

CATECHOLAMINES, G25, G28, J62

CATGUT
- sutures, C35, C36(table), C42, C56, C58
  - complications, D8
- tubal ligation, C34, C36(table)
- vas ligation, D5, D6–D7(table)
  - disadvantage of, D5
- vas occlusion, D27, D28(table)
  - infection, D28

CATHETER. See also specific types
- chemical tubal occlusion, C86, C87, C88
- extraovular PG administration, F74
- saline abortion, F70

CATHETER, FRENCH
- PG administration for cervical dilatation, G61

CATHETERIZATION, C54

CATHOLICS
- oral contraceptives, H4, J81
- rhythm method, I2, I3
  - developed countries, I14(table)
  - developing countries, I14(table), I15
  - endorsement, J81
- US, I9, I14

CAUTCHUK PESSARIUM
- historical cervical cap, H70

CAVANAUGH, A.T.
- use-effectiveness of contraceptive jelly, H45(table)

CAYMAN ISLANDS
- birth rate, J29(table), J207(table), J210 (table)
- marketing of oral contraceptives, A13 (table)

CCC
- active ingredients, H41(table)

C.D.S. CAUTERY MARK III, D13
CELIOSCOPY. See **LAPAROSCOPY**.
CELL-MEDIATED IMMUNITY
- vasectomy, D32

CENTRAL AFRICAN REPUBLIC
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- legal status of voluntary sterilization, CD105(table)
- marketing of oral contraceptives, A13 (table)

CENTRAL AMERICA. See also specific countries.
- adolescent births, J161(table)
- marital status of female adolescents, J164(table)
- oral contraceptive sales, A8(table)
- tropical plants threatened, J198

CENTRAL EMEK HOSPITAL (ISRAEL)
- frozen semen storage, D52

CENTRAL MAINTENANCE ORGANIZATION
- sterilization equipment, M3

CENTRIFUGATION
- sperm separation, I25

CENTRO EDUCACIONAL Y DE INVESTIGATION EN ENFERMERIA MATERNO-INFANTIL PARA MESOAMERICA (PANAMA)
- address, J106(table)
- training nonphysicians, J106(table)

CENTRO DE ORIENTACION FAMILIAR (COF), J302
CEPHALOPELVIC DISPROPORTION
- PG administration during induction of labor, G60

CERAMIC PLUG
- tubal occlusion, C90(table)

CEREALS
- factors affecting production, J184
- related to energy, J199
- reserves, J184–J185
- supply v. demand, J182(figure)
- world consumption, J184(figure)
- world production, J241

CEREBROVASCULAR DISEASE
- incidence in users and nonusers of orals compared, A31(figure)

CERNADA, G.P.
- promotion of family planning
  - Korea, J294
  - Taiwan, J306(table)

CERRUTI, R.E.
- outpatient vas anastomosis, D48

CERTANE JELLY
- venereal disease, H51(table)

CERTIFIED NURSE-MIDWIFE (CNM)
- training in pregnancy termination, J96

CERVICAL BIOPSY
- colpotomy, C40, C41

CERVICAL CANCER. See also **CERVICAL NEOPLASIA**.
- copper IUDs, B17
- Depo-Provera, K1, K9, K10
- diaphragm use, H64
- diethylstilbestrol during pregnancy, J146
- factors influencing, J135
- incidence
  - Connecticut (1955–1975), A117(chart), A118(chart), A119(chart)
  - Denmark (1953–1972), A121(chart)
  - Puerto Rico (1955–1974), A120(chart)
  - selected countries, A70(table)
- mortality in the US (1955–1975), A116(chart)
  - selected studies, J133(table)
- oral contraceptives, A46
  - selected studies, A44(table)
- prevalence, J135
- sexual activity, J162

CERVICAL CAP, H70(figure), J71(figure)
- acceptability, H70
- advantages, H70, H72
- compared with diaphragm, H70
- contraindications, H70, H71
- current research, H72
- disadvantages, H70
- discontinuation, H70, H71
  - lack of promotion, H70
- fitting, H70(figure), H70–H71
- history, H70
- India, H71, H72
- manufacture, H72
- materials, H70, H71, H72
- mode of action, H70
- precursor of IUD, B23
- quality control, H72
- removal, H71
- side effects, H71
- sizes, H71, H72
- spermicides, H71
- use-effectiveness, H71, H72

CERVICAL DILATATION. See also **DILATATION AND CURETTAGE**.
- abortion, F67, F85, F86–F87
- biochemical and physical changes, F98
- cervical fistulae, G12
- cervical stenosis, F85
- complications, F17, F36, F39, F85, F86, F87, G38
- current research, F98–F99
- degree, F38, F86, F90–F91
- diagnostic and therapeutic uses, F85
- dysmenorrhea, F85
- early technique, F26–F27
- equipment, F32(table), F38–F40
- historical perspective, F87–F89
- local anesthesia, F91, F92
- long-term consequences, F98
- menstrual regulation, F14(table)
- methods, F31
- microdilators, F96
- PGE_2, G68–G69
- $PGF_2\alpha$, G67–G68
- PGs, F94–F96
  - advantages, G62
  - compared with mechanical methods, G61
  - effectiveness, G61
  - pregnancy termination, G11, G12
  - route of administration, G57, G61
  - selected studies, G68(table)
  - side effects, G61
  - time required, G61–G62
- stages of gestation, F86(figure)
- technique with metal dilators, F90–F91
- timing for pregnancy terminations, F86
- uterine perforation. See **CERVICAL INJURIES**.
- vacuum aspiration, G61

CERVICAL DYSPLASIA
- diaphragm use, H64–H65

CERVICAL INJURIES, F85–F87
- abortion with urea, F78(table), F79
- causes and incidence, F35
- colpotomy, C42
- extraovular instillation of $PGF_2\alpha$, F75 (table)
- laminaria tent insertion, F39(table)
- metal dilators, F90
- nulliparity, F90
- PG administration, G72–G73
- plastic cannula, F15
- saline abortion, F69, F70
  - selected studies, F71(table)
- subsequent pregnancy, F87
- uterine aspiration, F33(table)

CERVICAL MUCUS
- cervical neoplasia, A83
- changes during menstrual cycle, 17
- injectable progestogens, K3
- minipill, A55
- oral contraceptives, A34
- ovluation, I8

CERVICAL NEOPLASIA. See also **CERVICAL CANCER**.
- age at first coitus, A80
- animal studies, A84, A85(table)
- cervical mucus, A83
- coital frequency, A83
- etiology, A83
- selected studies with orals, A81–A83(table)

CERVICAL OS
- ovulation, I8

CERVICAL SHOCK. See **SYNCOPE**.
CERVICAL TRAUMA
- menstrual regulation, F51, F52(table)

CERVICITIS
- menstruation disorders, K6
- uterine aspiration, F35

CERVIX (UTERINE)
- physiology, A83(figure)

CESAREAN SECTION
- chemical tubal occlusion, C87
- tubal ligation, C77, C78

CETYL PYRIDINIUM BROMIDE, H40
CEYLON. See **SRI LANKA**.
C-FILM. See also **SOLUBLE FILM**.
- active ingredients, H41(table)
- description, H42
- use-effectiveness, H45(table), H46

CHAD
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- drought and famine, J244–J245
- early marriage, J158
- marketing of oral contraceptives, A13 (table)

CHALLIS, J.R.G., author, G45–G54
- PGF concentration in umbilical cord, G48(table), G49

CHANDRASEKARAN, C.
- diaphragm failure, H65(table)

CHANG, H.C., A32
CHANG, W.
- population dynamics in China, J213

CHANNEL ISLANDS
- age-specific fertility rate, J227(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)

CHAO, J.C., author, J1–J20, J21–J39
- fertility silhouette technique, J206

CHATURACHINDA, K.
- insufflation of the abdomen, M10
- laparoscopic sterilization
  - complications, C19(table), C24(table)
  - failure, C22(table)
  - Thailand, C2, C14

CHAUDRY, S.L., author, F65–F83
CHEN, C.
- culdoscopy
  - operative complications, C66(table)
  - postabortion, C65
  - postoperative complications, C67 (table)
  - preoperative medication, C63(table)
  - side effects of anesthesia, C62
  - tubal occlusion, C65(table), G68(table)

CHEN, F.M.
- tubal ligation, C75

CHEN, L.C.
- duration of postpartum amenorrhea, J56, J57(table)
- maternal mortality in Bangladesh, J128

CHEN, L.S.
- population dynamics in China, J213

CHEN, P.-C.
- tubal ligation performed by barefoot doctors, J97

CHENG, M.
- side effects of anesthesia in culdoscopy, C62

CHERRY, T.
- culdoscopy, C62

CHIAZZE, L.
- menstrual cycle length, A60(table)

CHIBUNGO, M.M.
- medical complications of adolescent pregnancy, J165(table)

CHICAGO, UNIVERSITY OF, COMMUNITY AND FAMILY STUDY CENTER, J284
- communication of family planning with mailings, J291, J293
- population program assistance, J276(table)

CHILDBEARING. See **PREGNANCY**.
CHILDBED FEVER. See **SEPSIS**.
CHILE
- abortion
  - legal status, E29(table), E35(table)
  - mortality, F37
  - practice, E35(table)
- adolescents
  - birth rate, J159
  - marital status, J164(table)
  - trend in percentage of total births, J161(table)
- age-specific fertility rate, J3(graph), J6(graph), J25(graph), J35(graph), J222(graph)

- birth rate, J23(figure), J29(table), J207(table), J218(figure)
- bottle feeding and hygiene, J55
- cervical cancer
  - comparison between IUD and Depo-Provera users, K10
- change in number of births, J219(figure)
- chemical tubal occlusion, C87
- College of Physicians, J96
- condom
  - sales, H6
  - shipments, H15(table)
- copper IUD, B2, B18
- death from illegal abortion, E27, J256
- Depo-Provera
  - availability, K13(figure)
  - cervical cancer, K10
  - use-effectiveness, K4(table)
- diaphragm availability, H68(table)
- distribution and use of minipill, A63
- duration of postpartum amenorrhea, J57(table)
- family planning program, B28, J24
- fertility, J4
- infant and neonatal mortality, J166(table)
- injectable contraceptives, K2
  - Depo-Provera, K4(table), K10, K13(figure)
- in-school sex education, J171
- IUD
  - acceptors, B27(table)
  - cervical cancer, K10
  - insertion by nonphysicians, J96
  - use, J2
- lactation
  - effect of orals, J61(table)
  - effect of progestogen-only contraceptives, J63(table)
- legal status of voluntary sterilization, CD81-CD82, CD105(table)
- maternal mortality, J128(figure), J130 (table)
  - illegal abortion, E27, J256
  - induced abortion, J137-J138
- new acceptors, A18(table), J16(table)
- nonphysicians for family planning services, E41, E44(table)
  - E41, E44(table)
  - training, J95(table), J106(table)
- oral contraceptives, A17
  - government policy, E2, E4(table)
  - marketing, A13(table)
  - new acceptors, A18(table)
  - nonprescription, J74
  - supplied by USAID, A21(table)
- out-of-wedlock births, J160(figure)
- population policy, E41, E42, E43(table)
  - nonphysicians, E46
  - voluntary sterilization, E45(table), E48
- sterilization, CD70
- total fertility rate, J215(table), J216, J217 (table)
- training in culdoscopy, C70
- use-effectiveness of Norigest, K4(table)

CHIMCO BIO-MEDICAL ENGINEERING CO., F57
- silastic rings, M18(table)

CHINA, PEOPLE'S REPUBLIC OF
- abortion
  - cultural aspects, F2
  - legal status, E29, E30(table), E36 (table), F1, F2
  - methods, F66
- barefoot doctors
  - pregnancy termination, J97
  - tubal ligation, J97
  - vasectomy, J98
- birth rate, J29(table), J207(table), J211 (table), J212(table), J213(table), J237, J239, J250(table), J251(table)
- cervical cancer, J135
- diaphragm use, H60
- distribution of contraceptives, J83, J165
- estimated population, E30(table), E36 (table), J205, J211(table), J212(table), J213
- family planning program, J1, J239
- fertility levels, J208, J211(table), J212 (table), J213
- First National Peoples Congress, F2
- Flower of Canton, B44
- health care, A195
- incidence of early marriage, J160
- marriage law (1950), J160
- mortality rate, J211(table), J250(table)
- number of births, J212(table)
- oral contraceptives, A1, A2
  - low-dose, A12, A38
  - nonprescription, J74
- political credo, J201
- population estimates, F7(table), J250 (table)
- population policy, E18, J239, J246
- price of vaginal contraceptives, H48(table)
- stainless steel ring, B44
- uterine aspiration, F27
  - equipment, F41

CHINESE CENTER FOR INTERNATIONAL TRAINING IN FAMILY PLANNING (TAIWAN)
- address, J103(table)
- training nonphysicians, J94(table), J103(table)

CHINNATAMBY, S.
- continuation of contraceptives, K8
- effect of orals on lactation, J60(table)
- use-effectiveness of Depo-Provera, K4 (table)
- use-effectiveness of Norigest, K4(table)

CHLOASMA
- oral contraceptives, A47
  - incidence in users and nonusers compared, A31(figure)

CHLORAMINE, H41(table), H43(table)

CHLORHEXIDINE, F27

CHLORMADINONE ACETATE, K2
- breast nodules in beagles, A55
- component in oral contraceptives, K10
- continuation rate as minipill, A62(table)
- effect on lactation, A63, J63
- effect on menstrual cycle, A61
- principal progestogen, A6(table)
- role in development of minipills, A54-A55

CHLOROPROCAINE
- cervical dilatation, F91

CHLORPROMAZINE, C32(table)
- compared with droperidol and fentanyl, C62
- culdoscopy, C62, C63(table)

CHOLECYSTITIS
- oral contraceptives, A47

CHOLELITHIASIS
- oral contraceptives, A47

CHOLERA
- water pollution, J184

CHORIOADENOMA
- diagnosis, J114

CHORIOCARCINOMA, F31
- diagnosis, J113, J114

CHORIONEPITHELIOMA
- incidence in selected countries, A70(table)

CHORIONIC GONADOTROPIN
- hydatidiform mole, F31

CHOWDHURY, Z., J101(table)
- training nonphysicians in mini-laparotomy, J97

CHROMOSOMES. See **SEX CHROMOSOMES**.

CHULALONGKORN HOSPITAL MEDICAL SCHOOL (THAILAND)
- address, J103(table)
- training nonphysicians, J94(table), J103(table)

CHUN, D.
- laparoscopic sterilization, C2(table), C8
  - complications, C19(table)
  - failure, C22(table)
  - need for training, C14
  - operative procedure, C7(table)
  - technique for pneumoperitoneum, C5(table)

CHUNG WANG INSTRUMENT CO.
- address, M32
- vasectomy equipment, M25(table)

CHUNN, W.P.
- vaginal suppositories, H39

CHURCH WORLD SERVICE, J78
- address, J283
- funding of family planning activities, J269, J270, J271(table), J274(table)

CHYMORAL. See **TRYPSINCHYMO TRYPSIN**.

CIACOP. See **INTER-AMERICAN CENTER FOR TRAINING IN COMMUNICATIONS FOR POPULATION AND FAMILY HEALTH**.

CIBA-GEIGY
- oral contraceptives, A4(table)
  - worldwide marketing, A13-A15(table)

CINCHONA TREE
- quinine, J199

CINGESTOL
- effect on menstrual patterns, A58(table)
- minipill, A56(table)

CIVIL FREEDOM. See **INDIVIDUAL FREEDOM**.

CLAMP
- colpotomy, C33, C35, C36(table)

CLARKE, H.C.
- instruments for treatment of electrocoagulation complications, C12
- Pomeroy tubal ligation, C77

CLEMENS, G.
- clips for female sterilization, C45, C46-C47, C83
- insufflation equipment design, C51, C52(figure)

CLIMATE
- factors affecting, J187
- weather patterns, J187

CLINIC. See **FAMILY PLANNING CLINIC**.

CLINIQUE LA CROIX BLEUE (SENEGAL)
- address, J104(table)
- training nonphysicians, J98, J104(table)

CLIP STERILIZATION, C76(table). See also **CLIPS**; **CLIPS, TANTALUM**; **HEMOCLIPS**; **HULKA CLIP**; **PLASTIC CLIPS**; **SPRING-LOADED CLIPS**.
- advantages and disadvantages, C82
- compared with laparoscopic sterilization, C47
- complications, C46, C49
- contraindications, C48-C49
- culdoscopy, C64, C65(table)
  - failure rate, C68(table)
- effectiveness, C46, C50, C76(table)
  - selected studies, C83(table)
- equipment, C48(figure), C49(figure), C50-C52, M18-M19(table), M20
  - back-up system, C50-C51
  - problems, C50
- follow-up, C50
- history, C46-C47, C82-C83
- local anesthesia, C47
- operative procedure, C47-C48
  - postabortion, C48
  - postpartum, C48
- preoperative medication, C47(table)
- reversibility, C45, C46, C50, C82-C83
- route of approach, C76(table), C83
  - selected studies, C83(table)
- site of application, C83(table)

CLIPS. See also **CLIP STERILIZATION**; **CLIPS, TANTALUM**; **HEMOCLIPS**; **HULKA CLIP**; **PLASTIC CLIPS**; **SPRING-LOADED CLIPS**.
- advantages and disadvantages in laparoscopic sterilization, C12, C45
- failure, C46
- incision closure, C36(table)
- insertion into applicator, C51(figures)
- mechanism of action, C50
- placement, C46, C48, C50
- recommendations for improvement, C46
- tubal occlusion, C34
  - devices and applicators, M18-M19 (table)
- types, C12(figures)
- vas occlusion, D28(table)
  - reversibility, D53
- vasectomy, D7, D8
  - advantages, D7
  - contraindicated for scrotal incision, D9
  - experimental research, D7
  - failure rate, D7
  - number used, D7
  - placement, D7
  - possible side effects, D7

CLIPS, TANTALUM. See also **CLIPS**.
- advantages and disadvantages, C83
- application of silastic plug, C90(photo)
- culdoscopy, C65(table)
- description, C83
- failure, C68, C83

- selected studies, C83(table)
- laparoscopic application, C84(photo)
- site of application, C68
- vas occlusion, D33, D53
- vasectomy, D7

CLOGESTONE, POSTCOITAL
- acceptor characteristics, J150(table)
- dosage, J150(table)
- use-effectiveness, J150(table)

CLOUDSEEDING, J187

CLUB OF ROME
- mineral consumption, J194

CLYMAN, J.J.
- culdoscopy, C62
  - equipment, C69(figures)
  - local anesthesia, C64
  - operative procedures, C64
  - postoperative care, C64
  - preoperative medication, C63(table)
  - tubal occlusion, C65(table),C68(table)
- fimbriotexy for tubal occlusion, C91
- tantalum clip application, C68

CLYMAN FULCRUM PERINEAL RETRACTOR, M27(figure)

C.M.A.I. FAMILY PLANNING PROJECT (INDIA)
- address, J101(table)
- training nonphysicians, J94(table), J101(table)

COAGULOPATHY
- $PGF_2\alpha$ for abortion, F74
- saline abortion, F69, F70
  - selected studies, F71(table)
- urea abortion, F79

COAL, J200

COALE, A.J.
- demographic transition theory, J213
- generation length and population growth, J162

COATES AND COOPER LTD., H41(table)

COCA-COLA
- postcoital douching agent, J142

COCKRILL, J.R.
- uterine response to semen, G1

CODEINE, F12, F13(table), F29(table), F30 (table)

COE, B.B.
- use-effectiveness of postcoital diethylstilbestrol, J145(table)

COEZY, E.
- orals and breast neoplasia in animals, A78(table)

COFFEE GROWERS FEDERATION (COLOMBIA)
- community-based distribution, J80, J91

COFFEY, D.S.
- ethanol in male sterilization, D15
- granuloma prevention, D30

COFFMAN, R.B.
- vasectomy
  - complications, D28(table)
  - technique, D28(table)

COGNAT, M.
- laparoscopic sterilization, C7(table)

COHEN, E.
- coagulopathy with saline abortion, F70
- intraamniotic saline abortion, F71(table)

COHEN, M.R.
- culdoscopy
  - operative medication, C63(table)
  - preoperative medication, C63(table)
- laparoscopic sterilization
  - electrocoagulation, C8
  - failure, C22(table)
  - local anesthetic, C4
  - operative technique, C7(table)
  - technique for pneumoperitoneum, C5(table)

COIL-SPRING DIAPHRAGM, H68(table)
- description, H61
- indications, H61

COITAL FREQUENCY
- postcoital progestogens, J148
- sex ratio, I22

COITAL TIMING
- sex preselection
  - animal studies, I24
  - BBT changes, I24(chart)
  - effectiveness, I21, I24
  - history, I22, I24
  - physiological rationale, I22
  - pregnancy, I24
  - sperm survival, I24

COITUS
- age and cervical neoplasia, A80, A83
- following colpotomy, C35
- frequency, I9
- postvasectomy
  - contraception, D33
  - pain, D26

COITUS INTERRUPTUS, J213
- adolescents, J167
- early practice, H38
- lactation, J62

COLEURYNTER
- treatment of dysmenorrhea, F88

COLLABORATIVE GROUP FOR THE STUDY OF STROKE IN YOUNG WOMEN
- orals and thromboembolic disease, A41 (table)

COLLINS, J.A.
- sterilization by colpotomy, C31(table)
  - abortion, C43
  - combined anesthesia, C33
  - complications, C40(table)
  - fimbriectomy, C33(table)
  - outpatient, C35
  - preoperative medication and anesthesia, C32(table)

COLOMBIA
- abortion
  - legal status, E28, E34, E35(table)
  - practice, E35(table)
- adolescent births, J161(table)
- age-specific fertility rate, J35(graph), J222(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J195, J207 (table), J208, J209(table), J239
- community-based distribution, J80
  - evaluation, J84(table)
- condom distribution, H5
  - mail-order system, H13
  - problems, H16
- condom shipments, H14(table), H15(table)
  - importation costs, H5(table)
- contraceptive usage, H4(table)
- copper IUD, B10, B18
- diaphragm
  - fitted by nonphysicians, H67
  - use, H60
- duration of postpartum amenorrhea, J57 (table)
- family planning program
  - promotion, J293, J301-J302
  - service statistics system, J332-J333
- geography and family planning, J216
- health services, J195
- incidence of cancer in women, A70(table)
- in-school sex education, J171
- IUD acceptors, B27(table)
- low-cost housing, J186
- marketing of postcoital norgestrel, J147
- maternal mortality, J128(figure)
  - illegal abortion, J256
- new acceptors, J16(table)
  - orals, A18(table)
- oral contraceptives, A9(table)
  - commercial supply, A8(table)
  - marketing, A13(table)
  - new acceptors, A18(table)
  - sales, A8(table)
  - supplied by SIDA, A20(table)
  - supplied by USAID, A21(table)
- out-of-wedlock births, J160(figure)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- Profamilia
  - address, J106(table)
  - community-based distribution, J80, J91
  - rural program, J324
  - training nonphysicians, J95(table), J98, J106(table)
- rhythm method, I14(table)
  - acceptability, I2, I15
  - calendar method, I10, I11(table)
  - temperature method, I2, I12(table)
- terrorism, J193
- total fertility rate, J215(table), J216, J217(table)
- training in colpotomy, C43
- training in culdoscopy, C70
- training nonphysicians, J95(table), J98, J106(table)
- tubal occlusion with laser, C91
- vaginal contraceptives, H49
- vasectomy, CD77, D34(table)
  - sexual behavior, D35(table)
- voluntary sterilization, CD105(table)
  - penal code, CD75-CD76
- World Fertility Survey data, J216

COLOSTRUM, J50-J51, J59

COLPOTOMY
- advantages, C30
- Canada, C31(table)
- contraindications, C39
- defined, C29
- effect of parity, C39, C40
- equipment, C35-C38(figures, table), M23-M24
- failure rate, C39(table), C42, C43(table)
  - clips, C34
- film, C34
- general anesthesia, C32(table), C33
- history, C30
- India, C29, C31(table)
  - complication rates, C40, C41
  - infection, C42
- IUD removal, B31
- local anesthesia, C31, C32(table)
- midwives, J97
- morbidity, C40-C42
  - combined with other procedures, C41
  - developed and developing countries, C30, C40
- mortality, C42
- operating time, C35
  - abortion, C35
- outpatient procedure, C35
- postoperative care, C35
- preoperative procedure, C30-C31
  - medication and anesthesia, C32(table)
- sources of funding for kit, J270-J271
- spinal anesthesia, C31, C32(table)
- studies, C31(table)
- surgical sterility, C30-C31, C42
- timing of procedure, C42, C43
  - abortion, C41, C43
  - during pregnancy, C43
  - infection, C41-C42
  - interval sterilization, C30, C42
  - postpartum, C43
- tubal ligation, C74, C75, C76(table), C77
  - surgical kit, J282
- tubal occlusion
  - clips, C77(table), C83(table), C84
  - plug, C90
  - Yoon band, C76(table), C85
- Tunisia, C31(table)
- United Kingdom, C31(table)
- US, C31(table)

COLPOTOMY, ANTERIOR
- bladder injury, C35
- cystocele repair, C35
- incision, C30, C35
- Japan, C35
- operative procedure, C35

COLPOTOMY, POSTERIOR
- failure, C39(table)
- operative procedure, C33-C35
  - incision, C30, C33, C41

COLTON, F.B., A5(table)
- synthesis of norethynodrel, A32

COLUMBIA UNIVERSITY (NEW YORK), J91
- quinacrine tubal occlusion, C87
- vasectomy side effects, D47-D48

COLUMBIA UNIVERSITY CENTER FOR POPULATION AND FAMILY HEALTH
- funding of family planning activities, J274(table)

COMBINED ORAL CONTRACEPTIVES. See also **ORAL CONTRACEPTIVES**
- compared with minipill, A63-A64
- dysmenorrhea, A61
- effect on menstrual cycle, A61
- endometrial cancer, A84
  - animal studies, A87(table)
- liver tumors in animal studies, A89(table)
- pituitary tumors in animal studies, A90 (table), A91(table)
- postcoital use

    - dosage, J150
    - mode of action, J150
    - side effects, J150
    - use-effectiveness, J150
  - risk of thromboembolism, A61-A62
- **COMMITTEE ON SAFETY OF MEDICINES**. See **BRITISH COMMITTEE ON SAFETY OF MEDICINES**.
- **COMMUNICATION**. See also specific types, e.g., **NEWSPAPERS**; **RADIO**; **TELEVISION**.
  - family planning programs, J289-J317
  - role in fertility control, J214
- **COMMUNITY-BASED DISTRIBUTION (CBD)**, J69-J87
  - contraceptive supplies, J73-J75
  - development, J90-J91
  - evaluation, J75, J84(table)
  - household distribution
    - advantages, J81
    - China, J83
    - Egypt, J82
    - evaluation, J84(table)
    - Korea, J82-J83
    - questionnaires, J83(figure)
    - rural areas, J82-J83
    - Taiwan, J83
  - institutional distribution, J78-J79
    - advantages and disadvantages, J78
    - evaluation, J84(table)
    - India, J79
    - Philippines, J78-J79
    - supporting agencies, J78
  - oral contraceptives, J91
  - personnel, J72-J73
  - promotion, J75
  - recommendations, J83-J85
  - social marketing, H6-H7, H16
  - subsidized sales, J75-J78
    - advantages and disadvantages, J75-J76
    - Antigua, J76
    - Costa Rica, J76
    - Ghana, J78
    - government support, J75-J78
    - India, J76-J77
    - Indonesia, J78
    - Kenya, J77
    - Pakistan, J77-J78
    - private support, J75-J78
    - Sri Lanka, J77
  - training, J73
  - village distribution, J79-J81
    - advantages and disadvantages, J79
    - Brazil, J80-J81
    - Colombia, J80, J91
    - evaluation, J84(table)
    - Mauritius, J81
    - rural areas, J80-J81
    - Thailand, J81
- **COMMUNITY-BASED FAMILY PLANNING SERVICES (CBFPS) (THAILAND)**
  - contraceptive distribution by village leaders, J81
- **COMMUNITY ORIENTED FAMILY LIFE ACTION CENTER (COFLAC) (JOHNS HOPKINS UNIVERSITY)**, J43
- **COMORO ISLANDS**
  - age-specific fertility rate, J224(graph)
  - birth rate, J29(table), J207(table), J210 (table)
  - marketing of oral contraceptives, A13 (table)
- **COMSTOCK, G.W.**
  - orals and benigh breast neoplasia, A73 (table)
- **COMSTOCK LAW (US)**, H12, H58
- **CONCEPCION, M.**
  - continuation rates of contraceptives, I16
- **CONCEPT, INC.**
  - address, M32
  - thermocoagulator for vasectomy, M27 (table)
- **CONCEPTROL CREAM**
  - active ingredients, H41(table)
  - price and sales, H48(table)
- **CONDOM**
  - adolescents, J158, J169
  - advantages, J74
  - advertising in Bangladesh, J324
  - conception rate after discontinuation of use, K9(graph)
  - contraceptive failure, H2
  - cost to USAID, H49
  - dimensions, H11, H16
    - selected countries, H29(table)
    - standards, H28-H29
    - thickness, H28
  - distribution. See **CONDOM DISTRIBUTION**.
  - early prophylactic use, H3
  - effect on lactation, J59
  - fertility control, J1
  - history, H2-H3
  - IPPF provisional standards, H31(figure)
  - manufacture. See **CONDOM MANUFACTURE**.
  - manufacture in selected countries, J74
  - marketing, H4-H7, H34. See also **CONDOM PROMOTION**.
    - new methods, H1-H2
  - material, H21
    - latex, H23
    - plastic, H31
    - rubber, H22
    - skin, H30
  - new acceptors in Taiwan, J20(table)
  - Philippines, J79
  - preferred by young men, J1
  - prophylactic quality, H29, H32
  - rejected as contraceptive method, H21, J82
  - safety, J258(table)
  - shelf-life, H30
  - sources of funding, J270(table), J274-J276(table)
  - standards, H25-H30. See also **CONDOM TESTING**.
    - aging, H27-H28
    - country and testing method, H26(table)
    - dimensions in selected countries, H29(table)
    - packaging, H28
  - supply, H24
  - theoretical effectiveness, H21-H22, H32
  - types. See **CONDOM, LATEX**; **CONDOM, PLASTIC**; **CONDOM, SKIN**.
  - use-effectiveness, H22, H32, H37, H39 (figure), I9, J59, J258
    - comparative studies, H33(table)
    - in developed and developing countries, A35(table)
    - life table method, H33
    - variables, H33
  - venereal disease, H32
  - word origin, H3
- **CONDOM, LATEX**, H2, H12
  - cost analysis, H24
  - development, H22-H23
  - early deficiencies, H23
  - manufacturing process
    - automation, H23
    - development, H22-H23
    - electronic testing, H23
    - lubrication, H23
  - packaging, H23, H24
  - pricing, H24
    - compared with orals, H24
  - standards, H24
- **CONDOM, PLASTIC**
  - advantages, H31
  - manufacture, H31-H32
  - repeated use, H32
- **CONDOM, SKIN**, H2
  - advantage, H30
  - cost, H30
  - manufacture, H30
  - testing, H30
  - use, H30
- **CONDOM DISTRIBUTION**
  - Antigua, H10, J76
  - Austria, H12
  - Bangladesh, J72, J90
  - calculating supply needed, J74
  - Colombia, J80, J91
  - commercial organizations, H5(table)
    - problems, H16
  - community-based systems, J90-J91
    - door-to-door sales, J72, J77
    - household, J81-J83
    - subsidized, J75-J78
  - developing countries, H13, H14-H16
  - Egypt, J81, J82
  - family planning programs, H5(table)
    - limitations, H6
  - fieldworkers, J91
  - free, J78, J79, J81, J82, J83
  - Germany, H12
  - Ghana, J78
  - importation costs, H5(table)
    - problems, H5
  - India, H7-H8, H8(table), J76-J77, J90, J312
  - Indonesia, H11, J78, J312
  - institutional, J78-J79
  - IPPF, H16, J77
  - Japan, H11
  - Kenya, H9, J77
  - Korea, J72, J81, J82-J83
  - mail-order, H13
  - marketing, H1-H2, H4-H7
  - Morocco, H11
  - over-the-counter sales, J70(figure), J72
  - Pakistan, J77, J78
  - Philippines, J79
  - prices, H5-H6, J74, J75
    - Antigua, J76
    - India, J77
    - Indonesia, J78
    - Kenya, J77
    - Pakistan, J69, J77
    - Philippines, J79
    - Sri Lanka, J77
  - problems, H6-H7
  - Puerto Rico, J90
  - recommendations, H16, H17
  - retail outlets, E41, E42-E43
  - sales statistics, J77, J78
  - selected program evaluations, J84(table)
  - Sri Lanka, J77
  - Swedish International Development Authority, H14(table)
  - Taiwan, J81, J82
  - Thailand, H9, J81
  - training, J90, J91, J98
    - programs for nonphysicians, J94-J95(table)
  - United Kingdom, H12
  - US, H12-H13
    - pilot distribution program, J169
  - USAID, H15(table), J76, J78, J81, J82
  - use statistics, J77, J83
  - village distributors, J80, J81
- **CONDOM MANUFACTURE**. See also **CONDOM, LATEX, manufacturing process**.
  - mass production, H23
  - selected countries, J74
- **CONDOM PROMOTION**
  - Antigua, H10
  - Austria, H12
  - Germany, H12
  - Ghana, H11
  - India, H8(table)
  - Jamaica, H9-H10
  - Japan, H11
  - Kenya, H9
  - Sri Lanka, H10
  - Sweden, H11-H12
  - Thailand, H9
  - US, H12-H13, H17
- **CONDOM TESTING**
  - aging, H27-H28
  - effectiveness, H29
  - electronic, H24-H25
  - method for holes, H25, H27
    - effectiveness, H29
  - sampling techniques, H25
    - US, H27(table)
  - Sweden, H69(table)
  - tensile strength, H27
- **CONDOM USE**
  - advantages, H1, H2
  - Australia, H4(table)
  - barriers, H1
  - Colombia, H4(table)
  - combined with other methods, H4, H11, H12
  - consistency, H22, H32-H33, H34
  - estimated, H3-H4
  - Iran, H4(table)
  - Jamaica, H4(table)
  - Japan, H1, H4(table), H11, I14-I15
  - Kenya, J313
  - Korea, I15
  - menstrual regulation, F15
  - motivation, H33

  Panama, H4(table)
  Philippines, H4(table)
  Sweden, H4(table)
  Thailand, H4(table)
  United Kingdom, H4(table), H12
  US, H4(table), H12, H13, H17, H59 (table)
  vasectomy, D10
  venereal disease, H13
  Venezuela, H4(table)
CONFERENCE ON HUMAN STERILIZATION, CHERRY HILL, NEW JERSEY, 1969
  C46-C47
  reversible sterilization, D41
CONFERENCE ON ISLAM AND PLANNED PARENTHOOD, RABAT, 1971
  reversible sterilization, D41
CONFIDELLE
  do-it-yourself pregnancy test, J121, J122(photo)
CONGENITAL ABNORMALITIES
  Depo-Provera, K2
  etiology, J111
  hormonal-withdrawal test, A48, J116
  oral contraceptives, A47-A48
  progestogens, A62
    early pregnancy, K9
  rhythm method, I12-I13
  vaginal contraceptives, H42
CONGER, S.B.
  uterine aspiration, F28(table)
    perforation, F35(table)
CONGO. See **ZAIRE**.
CONJUGATED ESTROGENS
  postcoital use
    administration and dosage, J144, J145(table)
    use-effectiveness, J145(table)
  therapy for climacteric, J147
CONKIN SURGICAL INSTRUMENTS
  address, M32
    guarantee and service of sterilization equipment, M30(table)
    uterine manipulation devices, M22 (table)
CONLUMIN
  manufacture and marketing, A4(table)
CONLUNETT
  manufacture and marketing, A4(table)
CONLUTEN
  manufacture and marketing, A4(table)
CONNECTICUT
  incidence of breast cancer among women (1955-1975), A113(chart)
  incidence of cervical cancer (1955-1975), A117(chart), A118(chart), A119(chart)
  incidence of liver cancer among women (1955-1975), A131(table)
  incidence of ovarian cancer (1955-1975), A127(chart)
  incidence of uterine cancer (1955-1975), A123(chart)
CONNELL, E.B., H42
  orals and eye disease, A40
CONOVID
  manufacture and marketing, A4(table)
  patent information, A5(table)
CONRAD, C.C.
  side effects following IUD insertion, B30
CONRAD, J.T.
  cervical dilatation with PGs, F95
  PG reduction of cervical tissue tension, G61
CONSENSUAL MARRIAGE. See **CONVIVIENTE**.
CONTINUOUS MOTIVATION. See **COMMUNITY-BASED DISTRIBUTION**.
CONTRA CREME
  venereal disease, H51(table)
CONTRA FOAM
  venereal disease, H51(table)
CONTRACEPTION. See **FERTILITY CONTROL**.
CONTRACEPTIVE DISTRIBUTION. See **COMMUNITY-BASED DISTRIBUTION SYSTEMS**; **CONDOM DISTRIBUTION**; **ORAL CONTRACEPTIVE DISTRIBUTION**.
CONTRACEPTIVE INUNDATION. See **COMMUNITY-BASED DISTRIBUTION**.
CONVIVIENTE, J158
COOK ISLANDS
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
COOMBS, R.R.A.
  postvasectomy sperm antibodies, D48
COOPER, A.
  experimental work in vasectomy, D2
  testicular function after vasectomy, D30
COOPER CREME
  venereal disease, H51
COOPER LABORATORIES, INC.
  Vabra aspirator, F59
COPPER
  accumulation in body, B17
COPPER IUD, B33. See also specific types, e.g., **COPPER-7 IUD**
  adolescents, J158
  amount of copper, B4, B5(graph)
  animal studies, B2, B17
  bleeding, B5, B11, B18
  cervical and uterine perforation, B8-B9
  clinical status, B4
  compared with Lippes Loop, B2, B3(graph, table), B10, B11(table)
  configuration, B2, B18
  continuation rates, B3(table), B6(graph), B7(graph), B11(table), B14, B15(table)
    related to age and parity, B16(table)
  contraceptive effectiveness, B5
  description, B1-B2, B4
  displacement, B12
  distribution, B18
  embedding, B12
  experimental use, B18
  expulsion, B3(graph, table), B6(table), B7(graph), B10, B11(table), B15(table)
    related to age and parity, B16(graph, table)
  family planning programs, B18
  gonococcal infection, B12
  history and development, B2-B4, B5, B18
  insertion techniques, B6-B9, B29
    equipment, B7
    postabortion, B8
    timing, B6
    use of anesthesia or analgesia, B7, B15
  life span, B5, B14, B18, B38
  longterm use-effectiveness, B34
  menstrual flow, B11
  mode of action
    biochemical action, B5
    copper and zinc action, B5
    endometrial effects, B5
    enzymatic effects, B5
    glycogen metabolism, B5
    inhibition of carbonic anhydrase, B5
    inhibition of sperm motility, B5
  multiparas, B2
  nulliparas, B2, B14, B15(table), B18, B22, B25, B38
  packaging, B6
  pain, B5, B15
    cause of removal, B6(table), B12, B15(table), B16(graph, table)
  polyethylene composition, B4
  pregnancy rates, B3(table), B6(graph), B7(graph), B10, B11(table), B15(table)
  removal rates, B3(table), B6(graph), B7(graph), B9, B11(table), B15(table)
    related to age and parity, B16(graph, table)
  replacement, J168
  research, B18-B19
  "sleeve technique" for adding copper, B4
  systemic effects, B5, B17
  use, B18
COPPER SULFATE
  treatment for granulation tissue, C68
COPPER-T IUD, B43(figure)
  advantages, B22
  antifertility effect, B2
  bleeding, B11
  description, B43
  distribution, B43
  embedding, B12
  expulsion rates, B3(graph, table), B6(table), B7(graph), B10, B11(table), B15(table), B16(table)
  insertion
    nurse-midwives, J96
    procedure, B7, B8(figure), B30
  menstrual flow, B35
  multiparas, B2, B11, B15(table), B18
  nulliparas, B2, B11, B15(table), B18
  perforation rates, B8
  performance, B33
  postcoital insertion
    advantages over postcoital estrogen-progestin, J151
    continuation rate, J151
    contraindications, J151
    mode of action, J151
    side effects, J151
    timing, J151
    US, J141
    use-effectiveness, J150
  pregnancy rates, B3(graph, table), B4, B5, B6(table), B7(graph), B10, B11(table), B15(table)
    related to age and parity, B16(graph, table)
  removal, B9, B11
  termination rates, B3(graph), B6(table), B16(table)
    pain, B12
  use-effectiveness, B32(table)
COPPER-7 IUD, B43(figure)
  advantages, B22
  approval by British Committee on Safety of Medicines, B4, B18
  continuation rates, B6(table), B15(table)
  description, B43
  distribution, B43
  expulsion rates, B6(table), B15(table)
  insertion and withdrawal technique, B6, B7, B9(figure), B30
    multiparas, B7
    nulliparas, B8
    perforation, B8
  material and shape, B4
  menstrual flow, B11, B35
  nulliparas, B2, B15(table), B18
  pregnancy rates, B6(table), B15(table)
  rate of copper release, B13, B14(graph)
  termination rate, B23(table)
  use-effectiveness, B32(table)
COPPER-200 IUD
  defined, B4
  termination rate, B22(table), B23(table)
COPPER-220 IUD, J168
COPPER-300 IUD
  pregnancy rate, B5
COPPER-380
  studies for contraceptive effectiveness, B5
COREY, E.J.
  PG synthesis, G2, G17
CORFMAN, P.A.
  silastic tubal occlusion, C88
  tubal occlusion with methyl-2 cyanoacrylate, C88-C89
CORLETT, R.C., JR.
  intraamniotic instillation of PGF$_2\alpha$ for abortion, F73(table)
  menstrual regulation with PGs, G59(table)
  PGF$_2\alpha$ for midtrimester abortion, G72(table)
CORNELL UNIVERSITY MEDICAL COLLEGE (NEW YORK), J245
  intravaginal administration of PGs, H66-H67
    PG research, G53
CORNER, G.W.
  identification of progesterone, A30-A31
CORNUAL RESECTION, C75(figure), C76(table)
  advantages and disadvantages, C78
  procedure, C78
COROLLE, B38
CORPUS LUTEUM, A87
  hormone production, A34
  minipill, A55
  PG action, G51, G60-G61
    primates and nonprimates, G46
  pregnancy, G35, G46, J110, J111
  regression, G46
  role in reproduction, A30
CORSON, S.L.
  laparscopic sterilization
    complications, C19(table), C19-C20, C24(table)
    electrocoagulation with division and

      - biopsy, C8(table)
    - failure, C21, C22(table)
    - preoperative medication and anesthesia, C3(table)
    - prevention of hypercarbia, C19
    - technique for pneumoperitoneum, C5(table)
  - midtrimester abortion with laminaria and $PGF_{2}\alpha$, F94

CORTICOSTEROIDS, A32
- jaundice, A47

COSTA RICA
- age-specific fertility rate, J3(graph), J6(graph), J222(graph)
- birth rate, J23(figure), J29(table), J207(table), J218(figure), J239
- change in number of births, J219(figure)
- community-based distribution, J70, J76
  - coupon system, J76
  - subsidized, J75, J76
- condom
  - illegal sales, H5
  - importation costs, H5(table)
  - shipments, H14(table), H15(table)
- culdoscopy, C61, C69
  - operative complications, C66(table)
  - postoperative complications, C67(table)
  - tubal occlusion, C65(table), C68(table)
- Depo-Provera
  - availability, K13(figure)
  - IPPF distribution, K14
- diaphragm availability, H68(table)
- family planning program, J24, J76
  - promotion, J302
- fertility rate, J28
  - age-specific, J24(graph), J33(graph), J35(graph)
  - cumulative fertility, J33(graph)
- geography and family planning, J216
- in-school sex education, J171
- IUD acceptors, B27(table)
- IUD insertion by nonphysicians, J93
- legal rights of children, J163
- legal status of abortion, E29(table)
- legal status of voluntary sterilization, CD74, CD77, CD86, CD105(table)
- marketing of minipill, A64
- maternal mortality, J130(table)
- National Population Council (CONAPO), J76
- new acceptors, A18(table), J17(table)
- oral contraceptives
  - marketing, A13(table)
  - new acceptors, A18(table)
  - supplied by SIDA, A20(table)
  - supplied by USAID, A21(table)
- out-of-wedlock births, J160(figure)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- population growth, J247
- population per hospital bed, J71(table)
- population per physician, J71(table)
- sterilization, CD77
- total fertility rate, J215(table), J216, J217(table)
- training in laparoscopic sterilization, C14
- training nonphysicians, J95(table), J106(table)
- vasectomy, D34(table)
  - sexual behavior, D35(table)

COSTA RICAN DEMOGRAPHIC ASSOCIATION
- subsidized community-based distribution, J76

COTTON
- postvasectomy infection, D28
- tubal ligation, C74
- vas ligation, D5, D7

COUNSELING
- fertility control, F51, J72
- menstrual regulation, F12, F49, F50
- nonphysicians, B28
- oral contraceptives, J91
- postoperative procedure, F33
- preoperative procedure, F27
- rhythm method, I16
- training, J43
- vasectomy, D36

COUPLE-YEARS PROTECTION
- breast-feeding, J58
  - developing countries, J59(table)
- contraceptive distribution projects, J84(table)
- family planning programs, J58

COUPONS
- contraceptive distribution, J76
  - Antigua, J76
  - Costa Rica, J76
  - Taiwan, J82

COURNUT, R.
- Om-Ga, B48

COWPERTHWAITE, A.
- cervical dilatation tents, F89

COX, H.J.E.
- menstrual cycle length, A60(table)

C-QUENS
- breast neoplasia in rats, A78(table)
- formulation and dosage, A6(table)

CRAFT, I.L.
- abortion and hormonal-withdrawal test, J114
- ceramic plug for tubal occlusion, C90(table)
- cervical dilatation of multiparas, G67
- irrigation after vasectomy, D10
- midtrimester abortion
  - PGE_{2}, G72
  - urea, F78(table)
- PGs for induction of labor, G10(table)

CRAMER, S.D.
- spermicidal potency, H44

CRAMPS
- PG administration, G3, G7(table), G8(table)
- spring-clip sterilization, C84
- Yoon band application, C85

CREAM. See also **VAGINAL CONTRACEPTIVES**.
- active ingredients, H41(table), H43(table)
- duration of spermicidal effectiveness, H43(table)
- mode of action, H40
- mode of application, H43(table)
- packaging, H43(table)
- price and sales of selected products, H48(table)
- use-effectiveness in selected studies, H45(table)

CRIST, T.
- side effects of postcoital diethylstilbestrol, J148(table)
- use-effectiveness of postcoital conjugated estrogens, J145(table)

CRONIN, T.J.
- postpartum amenorrhea and lactation, J56

CROSS, R.G.
- midcycle coitus, I13

CRUDE BIRTH RATE. See **BIRTH RATE**.

CRUDE DEATH RATE. See **MORTALITY**.

CSAPO, A.I., author, G33-G40, J45
- menstrual regulation with PGs, G59(table)
  - pellet, G38(table)
  - suppository, G58
- PG antagonists, G47
- $PGF_{2}\alpha$ for abortion, G7(table), G8(table)
  - intrauterine administration, G66
  - single injection method, G70
- $PGF_{2}\alpha$ and uterine stimulation, G47
- saline abortion, F68

CUBA
- abortion
  - legal status, E29(table), E32, E34, E35(table)
  - maternal mortality, E36, E37
  - practice, E35(table)
- adolescent births, J161(table)
- age-specific fertility rate, J35(graph), J226(graph)
- birth rate, J29(table), J207(table), J208, J209(table)
- birth registration, J208
- condom shipments, H14(table)
- economic growth, J190

CUL-DE-SAC OF DOUGLAS
- access to during colpotomy, C33-C34
  - anterior colpotomy, C35
  - rectal injury, C42
- culdoscopy, C62, C64
  - incomplete puncture, C66(table)
  - separation from vaginal mucosa, C66(table)

CUL-DE-SAC RETRACTOR
- colpotomy, C36, C37(figure)

CULDOSCOPE, M5(photo)
- compared with laparoscope, C61
- comparison of selected products, M24(table), M25
- insertion, C61, C63(figure), C64
- sources of funding, J270-J271(table)

CULDOSCOPY, C1
- advantages, C61, C62
- compared with colpotomy, C61
- complications, C61, C66-C68
  - contributing factors, C68
  - operative, C66(table), C66-C67
  - postoperative, C67(table), C67-C68
  - preexisting pathology, C67
  - prevention, C66
  - rate, C66, C68
- contraindications, C65-C66
- diagnostic use, C62
- effectiveness, C62
- epidural anesthesia, C63
- equipment, C63(figure), C69(figures), M25
  - advantages, C61
  - compared with laparoscopic equipment, C69
  - cost, C69
  - distribution, C69
  - knee-chest support, C69, C70(figure)
  - vaginal instruments, C69(figures)
- establishing pneumoperitoneum, C64
- failure, C62, C68(table)
  - causes, C68
  - clips, C68
  - compared with laparoscopy, C68
  - prevention, C68
  - rate, C68
- general anesthesia, C63
- history, C62
- India, C61
- interval sterilization, C65
- IUD removal, B31
- local anesthesia, C61, C62, C64
- mortality, C68
- operative medication, C62-C63, C63(table)
  - route of administration, C63(table)
- operative procedure, C61, C64
- outpatient procedure, C61, C62
- postabortion, C65
- postoperative care, C64-C65
  - analgesia, C64
  - antibiotics, C64
- practice in selected countries, C61
- preoperative medication, C62-C63, C63(table)
  - route of administration, C63(table)
- preoperative procedure, C62
- spinal anesthesia, C63
- time required, C61, C62
- training, C69-C70
  - Jamaica, C69, C70
  - Mexico, C69
  - Singapore, C69, C70
  - US, C69, C70
- tubal ligation, C75, C77
- tubal occlusion, C76(table), C87
  - clips, C65(table), C83(table)
  - failure, C64, C68(table)
  - fulguration, C78
  - methods, C64, C65(table)
  - plug, C90
  - Yoon band, C85

CULLEN, T.S., J41

CUMMINS, G.T.M., E21(photo)
- IUD insertion by nurse-midwives, J93
- rationale for menstrual regulation, F49

CURAÇAO
- diaphragm availability, H68(table)
- marketing of minipill, A64(table)

CURARE, C32(table)

CURETTAGE
- abortion, F66
- compared with uterine aspiration, F42, F57, F59
- complication rate by length of amenorrhea, F66(figure)

- disadvantage, G38
- following PG administration, G11, G66
- following saline abortion, F72
- incomplete abortion, F60
- midtrimester abortion, F67

CURETTE
- uterine aspiration, F31, F32(table)
- uterine perforation, F36

CURTIS, L., C46

CUSCO SPECULUM
- menstrual regulation, F12

CU-T. See **COPPER-T IUD**.

CUTLER, J.C., J44
- vaginal contraceptives
  - prophylactic quality, H50
  - venereal disease, H51(tables)

CU-7. See **COPPER-7 IUD**.

CYCLIC 3', 5'-ADENOSINE MONOPHOSPHATE, G1

CYCLIC AMP, G47, G54
- production decreased by $PGF_2\alpha$, G60
- role in uterine contraction, G50(figure)

CYCLIC GMP
- production decreased by $PGF_2\alpha$, G60

CYPRUS
- birth rate, J29(table), J207(table), J208, J209(table)
- diaphragm availability, H68(table)
- estimated population, E30(table)
- legal status of abortion, E30(table), E32, E33(table)
- marketing of minipill, A64(table)
- oral contraceptives
  - marketing, A13(table)
  - supplied by SIDA, A20(table)
- out-of-wedlock births, J160(figure)
- population, F7(table)

CYSTITIS
- spinal anesthesia, C42

CYSTOCELE
- repair during anterior colpotomy, C35

CZECHOSLOVAKIA
- abortion, F66
  - adolescents, J171(table)
  - legal status, E29, E30, E36, E38
  - mortality, F37(table)
- age-specific fertility rate, J227(graph)
  - legalized abortion, J10(graph)
- birth rate, J21, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- legal status of voluntary sterilization, CD68, CD85, CD105(table), CD126
  - medical conditions, CD69
  - minimum number of children, CD70
  - restrictions, CD70
- marital status of female adolescents, J164(table)
- marketing of oral contraceptives, A13 (table)
- maternal mortality, J128(figure)
- population, F7(table)
- population policy, E1, J239
- uterine aspiration, F27
  - equipment, F41

D

DACRON
- tubal occlusion, C91
- valves, D15
- vas ligation, D5

DAFOE, C.A.
- tubal occlusion with paraldehyde, C86 (table)

DAHOMEY. See **BENIN**.

DALKON SHIELD, B25, B33, B42(photo)
- configuration, B37
  - conducive to infection, B36
- description, B42
- distribution, B36-B37, B42
  - USAID, B37
- expulsion, B38
- insertion technique, B30
- menstrual flow, B11, B35
- mortality, B36(table)
- septic abortion, B22
- termination rate, B22(table), B23(table)
- US, B37
- use-effectiveness, B32(table)

DALSIMER, I.A., author, H21-H36

DANA, B47(figure)
- description, B47
- distribution, B47
- use-effectiveness, B47

DANFORTH, D.N.
- changes in cervix during dilatation, F98

DANISH INTERNATIONAL DEVELOPMENT AGENCY (DANIDA)
- address, J284
- funding of family planning activities, J273, J274(table), J278(table)

D.A.P.
- cost, J119(table)
- diagnostic capability, J119(table)
- laboratory procedures, J118-J119
- sensitivity, J119(table)
- slide test, J116-J117

D.A.P.-TEST MACRO
- cost, J120(table)
- sensitivity, J120(table)
- time required, J120(table)

DARABI, K.F.
- failure rate of hysteroscopic fulguration, C81

DATA COLLECTION
- family planning programs, J321-J339

DAVID, L.H., J79(photo), J80(photo)

DAVID, P.
- menstrual regulation, F62

DAVIDSON, A.C.
- clip sterilization, C83(table)
- laparoscopic sterilization, C2(table)
- tantalum clips, C12
- tubal occlusion with quinacrine, C87

DAVIDSON, H.A.
- spermicidal potency, H44

DAVIDSON, O.W.
- tubal occlusion with quinacrine, C86(table)

DAVIS, G.
- menstrual regulation, F13(table)
  - mean blood loss, F17(table)
  - procedure and equipment, F14(table)

DAVIS, H.
- Dalkon Shield, B42
- training in laparoscopic sterilization, C13

DAVIS, J.E.
- postvasectomy procedures, D27
  - prevention of hematomas, D8
  - sperm count, D47
- sperm transport physiology, D47
- standards for vas occlusive devices, D52
- vasectomy
  - ligature, D5
  - local anesthetic, D4
  - psychological aspects, D31
  - side effects, D47

DAWN, C.S.
- culdoscopy
  - compared with colpotomy, C61
  - complications, C66(table), C67(table)
  - contraindications, C66
  - postabortion, C65
  - preoperative medication, C63(table)
  - tubal occlusion, C65(table), C68(table)
- sterilization by colpotomy, C31(table)
  - anesthetic, C32(table)
  - complications, C40(table)
  - postpartum, C43

DAWSON, E.R.
- sex preselection theory, I22

DAY BALDWIN AND CO.
- diaphragm manufacture, H67

DEAN, C., author, E1-E12

DEAN RUBBER CO., H29

DEATH RATE. See **MORTALITY**.

DECAMETHONIUM
- muscle relaxant for colpotomy, C34

DECASLIDE
- quantifying HCG activity, J118

DECKER, A.
- origin of culdoscopy, C62

DEFORESTATION, J188, J192-J193
- causes, J192

DEL MUNDO, F., E21(photo)

DELADROXATE
- components, K2

DELALUTIN
- component, K2

DELFEN CREAM
- active ingredients, H41(table)
- use-effectiveness, H44(table), H45(table)
- venereal disease, H51(table)

DELFEN FOAM, H40
- active ingredients, H41(table)
- Ghana, J78
- subsidized community-based distribution, J78
- use-effectiveness, H45(table)
- venereal disease, H51(table)

DELFS ASSAY
- sensitivity, J114

DELGADO, A.
- medical complications of adolescent pregnancy, J165(table)

DEMEROL. See **MEPERIDINE HYDROCHLORIDE**.

DEMOGRAPHIC TRANSITION
- theory, J212-J213

DEMOGRAPHY, J177

DEMOVIS
- manufacture and marketing, A64(table)

DEMULEN
- breast neoplasia in mice, A78(table)
- formulation and dosage, A6(table), A37 (table)
- manufacture and marketing, A4(table), A37(table)
- patent information, A5(table)
- sales to USAID, A23(table)

DEMULEN 28
- formulation and dosage, A6(table)

DENMARK
- abortion
  - incidence in midtrimester, F66
  - legal status, E2, E7(table), E30(table)
  - mortality, F37(table)
  - percent of legal abortions to women under 20, J171(table)
  - prevalence, E36
- adolescent births, J161(table)
- age-specific fertility rate, J38(graph), J227(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- condom standards, H25, H26(table)
  - test for holes, H27
- diaphragm availability, H68(table)
- incidence of cancer among women (1953-1972), A70(table)
  - breast, A115(chart)
  - cervix, A121(chart)
  - liver, A132(chart)
  - ovary, A129(chart)
  - uterus, A125(chart)
- marketing of minipill, A64(table)
- maternal mortality, J128(figure)
- oral contraceptives
  - lactation, J61(table)
  - marketing, A13(table)
- population, F7(table)
- population assistance. See **DANISH INTERNATIONAL DEVELOPMENT AGENCY (DANIDA)**.
- population trends, J240
- sales of vaginal contraceptives, H48
- voluntary sterilization, E2, E6(table)
  - legal status, CD69, CD70, CD71, CD72, CD106(table), E10

DENNISTON, G.C.
- culdoscopy
  - preoperative medication, C63(table)
  - tubal occlusion, C65(table)
- vasectomy
  - complications, D28(table)
  - electrocoagulation, D5
  - surgical kits, M26(table)
  - technique, D28(table)

DENOVAL
- manufacture and marketing, A4(table)

DENVER LABORATORIES, J121

DEPO-MEDROL. See **METHYLPREDNISOLONE ACETATE**.

DEPO-PROVERA. See also **INJECTABLE PROGESTOGENS; MEDROXYPROGESTERONE ACETATE**.
- administration by nonphysicians, J92
- availability, K1

    selected countries, K13(figure)
  body weight, K6
  breast milk, K12
  breast nodules
    animal studies, K10
    clinical study, K10
  causes of discontinuation, K8
  cervical cancer, K1, K9, K10
  cervical mucus, K3
  combined with estradiol cypionate, K3
  congenital abnormalities, K2
  continuation rates, K8(graph)
    compared with orals and IUDs, K7
    menstrual disturbances, K8(table)
    selected studies, K7(table)
  cost, K14
  distribution, K14
    Thailand, K12
  endometrial effects, K3
  indications for supplemental estrogens, K6
  international sales, K14
  menstrual cycle, K5
    bleeding, K5(table)
  ovulation suppression, K3
  ovum transport, K3
  promotion, K3(photo)
  purchase by UNFPA, K14
  regimen, K2
  regulation by USFDA, K10
    endometrial cancer, K2
  restricted use, K12-K13
  reversibility, K1, K9(graph), K12
    factors influencing, K9
  side effects, K4-K7
    compared with IUD, K7
  storage, K12
  therapeutic use, K2
  use-effectiveness, K4
    selected studies, K4(table), K5(table)
DEPRESSION (EMOTIONAL), D35
DERMATITIS
  antiseptics, D48
  quinacrine tubal occlusion, C87
DERRICK, F.C.
  vas anastomosis
    effectiveness, D49(table), D53
    partner fertility, D48
DEVADAS, R.P.
  age of menarche, J162(table)
DEVELOPED COUNTRIES
  birth rate, J206, J212
  birth registration, J206
DEVELOPING COUNTRIES
  birth registration, J206
  role of communication in family planning, J214, J289-J314
DEVELOPMENT ASSOCIATES INC. (DAI)
  address, J107(table)
  funding, J98
  training nonphysicians, J98, J107(table)
DEVLIN, J.
  decidua concentration of PGs, G49
  PGs in amniotic fluid, G49
DEWEES, L.
  diaphragm failure, H65(table)
DEXAMETHASONE, G50
DEXON SUTURE
  clip sterilization reversal, C84
DEXTRAN
  uterine distension for hysteroscopic fulguration, C81
DEYS, C.
  motivation for vasectomy, D35
DIABETES MELLITUS
  contraindication to postpartum laparoscopic sterilization, C23
  etiologic factors, J132
  gestational, J135
  injectable progestogens, K6
  maternal health, J135
  obstetrical complication in multiparas, J134-J135(table)
  oral contraceptives, A47
  related to parity, J132(table), J135
  steroidal contraceptives, A62
  test prior to menstrual regulation, F11
  vasectomy, D26
DIANOR
  manufacture and marketing, A64(table)
DIAPHRAGM, H70(figure)
  acceptability, H59, H60
  acceptors, H59, H60
    characteristics, H59
    US, H59(table), H60(table)
  administration of PGs for pregnancy termination, G59, H66-H67
  adolescents, J168
  advantages, H57-H58, H64
  availability, H58
    Latin America, H60
    selected countries, H68(table)
    US, H58
  care, H64
  cervical cancer, H64-H65
  contraindications, H64, H70
  current research, H66-H67
  demand, H59, H67, H68
  description, H57
  disadvantages, H58, H59
  discontinuation, H59, H60(table)
    conception rate, K9(graph)
    Sri Lanka, H60
  distribution, H60
    India, H59-H60
    Latin America, H60
  failure. See **DIAPHRAGM FAILURE**.
  fitting, H58(figure), H61(figure)
    criteria, H61-H62
    factors affecting, H62
    incorrect, H62(figures), H66
    procedures, H61-H62
    timing, H62
    training nonphysicians, H67
  history, H58
  indications, H57
  insertion, H63(figures)
    procedures, H62-H63
    proper fit, H58(figure)
    spermicides, H62-H63
  manufacture. See **DIAPHRAGM MANUFACTURE**.
  mode of action, H57
  removal, H63, H64(figure)
  safety, J258(table)
  shelf-life, H64, H68
  side effects, H64
  sizes, H58, H61, H68(table)
  sources of funding, J270(table), J274-J276(table)
  testing samples, H67, H69(table)
  theoretical effectiveness, H65
  training programs for fitting by nonphysicians, J92-J93, J98
    selected countries, J94-J95(table)
  types, H61, H68(table). See also specific types, e.g., **MENSINGA**.
  use. See **DIAPHRAGM USE**.
  use-effectiveness, H39(figure), H65(table), H66(table), H65-H66, I9, J258
    compared with cervical cap, H71
    developed and developing countries, A35(table)
    factors affecting, H62
    selected countries, H66(table)
    user characteristics for optimal use, H65
DIAPHRAGM FAILURE
  method failure, H66
  selected studies by age, H66(table)
  selected studies by country, H65(table)
  user characteristics, H65-H66
DIAPHRAGM MANUFACTURE
  cement process, H69-H70
  latex dip method, H69
  molding method, H69
  procedure, H69-H70
  quality control, H67-H68
  standards, H67
  Sweden, H67-H68
  testing, H68(photo), H69(photo)
    criteria, H68
    equipment, H68(photo), H69(photo)
    techniques, H67, H69
  United Kingdom, H67, H68(table)
  US, H58, H68(table)
DIAPHRAGM USE
  affected by other methods, H59
  Africa, H60
  Australia, H59
  China, H60
  compared with other methods, H59(table)
  continuation rates, H59, H60(table)
  developing countries, H57, H59
  discontinuation, H60(table)
  Germany, H58, H59
  Middle East, H60
  Netherlands, H58, H59
  Philippines, H60
  Sri Lanka, H60
  United Kingdom, H58, H59
  US, H57, H58, H59(table), H60(table), J168
DIARRHEA
  PG administration, G66, G67, G68, G69, G70(figure)
    abortion, F77(table), F95, G3, G7(table), G8(table), G9(table), G12, G59
    cervical dilatation, G61
    induction of labor, G10(table)
    menstrual regulation, G58, G59(table)
  $PGF_2\alpha$, F72, F73(table), F74, F75(table)
  $PGF_2\alpha$ methyl analogue, F74, F75(table), F76, F77(table)
  saline abortion
    selected studies, F71(table)
  saline solution, G72
DIAZEPAM, C3(table), C32(table), C47(table), C54, D3, F12, F13(table), F29(table), F30(table)
  culdoscopy, C63(table)
    administration, C63
    dosage, C63
  induced abortion with PGs, G35(figure), G38(figure)
  menstrual regulation with PGs, G58
DICKEY, R.
  guidelines for oral contraceptive dosage, A37
DICKINSON, R.L.
  hysteroscopic fulguration, C81
DIENESTROL
  postcoital estrogen-progestin, J150
    use-effectiveness, J144
  vaginal adenocarcinoma in offspring, J146
DIETHYLSTILBESTROL
  postcoital use
    administration and dosage, J143, J144, J145(table)
    carcinogenic effects, J146-J147
    menstrual pattern changes, J147
    selected studies, J145(table)
    side effects, J147, J148(table)
    teratogenic effects, J146-J147
    use-effectiveness, J145(table), J147
    USFDA approval, J144
  pregnancy maintenance, J146
DIHYDROXYPROGESTERONE ACETOPHENIDE, K2
  effect on lactation, J63(table)
DIHYDROXYPROGESTERONE ACETOPHENONE, K2
DI-ISOBUTYLPHENOXYPOLYETHOXY ETHANOL, H41(table), H43(table)
DILATATION AND CURETTAGE. See also **CERVICAL DILATATION**.
  colpotomy, C40, C41, C42
  compared with uterine aspiration, F26, F42
    perforation rates, F36
  culdoscopy, C65
  mortality, F38
  paramedical personnel, J96
DILATORS
  Bentov device, F96, F97(figure)
  Gutnick device, F97
  hydrophylic polymer, F98
  inflatable devices, F97-F98
  metal, F90-F91, F96-F97
  Metreurynter, F97
  plastic, F96
  vibrating devices, F98
DIMETHISTERONE, A7
  principal progestogen, A5(table), A6(table)
D.I.M.I.F. DIRECCION GENERAL DE SERVICIOS DE SALUD (GUATEMALA). See **GUATEMALA. D.I.M.I.F. DIRECCION GENERAL DE SERVICIOS DE SALUD**.
DIN, Y.F.
  treatment for postvasectomy side effects, D27
DINGFELDER, J.R.
  PG administration for cervical dilatation,

F95
PGF$_2\alpha$ methyl analogue for midtrimester abortion, F74
safeguards for uterine manipulation instruments, M23
DINGLE, J.T.
use-effectiveness of foam tablets, H45(table)
DIOSCARIDES
vaginal contraceptives, H38
DIOSCOREA COMPOSITA. See **BARBASCO ROOT**.
DIOSGENIN, A7
conversion to sex hormones, A32
progesterone production, A32
DIOSYNTH
oral contraceptives, A4(table)
DIPHENOXYLATE HYDROCHLORIDE, G69
DISINCENTIVES. See **INCENTIVES**.
DITMAR, F.W.
orals and lactation, J61(table)
D.I.U. PHARMATEX, B47(figure)
description, B47
distribution, B47
use-effectiveness, B47
DIURETICS, A32
DIZZINESS
injectable progestogens, K6
local anesthesia, F30(table)
minipill, A61
PG administration for abortion, G8(table)
postcoital estrogens, J148(table)
pseudopregnancy, A36
side effect of estrogens, K3, K6
DJERASSI, C., A4(table)
oral contraceptives in China, A2, A12, A38
synthesis of norethindrone, A32
DJIBOUTI
birth rate, J207(table), J210(table)
D,L-NORGESTREL. See **NORGESTREL**.
D-NORGESTREL. See **NORGESTREL**.
D-NORGESTREL, POSTCOITAL. See **NORGESTREL, POSTCOITAL**.
DOAR, J.W.H.
orals and carbohydrate metabolism, A47
DODDS, G.
Depo-Provera
continuation rate, K7(table), K8(table)
use-effectiveness, K4(table)
DODECAETHYLENE GLYCOL MONOLAURATE, H41(table)
DODSON, R.M., A5(table)
DOE V. BOLTON, E47, F5
DOISY, E.
identification of estradiol, A31
identification of estrogen, A31
DOLL, R.
orals and breast disease, A45, A46
DOMINICA
age-specific fertility rate, J226(graph)
birth rate, J23(figure), J29(table), J207(table), J210(table)
DOMINICAN REPUBLIC
adolescent births, J161(table)
age-specific fertility rate, J35(graph), J226(graph)
birth rate, J29(table), J207(table), J209(table)
condom shipments, H15(table)
contraceptive distribution program, E41, E42, E44(table)
diaphragm availability, H68(table)
family planning
promotion, J302
service statistics system, J335-J337
IUD acceptors, B27(table)
legal status of abortion, E28
legal status of voluntary sterilization, CD106(table)
marital status of female adolescents, J164(table)
marketing of minipill, A64(table)
maternal mortality, J128(figure)
mortality statistics, J128
National Council of Population and Family, J335
new acceptors, A18(table), J17(table), J170(table)
oral contraceptives
marketing, A13(table)
new acceptors, A18(table)
supplied by USAID, A21(table)
out-of-wedlock births, J160(figure)
percentage of married female acceptors under 20, J170(table)
percentage of married women of reproductive age under 20, J170(table)
Secretaria de Estado de Salud Publica
address, J106(table)
training nonphysicians, J95(table), J106(table)
training nonphysicians, J95(table), J106(table)
vaginal contraceptives, H48(table)
DONALD, I.
laparoscopic sterilization, C8
DONGKUK TRADING CO. LTD., H19
DOOR-TO-DOOR DISTRIBUTION. See **COMMUNITY-BASED DISTRIBUTION, household distribution.**
DORING, C.K.
use-effectiveness of temperature rhythm method, I10, I11(table)
DORING, G.K.
use-effectiveness of postcoital ethinyl estradiol, J145(table)
DORSAL LITHOTOMY POSITION
culdoscopy, C62
menstrual regulation, F58
uterine aspiration, F31
DORSEY, J.W.
vas anastomosis
effectiveness, D43, D49(table)
microsurgery, J51
operative procedures, D44(table)
DOUCHE
use-effectiveness, H39(figure), I9
DOUCHE, POSTCOITAL, J142-J143
history, J142
self-acting douche, J143(figure)
side effects, J142
use-effectiveness, J141, J143
user statistics, J143
DOUCHE, PRECOITAL
sex preselection
effectiveness, I21
theoretical mode of action, I24-I25
types, I25
DOW CORNING
intravasal silastic device, D53
DOWN BROTHERS, MAYER AND PHELPS, LTD., D11(figure)
DOWNS SURGICAL, LTD.
address, M32
laparoscopy equipment
electrosurgical generator, M14(table), M17(figure)
fiberoptic projector, M8(table)
uterine manipulation devices, M22(table)
vasectomy equipment, M25(table)
DOWN'S SYNDROME
maternal age, J255
DOWNSTATE MEDICAL CENTER (NEW YORK)
address, J107(table), J283
funding of family planning activities, J274(tables)
training nonphysicians, J95(table), J98, J107(table)
IUD insertion, B28
oral contraceptive dosage, A37-A38
DRILL, V.A.
orals and breast neoplasia in animals, A78, A79(table)
orals and cervical tumors in animals, A85(table)
DRISCOLL, S.G.
pregnancy tests
biologic, J115(table)
immunologic, J119(table)
DROPERIDOL, C3(table), C4, C32(table), C47, C55
compared with meperidine hydrochloride and chlorpromazine, C62
culdoscopy, C62, C63(table)
side effects, C58, C62
DRURY, W.L.
preoperative medication and anesthesia, C3(table)
DUENHOELTER, J.
intraamniotic instillation of PGF$_2\alpha$ for abortion, F73(table)
DUHRSSEN, A.
colpotomy, C30
tubal ligation, C74
DUMAS CAP. See **VAULT CAP**.
DUMM, J.J., author, H21-H36
DUNN, H.P.
fertile period identification, I3(table)
DUNN, L.J.
estrogen use and endometrial cancer in postmenopause, A86(table)
DUPONT DE NEMOURS, E.I., AND CO.
address, C91
teflon plug for tubal occlusion, C91
DURAFOAM TABLETS
use-effectiveness, H44(table), H45(table)
DURAGEL
price and sales, H48(table)
DUREX, H12, H68(table)
DUST
climatic effects, J187
DUTCH CAP, H58
DYSMENORRHEA, A33. See also **MENSTRUATION DISORDERS**.
colpotomy, C42
combined orals, A61
early cure, B23
incidence in users and nonusers of orals compared, A31(figure)
injectable progestogens, K6
minipill, A61
oral contraceptive therapy, A39
treatment, F89
DYSPAREUNIA
clip sterilization, C50
colpotomy, C42
diaphragm size, H64
vertical incision, C33
DYSPLASIA, A84

E

EAST GERMANY. See **GERMANY, EAST**.
EAST JAVA. See also **JAVA**.
early marriage, J158
family planning and birth rate decline, J216
training in culdoscopy, C70
EASTMAN, N.J., J41
obstetrical complications with multiparity, J134(table)
EAST-WEST CENTER (UNIVERSITY OF HAWAII). See **HAWAII, UNIVERSITY OF, EAST-WEST CENTER**.
EATON, C.J.
uterine aspiration, F28(table)
anesthesia, F29(table)
complications, F33(table), F39(table)
equipment, F42
incomplete abortion, F60(table)
EATON LABORATORIES, INC., H41(table)
ECCHYMOSIS
postvasectomy, D26
ECHEVERRY, G., J81(photo)
adverse publicity for orals, A11
use-effectiveness of postcoital norgestrel, J149(table)
ECKERLING, B.
menstrual pattern changes with ethynodiol diacetate minipill, A58(table)
ECKHOLM, E., author, J253-J262
ECKSTEIN, P.
norgestrel minipill
continuation rate, A62(table)
menstrual pattern changes, A59(table)
ECLAMPSIA, J126
adolescent pregnancy, J161-J162, J165(table)
definition, J136(table)
symptoms, J136(table)
ECOLE NATIONALE DE LA SANTE PUBLIQUE (FRANCE)
address, J105(table)
training nonphysicians, J98, J105(table)
ECONOMIC GROWTH
developing countries, J190
industrialized countries, J191
related to population growth, J190-J191
unemployment, J197-J198

ECTOPIC PREGNANCY. See **PREGNANCY, ECTOPIC**.
ECUADOR
  age-specific fertility rate, J27(graph), J35(graph), J223(graph)
  birth rate, J29(table), J207(table), J210(table)
  child mortality, J185
  condom shipments, H15(table)
  family planning program, E2, E3(table), J26
  fish industry, J179
  IUD acceptors, B27(table)
  legal status of abortion, E29(table)
  legal status of voluntary sterilization, CD106(table)
  marketing of minipill, A64(table)
  new acceptors, J17(table)
    orals, A18(table)
    vaginal contraceptives, H49(table)
  oral contraceptives
    marketing, A13(table)
    percentage of married female acceptors under 20, J170(table)
    percentage of married women of reproductive age under 20, J170(table)
    supplied by USAID, A21(table)
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population policy, E41, E42, E43(table)
  total fertility rate, J216(table)
  tuna war, J194
ECZEMA
  oral contraceptives, A47
EDELMAN, D.A.
  immunologic slide test for pregnancy, J119(table)
  length of amenorrhea and pregnancy, F53(table)
  midtrimester abortion complications, F67
EDEMA
  clip sterilization, C49
  culdoscopy, C67
  electrocoagulation of vas deferens, D5
  postcoital diethylstilbestrol, J147
  pseudopregnancy, A36
EDER INSTRUMENT CO., INC.
  address, M32
  guarantee and service of sterilization equipment, M30(table)
  laparoscopy equipment
    combination units, M11(table)
    fiberoptic projector, M8(table)
    insufflators, M12(table)
    laparoscopes, M4(table), M5(table)
    teaching attachments, M6(table)
  tubal occlusion equipment, M18(table)
  uterine manipulation devices, M22(table)
EDGERTON, W.D.
  laparoscopic fulguration, C79(table)
EDWARDS, L.E.
  sterilization by colpotomy, C31(table)
    complications, C40(table), C41
    contraindication, C41
    operative failure, C43(table)
    Pomeroy method, C33(table)
EDWARDS, R.G.
  anatomy of alveolus, J53(figure)
  postvasectomy sperm antibodies, D48
EDWARDS, R.J.
  blastocyst sex identification, I27
EGYPT, J194
  abortion
    legal status, E35(table), J164
    practice, E35(table)
  acceptability of contraceptives, K8
  adolescent births, J161(table)
  age-specific fertility rate, J25(graph), J34(graph), J222(graph)
  birth rate, J23(figure), J29(table), J207(table), J209(table), J239
  continuation rate of contraceptives, K7
  contraceptive practice, A12(table)
  Depo-Provera
    availability, K13(figure)
    use-effectiveness, K4(table)
  duration of postpartum amenorrhea, J57(table)
  experimental study of copper IUD, B18
  family planning program, J24, J206
  folk methods of postcoital contraception, J142
  geography and family planning, J216
  household distribution of contraceptives, J82
    evaluation, J84(table)
    oral contraceptives, J82
    rural areas, J82
  IUD acceptors, B27(table)
  lactation
    effect of orals, J61(table)
    effect of progestogen-only contraceptives, J63(table)
  laparoscopic sterilization, C2, C14
  legal status of voluntary sterilization, CD115(table)
  marketing of minipill, A64(table)
  maternal mortality, J128(figure), J130(table)
  menstrual flow with IUD, B35
  menstrual regulation, F51
  new acceptors, J11(table)
  oral contraceptives, J82
    lactation, J61(table)
    marketing, A15(table)
    new acceptors, A18(table)
    production, A17
    withdrawal bleeding, A38
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population policy, E2, E41, E42, E43(table)
    economic incentives, E48(table), E49
  schistosomiasis, J183
  termination rate with Spring Coil, B22(table)
  total fertility rate, J215(table), J217(table)
  training nonphysicians, J95(table), J103(table)
  use-effectiveness of Norigest, K4(table)
  Yoon band sterilization, C85
EGYPTIAN FAMILY PLANNING ASSOCIATION INSTITUTE FOR TRAINING IN FAMILY PLANNING.
  address, J103(table)
  training nonphysicians, J95(table), J103(table)
EIRE. See **IRELAND**.
EISAI CO.
  vaginal contraceptives, H40, H41(table)
EL-BUSHRA, J.
  family planning radio campaign, J302
ELECTRICAL VACUUM
  menstrual regulation, F12, F14(table), F19
ELECTROCOAGULATION, C76(table). See also **HYSTEROSCOPIC FULGURATION**; **LAPAROSCOPIC FULGURATION**.
  advantages and disadvantages, C79
  colpotomy, C34
  compared with spring-loaded clips, C85(table)
  compared with Yoon band, C85(table)
  culdoscopy, C64
    failure rate, C68(table)
  definition, C78
  equipment, C10, C78, M13(photo), M16-M20, M27(table)
  fascial barrier formation, D5
  hysteroscopy, C81-C82
  laparoscopic sterilization, C6, C8(table), C45, C79-C80
    advantages and disadvantages, C8, C17
    bleeding and treatment, C12
    tubal viability, C8
  prevention of sperm granulomas, D30
  techniques, C78-C82
  tubal occlusion, C56
  vasectomy, D5, D6-D7(table), D28(table), D33(table)
    area, D5
    complications, D5
    purpose, D5
ELECTRO MEDICAL SYSTEMS, INC. (EMS)
  electrosurgical generator, M15(table), M28(photo)
  guarantee and service of sterilization equipment, M30(table)
  vasectomy equipment, M27(table)
ELECTROPHORESIS
  sperm separation, I25, I27(photo)
ELECTROSURGICAL GENERATOR
  comparison of selected products, M14-M15(table)
ELEVENTH ALL UNION CONGRESS OF GYNECOLOGY, F27
ELI LILLY AND CO., A5
EL-KAMMASH, M.
  sexual sterilization and Islam, CD86
ELKINS, H., author, J321-J343
ELLIOTT, E., J309
ELLIS, B., A5(table)
EL-MAHGOUB, S.
  use-effectiveness of Depo-Provera and Norigest, K4(table)
ELMED INC.
  address, M32
  guarantee and service of sterilization equipment, M30(table)
  laparoscopy equipment
    combination units, M11(table), M13(figure)
    electrosurgical generators, M14-M15(table)
    fiberoptic projectors, M8(table)
    insufflator, M12(table)
EL SALVADOR
  abortion
    legal status, E2, E7(table), E29(table), E32, E47
    mortality, J256
  adolescent births, J161(table)
  age-specific fertility rate, J35(graph), J226(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J23(figure), J29(table), J207(table), J218(figure)
  change in number of births, J219(figure)
  condom shipments, H14(table), H15(table)
  culdoscopy, C69
  diaphragm availability, H68(table)
  family planning communication, J297, J302, J310(table)
  infant mortality by maternal age, J254(table)
  infant and neonatal mortality, J166(table)
  laparoscopic sterilization, C2
    training, C2, C13
  legal status of voluntary sterilization, CD113(table)
  marketing of minipill, A64(table)
  National Population Commission, E46
  new acceptors, A18(table), J17(table)
  oral contraceptives
    marketing, A13(table)
    new acceptors, A18(table)
    supplied by USAID, A21(table)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population policy, E41, E42, E43(table)
    voluntary sterilization, E45(table), E48
  training nonphysicians, J95(table), J106(table)
  vaginal contraceptives, H48(table)
  war with Honduras, J193
EL-SEROUR, G.A.
  laparoscopic fulguration, C79(table)
EL TAWI, N.Z.
  orals and lactation, J61(table)
EMBERSON, F., F61
EMBOLISM
  culdoscopy, C66, C68
  laparoscopic sterilization, C18
  mortality associated with IUD, B36(table)
  mortality during laparoscopy, C21
EMBREY, M.P.
  incomplete abortions, G11
  midtrimester abortion by extraamniotic administration of PGs, G69-G70(table)
  PG research, G17
  PGs for induction of labor, G10(table)
  PGs for pregnancy termination, G7(table), G8(table), G9(table)
    preferred route of administration and timing, G11
EMKO CO., H41(table), H47
EMKO CONCENTRATE
  venereal disease, H51(table)
EMKO FOAM, H40
  active ingredients, H41(table)

  - Ghana, J78
  - price and sales, H48(table)
  - subsidized community-based distribution, J78
  - use-effectiveness, H44(table), H45(table), H46
  - venereal disease, H51(table)
- **EMMETT'S WATER DILATOR**, F88(figure), F89
- **EMORY UNIVERSITY, INTERNATIONAL NURSING CENTER.**
  - address, J107(table)
  - training nonphysicians, J98, J107(table)
- **EMPEDOCLES**
  - coital timing method, I22
- **EMPEROR JUSTINIAN I**, F88
- **EMPHYSEMA**
  - air pollution, J184
  - laparoscopic sterilization, C18, C20
- **EMS, M.**
  - use-effectiveness of vaginal jelly, H45(table)
- **ENDANGERED WILDLIFE**, J198-J199
- **ENDOMETRIAL ASPIRATION**. See **MENSTRUAL REGULATION**.
- **ENDOMETRIAL CANCER**
  - conjugated estrogens, J147
  - Depo-Provera, K2
  - diagnosis with cannula, F59
  - oral contraceptives, A84, A85, A86-A87(table)
- **ENDOMETRIAL HYPERPLASIA**
  - incidence, A85
  - use of progestins, A87
- **ENDOMETRIAL NEOPLASIA**
  - menopausal use of estrogens, A85, A86-A87(table)
  - oral contraceptives, A84
    - animal studies, A87(table), A88
- **ENDOMETRIOSIS**, A33
  - contraindication to colpotomy, C40
  - contraindication to culdoscopy, C65
  - laminaria, F92, F94
  - medroxyprogesterone acetate, K2
  - oral contraceptives, A39
  - treatment, A5
  - uterine aspiration, F35
- **ENDOMETRIUM**
  - altered by postcoital contraceptives
    - combined estrogen-progestins, J148, J150
    - estrogens, J144, J146
    - progestogens, J148
  - changes compared during menstrual cycle, pregnancy, and use of orals, A33(figure)
  - minipill, A55-A56
  - progestogens, K3
- **ENDOSCOPE**
  - fulguration, C78
  - tubal sterilization, C73
- **ENERGY**
  - supply v. demand, J199-J200
- **ENGINEER, A.D.**
  - colpotomy
    - failure, C43
    - instruments, C36(table)
    - preoperative medication and anesthesia, C32(table)
  - Pomeroy method for tubal ligation, C33(table)
- **ENGLAND**. See **UNITED KINGDOM**.
- **ENGLEFRIED, O.**, A5(table)
- **ENGLISH MEDICAL DEFENCE UNION**
  - sterilization for fertility control, CD82-CD83
- **ENGLISH VASECTOMY ACT**, CD70
- **ENOVID**
  - animal studies
    - breast neoplasia, A78(table), A79(table)
    - endometrial tumors, A87(table)
    - liver tumors, A89(table)
    - pituitary tumors, A90(table), A91(table)
  - early clinical testing, A32
  - manufacture and marketing, A4(table)
  - patent information, A5(table)
  - therapeutic use for endometriosis, A39
- **ENOVID-E**
  - breast neoplasia in selected animal studies, A78(table)
  - formulation and dosage, A6(table)
- **ENOVID 5**
  - formulation and dosage, A6(table)
- **ENOVID 10**
  - formulation and dosage, A6(table)
  - USFDA approval for contraception, A33
  - USFDA approval for therapy, A33
- **ENVIRONMENTAL FUND**, J211
- **ENZYMES**
  - cervical dilatation, F98
  - sex ratio, I26
- **EPIDEMIOLOGY**
  - methods used to study oral contraceptives, A71-A72
- **EPIDIDYMAL CYSTS**
  - maternal use of diethylstilbestrol, J146
- **EPIDIDYMIS**
  - anatomy and physiology, D43(figure)
  - obstruction following vas reanastomosis, D46
  - postvasectomy alterations, D47
- **EPIDIDYMITIS**
  - etiology, D30
  - incidence, D28(table), D29(graph), D30
  - postoperative prevention, D2
  - treatment, D30
- **EPILEPSY**
  - contraindication for postpartum laparoscopic sterilization, C23
- **EPINEPHRINE**, F30(table)
  - culdoscopy, C64
  - tubal occlusion, C87
- **EPINEPHRINE-SALINE SOLUTION**
  - mesosalpinx formation for tubal ligation, C78
- **EQUATORIAL GUINEA**
  - birth rate, J29(table), J207(table), J210(table)
- **ERB, R.A.**
  - tubal occlusion
    - silastic, C86(table), C8
- **ERCOLI, A.**, A5(table)
- **ERGOCRYPTINE**
  - compared with PGF$_{2}\alpha$ for suppression of prolactin secretion, G61
- **ERGOMETRINE**, F29(table)
  - uterine aspiration, F60(table)
- **ERGONOVINE**, F29(table)
- **ERGOTRATE**, F29(table)
- **ERICCSON, R.J.**
  - sperm separation by sperm motility, I25
- **ERYTHEMA**
  - intramuscular injection of PG, F76
- **ERYTHROCYTES**
  - prostaglandins, G1
- **ESCHMANN BROS., AND WALSH, LTD.**, F40, F41(table)
- **ESHO, J.O.**
  - vasectomy
    - complications, D28(table)
    - failure, D33
    - technique, D27, D28(table)
- **ESKIMOS**
  - folk methods for sex preselection, I22
- **ESTERASE**, I26
- **ESTRADIOL**, A31
- **ESTRADIOL BENZOATE**
  - combined with norgestrel, K3
  - postcoital administration and dosage, J144
  - reversal of chemical tubal occlusion, C87
- **ESTRADIOL CYPIONATE**
  - combined with Depo-Provera, K3
- **ESTRADIOL DIPROPIONATE**
  - reversal of chemical tubal occlusion, C87
- **ESTRADIOL ENANTHATE**, K2
- **ESTRADIOL UNDECYLATE**, K3
- **ESTRADIOL VALERATE**, G49-G50
- **ESTRADIOL-17β**
  - parturition, G46
  - PGF synthesis, G47
  - placental PGs, G50
  - plasma level PGs, G36(table)
  - uterine contraction stimulation, G49
- **ESTRIOL**, A31
- **ESTROGEN**
  - breast cancer and postmenopausal use, A75, A77(table)
  - cervical mucus, I7
  - dosage in orals, A2, A6(table), A11-A12, A16
  - early studies, A31
  - identification, A31
  - indications for supplemental use, K6
  - lactation, J52(table)
    - suppression with orals, J58-J59
  - level during pregnancy, J50
    - early pregnancy, A33(figure)
  - levels during menstrual cycle, A33(figure)
    - with orals, A33(table)
  - liver tumors, A89
  - menopausal use and endometrial cancer, A85, A86-87(table)
  - natural production, A33-A34
  - oral contraceptives, A70, A72, A74
    - blood clotting, A41
    - blood pressure, A42
    - low-dose preparations approved by USFDA, A37(table)
    - side effects, A36, A37
  - pituitary tumors, A91
  - risk of thromboembolic disease, A54, A61-A62
  - role in human reproduction, A34
  - side effects, K3, K7
  - therapeutic use, K5
    - dosage, K5
  - tumors, A70, A75, A79, A80, A84, A85, A86(table), A91
- **ESTROGEN-PROGESTIN COMBINATION**. See **COMBINED ORAL CONTRACEPTIVES**
- **ESTROGENS, CONJUGATED**. See **CONJUGATED ESTROGENS**
- **ESTROGENS, POSTCOITAL**
  - administration and dosage, J144, J145(table)
  - carcinogenic effects, J146-J147
  - ectopic pregnancy, J144
  - history, J143-J144
  - menstrual pattern changes, J147
  - mode of action, J144, J146
  - side effects, J147
  - US, J141, J144
  - use-effectiveness, J143, J144
    - selected studies, J145(table)
- **ESTRONE**, A31
  - parturition, G46
- **ETHAERIDINE**
  - vas irrigation, D10
- **ETHANOL**
  - chemical sterilization, D15
- **ETHINYL ESTRADIOL**
  - breast neoplasia, A78(table)
  - combined in orals, A5, A6(table), A37(table)
  - endometrial tumors, A87(table)
  - liver tumors, A89
  - pituitary tumors, A90(table)
  - potency, A37
- **ETHINYL ESTRADIOL, POSTCOITAL**
  - administration and dosage, J143, J144, J145(table)
  - combined estrogen-progestin, J150
  - menstrual pattern changes, J147
  - selected studies, J145(table)
  - side effects, J148(table)
  - use-effectiveness, J145(table)
- **ETHIOPIA**
  - age-specific fertility rate, J223(graph)
  - birth rate, J29(table), J207(table), J209(table)
  - condom shipments, H14(table)
  - diaphragm availability, H68(table)
  - famine, J244, J245
  - legal status of abortion, E28, E29(table)
  - legal status of voluntary sterilization, CD78, CD106(table)
  - marketing of oral contraceptives, A13(table)
  - population growth, J188
  - total fertility rate, J216(table)
- **ETHISTERONE**, A32
- **ETHYLENE ETHYL ACRILATE**, H31
- **ETHYLENE OXIDE**
  - sterilization of laminaria tents, F39
  - sterilization of plastic cannula, F18
- **ETHYNERONE**
  - breast neoplasia, A78(table), A79(table)
  - liver tumors, A89(table)
- **ETHYNODIOL DIACETATE**, A7
  - combined orals, A37(table)
  - menstrual patterns, A58(table)
  - minipill

  - continuation rate, A62(table)
  - current users, A64(table)
  - marketing, A64(table)
- postcoital use
  - combined estrogen-progestin, J150
  - progestin-only, J150(table)
- potency, A37
- principal progestogen, A5(table), A6(table)

ETZIONI, A.
- potential social effects of sex preselection, I28

EUFLAVINE
- spermicidal agent, D10

EUGENIC PROTECTION LAW (JAPAN), F1, F6-F7
- revision, F6, F7

EUGYNON, A5, A19
- manufacture and marketing, A4(table)

EULER, U.S. von
- prostaglandins, G2, G17
- prostate secretions and seminal vesicle extracts, G1-G2

EUROPE. See also specific countries.
- age of menarche, J159, J162(table)
- birth rate, J29(table), J210(table)
- early marriage, J158
- fertility decline and socioeconomic development, J213
- mortality decline, J212
- percentage of population under 20, J168(figure)
- population per hospital bed and per physician in selected countries, J71(table)
- prevalence of iron deficiency anemia, J131(table)
- sex ratio, I23
- training nonphysicians in selected countries, J95, J105(table)
- trends in marital status of female adolescents, J164(table)

EUROPE, EASTERN. See also specific countries.
- abortion methods, F66
- birth rate, J237, J239, J249(table)
- food shortages, J241
- mortality rate, J239, J249(table)
- population growth, J239, J249(table)

EUROPE, WESTERN. See also specific countries.
- birth rate, J237, J239, J249(table)
- mortality rate, J249(table)
- population growth, J239, J249(table)

EVANOR
- manufacture and marketing, A4(table)

EVANS, T.N.
- clip sterilization, C46, C82
  - colpotomy, C30

EXCISION
- laparoscopic sterilization, C8(table)

EXETER, UNIVERSITY OF. FAMILY PLANNING RESEARCH UNIT.
- address, B48

EXLUTENA
- manufacture and marketing, A64(table)

EXLUTON
- manufacture and marketing, A64(table)

EXLUTONA
- manufacture and marketing, A64(table)

EXPANDED PROGRAM OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION (WHO)
- research in PGs, G11

EYE DISEASE
- oral contraceptives, A40

F

FAEROE ISLANDS
- age-specific fertility rate, J228(graph)
- birth rate, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)

FAIRBROTHER, P.F.
- electrocoagulation with division in laparoscopic sterilization, C8(table)

FALB, R.D.
- gelatin-resorcinol-formaldehyde for tubal occlusion, C89

FALKLAND ISLANDS
- birth rate, J29(table), J207(table), J210(table)

FALLOPIAN TUBES
- anatomy, C74(figure)
- ligation, C33(table), C34
- methods of occlusion, C64, C65(table)
  - clips, C45, C46, C50

FALLOPIO, G., H3, H32

FALOPE RING. See **YOON BAND**.

FAMILY PLANNING
- adolescents, J164-J166
- Africa, J206
- applying for funds, J279
- attitude in developing countries, J125
- Bali, J239
- Brazil, J206, J217, J239
- China, J239
- comparative safety of contraceptive methods, J258(table)
- definition, J321
- demographic effects, J214, J216
- Fiji, J325
- funding organizations, J274-J276(table)
  - addresses, J283-J284
  - bilateral, J266, J269, J270-J271(table), J272-J273, J277
  - multilateral, J266, J270-J271(table), J277-J279
  - nongovernmental, J266, J267-J269, J270-J271(table)
  - primary sources, J278(table)
- future of international funding, J279
- health aspects, J253-J260
- health care system, E19
- Hong Kong, J239
- incentive programs, E8(table)
- India, J325
- Indochina, J208
- Iran, J208
- Japan, J239
- Java, J239
- maternal health, J131
- Mexico, J239
- practice in selected countries, A12(table)
- problems of new clients, J324
- programs. See **FAMILY PLANNING PROGRAMS**.
- requests for assistance from developing countries, J201
- sources of funding, J265-J284
- surgical kits, J281(photo), J282
- Taiwan, J239, J324
- Tennessee, J325
- training programs, J94-J95(table), J98
  - directory, J101-J108(tables)
- vaginal contraceptives, H38
- worldwide law and policy changes, E1-E11, E5(map)

FAMILY PLANNING ASSOCIATION (GREAT BRITAIN)
- address, J105(table)
- training nonphysicians, J95(table), J105(table)

FAMILY PLANNING ASSOCIATION OF HONG KONG
- address, J101(table)
- training nonphysicians, J94(table), J101(table)

FAMILY PLANNING ASSOCIATION OF INDIA, J79

FAMILY PLANNING ASSOCIATION OF LIBERIA
- address, J104(table)
- training nonphysicians, J94(table), J104(table)

FAMILY PLANNING ASSOCIATION (PUERTO RICO)
- community-based distribution, J72

FAMILY PLANNING ASSOCIATION OF RHODESIA. SPILHAUS FAMILY PLANNING CENTER.
- address, J104(table)
- training nonphysicians, J94(table), J104(table)

FAMILY PLANNING ASSOCIATION OF SRI LANKA. MEDICO-LEGAL SOCIETY OF THE LAW AND POPULATION COMMITTEE, E34

FAMILY PLANNING ASSOCIATION OF TANZANIA
- address, J104(table)
- training nonphysicians, J94(table), J104(table)

FAMILY PLANNING ASSOCIATION OF TRINIDAD AND TOBAGO
- address, J107(table)
- training nonphysicians, J95(table), J107(table)

FAMILY PLANNING CLINIC. See also **OUTPATIENT**.
- advantages and disadvantages, J71-J72
- development, J70, J72
- services offered, J72

FAMILY PLANNING COUNCIL OF NIGERIA
- address, J104(table)
- film on family planning, J299
- training nonphysicians, J94(table), J104(table)

FAMILY PLANNING INTERNATIONAL ASSISTANCE (FPIA), C39
- address, C58, J85, J283
- funding of family planning activities, J266, J268, J270-J271(table), J274(table)
- institutional distribution programs, J78
- sterilization equipment, M2

FAMILY PLANNING ORGANIZATION OF THE PHILIPPINES
- address, J102(table)
- training nonphysicians, J94(table), J102(table)
- youth program, J171

FAMILY PLANNING AND POSTPARTUM PROGRAM. INSTITUTE FOR THE PROTECTION OF MOTHERS AND NEWBORNS (IRAN).
- address, J103(table)
- training nonphysicians, J95(table), J97, J103(table)

FAMILY PLANNING PROGRAMS. See also **MATERNAL HEALTH SERVICES**.
- administration, J280, J321-J325
- advantages of IUD, B26
- affected by geography, J216
- Bangladesh, J206
- breast-feeding, J50, J62
- Chile, B28
- communication, J289-J314
- community-based distribution, J69-J85
  - recommendations, J83-J85
- components, J265, J280
- considerations for vas anastomosis, B51
- continuation rates, J84(table)
- cost per acceptor, J84(table)
- definition of vigorous and nonvigorous, J214, J216
- demographic effectiveness, J21-J22, J205, J213, J216-J217
  - selected countries, J215(table), J217(table)
- effect of policy on fertility patterns, J4
- effect of strategy on fertility decline, J2
- Egypt, J206
- evaluation, J1, J2
  - fertility silhouettes, J4
- fertility patterns, J1-J20, J21-J22
- Ghana, J206
- government sponsorship, A22
- Hong Kong, B26
- India, B26
- Korea, B26, B28
- Lippes Loop, B2
- medical support, J74-J75
- menstrual regulation, F61-F62
- Mexico, J206, J217
- minipill, A63
- multiple method approach, B37
- new acceptors, A17(graph), A18(table), J11-J20(tables)
- oral contraceptives, A17-A24
- orientation of services, J164
- Pakistan, B26, J206, J217
- paramedical personnel, E2
- political aspects, B28
- promotion
  - film, J290, J297-J299
  - mailings, J289, J291, J292-J293(table), J294
  - multimedia, J290, J305-J306, J307, J308, J309, J310-J312(table), J313
  - newspapers, J290, J294-J297
  - radio, J289, J299-J303
  - telephone, J289, J290-J291
  - TV, J290, J303-J305

    - selected countries, J24
      - effect on age-specific fertility rate, J25(graph)
    - service statistics, J321-J339
      - Brazil, J333, J334(figure), J335(figure)
      - Colombia, J332-J333(figure)
      - Dominican Republic, J335(figure), J336(figure), J337
      - Indonesia, J326, J327(figure), J328 (figure), J329(figures), J330(figure)
      - Mexico, J330, J331(figure), J332
      - planning for future needs, J322
      - purposes, J322-J323
      - techniques, J323-J326
    - Singapore, B26, J2
    - sources of funding assistance, J274-J276(table)
    - South Korea, J2
    - Taiwan, B26, B28, J2
    - training nonphysicians, J89-J98
    - Tunisia, J206

- **FAMILY PLANNING SALES, LTD. (FPS)**
  - condom distribution, H12
- **FAMILY PLANNING TRAINING-CUM-RESEARCH INSTITUTE (BANGLADESH)**
  - training nonphysicians, J101(table)
- **FAMILY SIZE**
  - health aspects, J195, J255-J256
- **FAMILY WELFARE BUREAU (INDIA)**
  - postvasectomy sperm antibodies, D48
- **FAMILY WELFARE CENTER (KENYA)**
  - address, J103(table)
  - training nonphysicians, J95(table), J103(table)
- **FAMILY WELFARE CLINICS (PAKISTAN)**
  - subsidized community-based distribution, J78
- **FAMINE**
  - Bangladesh, J242-J243
  - Chad, J244-J245
  - Ethiopia, J244-J245
  - Haiti, J244
  - India, J242
  - Mauritania, J244-J245
  - Niger, J244-J245
  - Senegal, J244-J245
  - Somalia, J245
  - Sri Lanka, J244
  - Upper Volta, J244-J245
- **FARADAY LABORATORIES, INC.**
  - do-it-yourself pregnancy test, J121
- **FARLEY, J.U.**
  - commercialization of family planning, H6
- **FARRINGTON, C.**
  - postcoital estrogens
    - side effects, J148(table)
    - use-effectiveness, J145(table)
- **FASAL, E.**
  - orals and benign breast neoplasia, A73 (table)
- **FATHALLA, M.F.**
  - laparoscopic sterilization in Egypt
    - failure, C14, C22(table)
    - postabortion, C23
    - postpartum, C22
- **FATIGUE**
  - vasectomy, D34
- **FAUNDES, A.**
  - abortion in China, F2
- **FEAR, R.**
  - tantalum clips for sterilization, C12, C46
- **FECHNER, R.E.**
  - breast disease and orals, A45
- **FEDERAL REPUBLIC OF GERMANY**. See **GERMANY, WEST**.
- **FEDERATION OF FAMILY PLANNING ASSOCIATIONS (MALAYSIA)**
  - address, J102(table)
  - training nonphysicians, J94(table), J102(table)
  - Young Workers Community Education Project, J171
- **FEEDBACK**
  - hormones, A34
- **FELT, JUDY C.**, author, A69-A100
- **FEMAGEST**
  - manufacture and marketing, A4(table)
- **FEMALE STERILIZATION**. See **STERILIZATION, FEMALE**
- **FEMENAL**
  - manufacture and marketing, A4(table)
- **FEMULEN**
  - manufacture and marketing, A64(table)
- **FENTANYL**, C3(table), C4, C47(table), C55
  - compared with meperidine hydrochloride and chlorpromazine, C62
  - culdoscopy, C62, C63(table)
  - side effects, C62
- **FENTANYL CITRATE**, C32(table)
- **FERBER, A.S.**
  - vasectomy
    - general health, D35
    - sexual behavior, D35
- **FERIN, J.**, I5
- **FERNANDO, W.S.C.**
  - factors influencing cervical cancer, J133(table)
- **FERRARI, A.N.**
  - norethindrone minipill
    - menstrual pattern changes, A58(table)
  - norgestrel minipill
    - effectiveness, A56(table)
    - menstrual pattern changes, A59(table)
- **FERTILITY**
  - abortion, J2, J4
  - affected by availability of contraceptives, J2, J4
  - affected by family planning programs, J2, J21-J22, J25(graph)
  - world pattern, J28, J30-J31(map)
- **FERTILITY CONTROL**. See also specific contraceptive methods, e.g., **CONDOM**, **ORAL CONTRACEPTIVES**, etc.
  - breast-feeding, J62, J64
  - choice of method, E19
    - adolescents, J166-J169
  - conception rate after discontinuation, K9(graph)
  - continuation rates and demographic impact, B37
  - cultural aspects, I1
  - effect on fertility levels, J213
  - effect of mass media on use, J290, J291, J294, J295, J296, J300, J301, J302, J306, J307, J309
  - lactating women
    - methods, J58-J59, J64
    - timing, J62
  - maternal risk v. benefit, J257, J258
  - motivation, H46
  - prostaglandins, G17, G18-G21(maps), G58-G59
  - US, H12
  - worldwide use, J238-J239
- **FERTILITY CONTROL, POSTCONCEPTION**, G37-G38
- **FERTILITY MANAGEMENT**. See **MATERNAL HEALTH SERVICES**
- **FERTILITY MEASUREMENT**
  - birth registration, J206
  - estimations, J208
  - methods, J206, J208
  - replacement fertility, J216
  - sampling methods, J208
  - statistical reliability, J208
- **FERTILITY RATE**. See also **AGE-SPECIFIC FERTILITY RATE**
  - age-specific
    - legalized abortion, J10(graphs)
    - marital status, J2
    - selected countries, J3(graphs), J5-J9(graphs)
  - definition, J216
  - factors affecting, J2, J213, J214
  - family planning programs, J205, J216-J217
  - fertility silhouettes, J2
    - developed countries, J4, J9(graph)
    - purpose, J2, J22
    - selected countries, J3(graph), J5-J10(graphs), J215(table), J216 (table), J217(table), J222(graphs)
    - technique, J206
- **FETAL ABNORMALITIES**. See **CONGENITAL ABNORMALITIES**
- **FETAL SEX IDENTIFICATION**. See also **SEX PRESELECTION**
  - amniocentesis, I26
  - cervical mucus, I27
  - maternal blood, I26
  - preimplantation, I27
  - selective abortion, I26
- **FETUS**
  - effects of PGs, G50
  - length of gestation, G45
  - US legal definition, F5
- **FEVER**. See also **PYREXIA**.
  - culdoscopy, C67(table)
    - chemical tubal occlusion, C64
  - midtrimester abortion with PG, F77(table)
  - first trimester abortion with PGE$_2$ analogue, F95
  - postabortion, F39(table)
  - saline abortion, F69-F70, F72
    - selected studies, F71(table)
- **FIBEROPTIC PROJECTORS**, C69, M8-M9(table), M29
- **FIBROADENOMA**
  - effect of progestin, A74, A75
- **FIBROIDS**, A38
  - contraindication to culdoscopy, C65
  - oral contraceptives, A46, A88
  - surgical procedure, F67
- **FIBROSIS**
  - sterilization, M20
- **FIELDWORKERS**
  - role in family planning in Korea, B26
- **FIEUEZ, C.L.**
  - orals and squamous metaplasia, A84(table)
- **FIJI**
  - adolescent births, J161(table)
  - age-specific fertility rate, J3(graph), J7(graph), J25(graph), J37(graph), J222(graph)
  - average births per woman, J129(table)
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  - change in number of births, J219(figure)
  - condom shipments, H14(table)
  - contraceptive practice, A12(table)
  - family planning program, J24
  - folk methods for postcoital contraception, J142
  - marital status of female adolescents, J164(table)
  - oral contraceptives
    - marketing, A13(table)
    - nonprescription, J74
    - policy, E2, E4(table)
    - supplied by SIDA, A20(table)
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - total fertility rate, J215(table), J216, J217(table)
  - vacuum source testing, F56
- **FILM**
  - promotion of family planning, J297-J299
- **FILSHIE, G.M.**
  - PGs for pregnancy termination, G7(table), G9(table)
  - uterine aspiration
    - blood loss, F60
    - incomplete abortion, F60(table)
- **FIMBRIAL CAP**
  - tubal occlusion, C91
- **FIMBRIECTOMY**, C75(figure), C76(table)
  - advantages and disadvantages, C78
  - colpotomy, C30
  - culdoscopy, C64, C65(table)
    - failure rate, C68(table)
  - failure rate, C78
  - procedure, C78
  - reversibility, C78
  - tubal ligation, C33(table), C34
- **FIMBRIOTEXY**
  - adhesions, C91
  - advantages and disadvantages, C91
  - definition, C91
  - reversibility, C91
- **FINDLAY, A.L.R.**
  - anatomy of alveolus, J53(figure)
- **FINDLAY DIAPHRAGM**. See **ARCING DIAPHRAGM**.
- **FINKEL, M.J.**
  - orals and breast neoplasia in animals, A78, A79(table)
- **FINKLE, W.D.**
  - estrogen use and endometrial cancer in postmenopause, A87(table)
- **FINLAND**
  - age of menarche, J162(table)
  - age-specific fertility rate, J38(graph), J228(graph)

    historical perspective, J8(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  condom standards, H25
  contraception among adolescents, J166
  diaphragm availability, M68(table)
  hysterographic study of IUD embedding, B12
  legal restriction of copper IUDs, B18
  legal status of abortion, E30(table), J165
  legal status of voluntary sterilization, CD70, CD106(table)
  marital status of female adolescents, J164(table)
  marketing of minipill, A64(table)
  Ministry of Foreign Affairs
    address, J284
    funding of family planning activities, J273, J274(table)
  obstetrical complications with multiparity, J135(table)
  oral contraceptives
    commercial supply, A9(table), A10(graph)
    marketing, A13(table)
    sales, A8(table)
  out-of-wedlock births, J160(figure)
  percentage of legal abortions to women under 20, J171(table)
  PG research, G19, G20, G21, G22
  population, F7(table)
  price and sales of vaginal contraceptives, H48(table)
  vasectomy, D28(table)
FIREWOOD, J192, J199
  supply v. demand, J182
FIRMA W. DERENBURG K.G., F41(table)
FIRST NATIONAL PEOPLES CONGRESS (PEKING, CHINA)
  statement on abortion, F2
FISHERIES
  competition among countries, J194
  need for global management, J179, J180
  protein source, J179
  supply v. demand, J183(figure)
  world fish catch, J178-J179, J183, J241
FISTULAE
  cervical dilatation, G12
FITZGERALD, M.G.
  diabetes mellitus and parity, J132(table)
FITZGERALD, T.C.
  immunologic pregnancy tests, J118(table), J119(table)
FLAT SPRING DIAPHRAGM, H68(table)
  description, H61
  indications, M61
FLEHINGER, B.J.
  orals and cervical neoplasia, A81(table)
FLETCHER SCHOOL OF LAW AND DIPLOMACY, LAW AND POPULATION PROGRAMME, E2
FLOREY, C. DuV.
  diabetes mellitus and parity, J132(table)
FLORIDA
  water supply, J196
FLOWER OF CANTON, B44(figure)
  description, B44
  use-effectiveness, B44
FOAM. See also **AEROSOL FOAM**; **FOAM TABLET**; **VAGINAL CONTRACEPTIVES**; specific brand names
  application, H40
  distribution, J90-J91
    subsidized community-based, J78
    USAID, H49(table)
  duration of spermicidal effectiveness, H43(table)
  Ghana, J78
  ingredients, H41(table), H43(table)
  mode of action, H40, H43(table)
  packaging, H43(table)
  preference for in Africa, J74
  price and sales of selected products, H48(table)
  sales statistics, J78
  US, H47, H59(table)
  use-effectiveness, H37, H39(figure), H46, I9
FOAM TABLET. See also **FOAM**
  active ingredients, H41(table), H43(table)
  duration of spermicidal effectiveness, H43(table)
  mode of application, H43(table)
  packaging, H43(table)
  use-effectiveness, H44, H46
    selected studies, H45(table)
FOCAL NODULAR HYPERPLASIA
  oral contraceptives, A88-A90
FOLATE DEFICIENCY ANEMIA, J131. See also **ANEMIA**; **IRON DEFICIENCY ANEMIA**
FOLEY, M.
  menstrual pattern changes with lynestrenol minipill, A58(table)
FOLEY CATHETER, C58. See also **CATHETER**
  intrauterine infusion of PGs, G11
  saline abortion, F70
FOLIAKI, L.
  use-effectiveness of cervical mucus rhythm method, I11(table)
FOLK METHODS
  intravaginal preparations, H58
  postcoital contraception, J142
  sex preselection, I22
FOLLICLE STIMULATING HORMONE
  levels during early pregnancy, A33(figure)
  levels during menstrual cycle, A33(figure)
    with orals, A33(figure)
  postvasectomy level, D31
FOLLICULAR CYSTS
  culdoscopy, C67
FOLLISTREL
  manufacture and marketing, A64(table)
FOMOS
  use-effectiveness, H45(table)
FOOD AND AGRICULTURE ORGANIZATION (FAO)
  address, J284
  population program assistance, J271 (table), J274(table), J278(table)
FOOD PRODUCTION
  population growth, J184-J185, J237-J238, J242
  shortages, J241-J245, J246
  worldwide, J241, J242
FOOT-OPERATED PUMP
  menstrual regulation, F12, F14(table)
    description, F19
FORCEPS
  clip sterilization, C48
  culdoscopy, C64
  fulguration, C78
  uterine aspiration, F31, F38
  uterine perforation, F36
FORD FOUNDATION, C70, J243
  address, J283
  funding of family planning activities, J267-J268, J270-J271(table), J274, J278
  IUD conference, B25
FORTIER, L.
  expulsion, pregnancy, removal, and continuation rates with copper IUD and inert Lippes Loop D, B11(table)
  menstrual pattern changes with norethindrone minipill, A58(table)
  removal of copper-T IUD, B9
    after embedding, B12
  termination rate of IUDs for pain, B12
FOSS, G.L.
  norgestrel minipill
    effectiveness, A56(table)
    menstrual pattern changes, A59(table)
FOSSIL FUEL. See **ENERGY**
FOTHERBY, K.
  effectiveness of norgestrel as a minipill, A56(table)
FOUNTAIN, L.H.
  safety of Depo-Provera, K10
FRANCE
  adolescent access to family planning, J165
  age-specific fertility rate, J3(graph), J9(graph), J38(graph), J228(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  condom sales, H6
  copper IUDs, B18
  diaphragm availability, H68(table)
  distribution of contraceptives, E1, E2, E3 (table)
  legal rights of children, J163
  legal status of abortion, E30(table), E32, E33(table), E47, F61, J165, J237
  legal status of voluntary sterilization, CD106(table)
    criminality with consent, CD80
  marketing of minipill, A54
  maternal mortality, J128(figure)
  migration, J197
  oral contraceptives
    commercial supply, A9(table), A10(graph)
    marketing, A13(table)
    sales, A8(table)
  PG research, G20, G21, G22
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population trends, J240
  postcoital douches, J142
  rhythm method, I14(table)
    acceptability, I13-I14
    sympto-thermal method, I7
    use-effectiveness of temperature method, I11(table), I12(table)
  training nonphysicians, J98, J105(table)
  tubal occlusion via laparoscopy, C79
FRANDA, M.F.
  vasectomy camps in India, J313
FRANGEHEIM, H.
  complications of culdoscopy, C66(table)
  laparoscopic sterilization, C6
    electrocoagulation, C8
    operative procedure, C6, C7(table)
    tantalum clip application, C84(photo)
    technique for pneumoperitoneum, C5(table)
FRANK, R.
  use-effectiveness of vaginal jelly H45(table)
FRANK, R.T.
  biologic pregnancy test, J111
FRANKS, J., J108(table)
FREDA, V.J.
  Rh immunization in spontaneous abortion, F36
FREE, M.J.
  reversible intravasal occlusive device, D56, D57(photo)
FREEDMAN, D.S.
  promotion of family planning with TV, J304(table)
FREEDMAN, J.
  population density and social behavior, J190
FREEDMAN, R.
  effect of mass media on family planning, J306
FREEMAN, C.
  ethanol in male sterilization, D15
  granuloma prevention, D30
FREIBERG, H.B.
  vas anastomosis, D42
FREJKA, T.
  estimated Chinese fertility levels, J208, J211(table)
FRENCH GUIANA
  age-specific fertility rate, J226(graph)
  birth rate, J29(table), J207(table), J210 (table)
  marital status of female adolescents, J164(table)
  out-of-wedlock births, J160(figure)
FRENCH PACIFIC ISLANDS
  diaphragm availability, H68(table)
FRENCH POLYNESIA
  birth rate, J29(table), J207(table), J210 (table)
  marketing of oral contraceptives, A13 (table)
  out-of-wedlock births, J160(figure)
FRENSELLI, F.J.
  failure of vas reanastomosis, D53
FREUND, A.
  hysteroscopic fulguration, C81
FREUND, M.
  postvasectomy sperm count, D47
  sperm motility of frozen semen, D52
  sperm storage, D52
  sperm transport physiology, D47
  vasectomy
    psychological aspects, D36
    sexual behavior, D35(table)

FRICK, H.C.
- clip sterilization, C12, C46
  - reversibility, C82

FRICK, J.A.
- reversible vas occlusion, D53

FRIED, N.D.
- menstrual regulation with PGs, G59(table)

FRIEDMAN, H.L.
- rabbit pregnancy test, J110

FRITSCH, H.
- tubal ligation and resection, C75

FRONTIER NURSING SERVICE (KENTUCKY)
- distribution of orals, J92
- training nonphysicians, J95(table)

FROZEN SEMEN STORAGE. See **SPERM BANK**.

FUCHS, F.
- Antigon-F, B46
  - use-effectiveness, B32(table)
- Ypsilon use-effectiveness, B39

FUERTES-de la HABA, A.
- orals and cervical neoplasia, A81(table)

FUJI LATEX CO., LTD., H19

FULCRUM PERINEAL RETRACTOR
- cost, C69
- culdoscopy, C69(figure)

FULGURATION. See **ELECTROCOAGULATION; HYSTEROSCOPIC FULGURATION; LAPAROSCOPIC FULGURATION**.

FURUSAWA, Y.
- use-effectiveness of foam tablets, H45 (table)

G

GABON
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- oral contraceptives, J164
  - marketing, A13(table)

GAIL, L.J., author, A29–A51, G17–G24

GAITONDE, A.
- intraamniotic saline abortion, F71(table)

GAL, I.
- abortion and hormonal-withdrawal test, J114

GALACTORRHEA
- injectable progestogens, K6

GALL, S.A.
- orals and squamous metaplasia, A84(table)

GALLBLADDER DISEASE
- oral contraceptives, A47
  - incidence in users and nonusers compared, A31(figure)

GALLI-MAININI, C.
- male toad test for pregnancy, J111

GAMBIA
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- marketing of oral contraceptives, A13 (table)
- sex ratio, I23
- tourism, J180

GAMBLE, C.J.
- spermicidal potency, H44
- use-effectiveness of contraceptive foam and jelly, H45(table)

GAMETES. See also **OVA**; **SPERMATOZOA**.

GAMETRICS LIMITED, I25

GAMMA IRRADIATION
- sterilization of laminaria tents, F39

GANDHIGRAM INSTITUTE OF RURAL HEALTH AND FAMILY PLANNING (INDIA)
- village-based distribution of contraceptives, J72

GANGRENE
- vasectomy, D28

GANT, N.
- intraamniotic instillation of PGF$_2\alpha$ for abortion, F73(table)

GARB, A.E.
- tubal ligation, C75, C77

GARCIA, C.R.
- oral contraceptive research, A32, A34

GARCIA-DEVASA, C.
- use-effectiveness of temperature rhythm method in selected countries, I12 (table)

GARDI, R., A5(table)

GARDNER, R.
- blastocyst sex identification, I27

GARVIN, O.D.
- diaphragm failure, H65(table)

GASTRIC SECRETION
- prostaglandins, G1

GAUSS, C.J.
- hysteroscopic fulguration, C81

GAY, M.D.
- IUD insertion by nurse-midwives, J93

GAZA STRIP
- birth rate, J29(table), J207(table), J210 (table)

GEDEON RICHTER
- oral contraceptives, A4(table)

GELATIN-RESORCINOL-FORMALDEHYDE (GRF)
- tubal occlusion, C89

GEMZELL, C.A.
- HCG detection in pregnant women, J111

GENEESKUNDIGE HOOFDINSPECTIE VAN DE VOLKSGEZONDHEID (NETHERLANDS)
- address, J105(table)
- training nonphysicians, J95(table), J105(table)

GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER
- spermatogenesis after vasectomy, D30

GEORGIA
- availability and awareness of abortion services, E38
- family planning, J325

GERMAN DEMOCRATIC REPUBLIC. See **GERMANY, EAST**.

GERMANY, EAST
- abortion
  - legal status, E30(table)
  - mortality, E37
- adolescent births, J159, J161(table)
- age-specific fertility rate, J10(graph), J38(graph), J228(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure), J241(table)
- change in number of births, J219(figure)
- incidence of cancer in women, A70(table)
- legal status of voluntary sterilization, CD70, CD107(table)
- manufacturers of sterilization equipment, M2
- mortality rate, J241(table)
- population, F7(table)
- population growth, J240, J241(table)

GERMANY, WEST
- abortion, F7(table)
  - legal status, E2, E7(table), E30(table), E32, E33(table), E36(table)
- age-specific fertility rate, J38(graph), J228(graph)
- attitudes toward family size, J240
- availability of Depo-Provera, K13(figure)
- birth rate, J21, J23(figure), J29(table), J207(table), J218(figure), J240(figure), J241(figure)
- change in number of births, J219(figure)
- chemical tubal occlusion, C89
- complications of culdoscopy, C66(table)
- condom
  - distribution and promotion, H12, H13
  - manufacture, H5, H23
  - retail sales, E41, E42, E44(table)
  - standards, H25
- diaphragm availability, H68(table)
- estimated population, E36(table)
- Federal Ministry for Economic Cooperation
  - address, J284
  - funding of family planning activities, J273, J274(table), J278(table)
- legal status of voluntary sterilization, CD67, CD69, CD71, CD89, CD107 (table)
  - consent, CD78, CD82
  - draft amendment, CD71, CD72, CD128–CD130
- manufacture of sterilization equipment, M2
- marketing of minipill, A64(table)
- migration, J197
- mortality rate, J241(figure)
- oral contraceptives
  - commercial supply, A9(table), A10(graph)
  - lactation, J61(table)
  - marketing, A13(table)
  - sales, A8(table)
  - use, J240
- PG research, G20, G21, G22
- policy change on contraceptives, E4(table)
- population, F7(table)
- population growth, J241(table)
- premarital sex among adolescents, J159
- rhythm method, I14(table)
  - temperature method, I2, I11(table), I12
- subsidized community-based distribution, J77
- uterine aspiration equipment, F41
- vaginal contraceptives
  - new acceptors, H49(table)
  - sales, H48
- water pollution, J181

GERON-X
- use-effectiveness of diaphragm, H66(table)

GERSH, I.
- abstinence after vasectomy, D9
- vasectomy technique, D6(table)

GESTATION
- calculation, F65
- degrees of cervical dilatation, F86, F90–F91

GEST-STATE
- cost, J120(table)
- sensitivity, J120(table)
- time required, J120(table)

GETZOFF, P.
- criteria for successful vas reanastomosis, D46

GHANA
- age-specific fertility rate, J3(graph), J27(graph), J34(graph), J224(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J209 (table)
- condom
  - importation costs, H5(table)
  - promotion, H11
  - sales, H6
  - shipments, H15(table)
- contraception among adolescents, J166
- family planning, J26
  - promotion, J296, J308, J310(table)
- in-school sex education, J171
- legal status of abortion, E29(table), E32, E34
- legal status of voluntary sterilization, CD79, CD107(table)
- new acceptors, J11(table)
  - orals, A17, A18(table)
  - vaginal contraceptives, H49(table)
- oral contraceptives
  - marketing, A13(table)
  - new acceptors, A17, A18 (table)
  - nonprescription, J74
  - supplied by USAID, A21 (table)
- percentage of married acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- population density, J189
- population per hospital bed, J71(table)
- population per physician, J71(table)
- subsidized community-based distribution, J78
  - evaluation, J84(table)
  - government administration and support, J75, J78
- training in laparoscopic sterilization, C2, C13
- vaginal contraceptives
  - new acceptors, H49(table)
  - sales, H49

GHANA NATIONAL TRADING CORP., J78

GHORBANI, F.S., J103(table)

GIBOR, Y.
- expulsion, pregnancy, removal, and continuation rates of copper-7 200 IUD, B6(table)
  - nulliparas, B15(table)
- use-effectiveness of copper-7 IUD, B32 (table)

GIBRALTAR
- age-specific fertility rate, J228(figure)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- marketing of oral contraceptives, A13 (table)

GIL DE REAL, A., J107(table)

GILBERT AND ELLICE ISLANDS
- birth rate, J29(table), J207(table), J210 (table)
- oral contraceptives supplied by SIDA, A20(table)

GILLESPIE, A.
- PGs for induction of labor, G10(table)
- PGs for pregnancy termination, G9(table)

GILLETT, P.G.
- $PGF_{2}\alpha$ for midtrimester abortion, G71(table)
- PGs for pregnancy termination, G7(table), G8(table)

GIRARD, Y.
- laparoscopic sterilization, C2(table)
  - complications, C19(table)
  - electrocoagulation with division and biopsy, C8(table)
  - failure, C22(table)
  - operative procedure, C7(table)
  - postpartum complications, C23(table)

GIRI, K.
- laparoscopic sterilization in Nepal, C1, C13, C14
- one-incision technique, C26

GLAUCOMA
- potential PG treatment, G1

GLAXO HOLDINGS, LTD., A5, A7
- oral contraceptives, A4(table)

GLUCOSE
- ovulation, I8

GLYCERINE, H42

GLYCEROL
- frozen sperm storage, D52

GODTS, P.
- use-effectiveness of contraceptive suppository, H45(table)

GOITER, J129

GOLDBERG, S.A.
- estimated Chinese fertility levels, J208 J211(table)

GOLDBLATT, M.
- prostaglandins, G2
- prostate secretions and seminal vesicle extracts, G1–G2

GOLDITCH, I.M.
- laparoscopic sterilization
  - anesthesia, C3(table), F29(table)
  - complications, F33(table)
  - electrocoagulation, C8
  - equipment, F32(table), F41(table)
  - operative procedure, C7(table)
  - perforations, F35(table)
  - postoperative medication, F29(table)
  - preoperative medication, F29(table)
  - pressure, F41(table)
  - technique for pneumoperitoneum, D5(table)
  - uterine aspiration, F28(table)
- midtrimester abortion with urea, F78 (table)

GOLDMAN, W., author, J205–J234

GOLDSMITH, A.
- vasectomy
  - general health, D34(table)
  - sexual behavior, D35(table)

GOLDSMITH, S.G.
- length of amenorrhea and pregnancy, F53(table)
- menstrual regulation, F13(table)
  - blood loss, F17(table)
  - follow-up, F15
  - procedure and equipment, F14(table)
  - uterine perforation, F15
  - vaginal cleansing, F12
- Rh sensitization, F36
- uterine aspiration, F28(table)
  - blood loss, F34(table)
  - equipment, F32(table)
  - local anesthesia, F29(table), F30(table)
  - preoperative medication, F29(table)
  - time required, F32(table), F34(table)

GOLDSTEIN, D.P.
- radioimmunoassay for pregnancy, J120

GOLDSTEIN, P.
- complication rate with colpotomy and vacuum aspiration, C41

GOLDZIEHER, J.
- oral contraceptive side effects related to dosage, A37

GOMEZ-REGUERA, L.
- vasectomy
  - complications, D28(table)
  - technique, D28(table)

GOMEZ-ROGERS, C.
- effect of progestogen-only contraceptives on lactation, J63(table)

GONADOTROPIN, HUMAN CHORIONIC. See **HCG**.

GONADOTROPINS, J62

GONADOTROPINS, PITUITARY. See **PITUITARY GONADOTROPINS**.

GONORRHEA. See **VENEREAL DISEASE**.

GONOSHASTHAYA KENDRA PEOPLES HEALTH CENTER (BANGLADESH)
- address, J101(table)
- training nonphysicians, J94, J101(table)

GONZALEZ, C.
- progestogen-only contraceptives and lactation, J63(table)

GOODALL, J.
- crowding and social behavior among monkeys, J190

GOODELL'S MODIFIED ELLINGER DILATOR, F89(figure)

GOODYEAR, C., H22

GORDAN, G.S.
- estrogen use and breast cancer in postmenopause, A77(table)

GORDON, M.J.
- sperm separation by electrophoresis, I25

GOSSELIN, P.
- testicular function after vasectomy, D30

GOULD, R.S.
- vasectomy
  - anesthesia, D3
  - complications, D28(table)
  - technique, D28(table)
  - treatment for postoperative pain and swelling, D26–D27

GRAAF, R. DE, A30

GRAEFENBERG, E., B24

GRAEFENBERG RING
- development, B24
- use-effectiveness, B24

GRAIN. See **CEREALS**.

GRAND MAL
- $PGF_{2}\alpha$, F72, F74

GRANULOMA
- complications, D29
- culdoscopy
  - postoperative complication, C67(table)
  - treatment, C68
- diagnosis, D29–D30
- etiology, C29
- postvasectomy, D28(table), D29(graph)
  - electrocoagulation, D30
- sperm antibodies, D48
- treatment, C68, D30
- vasectomy reversal failure, D46

GRASPING FORCEPS
- maintenance and repair, M31

GRAVES SPECULUM, M20
- menstrual regulation, F12

GRAVIGARD. See **COPPER-7 IUD**.

GRAVINDEX, J116, J117(photo)
- cost, J119(table), J120(table)
- diagnostic capability, J119(table)
- modifications, J119
- sensitivity, J119(table), J120(table)
- time required, J120(table)

GRAY, K.G.
- voluntary sterilization in Canada, CD83

GRAY, L.A.
- estrogen use and endometrial cancer in postmenopause, A86(table)

GREAT BRITAIN. See **UNITED KINGDOM**.

GREECE
- abortion
  - legal status, E29(table), E35(table), J165
  - practice, E33, E35(table)
- age-specific fertility rate, J38(graph), J228(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- diaphragm availability, H68(table)
- legal status of voluntary sterilization, CD78, CD107(table)
- marital status of female adolescents, J164(table)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A13(table)
  - sales, A8(table)
- out-of-wedlock births, J160(figure)
- population policy, E35
- training nonphysicians, J94(table), J103(table)

GREEK MIDWIVES ASSOCIATION OF ATHENS
- training nonphysicians, J95(table)

GREEN, C.P., author, J265–J285

GREEN REVOLUTION
- India, J244, J246

GREENBLATT, R.B.
- potency of progestogens in women, A37

GREENE, K.R.
- Pomeroy tubal ligation, C77

GREENE, L.F.
- vasectomy technique, D6(table)

GREENLAND
- age-specific fertility rate, J3(graph), J226(graph)
- birth rate, J21, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- IUD acceptors, J307
- promotion of family planning, J307, J310(table)

GREER, B.
- $PGF_{2}\alpha$ for abortion, F74

GREGOIRE, A.T.
- seminal plasma, D30

GRENADA
- age-specific fertility rate, J226(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J21, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- condom shipments, H15(table)

GRIMWADE, J.
- laparoscopic sterilization, C2(table)
  - electrocoagulation with division, C8(table)
  - operative procedure, C7(table)
  - technique for pneumoperitoneum, C5(table), C18

GRISWOLD v. CONNECTICUT, F5

GRODE, G.A.
- gelatin-resorcinol-formaldehyde for tubal occlusion, C89

GROWTH OF AMERICAN FAMILIES STUDY, I9

GROWTH HORMONE
- lactation, J52(table)
- milk production, J51

GRUENSTEIN, M.
- orals and breast neoplasia in animals, A78(table)

G.S. MEDICAL COLLEGE (INDIA)
- vasectomy reversibility, D41

GUADELOUPE
- age-specific fertility rate, J3(graph), J226(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(table)
- change in number of births, J219(figure)
- marketing of oral contraceptives, A13 (table)

GUAM
- age-specific fertility rate, J3(figure), J225(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)

- diaphragm availability, H68(table)
- marketing of oral contraceptives, A13 (table)

GUATEMALA
- age-specific fertility rate, J35(graph), J226(graph)
- availability of Depo-Provera, K13(figure), K14
- birth rate, J23(figure), J29 (table), J207(table), J218(figure)
- breast-feeding, J54
- change in number of births, J219(figure)
- condom shipments, H14(table), H15(table)
- cost of injectable progestogens, K14
- culdoscopy, C69
- diaphragm availability, M68(table)
- health services, J195
- IUD acceptors, B27(table)
- legal status of abortion, E2, E7(table), E29(table), E32
- legal status of voluntary sterilization, CD77, CD107(table)
- marketing of minipill, A64(table)
- new acceptors, J17(table)
  - client revisits, J20(table)
- oral contraceptives
  - marketing, A13(table)
  - new acceptors, A18(table)
  - supplied by SIDA, A20(table)
  - supplied by USAID, A21(table)
- out-of-wedlock births, J160(figure)
- population policy, E42, E43(table)
- price of vaginal contraceptives, H48 (table)
- training nonphysicians, J95(table), J106(table)

GUATEMALA. D.I.M.I.F. DIRECCION GENERAL DE SERVICIOS DE SALUD.
- address, J106(table)
- training nonphysicians, J106(table)

GUDGEON, D.
- complications of postabortion laparoscopic sterilization, C24(table)

GUERRERO, R.
- coital timing, I24
- incidence of spontaneous abortion, I13
- sex ratio and BBT shifts, I24(chart)

GUILOFF, E.
- orals and lactation, J61(table)
- progestogen-only contraceptives and lactation, J63(table)

GUINEA
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- marketing of oral contraceptives, A13 (table)

GUINEA-BISSAU
- birth rate, J207(table), J210(table)

GULATI, T.I.
- spinal anesthesia for culdoscopy, C63

GULHATI, K., J247

GUMCO SURGICAL MANUFACTURING CORP., F41(table)

GUNNING, J.E., J107(table)

GUPTA, D.R.
- Nirodh promotion, H8

GUPTA, I.
- postanastomosis sperm antibodies, D48

GUSII
- tribal attitude toward premarital sex, J159

GUSTAVII, B.
- PG release in labor and menstruation, G49
- saline abortion mechanism, G49

GUTIERREZ-NAJAR, A.J.
- clip sterilization, C83(table)
  - failure rate, C83
- culdoscopy
  - operative complications, C66(table)
  - operative medication, C63(table)
  - postoperative complications, C67 (table)
  - preoperative medication, C63(table)
- training in Mexico, C62
- tubal occlusion, C65(table), C68(table)

GUTNICK, M.
- inflatable dilator, F97

GUTNICK DEVICE, F97(figure)

GUTTMACHER, A.F., B24, J41
- colpotomy
  - India, C29
  - pregnancy, C43
- oral contraceptives, A3

GUY, F.
- use-effectiveness of temperature rhythm method, I11(table)

GUY, M.
- use-effectiveness of temperature rhythm method, I11(table)

GUYANA
- age-specific fertility rate, J226(graph)
- birth rate, J23(figure), J29(table), J207 (table), J210(table)
- colpotomy training, C43
- diaphragm availability, M68(table)
- marketing of oral contraceptives, A14 (table)
- population per hospital bed, J71(table)
- population per physician, J71(table)

GUYON, F.
- atrophy of prostate with vas occlusion, D2

GYNESTHESIN, F30(table)

GYNOMIN
- active ingredients, H41(table)
- price and sales, H48(table)

GYNOVLAR
- manufacture and marketing, A4(table)

H

HABERLANDT, L., A30

HADDOCK
- supply v. demand, J183(figure)

HAFEZ, E.S.E., G29, G53

HAFS, M.D.,
- electrophoresis device for sperm separation, I27(photo)

HAGEDOORN, J.P.
- vasectomy side effects, D47

HAGENFELDT, K.
- accumulation of copper in body, B17
- rate of copper-7 release, B13

HAGNER, F.R.
- success rate of vaso-epididymal anastomosis, D42

HAHN, J.
- electrocoagulation with division in laparoscopic sterilization, C8(table)

HAITI, A1
- birth rate, J29(table), J207(table), J209 (table)
- diaphragm availability, H68(table)
- food supply, J244
- legal status of voluntary sterilization, CD107(table)
- oral contraceptives
  - clinical testing, A32
  - marketing, A14(table)
- paramedical personnel for IUD insertion, B28

HAJJ, S.N., author, J45

HAKANSON, E.Y.
- contraindication for colpotomy, C41
- morbidity rates compared in colpotomy and laparotomy, C40, C41

HALBRECHT, I.
- carbon dioxide laser for tubal occlusion, C91

HALDER, B.N.
- general health after vasectomy, D34(table)

HALE, R.W.
- dilatation with laminaria tents, F92
  - complications, F93
- menstrual regulation, F13(table), F51 (table)
  - complications, F52
  - procedure and equipment, F14(table)
- testing vacuum sources, F56
- uterine aspiration and complications with laminaria, F39(table)

HALIM, A.
- postvasectomy antibodies, D31(table)

HALL, H., B24

HALL, J.L.
- nursing and midwifery personnel, J90 (figure)

HALL, M.N.
- postcoital diethylstilbestrol
  - side effects, J148(table)
  - use-effectiveness, J145(table)

HALL, R.E.
- diaphragm failure, H66(table)
- uterine aspiration, F28(table)
  - anesthesia, F29(table)
  - blood loss, F34(table)
  - complications, F33(table)
  - equipment, F32(table), F41(table)
  - postoperative medication, F29(table)
  - pressure used, F41(table)
  - time required, F32(table), F34(table)

HALOTHANE, C3(table), C32(table), C55

HAMBERG, M.
- urinary metabolites of PGs, G47

HAMMARBERG, L.
- IUD use in Sweden, B19

HAN JIN INSTRUMENT CO., D11

HANCOCK, T., H22

HAND-OPERATED PUMP
- menstrual regulation, F12, F14(table)

HANKS UTERINE DILATOR, F89(figure)

HANLEY, H.G.
- pain from electrocoagulation after vasectomy, D5
- vas anastomosis effectiveness, D49(table)

HANNEMA, D.H.J.
- oral contraceptive market, A16

HANSEL, W.
- $PGF_2\alpha$ role in luteolysis, G53-G54

HANSON, F.W.
- intraamniotic saline abortion, F71(table)

HARBOR GENERAL HOSPITAL (CALIFORNIA)
- address, J107(table)
- training nonphysicians, J95(table), J98, J107(table)
  - IUD insertion, B28, J93

HARDY, N.R.
- condom sampling techniques, H27(table)
- incidence of fertilization, H29
- surface active agents, H42

HARRIS, W.M.
- spermicidal potency, H44

HARTMAN, C.G.
- use-effectiveness of calendar rhythm method, I9, I11(table)

HARVARD UNIVERSITY
- PG research, G17

HARVEY, P.D.
- condom dimensions, H28
- promotion of family planning, J309, J312

HASKINS, A.L.
- clip sterilization, C83(table)
- sterilization by colpotomy, C31(table)
  - anesthetic, C32(table)
  - clips, C34
  - complications, C40(table)
  - equipment, C36(table)
  - failure, C39(table), C43(table)

HASPELS, A.A.
- postcoital diethylstilbestrol
  - side effects, J147, J148(table)
  - use-effectiveness, J145(table)
- postcoital estrogens
  - side effects, J147, J148(table)

HASSE, C.
- diaphragm, H58

HAWAII
- contraception following menstrual regulation, F51

HAWAII, UNIVERSITY OF. EAST-WEST CENTER.
- evaluation of household distribution, J82-J83
- funding of family planning activities, J274(tables)

HAWAII, UNIVERSITY OF. SCHOOL OF MEDICINE-MEDEX PROGRAM.
- address, J107(table)
- training nonphysicians, J98, J107(table)

HAWAII, UNIVERSITY OF. SCHOOL OF PUBLIC HEALTH.
- conference on menstrual regulation, F49

HAYASHI, M.
- culdoscopic sterilization with clips, C62, C65(table)

HAYES, O.J.
- use-effectiveness of Saf-T-Coil, B32(table)

HAYNAL, A.P.
  maternal mortality in Pakistan, J258
HCG
  bonding in latex agglutination tests, J118
  cross-reaction with luteinizing hormone, J120
  detection after ovulation, J120–J121
  diagnosis of testicular malignancy, J113–J114
  factors affecting level
    ectopic pregnancy, J112(figure), J117
    hydatidiform mole, A88, J111(figure)
    pregnancy, F12, J110, J111(figure), J112(figure)
    threatened abortion, J112(figure)
    trophoblastic disease, J118
  immunologic pregnancy test, J111–J112
  measurement, F53
  molecular structure, J120
  quantification of activity, J118
  radioimmunoassay for pregnancy, J112, J113(figure)
  radioreceptorassay for pregnancy, J121
  serum level, G66
  slide test, J116
  tube test, J116
HEADACHE, D35
  hormonal-withdrawal test, J116
  injectable progestogens, K6
  local anesthesia, F30(table), F31
  minipill, A61
  PG administration, G3, G7(table), G8(table), G9(table), G10(table)
  postcoital estrogens, J148, J148(table)
  pseudopregnancy, A36
  spinal anesthesia, C42
HEALTH SERVICES
  Colombia, J195
  Guatemala, J195
  Kenya, J195
  People's Republic of China, J195
  Thailand, J195
  worldwide deficiency, J195
HEART
  prostaglandins, G25, G26, G27
HEART DISEASE
  air pollution, J183–J184
  obstetrical complication in multiparas, J134–J135(table)
HEART RATE
  clip sterilization, C46, C49
HEFNAWI, F.
  blood loss during menstruation with IUD, B35
  progestogen-only contraceptives and lactation, J63(table)
  silastic tubal occlusion, C88
HEGAR DILATORS, F90, F93
  cervical dilatation, G61
HEILBRONER, R.
  political implications of regulatory government, J200–J201
HEIMAN, M.
  sperm cryofreezer, D52
HELLMAN, L.M., J41
  obstetrical complications, J136–J137(table)
HEMAGGLUTINATION INHIBITION PREGNANCY TEST. See **TUBE TEST**.
HEMATOMA
  chemical sterilization, D15
  culdoscopy, C67(table)
  definition, D27
  laparoscopic sterilization, C23(table)
  mini-laparotomy, C57, C58
  vasectomy, D4, D9, D28(table), D29(graph)
    incidence, D27
    prevention, D8, D27
    treatment, D27
HEMATOMA, PELVIC
  colpotomy, C40(table), C41
HEMOCLIP APPLYING FORCEPS, D12
HEMOCLIPS. See also **CLIPS**.
  culdoscopy, C68
  laparoscopic sterilization, C45
  Weck hemoclip, C46(figure)
HEMORRHAGE. See **BLEEDING**.
HEMOSTASIS. See **BLEEDING**.
HENDERSON, J.
  prevalence of abortion, E26
HENDRATA, L.
  distribution of condoms in Indonesia, J313
HENDRICKS, C.H.
  PGs for pregnancy termination, G7(table), G8(table), G9(table), G11
HENRY, J.B.
  postvasectomy antibodies, D31(table)
HEPATITIS
  water pollution, J184
HEPATOCELLULAR ADENOMAS
  oral contraceptives, A88–A90
HERBRAND KG, H41(table)
HERNANDEZ-TORRES, A.
  norgestrel minipill
    continuation rate, A62(table)
    effectiveness, A56(table)
    menstrual pattern changes, A59(table)
HERNIA
  contraindication for laparoscopic sterilization, C18
  contraindication for vasectomy, D26
HERNIORRHAPHY
  performed by barefoot doctors, J97
HERPES GENITALIS
  cervical malignancy, A83
HERTZ, R.
  orals and breast cancer, A43
HESTON, W.E.
  animal studies with orals
    breast neoplasia, A78(table)
    cervical tumors, A85(table)
    endometrial tumors, A87(table)
    liver tumors, A89(table)
    ovarian tumors, A91(table)
    pituitary tumors, A90(table)
HEXESTROL
  vaginal adenocarcinoma in offspring, J146
HEYERDAHL, T.
  pollution, J182
  threatened extinction of plankton, J199
HEYWOOD, J.T.
  availability of Depo-Provera, K13(figure)
HICKS, J.B.
  laminaria for cervical dilatation, F92
HILL, A.B.
  criteria for epidemiological evidence, A71(figure)
HILLIER, K.
  measurement of PGF$_2\alpha$ in amniotic fluid, G49
  PGs for pregnancy termination, G7(table), G8(table), G9(table)
HIMES, N.E.
  condom for prevention of venereal disease, H13
  early contraceptive methods, A30
  latex condom manufacture, H23
HIMMELMANN, A.
  extraovular instillation of PGF$_2\alpha$, F75(table)
HINDUSTAN LATEX, H8, H19
HIPPOCRATES, B23, C1
  cervical dilatation, F87–F88
  sex preselection theory, I22
HOBBS, J.J.
  silk sutures after scrotal incision, D8
  vasectomy technique, D6(table)
HOBSON, B.M.
  immunologic pregnancy tests
    slide test, J119(table)
    tube test, J118(table)
  testicular malignancy diagnosed by HCG level, J113–J114
HODGSON, J.
  extraovular instillation of PGF$_2\alpha$, F75(table)
HOFSTATTER, E.
  availability of Depo-Provera in selected countries, K13(figure)
HOLLAND. See **NETHERLANDS.**
HOLLAND-RANTOS CO., INC., H41(table)
  address, H68(table)
  diaphragm manufacture, H58, H68(table)
HOLLWEG, C.
  contraceptive use of pessaries, C23–C24
HOLTROP, H.
  training in culdoscopy, C69
HOMOSEXUALITY
  contraindication for vasectomy, D34
HONDURAS
  age-specific fertility rate, J36(graph), J226(graph)
  birth rate, J29(table), J207(table), J209(table)
  condom shipments, H15(table)
  Depo-Provera
    availability, K13(figure)
    use-effectiveness, K4(table)
  diaphragm
    availability, H68(table)
    training, nonphysicians, H67
  legal status of abortion, E29(table)
  legal status of voluntary sterilization, CD70, CD108(table)
    official authorization, CD71
  marketing of minipill, A64(table)
  new acceptors, A18(table), J18(table)
    revisits, J20(table)
  oral contraceptives
    marketing, A14(table)
    new acceptors, A18(table)
    supplied by USAID, A21(table)
  promotion of family planning, J299, J303
  training nonphysicians, J95(table), J106(table)
  war with El Salvador, J193
HONG KONG
  age of menarche, J162(table)
  age-specific fertility rate, J3(graph), J5(graph), J25(graph), J37(graph), J222(graph)
  birth rate, J21, J23(figure), J29(table), J207(table), J218(figure), J239
  change in number of births, J219(figure)
  clip sterilization, C82
  condom shipments, H14(table)
  contraceptive practice, A12(table)
  Depo-Provera
    availability, K13(figure), K14
    continuation rate, K7(table), K8(table)
    use-effectiveness, K4(table)
  diaphragm
    availability, H68(table)
    training nonphysicians, H67
  estimated population, E30(table)
  experimental study of copper IUD, B18
  expulsion, pregnancy, removal, and continuation rates of copper IUDs, B6(table)
  family planning, J24
    promotion, J294, J298
  injectable progestogens
    cost, K14
  IUD
    acceptability, B26
    acceptors, B27(table)
    continuation rate, B33(table)
  laparoscopic sterilization, C2, C14
    training, C2, C14
  legal status of abortion, E30(table), E32, E33(table)
  low-cost housing, J186
  marketing of minipill, A46(table)
  marriage practice and birth rates, J2
  new acceptors, A18(table), J13(table)
  oral contraceptives
    marketing, A14(table)
    new acceptors, A18(table)
    supplied by USAID, A21(table)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  price of vaginal contraceptives, H48(table)
  termination rate with Dalkon Shield, B22(table)
  total fertility rate, J215(table), J216, J217(table)
  training nonphysicians, J94(table), J101(table)
HONG KONG FAMILY PLANNING ASSOCIATION, B6
HOOD, L.H.
  culdoscopic equipment, C69, C70(figure)
HOOKS
  colpotomy, C33
HOOVER, R.
  estrogen use and breast cancer in postmenopause, A77(table)
HORAN, A.H.
  vasectomy complications, D47
HORMONAL-WITHDRAWAL TEST
  abortifacient nature, J114
  advantages, J115

- availability in US, J115
- congenital abnormalities, A48, J116
- development, J111
- disadvantages, J111
- effectiveness, J114
- mode of action, J111
- popularity, J114
- side effects, J116

HORMONES. See also specific hormones, e.g., **ESTROGEN**; **PROGESTERONE**; etc.
- feedback mechanism, A34
- role in lactation, J50-J51, J52(table)

HORMONES, OVARIAN
- changes during menstrual cycle, pregnancy, and oral contraceptive use, A33(figure)

HORMONES, PITUITARY
- changes during menstrual cycle, pregnancy, and oral contraceptive use, A33(figure)

HOROWITZ, A.J.
- intraamniotic saline abortion, F71(table)

HORWITZ, C.A.
- immunologic pregnancy tests
  - slide test, J119(table)
  - tube test, J118(table)

HOSPITAL MEXICO (COSTA RICA)
- address, J106(table)
- training nonphysicians, J95(table), J106(table)

HOSPITAL DE LA MUJER (MEXICO)
- training in culdoscopy, C62, C69

HOSSEINIAN, A.H.
- polyethylene plug for tubal occlusion, C90(table)

HOTAY
- C-film, H40

HOUSEHOLD DISTRIBUTION. See **COMMUNITY-BASED DISTRIBUTION, household distribution.**

HOUSING
- shortages, J185-J186

HOUSTON TEXAS MEDICAL CENTER
- artificial insemination, D52

HOWARD, J.H.
- postvasectomy antibodies, D31(table), D32

HOWARD, P.J.
- vasectomy technique, D6(table)

HOWKINS, J.
- cervical dilatation
  - degree, F86
  - technique, F91(figure)
- uterine perforation, F90(figure)

HSU, Y.
- family planning promotion in Taiwan, J300, J304

HUANG, K.E.
- clip sterilization, C83(table)

HUBER, D.H.
- screening oral contraceptive candidates, J91

HUBER, S.C., author, A29-A51, B21-B48, J69-J88
- acceptors of vaginal contraceptives in selected countries, H49(table)

HUG, GERHARD, GmbH
- address, M32
- Bleier clip, M18(table), M19(figure)
- guarantee and service of sterilization equipment, M30(table)

HUGHES, L.
- orals and lactation, J61(table)

HULKA, J.F., author, C45-C52
- cervical dilatation, F87
- clip sterilization, C12, C52, C83(table)
  - complications, C49
  - development, C45, C46-C47
  - effectiveness, C50
  - follow-up, C50
  - pain, C49
  - preoperative medication, C47(table)
- colpotomy
  - failure rates, C42
  - morbidity rates, C40
- dacron plug for tubal occlusion, C91
- laparoscope and local anesthesia channel, C50
- laparoscopic sterilization
  - clip application, C84(photo)
  - failure, C22(table)
  - postabortion, C23, C24
  - training, C13
- laparoscopy in multigravid and postabortal uteri, C6
- menstrual regulation, F13(table)
  - procedure and equipment, F14(table)
- spring-loaded clips
  - design, C83
  - failure rate, C84
  - laparoscopic application, C84(photo)
- standards for vas occlusive devices, D52

HULKA CLIP, C55, C56. See also **CLIPS.**
- description, C45, C48(figure)
- evaluation, C46-C52

HULL, H., J188(photo), J196(photo)

HUMAN CHORIONIC GONADOTROPIN. See **HCG.**

HUMANAE VITAE, CD87, I3

HUMORAL IMMUNITY
- postvasectomy, D31-D32

HUMPHREYS, G.A.
- effectiveness of vas anastomosis, D45

HUMPHREYS, R.H.
- operative procedures for vas anastomosis, D44(table)

HUNGARY
- abortion, F66
  - legal status, E6, E8(table), E29, E30 (table), E36, E38, J165
  - mortality, F37(table)
- adolescent births, J161(table)
- age-specific fertility rates, J10(graph), J38(graph), J228(graph)
- birth rate, J21, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- condom manufacture, H23
- condom standards, H25, H26(table)
  - aging, H27, J28
  - dimensions, H29(table)
  - strength, H27
- family planning policy, E1, E2, E3(table), E4(table)
- folk barrier methods, H58
- incidence of cancer in women, A70(table)
- IUD, J164
- legal status of voluntary sterilization, CD108(table)
- oral contraceptives, J164
  - distribution, E44(table)
  - marketing, A14(table)
- percentage of legal abortions to women under 20, J171(table)
- PG research, G11, G20, G22
- population, F7(table)
- postcoital dienestrol, J144
- postcoital estrogen-progestin combination, J150

HUNGER
- food production, J184-J185

HUNT, W.B. II, author, F65-F83, J109-J124, J157-J172

HUNTER, J.
- vas occlusion, D2

HUSBANDS, M.E., JR.
- failure rate of Pomeroy tubal ligation, C77

HUTCHINSON, J.
- family planning promotion in the US, J305

HUTTERITES
- birth rate, J127
- mortality rate, J127

HYALURONIDASE, I26
- cervical dilatation, F98

HYDATIDIFORM MOLE, F31. See also **TROPHOBLASTIC DISEASES**.
- diagnosis, J113, J114
- HCG level, J110, J111(figure)
- oral contraceptives, A88
- uterine aspiration, F60

HYDROCELE
- contraindication to vasectomy, D26
- postvasectomy, D29

HYDROGEN, G1

HYDROGEN PEROXIDE
- chemical sterilization, D15

HYDROQUINONE, H39

HYDROSALPINX
- clip sterilization, C48-C49
- culdoscopy, C67
- tubal ligation, C74

HYDROXYPROGESTERONE CAPROATE, K2

HYDROXYZINE HYDROCHLORIDE, F29 (table)

HYLAND, J116

HYPERCARBIA
- anesthesia administration, C18
- pneumoperitoneum, C19

HYPERNATREMIA, F79
- $PGF_2\alpha$ for abortion, F74
- saline abortion, F69, F70, F74

HYPERPLASIA, A85

HYPERTENSION
- adolescent pregnancy, J165(table)
- local anesthesia, F31
- obstetrical complication in multiparas, J134-J135
- oral contraceptives, A2, A42
  - incidence in users and nonusers compared, A31(figure)
  - reversibility, A42, A43
- symptoms, A43
- vasectomy, D26

HYPERTONUS
- PG administration, G7(table), G10(table)

HYPOCHONDRIA
- contraindication for vasectomy, D34, D35

HYPOGLYCEMIA
- vasectomy, D31

HYPOTENSION
- anesthesia and insufflation, C23, C62
- contraindication for culdoscopy, C66
- menstrual regulation, F16
- spinal anesthesia, C42
- spring-clip sterilization, C84
- uterine aspiration, F31

HYPOTHALAMUS
- hormone-releasing factors, A34

HYPOTHALAMUS-PITUITARY AXIS
- effect of progestogens, K3

HYSTERECTOMY
- colpotomy, C42
- luteolysis, G46
- mortality, E27(graph)
- uterine perforation, F35(table), F36

HYSTEROSALPINGOGRAM, C13
- locating IUD, B31
  - recanalization, C21

HYSTEROSCOPE, C81(figure)

HYSTEROSCOPIC FULGURATION, C76 (table). See also **ELECTROCOAGULATION**.
- advantages and disadvantages, C82
- contraindications, C81
- equipment, C81(figure)
- failure rate, C81, C82(table)
- history, C81
- procedure, C81
- selected studies, C82(table)
- voltage and temperature, C81, C82(table)

HYSTEROSCOPY
- compared with laparoscopy, C81
- tubal fulguration, C78, C81-C82
  - selected studies, C82(table)
- tubal occlusion
  - chemical, C77(table), C89
  - plugs, C90(table)

HYSTEROTOMY
- abortion, F66, F67
- compared with PGs for pregnancy termination, G12
- mortality rate, F38
- uterine perforation, F35(table), F36

I

IBADAN, UNIVERSITY OF (NIGERIA)
- address, J104(table)
- training nonphysicians, J94(table), J104(table)

IBRAHIM, A.
- orals and lactation, J61(table)
- sterilization and Islamic law, CD86

ICELAND
- age-specific fertility rate, J228(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- cod war, J194

- legal status of abortion, E30(table)
- legal status of voluntary sterilization, CD70, CD108(table)
- marketing of oral contraceptives, A14 (table)
- out-of-wedlock births, J160(figure)
- population, F7(table)

IDE, P.
- orals and squamous metaplasia, A84(table)

I.E.T., F41(table)

IGLESIA NI CRISTO (PHILIPPINES)
- institutional distribution of contraceptives, J78-J79
  - effectiveness, J79
  - program cost, J79
  - promotion of family planning, J75

IIT RESEARCH INSTITUTE (CHICAGO, ILLINOIS)
- reversible vas occlusive valves, D56(photo)

IKEMI, O.
- Yusei ring, B42

I.L. CRAFT VASECTOMY FORCEPS, D11

ILLITERACY. See **LITERACY**.

IMMOLIN VAGINAL CREAM-JEL
- active ingredients, H41(table)
- venereal disease, H51(table)

IMPLANTATION
- inhibition by IUDs, B25
  - copper, B5, J151
- postcoital estrogens, J144-J146
- postcoital progestogens, J148
- suppression by injectable progestogens, K3

IMPOTENCE
- contraindication for vasectomy, D34, D35

INCENTIVES, E42
- fieldworkers, B26
- population policy, E8, E49-E50
- selected countries, E8,E48(table)

INDIA, F51
- abortion
  - adolescents, J170
  - grounds, E36(table)
  - legal status, E29, E30(table), F1, F2, F4, J165
  - need for trained personnel, E38
  - practice, E34
- age of menarche, J162(table)
- age-specific fertility rate, J225(graph)
- availability of Depo-Provera, K13(figure)
- Bengal tigers, J198
- birth rate, J29(table), J207(table), J209 (table), J239
- cervical cancer, J135
  - factors influencing, J133(table)
- cervical cap
  - manufacture, H71(figure), H72
  - use-effectiveness, H72
- chemical tubal occlusion, C87, C88
- clip sterilization, C47(table)
- colpotomy, C29, C31(table)
  - complication rates, C40, C41
  - during pregnancy, C43
  - infection and treatment, C42
  - spinal anesthesia, C31
  - training, C43
- compulsory sterilization, E48, J237, J247
- condom
  - distribution, H7, H8
  - manufacture, H5, H23, J74
  - promotion, H1, H8
  - sales, H8
  - shipments, H14(table), H15(table)
  - standards, H25, H26(table), H28, H29(table)
  - testing, H27
  - use-effectiveness, H32, H33(table)
- culdoscopy, C61
  - compared with colpotomy, C61
  - complications, C66(table), C67(table)
  - training, C62, C70
  - tubal occlusion, C65(table), C68(table)
- deforestation, J192
- development policy, E18
- diaphragm
  - availability, H68(table)
  - distribution, H59-H60
  - failure rate, H65(table)
- distribution of contraceptives, E41, E42, E44, J90
  - institutional, J79, J84(table)
  - subsidized, J75, J76-J77, J84(table)
  - village-based, J72
- duration of postpartum amenorrhea, J57(table)
- early marriage, J158
  - cultural aspects, J158
- estimated population, E30(table), E36 (table)
- family planning program, J1, J325
  - promotion, J293, J294-J295, J298, J300, J305-J306, J310(table)
- folate deficiency anemia, J130
- folk methods for sex preselection, I22
- food shortages, J242, J244
- incidence of cancer in women, A70(table)
- infant mortality and birth interval, J256 (table)
- IUD
  - acceptors, B21, B26, B27(table)
  - copper, B18
  - insertion by paramedical personnel, B28
- labor force, J197
- lactation
  - effect of orals, J60(table)
  - effect of progestogen-only contraceptives, J63(table)
  - infant mortality, J58
- legal status of voluntary sterilization, CD70, CD78, CD89, CD108(table)
- low-cost housing, J186
- manufacturers of sterilization equipment, M2
- maternal mortality, J127
  - anemia, J131
- mean age of marriage, J160
- medical complications of adolescent pregnancy, J165(table)
- menstrual regulation, F20, F62
  - contraception following, F51
- Ministry of Health
  - condom distribution, promotion, and sales, H8(table)
- mortality rate, J244, J245(table)
- new acceptors, A18(table), B21, B26, B27(table), J13(table)
- Nirodh, H8(table), H15
- number of children and undernutrition, J255
- oral contraceptives
  - availability, A2
  - lactation, J160(table)
  - marketing, A14(table)
  - new acceptors, A18(table)
  - supplied by USAID, A21(table)
- overgrazing, J188-J189
- PG research, G11, G20, G22
- population, F7(table)
- population density, J192
- population policy, J200
  - economic incentive, E50
- postcoital douche, J142
- postcoital estrogens, J141
- promotion of family planning
  - film, J298
  - mailings, J293
  - multimedia, J305-J306, J310(table)
  - newspapers, J294-J295
  - radio, J300
- rhythm method, I2, I14(table), I15
  - use-effectiveness of calendar rhythm method, I10
- son preference and family size, I22
- tourism, J180
- training in laparoscopic sterilization, C2, C14
- training nonphysicians, J94(table), J101(table)
- tubal ligation, C74
- uterine aspiration, F27
- vaginal contraceptives, H39
  - promotion, H47-H48
- vasectomy, C24, D1, D27(photo), D34 (table)
  - camps, J313
  - contraception, D33
  - demand for reversal, D41
  - incentive payments, D9
  - mortality, D28
  - preoperative procedure, D3
  - religious aspects, D36
  - sexual behavior, D35(table)
  - sperm count, D10
- Yoon band sterilization, C85

INDIGENOUS DISTRIBUTION SYSTEMS. See **COMMUNITY-BASED DISTRIBUTION**.

INDIGENOUS MEDICAL PRACTITIONERS
- training in vasectomy, J97, J98

INDIGO CARMINE
- testing tubal occlusion, C64

INDIVIDUAL FREEDOM
- regulations to control resources, J200-J201

INDOMETHACIN
- inhibition of PG synthesis, G50
- prolonged gestation, G50
- uterine contractility, G47

INDONESIA
- abortion, F7(table)
  - legal status, E28, E30, E34, E36(table)
- adolescent births, J161(table)
- age-specific fertility rate, J222(graph)
- availability of Depo-Provera, K13(figure)
- average births per woman, J129(table)
- birth rate, J29(table), J207(table), J209 (table)
- breast-feeding, J54
- change in number of births, J239
- condom, J74, J78
  - distribution, H11
  - shipments, H14(table), H15(table)
- culdoscopy, C61, C69
  - training, C70
- Department of Health
  - address, J101(table)
  - training nonphysicians, J101(table)
- distribution of contraceptives, J70, J92, J165
  - Jamu, J78
  - subsidized community-based, J78
- economic incentives, E48(table), E50
- estimated population, E36(table)
- family planning program
  - communication, J310(table), J312-J313
  - service statistics system, J324, J326-J329
- impact of family planning, J206, J216
- IUD
  - acceptors, B27(table)
  - copper, B18
  - insertion by nonphysicians, B28, J93
- legal status of voluntary sterilization, CD82, CD108(table)
- modifications of slide test, J119
- National Family Planning Coordinating Board, J326, J327(figure), J328(figure), J329(figures), J330(figure)
  - address, J101(table)
  - subsidized community-based distribution, J78
  - training nonphysicians, J94(table), J101(table)
- new acceptors, A17, A18(table), J13(table)
- oral contraceptives
  - marketing, A14(table)
  - new acceptors, A17, A18(table)
  - supplied by SIDA, A20(table)
  - supplied by USAID, A21(table)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- population, F7(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- rubber plantations, H22, H23
- total fertility rate, J215(table), J217(table)
- training nonphysicians, J94(table), J101(table)
  - diaphragm fitting, H67
  - vasectomy, J98
- unemployment, J197

INDONESIAN PLANNED PARENTHOOD ASSOCIATION
- family planning education, J171

INDO-PAKISTANI WAR (1971), J193

INDURATION
- clip sterilization, C49

INDUSTRIAL REVOLUTION
- mortality decline, J212

INFANT MORTALITY. See **MORTALITY, INFANT**.

INFANTICIDE
- cultural aspects, J158
- sex selection, I22

INFECTION
- abortion with urea, F78(table)
- antibiotics, C35, C42
- chemical sterilization, D15
- clip sterilization, C46, C49
- colpotomy, C40(table), C41-C42
  - treatment, C42
  - vacuum aspiration, C41
- culdoscopy
  - contraindication, C65
  - postoperative complication, C67(table), C68
- diaphragm use, H64
- incomplete abortion, F60
- IUD insertion, B12
- IUD in situ, B12
- laminaria, F92
- laparoscopic sterilization, C18, C23
- menstrual regulation, F15, F16(table), F51, F52(table)
- midtrimester abortion, F67
- PG administration, G3
- $PGF_2\alpha$, F73(table), F74, F75(table)
- saline abortion, F69-F70, F72
  - selected studies, F71(table)
- tubal occlusion, C73
- uterine aspiration, F33(table), F60(table)
  - rate, F35
- vasectomy, D28(table), D29(graph)
  - antibiotics, D29
  - etiology, D27
  - incidence, D27
  - precautions, D28-D29

INFECUNDIN
- manufacture and marketing, A4(table)

INFERTILITY
- early cure, B23
- early studies, A31, A34
- menstrual regulation, F52
- sperm antibodies, D31

INFLATION
- supply v. demand of resources, J182-J183

INHOFFEN, H.H.
- ethisterone synthesis, A32

INJECTABLE CONTRACEPTIVES. See also **INJECTABLE PROGESTOGENS**.
- administration by nonphysicians, J92
- menstruation disorders, K2
- postcoital, J144, J145(table)
- sources of funding, J270(table), J274-J276(table)
- use in US, H59(table)

INJECTABLE PROGESTOGENS. See also **DEPO-PROVERA; INJECTABLE CONTRACEPTIVES; MEDROXYPROGESTERONE ACETATE; NORIGEST**.
- acceptability, K12
- addition of estrogens, K3
- advantages and disadvantages, K1
  - compared with IUDs and orals, K11(figure)
- carbohydrate metabolism, K6
- carcinogenic effects, K9-K11
  - etiology, K10
- continuation, K7-K8
- cost, K14
- development, K2-K3
- disadvantages, J59
- endometrial effects, K3
- estimated use, K1
- family planning programs, K11
- fetal effects, K9
- lactation, J59, K11
  - composition of breast milk, K12
- low-dose v. high-dose, K6
- mechanism of action, K3
- menstruation disorders, J59, K5
- mode of administration, K12
  - reversibility, K12
- program issues, K11-K13
- reversibility, K1, K8-K9, K12
- side effects, K4-K7
  - compared with orals, K7
  - lack of evidence, K7
- site of administration, K4
- use-effectiveness, K3-K4
- use with oral estrogens, K6

INMAN, W.H.W.
- orals and thromboembolic disease, A41(table)
  - age, A42

INNOVAR. See **FENTANYL**.

INOUE, T.
- use-effectiveness of contraceptive foam tablets, H45(table)

INSEMINATION, ARTIFICIAL. See **ARTIFICIAL INSEMINATION**.

INSEMINATION, TIMING OF. See **COITAL TIMING**

INSOMNIA, D35

INSTITUTE OF MATERNAL AND CHILD HEALTH (PHILIPPINES), J79

INSTITUTIONAL DISTRIBUTION. See **COMMUNITY-BASED DISTRIBUTION, institutional distribution**.

INSTRUCTION MANUAL FOR RETRAINING BAREFOOT DOCTORS, J97

INSUFFLATION. See also **PNEUMOPERITONEUM**.
- clip sterilization, C47
- equipment, C9-C10, C51-C52, M13(photo)
  - comparison of selected products, M12(table)
  - maintenance and repair, M29
- technique, M10-M11, M12

INTER-AMERICAN CENTER FOR TRAINING IN COMMUNICATIONS FOR POPULATION AND FAMILY HEALTH (CIACOP)
- address, J283
- population program assistance, J274(table)

INTER-AMERICAN INVESTIGATION OF MORTALITY IN CHILDHOOD, 1973
- selected countries, J166(table)

INTERCONTINENTAL MEDICAL STATISTICS, LTD., A1
- oral contraceptive purchases, A7
  - selected countries, A8(table), A10(graph), A11(graph), A12(table)

INTERNATIONAL ADVISORY COMMITTEE ON POPULATION AND LAW, E1
- symposium in Tunis, E1, E2

INTERNATIONAL CHOLERA RESEARCH LABORATORY, J242, J244(table)

INTERNATIONAL COMMITTEE FOR CONTRACEPTION RESEARCH (POPULATION COUNCIL)
- research on copper-7, B19

INTERNATIONAL CONFERENCE IN ANDROLOGY, DETROIT, 1975
- frozen semen storage, D52

INTERNATIONAL CONFERENCE ON THE PHYSICIAN AND POPULATION CHANGE, STOCKHOLM, 1974, E13, E19
- attendance, E19
- issues
  - family planning and health care, E19
  - health teams, E19-E20
  - medical institutional role, E20
  - physician's role, E19
- Strategy for Action, E13, E19, E22-E24

INTERNATIONAL CONFERENCE ON VOLUNTARY STERILIZATION, 2nd, GENEVA, 1973, C26, C27, CD95-CD96, D15
- fascial barrier in vasectomy, D8
- incision for colpotomy, C33
- program, C26
- psychological side effects of vasectomy, D34
  - prevention, D36
  - reversible, D41
- sperm count and male sterility, D10
- workshop on male sterilization, J97
- workshop on staffing patterns, J97

INTERNATIONAL CONFERENCE ON VOLUNTARY STERILIZATION, 3rd, TUNIS, 1976
- recommendations, E45, E48

INTERNATIONAL CONGRESS OF GYNECOLOGICAL LAPAROSCOPY, NEW ORLEANS, 1973, C25-C26

INTERNATIONAL DEVELOPMENT RESEARCH CENTRE, J93(figure)
- address, J284
- funding of family planning activities, J271(table), J275(table), J277
- IUD conference, B25
- research funding for copper IUD, B19

INTERNATIONAL FEDERATION OF GYNAECOLOGY AND OBSTETRICS (FIGO), COMMITTEE ON MATERNAL MORTALITY
- maternal death definition, J128

INTERNATIONAL FERTILITY RESEARCH PROGRAM (IFRP), J42
- address, B48, C59, J283
- cumulative abortion rates with intraamniotic PG administration, G12(figure)
- epidemiological studies with PGs, G12
- family planning activities, J268, J271(table), J275(table), M3
- IUD conference, B25
- IUD evaluation, B33, B39
  - termination rates, B22(table)
- maternity care monitoring, J339(figure)
- menstrual regulation, F50, F51
  - failure rates, F54, F55
  - research, F20, F22, F23
  - training, F20
- pregnancy termination studies, F44
  - questionnaire, F45
- pregnancy test effectiveness, F53
- workshop on Hulka clip, C46
- Yoon band effectiveness, C85

INTERNATIONAL LABOR ORGANIZATION (ILO)
- address, J284
- estimated world labor force, J198(table)
- population program assistance, J271(table), J275(table), J278
- unemployment, J197-J198

INTERNATIONAL MONETARY FUND
- supply v. demand of cereals, J182(figure)

INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF), A32, B30, C39, J201
- address, C58, J85
- administration of community-based distribution programs, J69, J77, J81
- condom
  - dimensions, H29
  - distribution, H10, H14, H16
  - packaging, H28
  - prices, H24
- conference sponsorship, E13, E19
- Depo-Provera
  - availability in selected countries K13(figure)
  - distribution, K14
  - restricted use, K12
  - worldwide use (1971-1975), K13(table)
- Directory of Contraceptives, H47
- distribution of oral contraceptives, A22
  - community-based, A22-A23
- Eighth International Conference, J93
- estimated use of contraception, A16
- funding of family planning activities, J266, J270-J271(table), J275(table), M3
- IUD Conference, B25
- laparoscopy equipment, C9
- menstrual regulation equipment, F19
- minipill, A63
- mortality
  - legal abortion, F37(table)
  - Sri Lanka, J244
- pregnancy and abortion rates, E26
- procurement of laparoscopy equipment, C9
- procurement of menstrual regulation equipment, F19
- procurement of uterine aspiration equipment, F38
- sperm count after vasectomy, D10
- supply of contraceptives, J76, J77
- test for total spermicidal power, H44
- training
  - colpotomy, C43
  - family planning, J96
  - menstrual regulation, F20
- uterine aspiration equipment, F38
- vaginal contraceptives, H47
  - distribution, H50(table)

INTERNATIONAL PLANNED PARENTHOOD FEDERATION, CENTRAL MEDICAL COMMITTEE
- contraception for lactating women, J62
- distribution of orals by nonphysicians, J74
- electrical aspirator, F42

- Medical Committee on the Distribution and Supervision of Oral Contraceptives, J91
- statement of distribution of orals, A22

INTERNATIONAL PLANNED PARENTHOOD FEDERATION-EUROPEAN REGION
- timing in IUD insertion, B29-B30

INTERNATIONAL PLANNED PARENTHOOD FEDERATION. PANEL OF EXPERTS ON MALE AND FEMALE STERILIZATION
- colpotomy, C29
  - antibiotics, C35
  - Madlener method, C34
- recommendations for laparoscopic fulguration techniques, C80
- recommendations for tubal ligation, C75, C77, C78
- vasectomy, D25
  - local anesthesia, D3
  - penicillin, D29
  - postoperative care, D9
  - reanastomosis, D36

INTERNATIONAL PLANNED PARENTHOOD FEDERATION. WORKING GROUP ON CONDOMS
- condom standards, H30, H31(figure)

INTERNATIONAL POSTPARTUM FAMILY PLANNING PROGRAM (POPULATION COUNCIL)
- IUD acceptors and continuation rates, B14
- IUD insertion, B29

INTERNATIONAL PREGNANCY ADVISORY SERVICE
- address, J283
- menstrual regulation equipment, F57
- population program assistance, J275 (table)

INTERNATIONAL PROJECT OF THE ASSOCIATION FOR VOLUNTARY STERILIZATION. See **ASSOCIATION FOR VOLUNTARY STERILIZATION-INTERNATIONAL PROJECT**.

INTERNATIONAL REFERENCE CENTER FOR ABORTION RESEARCH
- legal status of abortion, F3(figure), F7 (tables)

INTERNATIONAL STANDARDS ORGANIZATION, H30

INTERNATIONAL STATISTICAL INSTITUTE/WORLD FERTILITY SURVEY (ISI/WFS), J205, J216
- address, J283
- funding of demographic research activities, J269, J271(table), J275 (table)

INTERNATIONAL UNION FOR THE CONSERVATION OF NATURE AND NATURAL RESOURCES
- endangered wildlife species, J198

INTERNATIONAL UNION FOR THE SCIENTIFIC STUDY OF POPULATION (IUSSP)
- population program assistance, J275 (table)

INTERNATIONAL WOMEN'S YEAR CONFERENCE, MEXICO CITY, 1975, E30

INTERVAL STERILIZATION
- colpotomy, C30, C42, C[illegible]4, C77
- culdoscopy, C65, C77, C78
- fimbriectomy, C78
- fulguration, C78
- hysteroscopy, C78
- laparoscopy, C77, C78
- laparotomy, C77
- mini-laparotomy, C53, C77
  - history, C54
- performed by nonphysicians, J97
- spring-loaded clips, C84

INTRACERVICAL BLOCK
- menstrual regulation, F13(table)
- uterine aspiration, F29(table), F30 (table)

INTRAUTERINE DEVICE. See **IUD**.

INTRAUTERINE MEMBRANE, B46(figure)
- current status, B39
- description, B46
- distribution, B46
- use-effectiveness, B46

INTRAVAGINAL BARRIERS. See **CERVICAL CAP; DIAPHRAGM; VAULT CAP; VIMULE**.

INTRAVAS CONTRACEPTIVE DEVICE (IVCD). See also **INTRAVASAL THREAD (IVT)**.
- description, D53
- reversible vas occlusion, D53

INTRAVASAL THREAD (IVT), D53(figure). See also **INTRAVAS CONTRACEPTIVE DEVICE.**
- effectiveness, D14
- insertion, D14
- reversibility, D14, D53
- vas occlusion, D53

IODINE, F39

IRAN
- acceptors following communications campaign, J307(table), J308(tables), J311(table)
- age-specific fertility rate, J225(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J208, J210(table)
- condom
  - distribution, H5(table), H16
  - importation costs, H5(table)
  - shipments, H14(table)
- contraceptive usage, H4(table)
- copper-T
  - expulsion rate, B10
  - pregnancy rate, B10
- culdoscopy, C69
- diaphragm
  - availability, H68(table)
  - training nonphysicians, H67
- experimental study of copper IUD, B18
- family planning, J208
  - promotion, J296, J298, J303, J307, J311(table)
- infant mortality, J254
- legal status of abortion, E2, E7(table), E34
- menstrual regulation, F51
- Ministry of Health. Family Planning Division.
  - address, J103(table)
  - training nonphysicians, J95, J103 (table)
- new acceptors, A17, A18(table), J13(table)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A14(table)
  - new acceptors, A17, A18(table)
  - nonprescription, E41, E43, E44(table)
  - sales, A8(table)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- training nonphysicians, J95(table), J103(table)
- tubal ligations performed by nonphysicians, J97
- vaginal contraceptives, H48
- voluntary sterilization, E2, E45(table), E48
  - legal status, CD67, CD108(table)
- Yoon band sterilization, C85

IRAQ
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- condom shipments, H15(table)
- diaphragm availability, H68(table)
- IUD insertions, E44(table)
- legal status of abortion, E30
- oral contraceptives
  - marketing, A14(table)
  - nonprescription, E41, E43, E44(table)
  - supplied by SIDA, A20(table)

IRELAND
- age-specific fertility rate, J39(graph), J228(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- legal status of abortion, E30
- legal status of voluntary sterilization, CD106(table)
- marketing of minipill, A64(table)
- obstetrical complications with multiparity, J134(table)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A14(table)
  - sales, A8(table)
- policy changes on contraceptives, E4 (table)

IRON
- amount required during pregnancy, J131(table)
- oral contraceptives, A23
- world consumption, J194

IRON DEFICIENCY ANEMIA, J130. See also **ANEMIA; FOLATE DEFICIENCY ANEMIA**.
- oral contraceptives, A38, A48, J131-J132
  - incidence in users and nonusers compared, A31(figure)
- prevalence, J131(table)

IRVING, F.C.
- tubal ligation technique, C75

IRVING TECHNIQUE, C75(figure), C76(table)
- advantages and disadvantages, C75
- failure rate, C75, C76(table)
- procedure, C75

ISAACS, J.
- diagnosis of endometrial cancer, F59

ISAACS, S.L., author, J69-J88

ISHIHAMA, A.
- Ota ring, B24
- use-effectiveness of contraceptive foam tablets, H45(table)

ISHII, T.
- tubal occlusion via culdoscopy, C65(table)

ISLE OF MAN
- birth rate, J23(figure), J29(table), J207 (table), J281(figure)
- change in number of births, J219(figure)

ISLETA INDIANS
- fertile period identification, I3(table)

ISOCITRIC DEHYDROGENASE, D30

ISOQUINOLONE
- PG metabolism, G57, G61
- pregnancy termination
  - effectiveness, G57, G61
  - mode of action, G61
  - postabortion effects, G61

ISRAEL
- abortion
  - legal status, E29(table), E35(table)
  - practice, E35(table)
- age-specific fertility rate, J37(graph), J225(graph)
- birth rate, J21, J23(figure), J29(table), J207(table), J218(figure)
- change in number of births, J219(figure)
- condom
  - manufacture, H23
  - standards, H25, H26(table), H29(table)
- copper IUDs, B18
- diaphragm availability, H68
- Graefenberg ring, B24
- incidence of cancer in women, A70(table)
- IUD performance and attitude, B33
- legal status of voluntary sterilization, CD108(table)
  - Jewish religious law, CD87
- oral contraceptives
  - marketing, A14(table)
  - supplied by SIDA, A20(table)
- PG research, G20, G21, G22
- sex ratio, I24
- tubal occlusion
  - carbon dioxide laser, C91
  - culdoscopy, C65(table), C68(table)

ISRAEL. ARTIFICAL INSEMINATION COOP.
- frozen semen storage, D52

ISRAEL, L.S.
- obstetrical complications with multiparity, J134(table)

ISRANGKUN, C.
- hysteroscopic fulguration, C81, C82(table)
- tubal occlusion with quinacrine, C86 (table), C87

ITALY
- adolescent births, J161(table)
- age-specific fertility rate, J3(graph), J39(graph), J228(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- diaphragm availability, H68(table)
- Family Code, E41, E42
- legal rights of children, J163
- legal status of abortion, E29(table), E32, E33(table)

- legal status of voluntary sterilization, CD73, CD109(table)
- legalized family planning services, E41
- marketing of minipill, A64(table)
- maternal mortality, J128(figure)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A14(table)
  - sales, A8(table)
- PG research, G18, G20, G22
- population law, E43(table)
- population trends, J240
- rhythm method, I14(table)
  - sympto-thermal method, I7

IUD, B1-B20. See also **COPPER IUD**; **DALKON SHIELD**; **LIPPES LOOP**; etc.
- acceptability, B24
  - and availability, B26, J4
  - Iran, J307(table), J308(table)
  - Taiwan, J306
- acceptors in selected countries, B26-B38, B27(table), J307
- advantages and disadvantages
  - compared with injectables, K11(figure)
  - family planning prograns, B26
- associated with bleeding and pain, B11-B12
- Australia, H4(table)
- bulk v. individual costs, B37
- cervical cancer, K10
- cervical threads for detection, B34
- Chile, J4
- Colombia, H4(table)
- comparative study by CSP, B25
- conception rate after discontinuation, K9(graph)
- configuration, B2, B9
- continuation rate. See **IUD CONTINUATION RATE.**
- current research, B23, B38-B39
- declining use in India, Pakistan, B26
- demographic impact, A36
- developed and developing countries, H4(table)
- development, B23-B25
- distribution by USAID, B37, B38(table)
- drug therapy for bleeding and pain, B39
- ectopic pregnancy, B17, B34, J144
- effect on implantation, B34
- effectiveness, B2, B9-B14
- Egypt, A12(table)
- embedding, B12
- estimated use, B21, K1
- evaluation. See **IUD EVALUATION**.
- expulsion. See **IUD EXPULSION.**
- family planning programs in selected countries, B26, B28
- Fiji, A12(table)
- Hong Kong, A12(table)
- infection, B36
  - associated with pregnancy, B36
- insertion. See **IUD INSERTION.**
- international conference in Cairo, B25
- Iran, H4(table)
- Jamaica, H4(table)
- Japan, H4(table), H11
  - legal status, E41, E43, E44(table)
- lactation, J59, J64
- maternal health, J257, J258
- Mauritius, A12(table)
- menstrual flow, B35
- Mexico, A12(table)
- mode of action, B25
- Morocco, A12(table)
- mortality, B17, B22, B36
  - developed and developing countries, A35(table)
  - US, B36(table)
- multiparas, B22
- new acceptors, A17(graph), J11-J20(table)
- nulliparas, B14-B15
- packaging, B6
- Panama, H4(table)
- Philippines, A12(table), H4(table)
- problems, J257
- progesterone release system, B38
- recommended for adolescents, J168
- recommended size, B29
- removal. See **IUD REMOVAL**.
- research and development, B1-B2, B18
- risk of pelvic inflammatory disease, B35-B36
- safety, J258(table)
- side effects compared with Depo-Provera, K7
- Singapore, A12(table), J2
- sources of funding, J270-J271(table), J274-J276(table)
- South Korea, H4(table), J2
- spontaneous abortion, B17, B34
- surface area related to pregnancy and removal rates, B34(figure)
- Sweden, H4(table)
- Taiwan, A12(table), J2
- termination rates in selected countries, B22(table), B23(table)
- Thailand, A12(table), H4(table)
- United Kingdom, H4(table)
- US, H4(table), H47, H59(table)
  - FDA evaluation, B36
  - method change, H60(table)
  - sales, B37(table)
- use-effectiveness, B8, B21, B33-B34, H37, H39(figure), I9, J59
  - developed and developing countries, A35(table)
  - ectopic pregnancy, A57(table)
  - factors influencing, B23
- use by married women under 20 in selected countries, J170(table)
- Venezuela, H4(table)

IUD CONTINUATION RATE, B11(table), B14, I16, K8(graph)
- compared with injectable progestogens, K7
- definition, B37
- limited usefulness, B37
- physicians' attitude, B35
- related to nonphysician care, B28
- selected studies, B32(table), B33(table)

IUD EVALUATION
- age, B33
- agencies, B48
- cultural aspects, B33
- overall status, B33
- user-related factors, B33

IUD EXPULSION
- comparison of rates, B3(graph, table), B6(table), B7(graph), B10, B11(table), B15(table), B16(graph)
- copper IUDs, B10
- effect of age, B10
  - and parity, B34
- nulliparas, B14
- rate, B21, B34
- reinsertion, B34
- resistance, B38
- undetected, B34

IUD INSERTION
- anesthesia, B30
- Bangladesh, J96
- Barbados, J93
- candidate screening, J96(graph)
- Chile, J96
- complications and side effects, B8
- Costa Rica, J93
- equipment, B29, B31(figure), J281 (photo), J282
- follow-up, B8
- funding sources, J270-J271
- hysterographic studies, B12
- Indonesia, J93
- infection, B12
- Kenya, J96
- Korea, J93
- laminaria, F92
- multiparas, B7
- Nigeria, J93
- nonphysicians, B26, B28, E4, J72, J93, J96, J98
  - advantages, J96
  - compared with physicians, J93
  - complication rate, J93
  - drop-out rate, J93
  - effectiveness, J96
  - expulsion rate, J93
  - removal rate, J93
  - training, B28, J93, J94-J95(table)
- nulliparas, B6, B8, F92
- Pakistan, J96
- prevention of pelvic inflammatory disease, B36
- promotion by mail in Taiwan, J292-J293(table)
  - postpartum women, J294
- reinsertion, B35
- similarity to menstrual regulation, F9
- technique, B6-B9, B28-B31
  - equipment, B7
  - timing, B6
- Thailand, J96
- timing, B29-B30
  - following menstrual regulation, F52
  - postabortion, B22, F33-F35
  - postpartum, B26
- US, J93
- uterine perforation, B26
- uterine placement, B8, B12, B13, B30

IUD REMOVAL
- indications, B31
- pelvic inflammatory disease, B35
- pregnancy, B34
- rate, B21
- selected studies, B32(table)
- training nonphysicians, J93

IVORY COAST
- age-specific fertility rate, J27(graph), J34(graph), J223(graph)
- birth rate, J29(table), J207(table), J210 (table)
- deforestation, J192
- family planning program, J26
- legal status of voluntary sterilization, CD109(table)
- marketing of oral contraceptives, A14 (table)
- total fertility rate, J216(table)

J

JACKSON, H.
- chemical male sterilization, D15

JACKSON, W.P.U.
- diabetes mellitus and parity, J132(table)

JACOBAEUS, C3

JACOBS, A., H58
- family planning clinic, J70

JAIN, A.K.
- duration of postpartum amenorrhea, J56, J57(table)

JAMAICA
- abortion
  - legal status, E28, E34, E35(table), F61
  - practice, E35(table)
- age-specific fertility rate, J36(graph), J226(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- condom
  - distribution, H5(table), H16
  - importation costs, H5(table)
  - promotion, H9-H10
  - shipments, H10, H15(table)
  - use, H4
- contraceptive usage, H4(table)
- copper IUDs, B18
- culdoscopy, C69
  - training, C69, C70
  - tubal occlusion, C65(table)
- Depo-Provera
  - availability, K13(figure), K14
  - restricted use, K12
  - UNFPA distribution, K14
- diabetes mellitus and parity, J132(table)
- diaphragm
  - availability, H68(table)
  - training nonphysicians, H67
- incidence of cancer in women, A70(table)
- injectable progestogens
  - cost, K14
  - paramedical personnel, J92
- IUD acceptors, B27(table)
- legal status of voluntary sterilization, CD83, CD109(table)
- medical complications of adolescent pregnancy, J165(table)
- National Family Planning Board, H9
  - address, J106(table)
  - training nonphysicians, J95(table), J106(table)

- new acceptors, A18(table), H49(table), J18(table)
- nonphysicians
  - injectable contraceptives, J92
  - IUD insertion training, J95(table)
  - training, H67, J95, J106(table)
- oral contraceptives
  - availability, E4(table)
  - marketing, A14(table)
  - new acceptors, A18(table)
  - nonprescription, J74
  - supplied by USAID, A2(table)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- promotion of family planning, J297, J309, J311(table)
- vaginal contraceptives, H48
  - new acceptors, H49(table)
  - promotion, H43

JAMES, L.P.
- postvasectomy antibodies, D32

JAMES, W.H.
- coital timing and sex ratio, I24

JAMU (INDONESIA)
- condom distribution, J78, J312

JAPAN
- abortion
  - availability, I15
  - impact on fertility, E38
  - incidence in midtrimester, F66
  - inert devices, F67
  - legal status, E29, E30(table), E36, F1, F6–F7
  - Metreurynter, F97
  - mortality, E37, F37(table)
  - saline solution, F68
- adolescent births, J161(table)
- age of menarche, J159, J162(table)
- age-specific fertility rate, J3(graph), J10(graph), J32(graph), J37(graph), J225(graph)
  - cumulative fertility, J32(graph)
- anterior colpotomy, C35
- attitude toward family size, J240
- availability of Depo-Provera, K13(figure)
- birth rate, J21, J23(figure), J29(table), J206, J207(table), J218(figure), J240
  - postwar, F25
- change in number of births, J219(figure)
- condom
  - Asian market, H5
  - distribution, H1–H2, H5(table), H11
  - manufacture, H5, H23
  - standards, H25, H26(table), H27, H28, H29(table)
  - use, H1, H4, H11, I14–I15
- contraceptive usage, H4(table), H11
- copper IUDs, B18
- culdoscopy, C61
  - tubal occlusion, C65(table)
- diaphragm
  - availability, H68(table)
  - fitted by paramedical personnel, J93
  - training nonphysicians, H67
- door-to-door distribution of contraceptives, J82
- effects of population on environment, J246
- estimated population, E30(table), E36 (table)
- Eugenic Protection Law, F6–F7
- family planning, J239
  - survey, J295
- fertility, J4, J22
- folk barrier methods, H58
- folk methods for sex preselection, I22
- incidence of cancer in women, A70(table)
- International Cooperation Agency
  - address, J284
  - funding of family planning activities, J273, J375(table), J278(table)
- legal restrictions on contraceptive practice, I15
- legal status of IUD, B24, E41, E43, E44 (table)
- legal status of voluntary sterilization, CD70, CD89, CD90, CD91, CD109 (table)
- manufacturers of sterilization equipment, M2
- marital status of female adolescents, J164(table)
- maternal mortality, J128(figure)
- oral contraceptives
  - availability, A2
  - commercial supply, A9(table)
  - marketing, A14(table)
  - sales, A8(table)
  - use, H4(table)
- out-of-wedlock births, J160(figure)
- per capita fish consumption, J179
- percentage of legal abortions to women under 20, J171(table)
- PG research, G18, G19, G20, G21, G22
- population, F7(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- premarital sex among adolescents, J159
- recreation areas, J180
- rhythm method, I14(table), I15
- training nonphysicians, J94(table), J101(table)
- tubal ligation, C78
- vaginal contraceptives, H47
  - sales, H48(table)
- water pollution, J181
- Yusei ring, B42

JAPAN FAMILY PLANNING ASSOCIATION
- address, J101(table)
- training nonphysicians, J94(table), J101(table)

JARAMILLO-GOMEZ, J.B.
- use-effectiveness of calendar rhythm method, I11(table)

JARAMILLO-GOMEZ, M.
- rhythm method, I16

JARVINEN, P.A.
- menstrual pattern changes with lynestrenol minipill, A58(table)

JAUNDICE
- oral contraceptives, A47

JAVA. See also **EAST JAVA**.
- deforestation, J192
- family planning, J239

JAYEWARDENE, C.H.S.
- diaphragm use, H60

JELLIFFE, D.B.
- lactation and anxiety, J45(figure)
- let-down reflex, J53(figure)
- maternal depletion syndrome, J256
- prolactin release, J51(figure)

JELLIFFE, E.F.P.
- lactation and anxiety, J54(figure)
- let-down reflex, J53(figure)
- prolactin release, J51(figure)

JELLY. See also **VAGINAL CONTRACEPTIVES**.
- active ingredients, H41(table), H43(table)
- distribution by USAID, H49(table)
- duration of spermicidal effectiveness, H43(table)
- mode of action, H40
- mode of application, H43(table)
- packaging, H43(table)
- price and sales of selected products, H48(table)
- use-effectiveness, H44
  - selected studied, H45(table)

JENNINGS, J.
- IUD sales in the US, B37(table)
- mortality associated with IUDs, B36(table)

JENNINGS, P.B.
- postvasectomy antibodies, D31(table)
  - cell-mediated immunity, D32

JENSEN, E.I.
- estrogen use and endometrial cancer in postmenopause, A86(table)

JEPPSSON, S.
- continuation rate of Depo-Provera, K8 (table)

JESSIN v. COUNTY OF SHASTA
- vasectomy, CD84, CD130–CD131

JEWS
- niddah, I24
- sex ratio, I24

JHAVER, P.S.
- clips in vasectomy, D7, D53

JOHN, A.H.
- sterilization by colpotomy, C31(table)
  - anesthetic, C32(table)
  - complications, C32(table)
  - failure, C39(table)
  - incision for posterior colpotomy, C33
  - Pomeroy method, C33(table)

JOHNS HOPKINS UNIVERSITY (BALTIMORE, MARYLAND), C59, J41
- address, J283
- Advanced Techniques for Management of Fertility Program, C59, F20, J41, J42, J43–J45
- fertility management training program, C2, C13, F20, J43
  - address, J42
  - sterilization, M2
- funding of family planning activities, J269, J275(table)
- health program in Bangladesh, J243
- household distribution of contraceptives in Taiwan, J82
- laminaria tents, F92
- measuring force of cervical dilatation instruments, F87
- mini-laparotomy, C54
  - anesthesia, C55
  - complications, C58
  - orals and breast disease, A45
  - urea as abortifacient agent with augmenting agents, F76, F79
- Yoon band sterilization, C85

JOHNSON AND JOHNSON
- oral contraceptives, A4(table)

JOHNSON, V.E.
- comparative use-effectiveness of vaginal contraceptives, H44(table)
  - spermicidal potency, H44
- diaphragm
  - failure, H66
  - fitting, H62
- genitalia size, H29

JOINT PROGRAM FOR THE STUDY OF ABORTION
- colpotomy v. laparotomy after abortion, C41
- comparative menstrual regulation complication rates, F15
- complications with uterine aspiration, F68
- injuries from cervical dilatation, F86
- local anesthesia with suction and curettage, F29–F31
- local anesthesia with suction and uterine aspiration, F31
- uterine aspiration in the US, F26

JONES, J.R.
- menstrual regulation with PGs, G59(table)

JONGBLOET, P.H.
- coitus in postovulatory period, I13
- incidence of abnormal pregnancy, I13 (table)

JORDAN
- abortion
  - legal status, E29(table), E35(table)
  - practice, E35(table)
- age-specific fertility rate, J223(graph)
- average births per woman, J129(table)
- birth rate, J23(figure), J29(table), J207 (table), J209(table)
- legal status of voluntary sterilization, CD109(table)
- oral contraceptives
  - marketing, A14(table)
  - supplied by USAID, A21(table)
- population growth, J189
- total fertility rate, J216(table)

JORDAN, J.A.
- laparoscopic sterilization, C2(table)
  - complications, C19(table), C20
  - electrocoagulation, C8(table)
  - failure, C22(table)

JORGENSON, P.I.
- local anesthesia for uterine aspiration, F30(table)

JOSE FABELLA MEMORIAL HOSPITAL COMPREHENSIVE FAMILY PLANNING CENTER (PHILIPPINES)
- address, J102(table)
- training nonphysicians, J94(table), J102(table)

JUBHARI, S.
- quingestanol acetate minipill
  - continuation rate, A62(table)

  - effectiveness, A56(table)
  - menstrual pattern changes, A60(table)

JUNKMANN, K.
- synthesis of progestogen esters, K2

K

KABI
- copper-T IUD, B43

KAERN, T.
- effect of orals on lactation, J61(table)

KAHN CANNULA. See also **CANNULA**.
- chemical tubal occlusion, C87

KAI, I.
- colpotomy
  - postoperative care, C35
  - preoperative procedure, C30

KAISER, I.
- abortion mortality in Cuba, E37

KAISER, R.
- orals and ovarian cysts, A46

KAISER PERMANENTE MEDICAL CENTER (WALNUT CREEK, CALIFORNIA)
- oral contraceptives
  - blood pressure, A42
  - prospective study, A40

KAJANOJA, P.
- side effect of intraamniotic administration of $PGF_2\alpha$, G72

KAKAR, D.N.
- sexual behavior after vasectomy, D35 (table)

KAMAL, I.
- duration of postpartum amenorrhea, J57 (table)
- lactation
  - effect of orals, J61(table)
  - effect of progestogen-only contraceptives, J63(table)
- X-ray studies of IUD placement, B12

KAMPONG BIDANS. See **BIDANS**.

KANAGARATNAM, K.
- fertility reduction and use of orals in Singapore, J2

KANDANG KERBAU HOSPITAL (SINGAPORE)
- clip sterilization v. tubal ligation, C68
- training program in culdoscopy, C69, C70
  - address, C70
  - applicant qualifications, C70
  - funding, C70
  - participants, C70

KANEKO, E.J.
- effectiveness of vas anastomosis, J49 (table)

KANG, K.W.
- duration of postpartum amenorrhea, J57 (table)

KANITKAR, S.D.
- contraceptive practice, F51
- menstrual regulation, F51(table)
  - acceptability, F62
  - complications, F52(table)
  - IUD insertion, F52
- pregnancy tests, F54(table)

KANTNER, J.F.
- contraception among adolescents, J166, J167
- urbanization and premarital coitus, J161

KAPIOLANI HOSPITAL (HAWAII), J42
- address, J107(table)
- training nonphysicians, J95(table), J107(table)

KAPRIO, L., E21(photo)

KAR, A.B.
- animal studies with oral contraceptive hormones
  - cervical tumors, A85(table)
  - endometrial tumors, A87(table)
  - ovarian tumors, A91(table)
  - pituitary tumors, A90(table)
- IUD mode of action, B25

KARIM, M.
- use-effectiveness of Norigest, K4(table)

KARIM, S.M.M.
- abortion with PGs, G2, G7(table), G8 (table), G9(table), G17
  - first trimester, F95
  - intrauterine administration, G66
  - PGE_2 analogue, G69, G72
- cervical dilatation with PGs, G61, G68 (table)
- concentration of PGs
  - amniotic fluid, G2, G49
  - decidua, G49
  - level at term, G48
- induction of labor with PGs, G2, G10 (table), G50, G59
  - G50, G59
- menstrual regulation with PGs, G59(table)

KARMAN, H.
- cannula and syringe, F11
- measuring depth of uterine cavity, F12
- menstrual regulation, F13(table)
  - procedure and equipment, F14(table)
- plastic cannula, F55
- uterine aspiration, F28(table)
  - complications, F33(table)
  - equipment, F32(table), F38, F41(table)
  - pressure, F41(table)
  - time required, F32(table)

KARMAN CANNULA, F18(figure), F55. See also **CANNULA**.
- autoclaving, F18

KARMAN SYRINGE, F18(figure)
- danger, F19
- description, F19
- menstrual regulation, F12, F14(table), F51(table)
- uterine aspiration, F41(table)

KAROLINSKA INSTITUTE (SWEDEN)
- menstrual regulation with PGs, G58
- PG research, G2, G17
- PG synthesis, G2

KASABACH, H.Y.
- use-effectiveness of contraceptive jelly, H45(table)

KASE, S.
- vasectomy
  - complications, D28(table)
  - technique, D28(table)

KASPER, E., A5(table)

KASTURBA HOSPITAL (INDIA)
- culdoscopy, C68

KATAGIRI, T.
- oral contraceptives in China, A2

KAUFMAN, R.G.
- PGs for pregnancy termination, G8(table), G9(table)

KAUR, A., I15

KEIFER, W.
- norethindrone minipill
  - effectiveness, A56(table)
  - menstrual pattern changes, A58(table)

KEIRSE, M.J.N.C.
- PGE_2 in labor, G49

KEITH, L.
- laparoscopic sterilization, C2(table)
  - complications, C19(table), C23(table)
  - electrocoagulation with division and biopsy, C8(table)
  - failure, C22(table)
  - operative procedure, C7(table)
  - postpartum, C22, C23(table)
  - preoperative medication and anesthesia, C3(table)
  - technique for pneumoperitoneum, C5(table), C18

KELLING, C3

KELLOG, E.K., author, CD57–CD132

KELLY, H.A., J41
- diagnostic curettage, F11

KELMAN, C.D.
- orals and eye disease, A40

KELSEY, J.L.
- orals and benign breast neoplasia, A73 (table)

KEMAL, CD73

KENYA
- age-specific fertility rate, J34(graph), J223(graph)
- average births per woman, J129(table)
- birth rate, J29(table), J207(table), J209 (table)
- condom
  - distribution, H1, H9, H13, J77
  - importation costs, H5(table)
  - promotion, H9
  - sales, H6
  - shipments, H14(table), H15(table)
- contraception among adolescents, J166
- culdoscopy, C69
- Depo-Provera
  - availability, K13(figure)
  - IPPF distribution, K14
  - restricted use, K12
- diaphragm
  - availability, H68(table)
  - training nonphysicians, H67
- distribution of contraceptives, J75
  - condom, H1, H9, H13, J77
  - Depo-Provera, K14
  - orals, A20(table), A21(table)
  - retail outlets, J76(table)
- health services, J76(table), J195
- in-school sex education, J171
- IUD acceptors, B27(table)
- IUD insertion by nonphysicians, J96
- legal status of abortion, E29(table)
- low-cost housing, J186
- new acceptors, A18(table), J11(table)
- oral contraceptives
  - marketing, A14(table)
  - new acceptors, A18(table)
  - supplied by SIDA, A20(table)
  - supplied by USAID, A21(table)
- overgrazing, J188
- percentage of married female acceptors under 20, J190(table)
- percentage of married women of reproductive age under 20, J170(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- premarital sex, J159
- promotion of family planning, J296, J299, J301, J311(table), J313
- threatened wildlife, J198
- total fertility rate, J216(table)
- training nonphysicians, J94(table), J103(table)
- vaginal contraceptives
  - promotion, H48
  - sales, H49
- water resources, J196

KENYA INFORMATION SERVICES, J185(photo)

KERBER, I.J.
- immunologic pregnancy tests
  - slide test, J119(table)
  - tube test, J118(table)

KERENYI, T.D.
- saline abortion
  - complications, F69, F71(table)
  - gravity drip technique, F69
  - intraamniotic instillation, F71(table)

KERSLAKE, C.
- uterine aspiration, F28(table)
  - complications, F33(table)
  - equipment, F32(table), F38, F41
  - local anesthesia, F29(table), F30(table)
  - preoperative medication, F29(table)

KESSEL, E., C46
- clip sterilization, C52
- IUD termination rates in selected studies, B22(table)
- PGs for pregnancy termination compared with saline method and hysterotomy, G12
- spring coil, B45
  - evaluation, B39

KESSERU-KOOS, E.
- d-norgestrel minipill
  - effectiveness, A56(table)
  - menstrual pattern changes, A59(table)
- Norigest
  - continuation rate, K7(table)
  - nonmenstrual side effects compared with orals, K7
  - use-effectiveness, K4(table)
- postcoital norgestrel, J148
  - use-effectiveness, J149(table)

KETAMINE, C55

KETAMINE HYDROCHLORIDE
- laparoscopic sterilization, C4
  - average dose, C5
  - cardiovascular effects, C5

KETTING, E.J.
- training in laparoscopic sterilization in Malaysia, C14

KGATLA
- tribal attitude toward premarital sex, J159

- **KHAN, T.**
  - Depo-Provera
    - continuation rate, K7(table), K8(table)
    - use-effectiveness, K4(table)
- **KHANDWALA, S.**
  - clip sterilization, C46, C47
    - complications, C49
    - preoperative medication, C47(table)
  - laparoscope and local anesthesia channel, C50
  - metal cannula, F55(table)
    - advantages, F55
  - vasectomy techniques, D4
- **KHMER REPUBLIC**
  - availability of Depo-Provera, K13(figure), K14
  - birth rate, J29(table), J207(table), J208, J210(table)
  - cost of injectable progestogens, K14
  - marketing of oral contraceptives, A14 (table)
  - training in culdoscopy, C70
- **KICOVIC, P.M.**
  - cingestol minipill
    - effectiveness, A56(table)
    - menstrual pattern changes, A58(table)
  - lynestrenol minipill
    - effectiveness, A56(table)
    - menstrual pattern changes, A58(table)
- **KIDNEY**
  - release of PGs, G26
- **KIDNEY DISEASE**
  - obstetrical complication in multiparas, J134-J135(table)
- **KILIMANJARO CHRISTIAN MEDICAL CENTER, MCH ZONAL OFFICE (TANZANIA)**
  - address, J105(table)
  - training nonphysicians, J94(table), J105(table)
- **KILIN MEDICAL UNIVERSITY (PEOPLE'S REPUBLIC OF CHINA)**, J97
- **KIM, M.S.**, J101(table)
- **KIMBALL, F.A.**
  - PG binding proteins, G54
- **KING, P.**
  - condom failure, H29
- **KING, T.M.**, author, J43
  - catheterization, C54
  - midtrimester abortion with urea, F78(table)
  - training program, F20
- **KINGA CONDOM**
  - Kenya, H9, J77
- **KINOSHITA, K.**
  - PGs for induction of labor, G10(table)
  - PGs for pregnancy termination, G7(table), G8(table)
- **KIRKLAND, J.A.**
  - orals and cervical neoplasia, A81(table)
- **KIRSCHSTEIN, R.L.**
  - orals and breast neoplasia in animals, A79(table)
- **KIRSHEN, E.J.**
  - PGs for pregnancy termination, G7(table), G8(table)
- **KIRTON, K.T.**
  - uterine effects of PGs, G54
- **KLAPPROTH, H.J.**
  - vasectomy
    - complications, D28(table)
    - failure, D28(table), D33
    - semen analysis, D9
    - technique, D28(table)
- **KLEEGMAN, S.J.**
  - coital timing, I24
- **KLEINMAN, R.L.**
  - minimum pressure for electrical aspirator, F42
  - mortality following legal abortion, F37 (table)
- **KLEPPINGER, R.K.**
  - use-effectiveness of contraceptive foam, H45(table)
- **KLI, INC.**
  - address, M32
  - culdoscopy equipment, M24(table), M25 (table)
  - guarantee and service of sterilization equipment, M30(table)
  - laparoscopy equipment
    - combination units, M11(table)
    - electrosurgical generators, M15(table)
    - fiberoptic projectors, M8(table)
    - insufflators, M12
    - laparoscopes, M4(table), M5(table)
  - mini-laparotomy equipment, M20(photo)
  - uterine manipulation devices, M22(table), M25(table)
  - vasectomy equipment, M27(figure)
- **KLINGER, A.**
  - cervical dilatation, F39
  - repeated menstrual regulation, F17
- **KLINSTRA, P.D.**, A5(table)
- **KNAUER, E.**, A30
- **KNAUS, H.**
  - fertile period identification, I3(table)
  - timing of ovulation, I3, I4
- **KNEE-CHEST POSITION**
  - culdoscopy, C62, C63, C64
    - equipment, C69, C70(figure)
- **KNEPSHIELD, W.**, C46
- **KNICKERBOCKER HOSPITAL (NEW YORK)**, C62
- **KNODEL, J.**
  - age of marriage and family size, J163
- **KNOWLTON, C.**
  - postcoital douche, J142
- **KOCHHAR, M.**
  - culdoscopy
    - complications, C66(table), C67(table)
    - preoperative medication, C63(table)
    - tubal occlusion, C65(table), C68(table)
- **KOCKS, J.**
  - hysteroscopic fulguration, C81
- **KOETSAWANG, S.**
  - clip sterilization, C46, C47
    - follow-up, C50
    - preoperative medication, C47(table)
  - culdoscopy
    - complications, C66(table), C67(table), C68
    - preoperative medications, C63(table)
    - tubal occlusion, C65(table), C68(table)
  - Depo-Provera
    - continuation rate, K7(table)
    - menstrual cycle, K5(graph)
    - use-effectiveness, K4(table)
  - IUD removal for pain, B12
  - laparoscopic sterilization in Thailand, C2, C13, C14
  - progestogen-only contraceptives and lactation, J63(table)
  - use-effectiveness of Norigest, K4(table)
- **KOHLI, K.L.**
  - vasectomy
    - failure, D33
    - sexual behavior, D35(table)
- **KOLLER, O.**
  - continuation rate of chlormadinone acetate minipill, A62(table)
- **KOMMER, G.**, author, B21-B48
- **KONSTAM, P.**
  - clips for closure of scrotal incision, D8
- **KORA, S.J.**
  - orals and lactation, J60(table)
- **KORBA, V.D.**
  - norgestrel minipill
    - effectiveness, A56(table)
    - menstrual pattern changes, A59(table)
- **KOREA, NORTH**
  - birth rate, J29(table), J207(table), J210 (table)
  - legal status of voluntary sterilization, CD109(table)
- **KOREA, SOUTH**
  - abortion
    - adolescents, J165(table), J170
    - legal status, E2, E7(table), E29(table), E35(table), J164
    - practice, E35(table)
  - age of menarche, J162(table)
  - age-specific fertility rate, J2, J3(graph), J5(graph), J25(graph), J37 (graph) J222(graph)
  - availability of Depo-Provera, K13(figure)
  - availability of oral contraceptives, J2
  - average births per woman, J129(table)
  - birth rate, J29(table), J207(table), J208, J209(table)
  - condom
    - distribution, H5(table)
    - manufacture, H5, H23, J74
    - prices, H6(figure)
    - standards, H25
  - contraceptive usage, H4(table)
  - culdoscopy, C69
    - training, C70
  - distribution of contraceptives
    - condom, H5(table)
    - household, J82-J83
    - legal aspects, E2, E4(table)
    - orals, J92
    - village-based, J72
  - duration of postpartum amenorrhea, J57 (table)
  - economic growth, J190
  - family planning program, B28, J2, J24, J239
    - IUD, B26
    - mass communications techniques, J290, J294, J295, J300, J303, J304, J306, J311(table)
  - fertility rate, J2
  - fish industry, J179
  - IUD, B21, B26, J2
    - continuation rate, B33(table)
    - copper-T, B10, B12
    - experimental study with copper, B18
    - insertion by nonphysicians, B28, J93, J96
  - legal status of voluntary sterilization, CD70, CD89, CD109(table)
    - consent, CD77
  - marital status of female adolescents, J164(table)
  - medical complications of adolescent pregnancy, J165(table)
  - menstrual regulation, F20, F51
  - Mothers' Clubs, J72
  - National Family Planning Fertility Survey, J304
  - new acceptors, A18(table), J14(table)
  - oral contraceptives
    - marketing, A14(table)
    - new acceptors, A18(table)
    - nonprescription, J74
    - supplied by SIDA, A20(table)
  - rhythm method, I15
  - sex preference, I27, I28
  - total fertility rate, J215(table), J216
    - decline, J217(table)
  - training nonphysicians, J94(table), J101(table)
  - vaginal contraceptives, H48
    - marketing, H48
  - vasectomy, D28(table), D34(table)
    - demand for reversal, D41
    - sexual behavior, D35(table)
  - Yoon band sterilization, C85
- **KOREA, SOUTH, SEOUL**
  - population policy
    - economic incentive, E48(table), E49, E50
- **KOREAN ASSOCIATION FOR VOLUNTARY STERILIZATION**
  - maintenance and repair of sterilization equipment, M3
- **KOREAN INSTITUTE FOR FAMILY PLANNING**
  - address, J101(table)
  - training nonphysicians, J94(table), J101(table)
- **KOREAN INSTITUTE FOR RESEARCH IN THE BEHAVIORAL SCIENCES**
  - survey of contraceptive practice, I15
- **KOREAN MIDWIVES ASSOCIATION**
  - training in IUD insertion, J96
- **KORO-FLEX**, H68(table)
- **KOROMEX**, H68(table)
- **KOROMEX-A VAGINAL JELLY**
  - active ingredients, H41(table)
  - use-effectiveness, H45(table)
  - venereal disease, H51(table)
- **KOSASA, T.**
  - HCG
    - beta subunit, J120
    - level during pregnancy, J112(table)
    - measurement, F53
- **KOSASIH, E.N.**
  - slide test modifications, J119
- **KOTHARI, M.L.**
  - colpotomy combined with abortion, C43
  - intravas contraceptive device, D53

KOVACS, L.
- postcoital dienestrol, J144

KRISHNA, U.R.
- medical complications of adolescent pregnancy, J165(table)

KROENER, W.F., JR.
- fimbriectomy and ligation, C78
- sterilization by colpotomy, C31(table)
  - fimbriectomy, C33(table), C39

K.S. WING, B44(figure)
- description, B44
- distribution, B44
- use-effectiveness, B44
- use in Japan, B44

K.S. WING LABORATORY
- address, B44

KUCHARA, L.K.
- postcoital diethylstilbestrol
  - side effects, J147, J148(table)
  - use-effectiveness, J145(table)

KUMEKPOR, T.K.
- age of menarche, J162(table)

KUPRESANIN, M.
- menstrual regulation, F13(table)
  - procedure and equipment, F14(table)
- uterine aspiration
  - compared with curettage, F42
  - perforation rate compared in dilatation and curettage, F36

KUROKAWA, K.
- K.S. Wing, B44

KURZROK, R.J., A31
- early clinical study of PGs, G1, G2
- uterine response to semen, G1

KUWAIT
- age-specific fertility rate, J27(graph), J225(graph)
- birth rate, J29(table), J207(table), J209(table)
  - economic growth, J22
- diaphragm availability, H68(table)
- family planning program, J26
- marketing of minipill, A64(table)
- marketing of oral contraceptives, A14(table)

KWASHIORKOR, J50, J256

KWON, E.H.
- sexual behavior after vasectomy, D35(table)

L

L10503 See **ISOQUINOLONE**

LABOR
- complications among adolescents, J161

LABOR FORCE See also **UNEMPLOYMENT**
- projected growth, J198(table)
- US, A237

LABORATOIRES FANDRE
- D.I.U. Pharmatex, B47

LABORATOIRES PHARMELAC
- address, B47

LA CAMPANA
- oral contraceptives, A4(table)

LACASSAGNE, A.
- mammary cancer, A79

LACTATION See also **BREAST-FEEDING**; **SUCKLING**
- anxiety, J54
- caloric needs, J64
- contraception during
  - methods, J64
  - side effects, J58-J59
  - timing, J62
- duration of postpartum amenorrhea, J56
- effect on birth interval, J56
- hormonal role, J50, J52(table)
- infant growth, J54
- injectable progestogens, J59
  - composition of breast milk, K12
- nutritional needs, J130(table)
- oral contraceptives, A48, J50, J58-J59
  - research, J62
  - selected studies, J60-J61(table)
- ovulation, J56-J58
- physiology, J50-J51
- postpartum amenorrhea
  - duration, J54, J56-J57
  - selected studies, J57(table)
- pregnancy, J57
  - cultural factors, J58
- progestogen-only contraceptives, J50
  - selected studies, J63(table)
- rhythm method contraindicated, J59, J62
- steroidal contraceptives, A63, K11
- stimulated by thyrotropin releasing hormone, J62
- suckling, J51, J55, J59

LACTIKOL CREME
- use-effectiveness, H44(table)

LACTIKOL JELLY
- use-effectiveness, H44(table), H45(table)

LADY FAMILY PLANNING VISITOR (PAKISTAN) See **LADY HEALTH VISITOR**

LADY HEALTH VISITOR (PAKISTAN)
- IUD insertion, J96
- training in fertily control, J96

LAGAP SA
- C-film, H42

LAGOS, UNIVERSITY OF. DEPARTMENT OF COMMUNITY HEALTH (NIGERIA).
- address, J104(table)
- training nonphysicians, J94(table), J104(table)

LAHIRI, B.C.
- sterilization by colpotomy, C31(table)
  - equipment, C36(table)
  - Pomeroy method, C33(table)
  - preoperative medication and anesthesia, C32(table)
  - tubal ligation, C34

LAI, I.
- combined anesthesia for colpotomy, C32(table), C33

LAING, J.
- condom supply, H34
- rhythm method, I16

LAKOFF, K.M.
- Rh immunization, F36

LALOR FOUNDATION
- address, B47

LAM, P., J101(table)
- marketing family planning by mail, J294

LAMB, E.J.
- immunologic pregnancy tests
  - slide test, J119(table)
  - tube test, J118(table)

LAMBERTS (DALSTON) LTD., H19
- manufacture of intravaginal barriers
  - cervical cap, H72
  - diaphragm, H67
  - vault cap, H72
  - vimule, H72

LAMINARIA TENTS, F68(photo), G73
- abortion, F66, F67, F72, F74, F75(table)
  - instillation-abortion interval, F69, F70, F71(table)
  - saline, F71(table)
- advantages, F92
- cervical dilatation, F31, F39(figure)
- complications, F39(table)
- derivation, F39, F92
- disadvantages, F92
  - preventive measures, F93
- hygroscopic quality, F39
- insertion procedure, F39
- intraamniotic injection of PGs, G59
- manufacturers, F40
- midtrimester abortion
  - $PGF_2\alpha$, F94
  - saline solution, F94
- nulliparas and multiparas, F39
- placement, F93(figure)
- side effects, F40
- sizes, F39, F93
- sterilization, F39
- suction curettage, F93
- time needed for dilatation, F92

LAMPRECHT GUMMIWARENFABRIK, H19

LANCTOT, C.A.
- temperature rhythm method
  - psychosocial aspects, I13
  - use-effectiveness, I12(table)

LAND USE
- government regulation, J200

LANDESMAN, R.
- copper-T for nulliparas, B15
- infection with IUD in situ, B12
- IUD displacement, B12
- radioreceptorassay, J121
  - procedure, J109

LANDSBERG, H.
- climatic effects of dust, J187

LANE COMMITTEE See **UNITED KINGDOM. COMMITTEE ON THE WORKING OF THE ABORTION ACT**

LANESTA GEL
- use-effectiveness, H44(table), H45(table)
- venereal disease, H51(table)

LANGLOIS, P.
- uterine aspiration, F42
  - incomplete abortion, F60

LAOS
- birth rate, J29(table), J207(table), J210(table)
- Lao Family Welfare Association
  - address, J102(table)
  - training nonphysicians, J94(table), J102(table)
- oral contraceptives
  - marketing, A14(table)
  - new acceptors, A18(table)
  - supplied by USAID, A21(table)
- training nonphysicians, J94(table), J102(table)

LAPAROSCOPE, C80(figure)
- angle and field of vision, M7
- care and maintenance, M29, M31
- clip sterilization, C46. See also **LAPAROSCOPIC STERILIZATION**
- comparison of products
  - diagnostic, M4(table), M6
  - operating, M5(table), M6
- description, C1, C9
- identification, C9
- insertion, C6
- manufacturers, C9
- prevention of lens fogging, C47, C50
- surgery, C9, C17. See also **LAPAROSCOPY**
- surgical sterilization, C50
- teaching attachments, M6(table), M7

LAPAROSCOPIC FULGURATION See also **ELECTROCOAGULATION**
- advantages and disadvantages, C81
- burns, C79, C80
- coagulation current, C79
- cutting current, C79
- equipment, C12, C79, C80(figure), M11(table), M14-M15(table)
- failure rate, C79, C80
  - selected studies, C79(table)
- France, C79
- history, C79
- Nepal, C80
- procedure, C79, C81(photo)
- reversibility, C80
- techniques, C79(table), C79-C80
- US, C80
- voltage and temperatures, C79, C80

LAPAROSCOPIC STERILIZATION See also **CLIP STERILIZATION**
- advantage, C45
- anesthesia, C3(table), C4-C5, C11
  - compared in one- and two-incision techniques, C4(table)
- coagulation of fallopian tubes, C6, C8
  - without division, C21
- complications, C19(table), C20, C26
  - postabortion period, C24(table)
  - postpartum, C23
  - prevention, C20, C21
- conferences, C25-C26
- contraindications, C17, C18-C19
- developing countries, C17
  - training, C14, C27
- effectiveness
  - failure rate, C17, C21, C22(table)
  - incomplete coagulation, C21
  - postoperative contraceptives, C21
  - recanalization, C21
  - related to hysterosalpingograms, C21
- Egypt, C2, C14
- El Salvador, C2, C13
- equipment, M5-M16. See also **LAPAROSCOPE**
  - complications in electrocoagulation, C12
  - cost, C3, C9
  - development, C10(figures)

- one-incision method, C9, C10, C25
- procurement, C9
- two-incision method, C9, C11, C25
- vaginal instruments, C6
- establishing pneumoperitoneum, C5
- failure, C17, C21, C22(table)
- fulguration. See also **LAPAROSCOPIC FULGURATION**
- history, C3-C4
- Hong Kong, C2, C14
- incision, C6
- inpatient procedure with abortion, C24
- local anesthetic, C1, C2, C4(table)
- manpower, C26
- mortality, C17, C21
- one-incision method, C7(table), C11
  - advantages, C11
  - disadvantages, C11
  - equipment, C9, C10, C25
- operative procedures, C6, C7(table), C8 (table), C11, C12, C26
  - outpatient procedure, C1, C2, C3, C12, C24-C25
  - postabortion, C23-C24
    - timing, C23
  - postpartum, C21-C23
- postoperative care, C12-C13
  - contraceptives, C21
  - postabortion, C24
- preferred over laparotomy by Chinese, C2
- preoperative medication, C3(table), C4
- preoperative procedure, C4
- previous abdominal surgery, C18
- reversibility, C8
- significance, C1
- studies, C2(table)
- surgical problems, C17-C18
- technique. See **LAPAROSCOPIC STERILIZATION, operative procedures**
- Thailand, C2, C13
- timing, C21, C26
  - postabortion, C23-C24
  - postpartum, C22
  - puerperium, C21-C22
- training, C2-C3, C13-C14, C25, C26
  - schools in US, C2, C13
- two-incision method, C6, C7(table), C11
  - equipment, C9, C11, C12

LAPAROSCOPY
- defined, C3
- equipment, M5-M16. See also **LAPAROSCOPE**
  - fiberoptic projectors, M8-M9(table)
- IUD removal, B31
- training, J43
- tubal ligation, C75, C77
- tubal occlusion, C76(table)
  - clips, C83(table), C84(photo)
  - plugs, C90
  - Yoon band, C85

LAPAROTOMY
- clip sterilization, C50
- compared with colpotomy
  - failure rate, C42
  - morbidity, C41
- complications with laparoscopic fulguration, C80
- equipment, M23
- following uterine perforation, F35(table), F36
  - postpartum, C21, C23
  - treatment of abscesses, C42
- IUD removal, B31
- performed by midwives, J97
- tubal ligation, C74, C75, C77, C78
- tubal occlusion, C76(table)
  - clips, C83(table), C84
  - laser, C91
  - plugs, C90
  - Yoon band, C85

LAPHAM, M.E.
- rabbit pregnancy test, J110

LAPPE, M.
- sex ratio affected by spleen removal, I26

LAROQUE, G.
- vas ligation technique, D5

LAROS, R.K.
- tubal ligation, C34

LARRANAGA, A.
- nonmentrual side effects of Norigest compared with orals, K7

LARSEN, J.W.
- uterine contraction stimulation, G49

LARSSON-COHN, U.
- effectiveness of norethindrone minipill, A56(table)

LASER
- tubal occlusion, C91

LATERAL POSITION
- menstrual regulation, F12
- uterine aspiration, F31

LATEX AGGLUTINATION
- bonding of HCG, J118
- slide tests, J116
- tube tests, J113, J116

LATEX LEAF, B46(figure)
- current status, B39
- description, B39, B46
- distribution, B46
- use-effectiveness, B46

LATHAM, M.
- famine in the Sahel, J245

LATHROP, A.
- ovariectomy and tumors, A79

LATIN AMERICA. See also specific countries.
- abortion, J257
  - illegal, J170
- adolescents
  - availability of family planning services, J166
  - cultural attitudes toward sexual activity, J157
- attitude toward out-of-wedlock pregnancy, J163
- birth rate, J29(table), J207(table), J209 (table), J210(table), J249(table)
- Depo-Provera
  - availability, K13(figure)
  - continuation rate, K7(table)
  - use-effectiveness, K4(table), K5(table)
- diaphragm distribution, H60
- estimated urbanization, J161
- family planning programs, B28
- IUD, B21
  - distribution by USAID, B37, B38(table)
- menstrual regulation, F49
- mortality rate, J249(table)
- neonatal and infant mortality, J162
- nonprescription oral contraceptives, J74
- number of children and risk of undernutrition, J255-J256
- percentage of married female acceptors under 20 in selected countries, J170(table)
- percentage of married women of reproductive age under 20 in selected countries, J170(table)
- percentage of population under 20, J168(figure)
- population growth, J185, J239, J249(table)
- training nonphysicians, J95(table), J98
  - selected countries, J105-J107(table)
- unemployment, J197
- urbanization, J191
- vaginal contraceptives
  - distribution, H49(table), H50(table)
  - sales, H48(table)

LATZ, L.J.
- coital frequency, I9
- rhythm method, I13
- use-effectiveness of calendar rhythm method, I9, I11(table)

LAU, L.
- capillary test, J110, J122

LAUDERDALE, J.W.
- PGs for estrous synchronization, G54

LAUERSEN, N.H.
- intravaginal administration of PGs, H66-H67
  - PGE$_2$, F76, F77(table)
  - PGF$_2\alpha$ methyl ester, F76
- midtrimester abortion with PGF$_2\alpha$, G69, G72(table)

LAUFE, L.E., J44(photo)
- menstrual flow with IUDs, B11
- mini-laparotomy retractor, M20
- reversibility of fimbriotexy, C91
- sterilization by colpotomy, C31(table)
  - complications, C40(table)
  - failure, C39(table)
  - film, C33(table), J34
- training in menstrual regulation, F20
- use-effectiveness of Saf-T-Coil, B32(table)

LAURENCE, K.A.
- reversible vas occlusion, D53

LAW, B.
- intravaginal barriers, H70(figure)

LAWRENCE, P.S.
- early theories of sex preselection, I22

LAWSON, J.P.
- menstrual pattern changes with norethindrone minipill, A59(table)

L.D.S. INSTRUMENT, D12

LEADER, A.J.
- clips and sutures contraindicated after scrotal incision, D9
- vasectomy
  - complications, D28(table), D29
  - failure rate, D7
  - recanalization, D33
  - technique, D28(table)

LEADER VAS HOOK, D11(figure)

LEADER VAS ISOLATION FORCEPS, D11(figure)

LEAN, H., C47

LEAN, T.H.
- menstrual regulation, F51(table)
  - complications, F52(table)
- pregnancy tests, F54(table)

LEAVITT, H.J.
- commercialization of family planning, H6

LEBANON
- abortion
  - legal status, E29(table), E35(table)
  - practice, E35(table)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- culdoscopy, C61, C69
  - tubal occlusion, C65(table), C68(table)
- diaphragm availability, H68(table)
- legal status of voluntary sterilization, CD86, CD110(table)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A14(table)
  - prescription, E43, E44(table)
  - sales, A8(table)
  - supplied by SIDA, A20(table)
- overgrazing, J188
- suction curettage, J45

LEBECH, P.E.
- Antigon-F, B46

LEDERLE LABORATORIES, A5
- manufacture of low-estrogen orals, A37(table)

LEE
- vasectomy
  - hook, D11(figure)
  - kits, M26(table)

LEE, C.M., author, A1-A26, G1-G15

LEE, H.Y.
- intravasal thread for occlusion, D14, D53(figure)
- vas anastomosis
  - effectiveness, D49(table), D51
  - hospitalization, D48
  - microsurgery, D51
  - operative procedures, D44(table)
  - sperm count, D47
- vasectomy, D26
  - complications, D28(table)
  - general health, D34(table)
  - psychological aspects, D34
  - sexual behavior, D35(table)
  - technique, D28(table)

LEE, L.T., author, F1-F8
- legal aspects of pregnancy termination, F61
- legal equality for children, J163
- UN resolution and population law, E29

LEECHES
- uterine aspiration, F26

LEFEBVRE, Y.
- menstrual pattern changes with norethindrone minipill, A58(table)

LEHFELDT, H., B24
- cervical cap, H70
  - use-effectiveness, H71
- ectopic pregnancy rate with IUD, A57(table)
- postcoital ethinyl estradiol
  - side effects, J148(table)
  - use-effectiveness, J145(table)

LEHTONEN, R.
- vasectomy

  - complications, D28(table)
  - technique, D28(table)

LEIMAN, G.
- use-effectiveness of Depo-Provera, K4 (table)

LENNANDER, H.G.
- vasectomy to avoid postoperative epididymitis, D2

LEO PHARMACEUTICAL, G68

LEOSTESINNORADRENALINE, F30(table)

LEPETIT RESEARCH LABORATORIES, G61

LEPSKY, H.O.
- vas anastomosis, D42

LERIDON, H.
- duration of postpartum amenorrhea, J57(table)

LERNER, I.
- Dalkon Shield, B42

LERNER, L.J.
- inhibition of PG metabolism by isoquinolone, G61

LESOTHO
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- diaphragm availability, H68(table)
- marketing of oral contraceptives, A14 (table)

LESZNYAK, J.
- menstrual induction, G37(table)

LEUCINE AMINOPEPTIDASE, D30

LEUKOCYTOSIS
- chemical tubal occlusion, C64

LEVI, J.V.
- sperm count with epididymitis, D42

LEVINE, S.R.
- vasectomy
  - complications, D28(table)
  - technique, D28(table)

LEVINSON, J.
- training in laparoscopic sterilization in Malaysia, C14

LEVITICUS
- douching, J142

LEWIS, S.C.
- cannula resterilization, F18
- menstrual regulation, F13(table)
  - blood loss, F17(table)
  - follow-up, F15
  - procedure and equipment, F14(table)
- uterine aspiration, F28(table)
  - blood loss, F34(table)
  - complications, F33(table)
  - equipment, F32(table), F41
  - handpump v. electrical procedure, F43
  - local anesthesia, F29(table), F30(table)
  - pressure, F41(table)
  - time required, F32(table), F34(table)

LEWIT, S.
- expulsion, pregnancy, removal, and continuation rates in nulliparas, B15(table)
  - with copper IUD, B6(table)
  - with inert Lippes Loop D, B11(table)
- use-effectiveness of contraceptive foam, H45(table), H46
- use-effectiveness of copper-T IUD, B32 (table)

LIBERIA
- adolescent births, J161(table)
- age-specific fertility rate, J3(graph), J224(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- legal status of voluntary sterilization, CD110(table)
- marital status of female adolescents, J164(table)
- marketing of oral contraceptives, A14(table)
- rubber plantations, H23
- training nonphysicians, J94(table), J104 (table)
  - diaphragm fitting, H67

LIBIDO
- injectable progestogens, K6

LIBYA
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- diaphragm availability, H68(table)
- legal status of abortion, E28
- marketing of oral contraceptives, A14 (table)

LICHTMAN, A.S.
- menstrual regulation with PGs, G59(table)

LIDOCAINE, C32(table), C55, C56, D26. See also **XYLOCAINE**
- cervical dilatation, F91
- culdoscopy
  - administration, C63
  - dosage, C63, C64
- menstrual regulation, F13(table)
- paracervical block, F28
- vasectomy, D3, D6-D7(table)

LIEB, C.C.
- early clinical study of PGs, G1, G2

LIEBERMAN, B.
- clip sterilization, C46, C47
  - complications, C49
  - follow-up, C50
  - preoperative medication, C47(table)
- insufflation complications, C47

LIEBERMAN, E.J.
- psychological aspects of abortion, J170

LIEBERMAN, S.S.
- contraceptive acceptors in Iran, J308 (figures)

LIEBMANN, H.G.
- cervical cap, H70

LIECHTENSTEIN
- birth rate, J29(table), J207(table), J210 (table)

LIEDHOLM, P.
- use-effectiveness of copper-T IUD, B32 (table)

LIFE TABLE ANALYSIS, H46, I9
- band sterilization failure, C85
- IUD performance, B31
  - factors influencing, B33
  - pertinent events, B33

LIGGINS, G.C.
- PG-induced uterine contractions, G46-G47
  - progesterone level, G47

LINACRE LABORATORIES
- thermometers, I5(figure)

LINCOLN, R.
- mortality rates for selected operative procedures in the US, E27(graph)

LINDEMANN, H.J.
- hysteroscopic fulguration, C82(table)
  - equipment, C81-C82
  - pregnancy, C81
- tubal occlusion with methyl-2-cyanoacrylate, C86(table), C89

LINEN
- tubal ligation, C74, C77

LINTHORST, G.
- use-effectiveness of Depo-Provera, K4 (table)

LIOTHYRONINE
- vas anastomosis, D51

LIPPES, J., B21, B25
- comparative studies of IUD expulsion rates, B10
- copper IUD
  - expulsion, pregnancy, removal, and continuation rates, B6(table)
  - postcoital insertion, J150, J151
- experimentation with "sleeve" technique for IUDs, B4
- inert Lippes Loop D, B11(table)
- IUD insertion technique, B8
- Lippes Loop, B42
  - experiments with copper, B4
  - use-effectiveness, B32(table)

LIPPES LOOP, B42(photo). See also **LIPPES LOOP A**; **LIPPES LOOP D**
- comparative IUD study, B25
- compared with copper-T and copper-7, B2, B11
- complication, B1
- continuation rate, B3(graph, table), B11 (table)
- description, B42
- development, B21
- distribution, B42
  - USAID, B37
- embedding, B12
- expulsion rate, B34
- family planning, B2
- insertion, B25, B29, B30
  - pain, B30
- material, B25
- menstrual flow, B35
- mortality, B36(table)
- multiparas, B2
- nulliparas, B2
- Singapore, B26
- surface area related to pregnancy and removal rates, B34(figure)
- Taiwan, B26
- termination rate for bleeding, B11
- termination rate for pain, B12
- tests with copper, B2
- US, B37
- use-effectiveness, B32(table)

LIPPES LOOP A. See also **LIPPES LOOP**
- continuation rate, B6(table)
- expulsion rate, B6(table), B10
- pregnancy rate, B6(table), B10
- removal rate, B6(table)

LIPPES LOOP D. See also **LIPPES LOOP**
- continuation rate, B10, B11(table), B14
- expulsion rate, B3(graph, table), B11 (table)
- long-term use-effectiveness, B32
- multiparas, B15
- performance, B25, B33
- pregnancy rate, B3(graph, table), B11 (table)
- termination rate, B3(table), B11(table), B22(table), B23(table)
  - bleeding, B11

LISTON, W.A.
- laparoscopic sterilization, C2(table)
  - complications, C19(table)
  - electrocoagulation and division, C8 (table)
  - failure, C22(table)
  - postabortion, C23, C24(table)

LITERACY
- impact of population dynamics, J178
- political aspects, J178
- rate worldwide, J178
- role in social equality, J178

LITHOTOMY POSITION
- contraindicated with general anesthesia, C33
- menstrual regulation, F12
- posterior colpotomy, C33

LITHOTOMY POSITION, MODIFIED
- laparoscopy, C6

LITTLE, ARTHUR D., INC.
- commercial distribution of condoms, H16
- survey on contraceptive distribution, H48-H49

LITTLE, V.
- potency of progestogens in women, A37
  - with estrogen, A37

LITTLE, W.
- address, C70
- culdoscopy
  - adhesions, C66
  - anesthesia administration, C63
  - operative procedures, C64
  - postoperative complications, C67 (table)
  - preoperative medication, C63(table)
  - preoperative procedures, C62, C63
  - training program, C70
  - tubal occlusion, C65(table), C68(table)
- fimbriotexy for tubal occlusion, C91

LI-TZU, S.
- statement on abortion, F2

LIU, D.T.Y.
- operative procedure in laparoscopic sterilization, C7(table)
- postpartum sterilization coagulation, C23

LIVER CANCER
- incidence in Connecticut (1955-1975), A131(table)
- incidence in Denmark (1953-1972), A132 (table)
- incidence in Puerto Rico (1955-1975), A131(table)
- mortality in the US (1958-1975), A130 (chart)

LIVER DISEASE
- oral contraceptives, A47

LIVER TUMORS
- anabolic androgens, A90
- anagestone acetate, A89(table)

    effects of OCs in animal studies, A89 (table)
    incidence among women in the US, A88
      use of OCs, A88, A89(table)
LIVINGSTONE, E.S.
  infection after vasectomy, D27
LLEWELLYN-JONES, D.
  complications with saline abortion, F72
L & M INSTRUMENTS
  address, M32
  guarantee and service of sterilization equipment, M30(table)
LOEB, L.
  ovariectomy and spontaneous tumors, A79
LOEFFLER, F.E.
  Pomeroy tubal ligation, C77
LOESTRIN, A12
  manufacture and marketing, A4(table)
LOESTRIN 1/20
  formulation and dose, A6(table), A37 (table)
  manufacturer, A37(table)
LOESTRIN 1.5/30
  formulation and dose, A6(table), A37 (table)
  manufacturer, A37(table)
LOH, S.K., J102(table)
LOMOTIL
  menstrual regulation with PGs, G58
LONDON RUBBER INDUSTRIES, LIMITED, H8, H12, H19
  address, H68(table)
  condom supply, H24
  diaphragm
    manufacture, H68(table)
    testing, H67(photo)
LONDONO, J.B.
  rhythm method, I16
  use-effectiveness of calendar rhythm method, I11(table)
LO-OVRAL
  formulation and dose, A37(table)
  manufacturer, A37(table)
LOPEZ-ESCOBAR, G.
  laser beam for tubal occlusion, C91
LORENZO, C.
  continuation rates of contraceptives, I16
LORINEZ, B.
  electrical suction with curettage, F27
LOROPHYN JELLY
  use-effectiveness, H45(table)
LOROPHYN SUPPOSITORY
  active ingredients, H41(table)
  use-effectiveness, H44(table)
  venereal disease, H51(table)
LOUNG, K.C.
  uterine aspiration, F28(table)
    anesthesia, F29(table)
    complications, F33(table)
    perforation, F35(table)
    preoperative medication, F29(table)
L.R. INDUSTRIES LTD., See **LONDON RUBBER INDUSTRIES, LIMITED.**
LU, L.P.
  multimedia campaign in Taiwan, J306 (table)
LUITPOLD-WERK, H41(table)
LUKKAINEN, T.
  abortion in China, F2
LUNDIN, F.E.
  factors influencing cervical cancer, J133 (table)
LUNG CANCER
  air pollution, J184
LUNGREN, S.S.
  tubal ligation, C74
LUTEINIZING HORMONE, G53, G54
  binding capacity, G60
    prostaglandins, G60-G61
  cross-reaction with HCG, J120
  levels during early pregnancy, A33(figure)
  levels during menstrual cycle, A33(figure)
    with orals, A33(figure)
  postvasectomy level, D31
  role in ovulation, A55
  suppression by progestogens, K3
LUTEOLYSIS
  prostaglandins, G60-G61
LUTESTRAL
  breast neoplasia in mice, A78(table)
LUTWAK-MANN, C.
  postcoital estrogen research with rabbits, J146
LUXEMBORG
  age-specific fertility rate, J228(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure), J241(table)
  change in number of births, J219(figure)
  diaphragm availability, H68(table)
  legal status of voluntary sterilization, CD110(table)
  marketing of minipill, A64(table)
  marketing of oral contraceptives, A14 (table)
  mortality rate, J241(table)
  population growth, J240, J241(table)
  training nonphysicians, J95(table)
LYLE, J.
  general anesthesia for mini-laparotomy, C54
LYMPHOCYTOTOXINS
  occurrence, D32
LYNDIOL
  manufacture and marketing, A4(table)
LYNEHAM, R.C.
  side effects of intraamniotic injection of $PGF_2\alpha$, G72
LYNESTRENOL, A7
  blood pressure, A62
  lactation, J63(table)
  menstrual patterns, A58(table)
  minipill
    current users, A64(table)
    effectiveness, A56(table)
    marketing, A64(table)
LYONS, T.C., JR.
  age of marriage and family size, J163
  hypothetical model of population growth, J167(table)
LYSOL
  postcoital douching agent, J142

M

M-211. See **M-DEVICE**.
M-213. See **M-DEVICE**.
MA, H.K.
  reversibility of clip sterilization, C82
  use-effectiveness of Dalkon Shield, B32 (table)
MACAO
  birth rate, J29(table), J207(table), J208, J210(table)
  marketing of orals, A14(table)
MACK, T.M.
  estrogen use and endometrial cancer in postmenopause, A86(table)
MACKAY, E.V.
  use-effectiveness of Depo-Provera, K4 (table)
MacKENZIE, I.Z.
  extraovular instillation of PGE_2, F75(table)
MacKINNON, D.S.
  use-effectiveness of postcoital diethylstilbestrol, J145(table)
MacMAHON, B.
  etiology of breast cancer, A46
MADAGASCAR
  adolescent births, J159, J161(table)
  age-specific fertility rate, J224(graph)
MADLENER METHOD, C75(figure), C76 (table)
  advantages and disadvantages, C75
  compared with other methods, C74
  culdoscopy, C65(table)
  failure rate, C74, C75
    colpotomy, C42
    factors affecting, C75
  procedure, C74
  route of approach, C75
  Taiwan, C75
  tubal ligation, C33(table), C34
MADRIGAL, V.
  Graves speculum, M20
  laparoscopic sterilization in El Salvador, C2, C13
MAIA, H.
  menstrual pattern changes with norethindrone minipill, A59(table)
MAILINGS
  family planning communication
    Colombia, J293
    Hong Kong, J294
    India, J293-J294
    Korea, J294
    Taiwan, J292-J293(table)
    US, J291, J293
MAIL-ORDER
  Taiwan, J82
  vaginal contraceptives, H48
MAINICHI SURVEY, H11, J295
MAJZLIN SPRING
  expulsion, B38
MAKERERE UNIVERSITY (UGANDA)
  PG research, G2, G17
MALAGASY
  availability of Depo-Provera, K13 (figure)
  birth rate, J29(table), J207(table), J210 (table)
  legal status of voluntary sterilization, CD110(table)
  marketing of orals, A14(table)
MALARIA
  pregnancy, J131
MALAVIYA, B.
  reversibility of quinacrine tubal occlusion, C87
MALAWI
  birth rate, J29(table), J207(table), J210 (table)
  legal status of voluntary sterilization, CD110(table)
  marketing of orals, A14(table)
  premarital sex, J159
MALAYSIA
  age of menarche, J162(table)
  age-specific fertility rate, J37(graph)
  attitude toward out-of-wedlock pregnancy, J163
  average births per woman, J129(table)
  birth rate, J29(table)
  condom
    importation costs, H5(table)
    manufacture, H5
    shipments, H14(table), H15(table)
  contraception among adolescents, J166
  culdoscopy, C61, C69
    complications, C67(table)
    tubal occlusion, C65(table)
  Depo-Provera
    availability K13(figure), K14
    continuation rate, K7(table), K8(table)
    distribution, K14
    restricted use, K12, K13
  diaphragm
    availability, H68(table)
    training nonphysicians, H67
  distribution of contraceptives, J165
    Depo-Provera, K14
    orals, J92, J93(figure)
  family planning policy, E2
  IUD acceptors, B27(table)
  IUD continuation rate, B33
  legal status of abortion, E28
  legal status of voluntary sterilization, CD78, CD79, CD110(table)
    Islamic law, CD86
  marketing of minipill, A64(table)
  Ministry of Health
    address, J102(table)
    training nonphysicians, J94(table), J102(table)
  National Family Planning Board
    address, J102(table)
    training nonphysicians, J94(table), J102(table)
  new acceptors, A18(table), J14(table)
  oral contraceptives
    distribution, J92, J93(figure)
    marketing, A14(table)
    new acceptors, A18(table)
    supplied by SIDA, A20(table)
  paramedical personnel
    injectable contraceptives, J92
    vasectomy, J98
  percentage of married female acceptors under 20, J170(table)

  percentage of married women of reproductive age under 20, J170(table)
  rubber plantations, H22, H23
  sexual behavior after vasectomy, D35 (table)
  training
    culdoscopy C62
    laparoscopic sterilization, C14
    nonphysicians, J94(table), J102(table)
  unemployment, J197
MALAYSIA, EAST
  birth rate, J210(table)
MALAYSIA, WEST
  adolescent births, J161(table)
  age-specific fertility rate, J222(graph)
  birth rate, J23(figure)
  change in number of births, J219(figure)
  geography and family planning, J216
  oral contraceptives supplied by USAID, A21(table)
  total fertility rate, J215(table), J217(table)
  World Fertility Survey data, J216
MALDIVES
  birth rate, J29(table), J207(table), J210 (table)
MALGOUYAT, R.
  Om-Ga, B48
MALI
  age-specific fertility rate, J224(graph)
  birth rate, J29(table), J207(table), J210 (table)
  condom shipments, H14(table)
  drought and famine, J244–J245
  early marriage, J158
  oral contraceptives
    marketing, A14(table)
    supplied by SIDA, A20(table)
  population growth, J188
MALIK, T.
  postcoital copper IUD insertion, J150
MALIN, W., C46
MALINAK, L.R.
  aloplastic plug for tubal occlusion, C90 (table)
MALIPHANT, R.G.
  factors influencing cervical cancer, J133(table), J135
MALPRESENTATION
  among multiparas at childbprth, J134–J135(table)
MALSTROM VACUUM EXTRACTOR, F43 (figure)
MALTA
  age-specific fertility rate, J228(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  diaphragm availability, H68(table)
  legal status of voluntary sterilization, CD110(table)
  marketing of minipill, A64(table)
  marketing of oral contraceptives, A14 (table)
MALTHUS, T.R., J237
  population growth theory, J177
MAMMARY TUMOR VIRUS (MTV), A79
MANABE, Y.
  insertion of laminaria, F93(figure)
MANCHESTER, UNIVERSITY OF. (ENGLAND)
  synthesis of norgestrel, A32
MANISOFF, M., J103(table)
MANTEGAZZA, P.
  frozen semen storage, D52
MANTRI (INDONESIA). See **INDIGENOUS MEDICAL PRACTITIONERS**.
MAORI (NEW ZEALAND)
  folk methods for sex preselection, I22
MAPA GmbH, H19
MAQUEO, M.
  oral contraceptives and squamous metaplasia, A84(table)
  quingestanol acetate minipill
    effectiveness, A56(table)
    menstrual pattern changes, A60(table)
MARCH, C.M.
  hysteroscopic fulguration, C82(table)
MARCO, JOHN, AND SON
  address, C64, C69, M32
  culdoscopic equipment, C64, C69(figures)
  guarantee and service of sterilization equipment, M30(table)
  perineal retractors for culdoscopy, M25 (table)
MARGARET PYKE CENTER
  vasectomy, D26
    complications, D28(table)
    technique, D28(table)
MARGARET SANGER CENTER, INTERNATIONAL TRAINING PROGRAM
  address, J283
  population program assistance, J275(table)
MARGARET SANGER CENTER, PLANNED PARENTHOOD OF NEW YORK, D33, J70
  address, J107(table)
  training nonphysicians, J95(table), J98, J107(table)
MARGOLIS, A.J.
  menstrual regulation, F13(table)
    blood loss, F17(table)
    follow-up, F15
    procedure and equipment, F14(table)
    vaginal cleansing, F12
  Rh sensitization, F36
  use-effectiveness of contraceptive jelly, H45(table)
  uterine aspiration, F28(table)
    anesthesia, F29(table)
    blood loss, F34(table)
    complications, F33(table)
    equipment, F32(table)
    preoperative medication, F29(table)
    time required, F32(table), F34(table)
MARGULIES, L., B24
MARGULIES SPIRAL
  barium sulfate, B24
  comparative IUD study, B25
  pain after insertion, B30
  surface area related to pregnancy and removal rates, B34(figure)
  termination rate, B23(table)
MARIANAS ISLANDS
  marketing of oral contraceptives, A14 (table)
MARIE STOPES CLINIC (ENGLAND), J70
  address, J105(table)
  cervical cap promotion, H70
  diaphragm distribution, H67
  training nonphysicians, J95(table), J105(table)
MARIK, J.J.
  uterine aspiration
    effectiveness, F42
    incomplete abortion, F60
MARIKA ELIADIS MATERNITY HOSPITAL (GREECE)
  address, J103(table)
  training nonphysicians, J103(table)
MARINO, A.
  family planning radio campaign, J302
MARITAL PATTERNS
  demographic impact, J214
MARITAL STATUS
  cervical cancer, J133(table)
MARKER, R.
  diosgenin, A32
MARKETING. See also **PROMOTION**.
  condom, J77
  family planning, J75
    Antigua, J76
    Ghana, J78
    India, J77
    Kenya, J77
    Pakistan, J78
    Sri Lanka, J77
  IUD, B37
  minipill, A63, A64(table)
  oral contraceptives, A3–A5, A13–A15(tables)
    commercial sales, A7–A12, A16
    family planning program distribution, A17–A24
  postcoital norgestrel, J147
  prohibition of contraceptive advertising, E44
  vaginal contraceptives, H47–H48
    effect on sales, H49
    IPPF directory, H47
MARRIAGE
  incidence at early age, J158
MARRIAN, G.F.
  identification of estriol, A31
MARRIED COUPLES' ASSOCIATION (PHILIPPINES), J79
MARSHALL, B.R.
  use-effectiveness of Dalkon Shield, B32 (table)
  uterine aspiration for incomplete abortion, F60(table)
MARSHALL, J.
  age of sperm, I12
  anxiety with rhythm method, I13
  cervical mucus and ovulation, I8
  coital timing, I24
  fertile period identification, I3(table), I6(figure)
  use-effectiveness of cervical mucus rhythm method, I11(table)
  use-effectiveness of temperature rhythm method, I10, I11(table)
MARSHALL, L.
  sperm count after vasectomy, D10
MARTIN, E.
  sperm count with epididymitis, D42
  vaso-epididymal anastomosis, D42
MARTIN, J.B.
  use-effectiveness of contraceptive foam, H45(table)
MARTIN, J.N.
  midtrimester abortion with PGE_2
    side effects, G70(figure)
    time required, G69(figure)
MARTIN, W.
  duration of postpartum amenorrhea, J57(table)
MARTINEZ-MANAUTOU, J.
  development of minipill, A54
  progestogen-only contraceptives and lactation, J63(table)
MARTINIQUE
  age-specific fertility rate, J36(graph), J227(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  marketing of oral contraceptives, A14 (table)
MASAI
  tribal attitude toward premarital sex, J159
MASS MEDIA
  family planning, J214, J289–J314
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (BOSTON, MASSACHUSETTS)
  climatic changes, J187
MASSE, N.
  age of menarche, J162(table)
MASSEY, B.D.
  vas anastomosis effectiveness, D43
MASSEY, J.B.
  postcoital diethylstilbestrol
    side effects, J148(table)
    use-effectiveness, J145(table)
MASSOURAS, H.G., B46
MASSOURAS DUCK'S FOOT, B46(figure)
  description, B46
  distribution, B46
  use-effectiveness, B46
MASTECTOMY
  mortality, E27(graph)
MASTERS, W.H.
  comparative effectiveness of vaginal contraceptives, H44(table)
  diaphragm
    failure, H66
    fitting, H62
  genitalia size, H29
  spermicidal potency, H44
MASTITIS
  etiology and treatment, J53
MATBURN SURGICAL EQUIPMENT LTD., F41(table)
MATERNAL AGE
  congenital abnormalities, I12
  health risks, J254–J256
  morbidity and mortality, J126
MATERNAL AND CHILD HEALTH SERVICE, DIRECTORATE OF PUBLIC HEALTH. (VIETNAM)
  address, J103(table)
  training nonphysicians, J103(table)
MATERNAL DEPLETION SYNDROME, J129

- **MATERNAL HEALTH**. See also **MORTALITY, MATERNAL**.
  - nutrition, J131
    - birth interval, J129
  - optimal childbearing age, J126, J127
  - parity, J129(figure)
  - volume of literature compared with child health literature, J129(figure)
- **MATERNAL HEALTH SERVICES**. See also **FAMILY PLANNING PROGRAMS**.
  - family planning, E20
  - fertility management training, J42-J45
    - country participants, J44
    - individual participants, J46-J47
    - program goals, J41
  - menstrual regulation, F62
- **MATRISALUS DIAPHRAGM**
  - description, H61
  - indications, H61
- **MAUDSLEY PERSONALITY INVENTORY**, D34
- **MAURITANIA**
  - age-specific fertility rate, J224(graph)
  - birth rate, J29(table), J207(table), J210 (table)
  - drought and famine, J244-J245
  - marketing of oral contraceptives, A14 (table)
- **MAURITIUS**
  - age-specific fertility rate, J3(graph), J7(graph), J25(graph), J34(graph), J22(graph)
  - availability of Depo-Provera, K13(figure)
  - birth rate, J23(table), J29(table), J207 (table), J218(figure)
  - change in number of births, J219(figure)
  - condom shipments, H14(table)
  - contraceptive practice, A12(table)
  - diaphragm
    - availability, H68(table)
    - training nonphysicians, H67
  - family planning program, J24
  - legal status of abortion, E29(table)
  - marketing of minipill, A64(table)
  - maternal mortality, J128(figure)
  - new acceptors, A17, A18(table), J11(table)
  - oral contraceptives
    - marketing, A14(table)
    - new acceptors, A17, A18(table)
    - supplied by SIDA, A20(table)
    - supplied by USAID, A21(table)
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - rhythm method, I2, J74
    - continuation rates, I16
    - drop-outs, J82(table)
    - effectiveness, J81
    - program evaluation, J84(table)
    - taught by trained couples, J81
    - use-effectiveness, I11(table), I12(table)
  - total fertility rate, J215(table), J216, J217(table)
  - training nonphysicians, J94(table), J104(table)
- **MAURITIUS FAMILY PLANNING ASSOCIATION**
  - address, J104(table)
  - training nonphysicians, J94(table), J104(table)
- **MAURITZEN, K.**
  - vas anastomosis effectiveness, D43
- **MAYER, J.**, J242
- **MAYO, R.W.**
  - biologic pregnancy test, J115(table)
  - immunologic pregnancy tests
    - slide test, J119(table)
    - tube test, J118(table)
- **McCANN, S.M.**
  - PG stimulation of pituitary-hypothalamus, G54
- **McCORMACK, K.D.**, A32
- **McCORMICK HOSPITAL (THAILAND)**,
  - K3(photo), K12(photo)
  - injectable progestogens
    - cost, K14
    - supplemental estrogens, K6
  - new acceptors of Depo-Provera, K13
- **McDANIEL, E.B.**
  - attitude toward physicians, K11
  - benefit v. risk of contraception, K12
  - comparative contraceptive continuation rates, K8(graph)
  - Depo-Provera
    - body weight, K6
    - continuation rate, K7(table), K8(table)
    - incidence of breast nodules, K10
    - supplemental estrogens, K6
    - use-effectiveness, K5(table)
  - injectable progestogens
    - advantage, K12
    - reversibility, K9
- **McDONALD, T.W.**
  - estrogen use and endometrial cancer in postmenopause, A86
- **McEWAN, J.**
  - vasectomy
    - complications, D28(table)
    - technique, D28(table)
- **McGRATH, P.L.**, author, J177-J202
- **McIVER, D.D.**
  - immunologic pregnancy tests
    - slide test, J119(table)
    - tube test, J118(table)
- **McKEAN, C.M.**
  - HCG detection in pregnant women, J111
- **McKENNA SURGICAL SUPPLY**, D13
- **McKINNEY, G.R.**
  - oral contraceptive hormone studies with animals
    - breast neoplasia, A78(table)
    - endometrial tumors, A87(table)
    - liver tumors, A89(table)
    - pituitary tumors, A90(table)
- **McMASTER, R.H.**
  - sterilization by colpotomy, C31(table)
    - anesthetic, C32(table)
    - complications, C40(table), C41(table)
    - equipment, C36(table)
    - Pomeroy method, C33(table)
    - postpartum abortion, C43
- **McQUARRIE, H.G.**
  - norethindrone minipill
    - effectiveness, A56(table)
    - menstrual pattern changes, A59(table)
- **McRAE, L.A.**
  - morbidity with colpotomy, C30
- **McROBERTS, W.**
  - prevention of sperm granulomas, D30
- **M-DEVICE**
  - expulsion, B38
  - termination rate, B22(table), B23(table)
- **MEAD JOHNSON**
  - oral contraceptives, A4(table)
    - worldwide marketing, A13-A15(tables)
- **MEDICAL TECHNOLOGY INTERNATIONALE, INC.**, C10, C46
  - insufflation equipment, C51-C52
- **MEDICAL TERMINATION BILL (INDIA)**, F1, F2, F4
- **MEDITERRANEAN SEA**
  - pollution, J182
- **MEDROXYPROGESTERONE**
  - principal progestogen, A6(table)
- **MEDROXYPROGESTERONE ACETATE**, A87. See also **DEPO-PROVERA; INJECTABLE PROGESTOGENS**.
  - component in oral contraceptives, K10
  - fetal effects in animal studies, K9
  - first developed, K2
  - habitual abortion, K2
  - lactation, J63(table)
- **MEEKER, C.I.**
  - Teflon plug for tubal occlusion, C91
- **MEGESTROL ACETATE**, A7
  - breast neoplasia, A78(table)
  - continuation rate as minipill, A62(table)
  - derivation, A55
  - endometrial tumors, A87(table)
  - lactation, J63(table)
  - liver tumors, A89(table)
  - pituitary tumors, A90(table)
  - principal progestogen, A5(table)
- **MEHARRY MEDICAL COLLEGE. TRAINING AND RESEARCH CENTER. (TENNESSEE)**
  - address, J107(table)
  - training nonphysicians, J98, J107(table)
- **MEHTA, K.C.**
  - vas anastomosis
    - effectiveness, D49(table)
    - operative procedures, D44(table)
- **MEJIA, R.M.**
  - family planning in Ecuador, E2
- **MEJIA, W.**
  - duration of postpartum amenorrhea, J57(table)
- **MELAMED, M.R.**
  - cervical cancer and diaphragm use, H64
  - orals and cervical neoplasia, A44(table), A81(table)
- **MELKS, E.**
  - uterine aspiration, F27
- **MENARCHE**, J159-J160
  - compared with age of marriage, J163(figure)
  - factors affecting, J159
  - trends in selected countries, J162(table)
- **MENCHER, J.**
  - family planning for childless couples, J164
- **MENGERT, W.F.**
  - local anesthesia for uterine aspiration, F30(table)
- **MENKEN, J.A.**
  - natural selection process of cumulative fertility, J163
- **MENOPAUSE**
  - estrogen use and endometrial cancer, A85
  - rhythm contraindicated, I7
- **MENORRHAGIA**
  - incidence in users and nonusers of orals compared, A31(table)
- **MENSINGA, W.**
  - diaphragm and spermicide, H39
- **MENSINGA DIAPHRAGM**, H58. See also **FLAT SPRING DIAPHRAGM**.
- **MENSINGA PESSARY**, H58
- **MENSTRUAL CYCLE**
  - combined oral contraceptives, A38, A61
  - endometrial changes, A33(figure)
  - minipill, A57, A61
  - ovarian changes, A33(figure)
  - ovulation, I2-I3
  - plasma hormone levels, A33(figure)
  - postcoital combined estrogen-progestogen, J150
  - postcoital estrogens, J147
  - postcoital progestogens, J148
  - probability model of cycle length, I10(graph)
  - selected studies, A58-A60(tables)
  - variability, I1, I10
- **MENSTRUAL DISORDERS**
  - treatment, A5
- **MENSTRUAL EXTRACTION**. See **MENSTRUAL REGULATION**.
- **MENSTRUAL FLOW**
  - copper IUDs, B11
  - Dalkon Shield, B11
  - minipill, A61
    - selected studies, A58-A60(tables)
  - Saf-T-Coil, B11
- **MENSTRUAL INDUCTION**. See **MENSTRUAL REGULATION**.
- **MENSTRUAL PLANNING**. See **MENSTRUAL REGULATION**.
- **MENSTRUAL REGULATION**. See also **UTERINE ASPIRATION; VACUUM ASPIRATION**.
  - acceptability, F62
  - advantages, F9, F15, F49
  - anesthesia, F12, F13(table), F50, F51(table)
    - failure rate, F54(table)
  - Asia, F49
  - availability in US and Great Britain, F9
  - blood loss, F15, F17(table)
  - capillary test, J122
  - complement to family planning programs, F61
  - complications, F15-F16(table), F50, F51-F52
    - delayed, S52(table)
    - immediate, F52(table)
    - rate by length of amenorrhea, F66 (figure)
  - conference, F49-F50
  - confirmation of pregnancy, E28
  - cost, F62
  - counseling, F12, F49, F50
  - definition, G33, J96
  - diagnostic uses, F57, F59
  - early abortion, E28
  - effectiveness, F53-F55
  - equipment, F10(figure), F18, F19, F50, G38
    - cannula, F12, F14(table), F51(table), F55

    cleaning, F58
    kits, F57
    manufacture, F56-F57
    polyethylene, F11
    suction source, F51(table), F55-F56
    syringe, F59(figure)
    vacuum source, F14(table), F18-F19
  evaluation, F50
  failure rate, F17, F54-F55
  family planning, F18, F61
  follow-up, F15, F58
  history, F11
  India, F62
  integration in health care system, F62
  IUD insertion, F52
  Latin America, F49
  legal status, E25, E28, F50, F61, J113
  manpower, F20
  maternal health services, F62
  operative procedure, F12, F14(table), F51(table), F58
    aspiration time, F12, F14(table)
  outpatient procedure, F12, F50-F51
  paramedical personnel, J96
    Bangladesh, J97
    effectiveness, J96-J97
    US, J96
  physiological mechanism with PGs, G34-G35
  postoperative procedure, F15, F51, F58
  pregnancy tests, F12, F50, F53
  preoperative procedure, F11, F12, F58
    anesthesia and analgesia, F13(table), F51(table)
  preventive medicine, F62
  problem issues, F10, F50
  procedure, G38
  program development, F61-F62
  prostaglandins, G58
    dosage, G59(table)
    effectiveness, G59(table)
    impact, G36(table), G37(table)
    route of administration, G59(table)
    side effects, G59(table)
    timing, G59(table), J113
  rationale, F49
  repeated use, F62
  research, F20
  similarity to IUD insertion, F9
  sources of funding, J271(table)
  studies, F11, F13(table), F14(table)
  therapeutic use, F59
  timing, F18, F53(graph), F61
  training, F20
    paramedical personnel, F62
    selected countries, J94-J95(table)
MENSTRUATION
  after colpotomy, C42
  breast-feeding, J50, J54, J56, J58(figure)
  cultural aspects, J158
  early method of induction, F26, F27
  effect of IUDs, B35
  gonorrhea symptoms, B36
  PG release, G49
  regulation with pessary, B24
  religious attitudes, A61
MENSTRUATION DISORDERS. See also **AMENORRHEA**; **DYSMENORRHEA**.
  cause of discontinuation of Depo-Provera in selected studies, K8(table)
  etiology, K6
  injectable contraceptives, K2
    continuation, K7
  postcoital combined estrogen-progestogen, J150
  postcoital estrogens, J147
  postcoital progestogens, J148
MEPERIDINE, C3(table), F29(table), F30 (table)
MEPERIDINE HYDROCHLORIDE, C32(table), C35, C54, G67
  compared with droperidol and fentanyl, C62
  culdoscopy, C62, C63(table)
    administration, C63
    dosage, C63
  menstrual regulation with PGs, G58
MEPIVICAINE
  cervical dilatation, F91
MERCER, J.P.
  laparoscopic sterilization, C2(table)
    electrocoagulation with division, C8 (table)
    morbidity, C19
    operative technique, C7(table)
    preoperative medication and anesthesia, C3(table)
MERCK, E., CO., A5
MERCK-DARMSTADT, E. (WEST GERMANY)
  injectable contraceptives, K2
MERCURIAL ANTISEPTICS
  contraindicated for vas anastomosis, D48
MERCURY, A30
MERCURY BICHLORIDE
  postcoital douching agents, J142
MERNISSI, F.
  radio promotion of family planning, J303
MERTHIOLATE
  contraindicated for vas anastomosis, D48
MERZ, W.
  tubal ligation, C75
MESOSALPINX CLAMP, M25
  cost, C69
  culdoscopy, C64, C69(figure)
MESTRANOL
  breast neoplasia, A78(table), A79(table)
  liver tumors, A89
  oral contraceptives, A5, A6(table), A37(table)
  potency, A37
METAL DILATORS, F90-F91
METAPLASIAS
  in adolescents, A83
METHERGINE, F29(table)
METHERGINEL AMPULE, F29(table)
METHOHEXITONE SODIUM, F29(table)
METHOXYPOLYOXYETHYLENE GLYCOL 550 LAURATE, H41(table), H42
METHYLBENZETHONIUM CHLORIDE, H41(table)
METHYL-2-CYANOACRYLATE (MCA)
  tubal occlusion, C77(table), C86(table), C88-C89
METHYLERGONOVINE, F60(table)
METHYLERGONOVINE MALEATE, F29(table)
METHYLPREDNISOLONE ACETATE, D3
  therapeutic use, D26
METREURYNTER
  dilator, F97
METROPOLITAN HOSPITAL CENTER (NEW YORK)
  training nonphysicians, J98
METRORRHAGIA, A33
METRULEN
  breast neoplasia in mice, A78(table)
MEXICO, J194
  adolescent births, J161
  age-specific fertility rate, J3(graph), J6(graph), J27(graph), J36(graph), J223(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J23(figure), J29(table), J207 (table), J209(table)
    economic growth, J22
  chemical tubal occlusion, C87
  condom
    importation costs, H5(table)
    sales, H6
    shipments, H14(table)
  contraceptive practice, A12(table)
  culdoscopy, C61
    postoperative complications, C67(table)
    training, C62, C69, C70
    tubal occlusion, C[illegible](table), C68(table)
  diaphragm availability, H68(table)
  family planning programs, E1, E2, E3(table), J4, J26, J206, J217, J239
    service statistics system, J330-J332
  General Population Law, E42, E46
  infant and neonatal mortality, J166(table)
  injectable contraceptives, K2
  in-school sex education, J171
  IUD
    acceptors, B27(table)
    experimental study with copper, B18
    insertion by paramedical personnel, B28, E4(table)
  lactation
    effect of orals, J61(table)
    effect of progestogen-only contraceptives, J63(table)
  legal status of abortion, E29(table), F61
  legal status of voluntary sterilization, CD80, CD111(table)
  low-cost housing, J186
  marital status of female adolescents, J164(table)
  marketing of minipill, A64(table)
  maternal health programs, E14
  maternal mortality, J128(figure), J130(table)
  new acceptors, A18(table), J18(table)
  oral contraceptives
    carcinogenic effects, A44(table)
    commercial supply, A9(table)
    lactation, J61(table)
    marketing, A4(table)
    new acceptors, A18(table)
    production, A1
    sales, A8(table)
    supplied by SIDA, A20(table)
  out-of-wedlock births, J160(figure)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  PG research, G20, G22
  population, J206
  population policy, E9, E41, E42, E43(table), J237, J246, J248
  progesterone production, A32
  total fertility rate, J216(table)
  use-effectiveness of Norigest, K4(table)
  vasectomy, D28(table)
  Yoon band sterilization, C85
MEYER, J., C54
MIAMI, UNIVERSITY OF (FLORIDA)
  reversible occlusion with vas valves, D53
  training program in culdoscopy, C69, C70
    address, C70
MICHIGAN, UNIVERSITY OF, J284
  population program assistance, J276(table)
MICRODILATORS
  cervical dilatation, F96
MICRODOSE PROGESTOGEN-ONLY ORAL CONTRACEPTIVES. See **MINIPILL**.
MICROGYNON
  manufacture and marketing, A4(table)
MICROLUT
  manufacture and marketing, A4(table), A64(table)
MICRONETT
  manufacture and marketing, A64(table)
MICRONOR, A16
  formulation and dosage, A6(table)
  manufacture and marketing, A64(table)
  USFDA approval, A55
MICRONOVUM
  manufacture and marketing, A64(table)
MICROSURGERY
  tubal ligation, C75
  vas anastomosis, D43, D51(photo)
MICROVAL
  manufacture and marketing, A64 (table)
MIDDLE EAST. See also specific countries.
  birth rate, J249(table)
  changes in births, J239
  diaphragm use, H60
  folk methods of postcoital contraception, J142
  mortality rate, J249(table)
MIDDLETON, G.D.
  diabetes mellitus and parity, J132(table)
MIDMENSTRUATION
  IUD insertion, B29
MIDWIFE ASSOCIATION (SWEDEN)
  training nonphysicians, J95 (table)
MIDWIVES. See also **AUXILIARY PERSONNEL**; **BAREFOOT DOCTORS**; **BIDANS**; **NURSING PERSONNEL**; **PARAMEDICAL PERSONNEL**.
  diaphragm fitting, J93
  distribution of orals, J92
    training, A37
  female sterilization, J97
  IUD insertion, B28
    training programs, J96
  Japan, H11
MIGRATION
  labor force, J197

MIKRO-30 WYETH
  manufacture and marketing, A64 (table)
MIKULICA-RADECKI, A.
  hysteroscopic fulguration, C81
MILEX CRESCENT
  venereal disease, H51(table)
MILEX PRODUCTS, INC., F40
  cervical dilatation with laminaria, F39(figure)
  diaphragm manufacture, H67
MILLER, A.G.
  use-effectiveness of calendar rhythm method, I9
MILLER, A.W.F.
  PGs for pregnancy termination, G8(table), G9(table)
MILLER, D.F.
  male toad test for pregnancy, J111
  orals and cervical neoplasia, A82(table)
MILLER, E.
  obstetrical complications with multiparity, J134(table)
MILLER, E.G., JR.
  uterine response to semen, G1
MILLER, G.
  orals and lactation, J61(table)
MILLMAN, N.
  spermicidal potency, H44
MINERALS
  availability, J194-J195
  world consumption, J194-J195
MINGEOT, R.
  orals and squamous metaplasia, A84(table)
MINI-LAPAROTOMY
  advantages, C53, C54
  clinical research, C59
  complications, C57-C58
  contraindications, C57
  equipment, C55-C56, J281(photo), J282, M20, M21
    kit, C58(figure)
    uterine elevator, C55(figure)
  failure, C58
  general anesthesia, C54, C55
  history, C54
  local anesthesia, C54, C55
  mortality, C58
  operative procedures, C55-C56, M20
    incision, C55
    incision closure, C56-C57
    uterine manipulation, C55
  performed by nonphysicians, J97
  Philippines, C58
  postoperative care, C57
  preoperative procedure, C54-C55
  proctoscope, C54
  Thailand, C53-C54
  training, C59
    film, M20
  tubal ligation, C74, C75, C77, C78
  tubal occlusion, C76
    clips, C84
    plugs, C90
    Yoon band, C85
MINILYN
  manufacture and marketing, A4(table)
MINIPILL, A34, A53-A67
  17-acetoxyprogesterone derivative, A54, A55
  advantages, A54, A61
    compared with combined orals, A63-A64
  blood pressure, A42
  body weight, A61
  brands approved by USFDA, A55
  carbohydrate metabolism, A62, K6
  components, A53, A54, A55
  congenital defects, A61, A62
  continuation rates, A61
    selected studies, A62(table)
  development, A53-A54
  disadvantages, A53-A54
  distribution, A64(table)
  dysmenorrhea, A61
  ectopic pregnancy, A54, A57(table), A63, J144
  history, A53, A54-A55
  lactation, A54, A62-A63, A64, J50, J59
    selected studies, J63(table)
  marketing, A63-A64(table)
  mode of action, A53, A55-A56
  19-norsteroids, A55, A62
  packaging, A54
  recommended for adolescents, J168
  side effects
    menstrual pattern changes, A57, A61
    nonmenstrual, A61
  thromboembolism, A54, A61-A62
  use-effectiveness, A53
    selected studies, A56(table)
    v. theoretical effectiveness, A56(table), A57
  worldwide use, A53, A63-A64
MINIPLANOR
  manufacture and marketing, A4(table)
  patent information, A5(table)
MINNESOTA MULTIPHASIC PERSONALITY INVENTORY, D34
MINOVLAR
  manufacture and marketing, A4(table)
  patent information, A5(table)
MIRAMONTES, L., A5(table)
MISCHLER, T.W.
  use-effectiveness of postcoital quingestanol acetate, J149(table)
MISHELL, D.R.
  copper-T in nulliparas, B15
  expulsion, pregnancy, removal, and continuation rates of IUD in nulliparas, B14, B15(table)
  IUD insertion, B28
    uterine effects, B35
  IUD removal after perforation, B31
  use-effectiveness of Depo-Provera, K4 (table)
  X-rays for diagnosis of uterine perforation, B31
MISUGAMI
  used as a barrier method, H58
MITHURI (SRI LANKA)
  oral contraceptive distribution, J77
MITRA, K.N.
  tubal ligation, C34
MITY-VAC, F56, F57(figure)
  menstrual regulation, F51(table)
MIZUTANI SHIKI LAMINARIA, F40
MOBILE CLINIC, J72
MOCSARY, P.
  menstrual regulation with PGs, G38(table), G59
MODICON
  formulation and dosage, A37(table)
  manufacturer, A37(table)
MODIFIED POMEROY METHOD. See **POMEROY METHOD**.
MOGGIA, A.
  quingestanol acetate minipill
    effectiveness, A56(table)
    menstrual pattern changes, A60(table)
  use-effectiveness of postcoital progestogens, J149(table)
MOHR, J.
  tubal occlusion with methyl-2-cyanoacrylate, C89
MOLESWORTH UTERINE DILATOR, F88 (figure), F89
MOLITOR, M.P.
  psychological aspects of menstruation, K8
MOLNOS, A.
  cultural restrictions on premarital sex in East Africa, J159
MONACO
  birth rate, J29(table), J207(table), J210 (table)
MONGOLIA
  birth rate, J29(table), J207(table), J210 (table)
MONILIASIS
  menstruation disorders, K6
MONTSERRAT
  birth rate, J29(table), J207(table), J218 (figure)
  change in number of births, J219(figure)
  sex ratio, I23
MOON, K.H.
  reversible vas occlusion, D53
MORAN, M.J.
  seminal plasma, D30
MORBIDITY
  colpotomy, C40-C42
  laparoscopic sterilization, C19
    postabortion, C24
  uterine aspiration, F33(table)
MORGAN, R.
  vas isolation after scrotal incision, D4
MORNING-AFTER PILL. See specific hormones, e.g., **ESTROGENS**; **POSTCOITAL DIETHYLSTILBESTROL**.
MOROCCO, J194
  age-specific fertility rate, J3(graph), J34(graph), J224(graph)
  birth rate, J29(table), J207(table), J209 (table)
  communication of family planning, J303
  condom
    sales, H11
    shipments, H14(table)
  contraceptive distribution program, E41, E42, E44(table)
  contraceptive practice, A12(table)
  IUD acceptors, B27(table)
  legal status of abortion, E29(table), J164
  legal status of voluntary sterilization, CD111(table)
  marital status of female adolescents, J164(table)
  new acceptors, A18(table), J11(table)
  oral contraceptives
    marketing, A14(table)
    new acceptors, A18(table)
    supplied by SIDA, A20(table)
    supplied by USAID, A21(table)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  son preference and family size, I27
MORRIS, J.A.
  sterilization by colpotomy, C31(table)
    anesthetic, C32(table)
    bleeding with posterior incision, C41
    complications, C40(table)
    equipment, C36(table)
    failure, C39(table)
    fimbriectomy, C33(table)
    general anesthesia, C33(table)
    morbidity with abortion, C41
MORRIS, J.M.
  postcoital estrogens, J143
    diethylstilbestrol, J148(table)
    ectopic pregnancy, J144
    use-effectiveness, J144, J145(table)
MORSON, C.
  surgical error in vasectomy, D33
MORTALITY
  abortion, F36-F38, F37(table), F39
    US, F67(figure)
  auto accidents, J254
  breast cancer, A43
  China, F2, J211, J213(table)
  colpotomy, C42
  contraceptive practice, J258-J259
  culdoscopy, C68
  demographic transition, J212
  infant. See **MORTALITY, INFANT**.
  intraamniotic instillation of $PGF_{2}\alpha$, F74
  IUD, B22, B36
    developed and developing countries, A35(table)
    US, B36(table)
  laparoscopic sterilization, C17, C21
  maternal. See **MORTALITY, MATERNAL**.
  men and women, J127
  mini-laparotomy, C58
  postcoital douche, J142
  pregnancy, F65
  saline abortion, F70
  selected operative procedures, E27(graph)
  US
    abortion, F67(figure)
    age-specific trends from complications of childbearing (1955-1975), A108(chart)
    breast cancer among women (1955-1975), A112(chart)
    broad ligament cancer (1955-1975), A126(chart)
    cervical cancer (1955-1975), A116(chart)
    fallopian tube cancer (1955-1975), A126(chart)

- IUD, B36(table)
- liver cancer in women (1958–1975), A130(chart)
- malignant neoplasia, A109(chart), A110(chart), A111(chart)
- ovarian cancer (1955–1975), A126(chart)
- uterine cancer (1960–1975), A122(chart)

MORTALITY, CHILD
- malnutrition, J185

MORTALITY, INFANT
- adolescent mothers, J162
- birth intervals, J256
    - India, J256(table)
- breast-feeding, J58, J62
- Canada, A36
- maternal age, J254
    - selected countries, J254(table), J255(table)
- nutrition, J50, J255
- Rwanda, J255
- selected countries, J166(table), J254(table)
- US, A36

MORTALITY, MATERNAL, J127. See also **MATERNAL HEALTH**.
- abortion, F25, F37
    - illegal, E27, E28
    - induced, J137–J138
    - legal, E28, E36
    - risk in first and second trimesters, E27
- adolescents, J161, J254
- age, J126
- anemia, J130, J131
- Bangladesh, J127, J128, J255(table)
- birth interval, J126
- Canada, A36
- Chile, J130(table)
- compared with IUD mortality, B22
- Costa Rica, J130(table)
- definitions, J128
- developing countries, A35(table), J125
- Egypt, J130(table)
- Hutterites, J127
- Mexico, J130(table)
- multiparas, J126
- Panama, J130(table)
- Paraguay, J130(table)
- parity, J126
- resulting from pregnancy complications, J130(table)
- statistical problems, J128
- Thailand, J130(table), J254–J255(table)
- US, A36, F67(figure), J126, J255(table)
- Venezuela, J130(table)

MOSS, W.
- vasectomy
    - clips, D7
    - postoperative care, D9
    - technique, D6(table)

MOTIVATION
- contraceptive effectiveness, I9
- family planning, H46
- oral contraceptives, J92
- vasectomy, D35

MOULDING, T.S.
- recommendations for quinacrine tubal occlusion, C87

MOUNT SINAI HOSPITAL (NEW YORK, NEW YORK), C62

MOZAMBIQUE
- birth rate, J29(table), J207(table), J210 (table)
- diaphragm availability, H68(table)
- marketing of oral contraceptives, A14 (table)

MPILO FAMILY PLANNING CLINIC (RHODESIA)
- address, J104(table)
- training nonphysicians, J94(table), J104(table)

MROUEH, A.
- clip sterilization, C83(table)
- culdoscopy
    - advantages, C61
    - spinal anesthesia, C63
    - tubal occlusion, C65(table), C68(table)

MUELLER, and co., F40
- address, M32
- vasectomy equipment, M25(table)

MUENZER, R.W.
- silastic cannula, F59

MUKERJI, B.
- culdoscopic complications, C66(table), C67(table)

MULLICK, B.
- length of amenorrhea and pregnancy, F53(table)
- menstrual regulation, F51(table), F62
    - complications, F52(table)
    - equipment, F51(table)
    - India, F62
    - procedure, F51(table)
- pregnancy tests, F54(table)

MULTIPARAS
- anemia, J130
- cervical dilatation with $PGF_{2}\alpha$, C67
- colpotomy, C34
- copper IUDs, B2
- copper-7 insertions, B7
- extrauterine administration of PGE_2, F77(table)
- IUD, B22
    - insertion, B30, B35
    - removal for bleeding, B11
- laminaria tents, F39
- maternal mortality, J126
    - anemia, J131
    - Hutterites, J127
- nutritional needs, J129
- obstetrical complications, J134–J135(table)

MUMFORD, D.M.
- cell-mediated immunity postvasectomy, D31(table), D32

MUMFORD, L.
- economic aspects of urbanization, J191

MUNRO, H.N.
- diabetes mellitus and parity, J132(table)

MUNSHI, V.
- colpotomy combined with abortion, C43

MUNSICK, R.A.
- culdoscopic equipment, C69, C70(table)
- mini-laparotomy, C54

MURAYAMA, S.
- IUD continuation, B35

MURSTEIN, M.C.
- midtrimester abortion among adolescents, J170

MUSCLE SPASM
- side effect of anesthesia, C62

MUSSOLINI, B., CD73

MUSTACCHI, P.
- estrogen use and breast cancer in postmenopause, A77(table)

MUTCHNIK, H., J43(photo)

MYOMETRIUM
- PG effect, G50(figure), G51

MZALI, M., E11(photo)

N

NACENYL, A55

NACHTIGALL, L.E.
- estrogen use and endometrial cancer in postmenopause, A86(table)

NAFISA, M.A.
- sexual sterilization and Islamic law, CD87

NAG, M
- sexual practice in African cultures, J159

NAGY, T.
- menstrual induction, G37(table)

NAJEK, Z.
- PGE_2 and cervical dilatation, F95

NALGE SYBRON CORP., F57

NAMIBIA
- birth rate, J207(table), J210(table)
- marketing of oral contraceptives, A14(table)

NANTU TRIBE
- fertile period identification, I3(table)

NAPROXEN
- PG antagonist, G47, G50
- therapeutic use for IUD pain, B39

NARCO PILLING
- address, M33
- fiberoptic projectors, M8(table)
- guarantee and service of sterilization equipment, M30(table)

NARCOTICS. See also **ANALGESIA**; **ANESTHESIA**.
- culdoscopy, C63(table)

NASAL CONGESTION
- side effect of anesthesia, C62

NASH, J.L.
- vasectomy
    - complications, D28(table)
    - sexual behavior, D35(table)
    - technique, D28(table)

NATHANSON, B.N.
- uterine aspiration, F28(table)
    - blood loss, F34(table)
    - complications, F33(table)
    - equipment, F32(table)
    - incidence and management of perforation, F35(table)
    - local anesthesia, F29(table), F30(table)
    - postoperative medication, F29(table)
    - preoperative medication, F29(table)
    - time required, F32(table), F34(table)

NATION, E.F.
- vas anastomosis effectiveness, D43

NATIONAL ACADEMY OF SCIENCES (US), J245
- climate change, J187
- environmental illnesses, J184
- risk of mortality with abortion, E28

NATIONAL CANCER INSTITUTE (US)
- incidence of cervical carcinoma in situ with Depo-Provera, K10
- incidence of types of cancer in US women, A43(figure)

NATIONAL COMMITTEE ON MATERNAL HEALTH (US)
- condom safety, H23

NATIONAL LIBRARY OF MEDICINE (US)
- cervical dilatation instruments, F88–F89(figures)

NATIONAL SCIENCE FOUNDATION (US)
- funding of PG research, G5(table)

NATURAL FAMILY PLANNING. See **PERIODIC ABSTINENCE**.

NAUSEA
- abortion
    - analgesia, C66
    - PGE_2, F77(table)
    - $PGF_{2}\alpha$, F72, F73(table), F74, F75(table)
        - methyl analogue, F74, F75(table), F76, F77(table)
    - saline, F71(table)
    - urea, F78(table), F79
- clip sterilization, C46, C49
    - insufflation, C47
- estrogens, K3, K6
- hormonal-withdrawal test, J116
- injectable progestogens, K6
- local anesthesia, F30(table), F31
- minimized by timing of pill administration, A37
- minipill, A61
- PG administration, G3, G59(table), G72
    - during abortion, G7(table), G8(table), G9(table)
    - during induction of labor, G10(table)
- postcoital combined orals, J150
- postcoital copper IUD, J151
- postcoital estrogens, J141, J147, J148 (table)
- postcoital progestogens, J148
- pseudopregnancy, A34, A36
- spring-clip sterilization, C84

NEAR EAST
- birth rate, J209(table), J210(table)

NEELY, M.R.
- postpartum laparoscopic sterilization
    - complications, C23(table)
    - trocar insertion, C22

NELSON, C.S.
- vas anastomosis, D42

NELSON, J. H.
- obstetrical complications with multiparity, J134(table)

NEO SAMPOON LOOP
- active ingredients, H41(table)
- price and sales, H48(table)
- use-effectiveness, H45(table), H46

NEOCON
- formulation and dosage, A37(table)
- manufacturer, A37(table)

NEOGYNON
- manufacture and marketing, A4(table)

NEOPLASTIC DISEASE. See also specific types, e.g., **BREAST NEOPLASIA**; **CERVICAL NEOPLASIA**.
- breast, A74, A76(table)
- cervical, A80, A81-A82(table)
- hormonal effects, A72
- liver tumors, A88, A89(table)
- mortality in the US (1955-1975), A109(chart)
  - men, A111(chart)
  - women, A110(chart)
- neoplasia of other sites, A90
- problems in epidemiologic studies, A71-A72
- uterine corpus, A84

NEPAL
- birth rate, J29(table), J207(table), J210 (table)
- condom shipments, H15(table)
- culdoscopy, C69
  - training, C70
- early marriage, J158
- laparoscopic sterilization
  - complications and failures, C26
  - fulguration, C80
  - training, C2, C13, C14
- legal status of abortion, E34
- legal status of voluntary sterilization, CD111(table)
- male sterilization, D1
- marital status of female adolescents, J164(table)
- new acceptors, A18(table), J14(table)
- oral contraceptives
  - marketing, A14(table)
  - new acceptors, A18(table)
  - supplied by USAID, A21(table)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)

NERVOUSNESS
- minipill, A61
- postcoital progestogens, J148
- quinacrine tubal occlusion, C87

NETHERLANDS
- aboriton
  - legal status, E30, E35(table)
  - practice, E33, E35(table)
- age-specific fertility rate, J39(graph), J228(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- copper IUDs, B18
- Depo-Provera
  - availability, K13(figure)
  - use-effectiveness, K4(table)
- diabetes mellitus and parity, J132(table)
- diaphragm
  - availability, H68(table)
  - use, H58, J59
- family planning clinic, J70
- legal status of voluntary sterilization, CD111(table)
- marketing of minipill, A64(table)
- Ministry of Foreign Affairs
  - address, J284
  - funding of family planning activities, J273, J278(table)
- nonphysicians
  - training, J95(table), J105(table)
  - vasectomy, J98
- oral contraceptives, A1
  - commercial supply, A9(table), A10 (graph)
  - marketing, A14(table)
  - sales, A8(table)
- PG research, G20, G21, G22
- population trends, J240
- training in culdoscopy, C70
- tubal ligation, C74, C77

NETHERLANDS ANTILLES
- birth rate, J29(table), J207(table), J210 (table)
- marketing of oral contraceptives, A14 (table)

NEUMANN, H.H.
- clip sterilization, C12, C46
  - reversibility, C82

NEUMANN, M.
- ligation by cornual resection, C78

NEUMANN, O.H.
- clips and sutures contraindicated after scrotal incision, D9

NEUROLEPTOANALGESIA
- laparoscopic sterilization, C4

NEUWIRTH, R.S.
- laparoscopic sterilization, C2(table)
  - electrocoagulation with division, C8 (table)
  - operative technique, C7(table)
  - pneumoperitoneum, C5(table)
  - postabortion, C24(table)
- tubal occlusion via culdoscopy, C64

NEW CALEDONIA
- age-specific fertility rate, J226(graph)
- birth rate, J29(table), J207(table), J210 (table)

NEW GUINEA
- termination rate with Lippes Loop D, B22(table)

NEW HEBRIDES
- birth rate, J207(table), J210(table)
- oral contraceptives supplied by SIDA, A20(table)

NEWLAND, K., author, J253-J262

NEWSPAPERS
- promotion of family planning, J294-J297

NEWTON, B.F.
- pregnancy duration and cervical dilatation, F86

NEWTON, B.W.
- complications with laminaria, F39(table)

NEWTON, J.
- expulsion, pregnancy, removal, and continuation rates of copper-7, B6(table)
- IUD termination for pain, B12

NEW YORK
- abortion for adolescents, J170
- maternal mortality with abortion, E27
- use-effectiveness of condom, H33(table)
- water supply, J196

NEW YORK MEDICAL COLLEGE
- physiology of sperm transport, D47
- reversible occlusion with vas valves, D57

NEW ZEALAND
- adolescent births, J161(table)
- age-specific fertility rate, J3(graph), J37(graph), J226(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- diaphragm availability, H68(table)
- distribution of contraceptives, E44(table)
- incidence of cancer in women, A70(table)
- legal restriction of copper IUDs, B18
- legal status of abortion, E34
- legal status of voluntary sterilization, CD111(table)
- marital status of female adolescents, J164(table)
- marketing of minipill, A64(table)
- Ministry of Foreign Affairs
  - address, J284
  - funding of family planning activities, J277
- oral contraceptives, A1, A9(table)
  - commercial supply, A10(graph)
  - marketing, A14(table)
  - sales, A8(table)
- out-of-wedlock births, J160(figure)
- percentage of legal abortions to women under 20, J171(table)
- PG research, G19, G20, G21, G22
- population per hospital bed, J71(table)
- population per physician, J71(table)
- population policy, E41, E42, E43(table)
  - voluntary sterilization, E45(table), E48
- population trends, J240
- training nonphysicians, J94(table)

NICARAGUA
- age-specific fertility rate, J27(graph), J36(graph), J223(graph)
- average births per woman, J129(table)
- birth rate, J29(table), J207(table), J209 (table)
- condom shipments, H15(table)
- diaphragm availability, H68(table)
- family planning program, J26
- IUD acceptors, B27(table)
- legal status of voluntary sterilization, CD74, CD77, CD111(table)
- marketing of minipill, A46(table)
- mortality, J128
- new acceptors, A18(table), J18(table)
- oral contraceptives
  - marketing, A14(table)
  - new acceptors, A18(table)
  - supplied by USAID, A21(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- total fertility rate, J216(table)

NIDATION. See **IMPLANTATION**.

NIDDAH, I24

NIGER
- age-specific fertility rate, J224(graph)
- birth rate, J29(table), J207(table), J210 (table)
- drought and famine, J244-J245
- early marriage, J158
- legal status of voluntary sterilization, CD111(table)
- marketing of oral contraceptives, A14 (table)
- population growth, J188

NIGERIA
- abortion, F7(table)
  - adolescents, J165(table), J169
  - legal status, E29(table), E34, E36(table)
  - maternal mortality, E27
- abstinence during breast-feeding, J58
- age of menarche, J162(table)
- age-specific fertility rate, J224(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- condom
  - importation costs, H5(table)
  - shipments, H15(table)
- diaphragm
  - availability, H68(table)
  - training nonphysicians, H67
- duration of postpartum amenorrhea, J57(table)
- estimated population, E36(table)
- incidence of cancer in women, A70(table)
- IUD insertion by nonphysicians, B28, J93
- legal status of voluntary sterilization, CD79, CD112(table)
- medical complications of adolescent pregnancy, J165(table)
- new acceptors, A18(table), J12(table)
- oral contraceptives
  - marketing, A14(table)
  - new acceptors, A18(table)
  - supplied by USAID, A21(table)
- percentage of married female acceptors under 20, J170(table)
- percentage of married women of reproductive age under 20, J170(table)
- population, F7(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- promotion of family planning, J296, J299, J301, J308, J311(table)
- training nonphysicians, J94(table), J104(table)
- vaginal contraceptives, H49

NILSSON, S.B., E21(photo)

NIPPLE, RETRACTED, J53

NIRODH (INDIA)
- costs, H8
- manufacture and marketing, H8
- promotion campaign, H2, H8
- sale, distribution, and promotion costs, H8(table)
- subsidized community-based distribution, J76-J77
  - effectiveness, J77
  - evaluation, J84(table)
  - marketing, J77

NISHIO, N.
- culdoscopy sterilization with clips, C62

NITROGEN, LIQUID
- frozen sperm storage, D52

NITROGEN FERTILIZER, J199

NITROUS OXIDE
- abdominal insufflation, C47
- uterine distension, C81

NIYEURT, A. DE
  treatment of postvasectomy side effects, D27
NOAH, M.
  oral PGs for induction of labor, G57, G59-G60
NOMINE, G., A5(table)
NOMURA, A.
  orals and benign breast neoplasia, A73 (table)
NONCLINICAL DISTRIBUTION. See **COMMUNITY-BASED DISTRIBUTION**.
NONOXYNOL-9, H40, H42, H43(table)
NONPHYSICIANS, J89. See also **AUXILIARY PERSONNEL**; **MIDWIVES**; **NURSING PERSONNEL**; **PARAMEDICAL PERSONNEL**.
  acceptability, J90
  advantages, J90
  classification, J89, J90(figure)
  diaphragm fitting, H67
  distribution of contraceptives, E41, E42, E43, E44
  insertion of IUDs, E41, E44
  nutrition education, J94-J95(table)
  oral contraceptives, E44, J91, J92, J94-J95(table), J98
  screening IUD candidates, J96(figure)
  training, J90, J94-J95(table), J101-J108(table)
NONYLPHENOXYPOLYETHOXYETHANOL. See **NONOXYNOL-9**.
NORACYCLIN
  manufacture and marketing, A4(table)
NORDBERG, O.S., author, J321-J343
NORDENTOEFT, C3
NORDIOL
  manufacture and marketing, A4(table)
NORDROGEST
  manufacture and marketing, A64(table)
NOREPINEPHRINE
  prostaglandins
    adrenergic transmission, G26(figure)
    inhibition, G25-G26, G27
    vascular response, G27
  vas motility, D47
NORETHINDRONE
  combined orals, A37(table)
  derivation, A54
  lactation, J59
  marketing, A5
  minipill, A55
    current users, A64(table)
    effectiveness, A56(table)
    marketing, A64(table)
    menstrual pattern, A58-A59(table), A61
  ovarian tumors, A91
  potency, A37
  principal progestogen, A5(table), A6(table)
  synthesis, A32
NORETHINDRONE, POSTCOITAL
  acceptor characteristics, J150(table)
  administration and dosage, J150(table)
  use-effectiveness, J150(table)
NORETHINDRONE ACETATE, A5, A7
  androgenic effect, A37
  combined orals, A37(table)
  potency, A37
  principal progestogen, A5(table)
NORETHINDRONE ENANTHATE, K3. See also **NORIGEST**.
  first developed, K2
NORETHYNODREL
  estrogenic effect, A37
  lactation, J59
  ovarian tumors, A91
  potency, A37
  principal progestogen, A5(table), A6(table)
  synthesis, A32
NORGESTREL, A7
  androgenic effect, A37
  combined with estradiol benzoate, K3
  combined with ethinyl estradiol, A5
  combined orals, A37(table)
  derivation, A54
  minipill, A55
    continuation rate, A62(table)
    current users, A64(table)
    marketing, A64(table)
    menstrual pattern, A59-A60(table), A61
  potency, A37
  principal progestogen, A5(table), A6(table)
NORGESTREL, POSTCOITAL
  acceptor characteristics, J149(table)
  administration and dosage, J147, J148, J149(table)
  Colombia, J147
  estrogen-progestogen combination, J150
  marketing, J147
  mode of action, J148
  side effects, J148
  South America, J141, J147
  use-effectiveness, J148, J149(table)
    compared with other methods, J147
NORGESTRIENONE, A7
  postcoital use, J150(table)
  principal progestogen, A5(table)
  synthesis, A32
NORIDAY
  manufacture and marketing, A64(table)
NORIDEI
  manufacture and marketing, A64(table)
NORIGEST. See also **INJECTABLE PROGESTOGENS**; **NORETHINDRONE ENANTHATE**.
  availability, K1
  breast and pituitary nodules, K10
  carbohydrate metabolism, K6
  carcinogenic effects, K10
    animal studies, K9, K11
    etiology, K11
    humans, K11
  combined with estradiol undecylate, K3
  continuation rate
    compared with orals and IUDs, K7
    Peru, K7(table)
  development, K2
  incidence of cervico-vaginal abnormalities, K10
  marketing, K2, K10
  purchase by UNFPA, K14
  reversibility, K9
  side effects
    cervical mucus, K3
    compared with orals, K7
    endometrium, K3
    menstrual cycle, K5
    ovulation, K3
    ovum transport, K3
  storage, K12
  use-effectiveness, K4
    selected studies, K4(table)
NORINYL
  distribution by USAID, D38
  manufacture and marketing, A4(table), A5, A19
  patent information, A5(table)
  supplied by USAID, A19
NORINYL 1+5
  sales to USAID, A23(table)
NORINYL 1+50
  formulation and dosage, A6(table), A37(table)
  manufacturer, A37(table)
NORINYL 1+50/21
  formulation and dosage, A6(table)
NORINYL 1+50/28
  formulation and dosage, A6(table)
NORINYL 1+80
  sales to USAID, A23(table)
NORINYL 1+80/21
  formulation and dosage, A6(table)
NORINYL 1+80/28
  formulation and dosage, A6(table)
NORINYL 2
  formulation and dosage, A6(table)
NORINYL 10
  formulation and dosage, A6(table)
NORISTERAT. See **NORIGEST**
NORLESTRIN
  endometrial tumors in rats, A87(table)
  liver tumors in rats, A89(table)
  manufacture and marketing, A4(table), A5
  patent information, A5(table)
  pituitary tumors in rats, A90(table), A91(table)
  sales to USAID, A23(table)
  side effects, A19
  supplied by USAID, A19
NORLESTRIN 1.0 FE
  formulation and dosage, A6(table)
NORLESTRIN 1.0 21
  formulation and dosage, A6(table)
NORLESTRIN 1.0 28
  formulation and dosage, A6(table)
NORLESTRIN 1/50
  formulation and dosage, A37(table)
  manufacturer, A37(table)
NORLESTRIN 2.5
  formulation and dosage, A6(table), A37 (table)
  manufacturer, A37(table)
NORLESTRIN 2.5 FE
  formulation and dosage, A6(table)
NORLESTRIN 2.5 21
  formulation and dosage, A6(table)
NORLUTIN
  early clinical testing, A32
  menstrual disorders and endometriosis, A5
  therapeutic use for endometriosis, A39
NORMINON
  marketing, A55
19-NORPROGESTOGENS
  synthesis, A32
NOR-Q.D., A16
  formulation and dosage, A6(table)
  manufacture and marketing, A64(table)
  USFDA approval, A55
NOR-S.Q.
  manufacture and marketing, A4(table)
NORQUEN
  formulation and dosage, A6(table)
NORTH AMERICA. See also specific countries.
  adolescent births, J161(table)
  birth rate, J29(table), J207(table), J210 (table)
  marital status of female adolescents, J164(table)
  percentage of population under 20, J168(figure)
  population growth, J185, J239, J249(table)
  population per hospital bed and per physician in selected countries, J71(table)
  postcoital estrogens, J141
  training nonphysicians, J95(table), J107-J108(table)
NORTH CAROLINA, UNIVERSITY OF. (CHAPEL HILL) CAROLINA POPULATION CENTER.
  address, J283
  funding of family planning activities, J268, J276(table)
  laparoscopic fulguration procedure, C81(photo)
  measuring force of cervical dilatation instruments, F87
  newspaper column on family planning, J296
  spring-clip sterilization, C84
  training paramedical personnel in pregnancy termination, J96
  use-effectiveness of condom, H33(table)
NORTHWEST ATLANTIC FISHERY, J179
NORTHWESTERN UNIVERSITY
  Program for Applied Research on Fertility Regulation, J268, J274-J276(table)
NORTMAN, D., A7
  availability of Depo-Provera in selected countries, K13(figure)
  IUD acceptors in selected countries, B27(table)
  maternal mortality, J259
    age-related, J126
  obstetrical complications, J136-J137(table)
NORWAY
  age-specific fertility rate, J39(graph), J228(graph)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  condom standards, H25, H26(table)
    dimensions, H29(table)
  diaphragm availability, H68(table)
  legal status of abortion, E30(table), E32, E33(table)
  legal status of voluntary sterilization, CD70, CD112(table)
  marital status of female adolescents, J164(table)
  marekting of minipill, A64(table)
  marketing of oral contraceptives, A14 (table)
  population, F7(table), J240

    population assistance. See **NORWEGIAN AGENCY FOR INTERNATIONAL DEVELOPMENT**.
    population per hospital bed, J71(table)
    population per physician, J71(table)
    subsidy for foreign community-based distribution, J77
    training nonphysicians, J95(table)
NORWEGIAN AGENCY FOR INTERNATIONAL DEVELOPMENT (NORAD)
    address, J284
    funding of family planning activities, J273, J275(table)
NORWEGIAN HEALTH SERVICE
    training nonphysicians, J95(table)
NOVAK, E.
    suction with curettage, F27
NOVEY, M.J.
    fetal circulatory effects of PGs, G50
NTC THERMOPROBE
    hysteroscopic fulguration, C82
NULLIPARAS
    cervical dilatation, F90
        laminaria tents, F92, F94
        PG analogues, F95, G68
        PGF$_2\alpha$, G67
    contraception, B22
    extrauterine administration of PGE$_2$, F77(table)
    IUD, J168
        acceptors, B14-B15
        bleeding, B11, B14-B15
        copper, B2, B14, B15(table), B18, B25, B38
        displacement, B12, B15
        expulsion and removal rate, B33
        inserter design, B29
        insertion, B6, B8
        pain, B30, B35
        progesterone-releasing, B38
        size, B29
    laminaria tents, F39
        menstrual regulation, F50
        preference for oral contraceptives, J1
NUMMI, S.
    oxytocin to assist abortion, F70
NUN, S.
    seminal plasma, D30
NUNEZ, J.A., J106(table)
    use-effectiveness of Depo-Provera, K4 (table)
NURSE-CLINICIAN. See **NURSING PERSONNEL**.
NURSE-MIDWIFERY SCHOOLS (LUXEMBOURG)
    training nonphysicians, J95(table)
NURSE-MIDWIVES. See **NURSING PERSONNEL**.
NURSE-PRACTITIONERS. See **NURSING PERSONNEL**.
NURSES ASSOCIATION (NEW ZEALAND)
    training in family planning, J94(table)
NURSING PERSONNEL. See also **MIDWIVES**; **PARAMEDICAL PERSONNEL**.
    counseling, B28
    diaphragm fitting, J93
    IUD insertion, B28
        compared with physicians, J93
        effectiveness, J93
        training programs, J93, J96
        pregnancy termination, J96-J97
        training in family planning, J91, J98
NUTRITION
    age of menarche, J159-J160
    maternal health, J128-J129
    oral contraceptives, A48
    postpartum amenorrhea, J56
    requirements for breast-feeding, J54
    requirements for women, J130(table)
    training programs for nonphysicians in selected countries, J94-J95 (table)
NUVACON
    patent information, A5(table)
NUWAYSER, E.S.
    vas anastomosis operative procedures, D50
NYBERG, R.
    PGF$_2\alpha$ for midtrimester abortion, G71 (table)
NYGREN, K.-G.
    use-effectiveness of postcoital norethindrone, J150(table)
NYLON
    postvasectomy infection, D27

O

OBERNDORFER, L.
    duration of postpartum amenorrhea, J57(table)
OBESITY
    colpotomy, C39(table)
        bleeding, C41
    culdoscopy, C65, C66
    diabetes mellitus, J133
    laparoscopic sterilization, C18-C19, C23(table)
    mini-laparotomy, C57
O'BYRNE, M., J107(table)
OCEANIA. See also specific countries.
    adolescent births, J161(table)
    birth rate, J29(table), J207(table), J208 (table), J210(table), J249(table)
    early marriage, J158
    legal status of abortion, E30(table)
    marital status of female adolescents, J164(table)
    mortality rate, J249(table)
    percentage of population under 20, J168(figure)
    population growth, J249(table)
    population per hospital bed and per physician in selected countries, J71(table)
O'CONOR, V.J.
    vas anastomosis
        effectiveness, D43, D49(table)
        operative procedures, D44(table)
ODELL, W.D., A33(figure)
OESTERLING, T.O.
    PG pellet, G36
OGINO, K.
    fertile period identification, I3(table)
    rhythm method in Japan, I15
    timing of ovulation, I3, I4
OGINO-KNAUS METHOD. See **RHYTHM METHOD, CALENDAR**.
OHIO
    use-effectiveness of condom, H33(table)
OTHA RINGS KENKYU-SHO
    Ota ring, B43
    Spira ring, B44
OIL. See **PETROLEUM**.
OIL AND PETROLEUM EXPORTING COUNTRIES. See **OPEC**.
OJO, O.A., J104(table)
OKAMOTO RIKEN COMU CO., LTD., H19
OKEREKE, T.
    accumulation of copper in body with IUD, B17
OLLA GUMMI UND PLASTIKWAREN, H19
OMAN
    birth rate, J29(table), J207(table), J210 (table)
    marketing of oral contraceptives, A14 (table)
OM-GA, B48(figure)
    description, B48
    distribution, B48
    use-effectiveness, B48
OMNOPON, F29(table)
OMRAN, A.R.
    maternal health and parity, J129(figure)
OMRAN, K.F.
    clip sterilization, C46
    colpotomy
        failure, C42
        morbidity, C40
    dacron plug for tubal occlusion, C91
ONE-FINGER TECHNIQUE
    tubal ligation via mini-laparotomy, C75
ONETTO, E.
    use-effectiveness of Depo-Provera, K4 (table), K5(table)
    use-effectiveness of Norigest, K4(table)
ONO PHARMACEUTICAL
    PGs for research G2
OO CHROMIC SUTURE, C64
OPEC (OIL AND PETROLEUM EXPORTING COUNTRIES), J182
    funding of family planning activities, J277, J278(table)
OPERATIVE PROCEDURES
    clip sterilization, C47-C48
    culdoscopy, C64
    laparoscopic sterilization, C6, C7 (table), C8(table), C23-C25, C26
    menstrual regulation, F51, F58
    mini-laparotomy, C55-C56
    tubal fulguration, C78-C82
    tubal ligation, C74-C78
    tubal occlusion, C83-C86, C89-C91
    vas anastomosis, D44-D45(table), D50-D51
OPHULS, W., J200
OPIUM
    barrier method, H58
OPPENHEIMER, W.
    use-effectiveness of Graefenberg ring, B24
ORACON
    formulation and dosage, A6(table)
    manufacture and marketing, A4(table)
    patent information, A5(table)
ORACON 28
    formulation and dosage, A6(table)
ORAL CONTRACEPTIVE DISTRIBUTION, A1, A2-A3, A7, A16, A30, E19, J91-J92
    Antigua, J76
    Bangladesh, J74
    black market availability, J74
    Brazil, J80-J81, J92
    calculating supply needed, J74
    China, J83
    Colombia, J80
    community-based, A48, J77, J80-J83
        subsidized, J75-J78
    Costa Rica, J76
    effectiveness, J92
    Egypt, J81, J82
    family planning programs, A17-A22, J92
    free, J78, J79, J80, J81, J82, J83
    India, J79
    Indonesia, J92
    institutional distribution, J78-J79
    IPPF, J76, J77
    Kentucky, J92
    Korea, J72, J81, J82-J83, J92
    nonphysicians, E44, J91
        training, J92, J98, J94-J95(table)
    nonprescription, E41, E43, E44, J69-J70
        selected countries, J69, J74, J77, J81-J83
    Pakistan, J74, J77, J78
    Philippines, J78-J79, J92
    price per cycle, J70, J74
        Antigua, J76
        Brazil, J80
        Colombia, J80
        Costa Rica, J76
        Pakistan, J77
        Sri Lanka, J77
    program evaluation, J84(table)
    rural areas, J91
    SIDA, A20(table)
    Sri Lanka, J77
    standards, A24
    Taiwan, J81, J82
        via mail, J292(table)
    Thailand, J81, J92, K12
    USAID, A1-A2, A17, A21, J77, J81, J82
    West Malaysia, J92
    worldwide, A13-A15(tables)
ORAL CONTRACEPTIVES. See also **COMBINED ORAL CONTRACEPTIVES**; **SEQUENTIAL ORAL CONTRACEPTIVES**.
    acceptability, J4
        Iran, J307(table), J308(table)
    adenomatous lesions, A83-A84
    adjustment to hormonal change, A34, A38
    adolescents, J158
        contraindications, J167-J168
    advantages and disadvantages, J91
        compared with injectables, K11(figure)
        in users and nonusers compared, A31 (graph)
    amenorrhea, A90
    anemia, J131, J258

animal studies, A72, A78–A79(table), A85 (table), A87(table), A90(table), A91 (table)
  liver tumors, A89(table)
  v. clinical research, A37
Antigua, H10
Australia, H4(table)
availability, A1, A2
  Latin America, B28
Bangladesh, J96
beneficial and adverse conditions in users and nonusers compared, A31(graph)
biological dissimilarities to pregnancy and lactation amenorrhea, A34
brand names, formulations, and dosages approved by USFDA, A6(table)
breast neoplasia
  animal studies, A78–A79(table), A79–A80
  benign breast disease, A44(table), A46, A73–A74(table), A74–A75
  cancer, A43, A44(table), A45–A46, A75, A76–A77(table), A79
Canada, A36
carcinogenic risks, A43, A45–A46, A90
  protective effect, A46
  selected studies, A44–A45(table)
cervical dysplasia, H64–H65
  selected studies, A44(table), A81–A83(table), A84(table)
cervical mucus, A34
cervical neoplasia, A46, A80
change in brand use, A19
China, A1, A2
Colombia, H4(table)
commercial sales, A7–A16
  affected by medical reports, A11
condom use, H2
congenital abnormalities, A47–A48
continuation rates, A36, A39, K8(graph)
  compared with injectable progestogens, K7
  cultural variables, A39
cost compared with condoms, H24
Costa Rica, J4
cross licensing, A5, A7
demographic impact, A36, J4
developed and developing countries, A1, H4(table). See also specific countries.
  mortality, A35(table)
diabetes mellitus, A47
directions for use, J73(figure)
distribution. See **ORAL CONTRACEPTIVE DISTRIBUTION**.
dosage level, A35, D37
  estrogen and thromboembolic disease, A41
  official recommendations, A47
  progestogen, A37
  selected combined preparations, A37 (table)
  side effects, A37
drug development, A3, A5, A7
drug interactions, A48
early clinical testing, A32–A33
effect on laboratory tests, A48
Egypt, A12(table)
elimination of prescription requirements, E4
endometrial effects, A33(figure), A34
endometrial neoplasia, A84, A87
  animal studies, A87(table), A88
estimated use, A3, A16, A17, K1
  US (1964–1976), A107(chart)
estrogen-free products, A16
estrogen and progestogen content, A12 (table)
evaluation problems, A39–A40
family planning programs, A17, J92
  Chile, B28
Fiji, A12(table)
focal nodular hyperplasia, A88, A90
folic acid level, J131
Gabon, J164
gallbladder disease, A47
hepatocellular adenomas, A88–A90
history and development, A30–A33
Hong Kong, A12(table)
Hungary, J164
hydatidiform mole, A88
hypertension, A42
  reversibility, A42, A43
indications for use, B22
Iran, H4(table)
iron content, A23
iron deficiency anemia, A38, A48
iron supplements, J131–J132
IUD drop-outs, B26
Jamaica, H4(table)
Japan, H4(table)
Korea, B28
lactation, A48, A63, J50, J58–J59, K11
  research, J62
  selected studies, J60–J61(table)
liver disease, A47
  tumors, A88, A89(table)
low-dose, A11–A12, A16
low estrogen formulations, A37(table)
  China, A38
manufacture, A3–A5, A32
marketing, A3–A5, A23–A24
  Blue Lady, A24(figure)
  commercial sales, A7–A11, A16
  family planning program distribution, A17–A22
  worldwide, A13–A15(table)
Mauritius, A12(table), I16
menstrual blood loss, A38
menstrual cycle, A38
Mexico, A12(table)
mode of action, A33–A35
Morocco, A12(table)
motivation, J92
neoplasia and epidemiologic methods, A71 (table)
neoplastic diseases, A69–A92
new acceptors, A17, J92
  Brazil, J80
  developing countries, A18(table)
  Philippines, J79
  selected countries, J11–J20(table)
  Sri Lanka, J77
nonphysicians
  candidate screening, J91, J92 (figure)
  counseling acceptors, J91
nutrition, A48, J257–J258
ophthalmological effects, A40
ovarian effects, A33(figure)
ovarian neoplasia, A45(table), A91
packaging, A2(figure), A23–A24
  local tableting and packaging, A16
Panama, H4(table)
patents, A5(table), A7
Philippines, A12(table), H4(table)
pituitary tumors, A90
plasma hormone levels, A33(figure)
preferred by nulliparas, J1
prescription sales, A7, A16
price per cycle, A16, A19, A23
production, A1
pseudopregnancy, A34
rejected as contraceptive method, J82
research needs, A48
retrospective case-control studies, A40
reversibility, K9
safety, J258(table)
sales, A1, A12(table)
  commercial, A7–A16
  selected countries, A8(table), A9 (table), A10(graph), A11(graph)
Saudi Arabia, E42
side effects, A36–A39, A40. See also specific side effects.
  compared with injectable contraceptives, K7
  developed and developing countries, A48
  estrogen component, K7
Singapore, A12(table), B26, J2
skin disorders, A47
sources of funding, J270(table), J274–J276(table)
South Korea, H4(table), J2
squamous metaplasia, A83, A84(table)
supplied by SIDA to selected countries, A20(table)
supplied by USAID, A17, A23(table)
  brands, A19
  cost, H49
  selected countries, A21(table)
Sweden, H4(table)
systemic effects, A35
Taiwan, A12(table), B28, J2
Thailand, A12(table), H4(table)
theoretical effectiveness, A35
therapeutic use, A38–A39
  approval by USFDA, A32–A33
thromboembolic disorders, A40–A42
  selected studies, A41(table)
Trinidad and Tobago, J4
trophoblastic tumor, A88
United Kingdom, H4(table)
  monthly sales, A11(graph)
urinary tract infection, A47
US, A36, H4(table), H12, H47, H59(table)
  method change, H60(table)
use by married women under 20 in selected countries, J170(table)
use by women aged 15–44 in selected countries, A9(table), A10(graph)
use-effectiveness, A35–A36, H37, H39 (figure), I9, K6
  Colombia, J80
  developed and developing countries, A35(table)
  Philippines, I16
uterine fibroids, A88
uterine neoplasia, A84–A88
Venezuela, H4(table)
ORAL CONTRACEPTIVES, PROGESTOGEN-ONLY. See **MINIPILL.**
ORCHIODEXY
  contraindication to vasectomy, D26
ORCHITIS
  postvasectomy, D29
OREGON REGIONAL PRIMATE RESEARCH CENTER
  antibody formation after vasectomy, D31
  postanastomosis sperm count, D47
ORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT (OECD)
  GNP growth rate of industrialized countries, J191(figure)
  population density and air pollution, J181
  population program assistance, J275 (table)
ORGANON, A7, J116, J118(table), J119(table)
  address, F53
  factors affecting HCG level, J111(figure)
    hydatidiform mole, J111(figure)
    pregnancy, J111(figure)
    threatened abortion, J112(figure)
  marketing of minipill, A64(table)
  oral contraceptives, A4(table)
    worldwide marketing, A13–A15(table)
  pregnancy test, F12
  slide tests, J116
  tube tests, J116
ORGEBIN-CRIST, M.-C.
  late conception, I13
ORLANS, F.B., author, B1–B20, B21–B48
ORLEANS, L.A.
  estimated fertility levels in China, J211 (table)
  population estimates for China, J250 (table)
ORTHO CREME
  venereal disease, H51(table)
ORTHO DIAGNOSTICS, J116, J119(table)
ORTHO PHARMACEUTICAL CORP., B37, H40, H41(table), H47, H48
  address, H68(table)
  diaphragm
    fitting, H61(figure)
    manufacture, H68(table)
  estrogen-free product, A16
  Lippes Loop, B42
  manufacture of low-estrogen orals, A37 (table)
  marketing of minipill, A64(table)
  marketing of Ortho-Novum, A5
  oral contraceptives, A4(table)
    worldwide marketing, A13–A15(table)
ORTHO WHITE, H68(table)
ORTHOGYNOL JELLY
  active ingredients, H41(table)
  use-effectiveness, H45(table)
  venereal disease, H51(table)
ORTHO-NOVUM (ORTHO-NOVIN)
  manufacture and marketing, A4(table), A5
  patent information, A5(table)
  US, A17

- **ORTHO-NOVUM 1/50**
  - formulation and dosage, A36(table)
    - manufacturer, A36(table)
- **ORTHO-NOVUM 1/50 20**
  - formulation and dosage, A6(table)
- **ORTHO-NOVUM 1/50 21**
  - formulation and dosage, A6(table)
- **ORTHO-NOVUM 1/80 21**
  - formulation and dosage, A6(table)
- **ORTHO-NOVUM 2**
  - formulation and dosage, A6(table)
- **ORTHO-NOVUM 10**
  - formulation and dosage, A6(table)
- **ORTHO-NOVUM SQ**
  - formulation and dosage, A6(table)
- **ORY, H.W.**
  - oral contraceptives
    - benign breast neoplasia, A73(table)
    - breast cancer, A76(table)
    - cervical neoplasia, A82(table)
    - ovarian cysts, A45(table)
- **OSHIMA, H.T.**
  - unemployment, J197
- **OSLER, M.**
  - Antigon-F, B46
- **OSTEOMALACIA**, J129
- **OSTERGAARD, E.**
  - estrogen use and endometrial cancer in postmenopause, A86(table)
- **OSTERGARD, D.R.**
  - use-effectiveness of Dalkon Shield, B32 (table)
- **OSTERIA, T.**
  - contraceptive impact of breast-feeding in Philippines, J50
  - duration of postpartum amenorrhea, J57 (table)
    - birth interval, J58
  - orals and lactation, J60(table)
- **O'SULLIVAN, J.F.**
  - obstetrical complications with multiparity, J134(table)
- **OTA, T.**, B24
  - Ota ring, B43
  - Spira ring, B44
- **OTA RING**, B43(figure)
  - description, B43
  - development, B24
  - distribution, B43
  - legalized in Japan, E41, E43
  - use-effectiveness, B24, B43
- **OTT, E.R.**, author, F85-F103
- **OU, Y.Y.**
  - tubal ligation via mini-laparotomy, C75
- **OUTOKUMPU OY**
  - copper-T IUD, B43
- **OUTPATIENT**. See also **FAMILY PLANNING CLINIC**.
  - colpotomy, C35
  - laparoscopic sterilization, C1, C2, C3, C12, C24-C25
  - menstrual regulation, F50-F51
  - uterine aspiration, F57
  - vasectomy, D9
- **OVA**
  - aging and chromosomal abnormalities, I12
  - sex chromosomes, I22-I23
- **OVA II**
  - cost, J121
  - mode of action, J121
- **OVARIAN CANCER**
  - incidence in Connecticut (1955-1975), A127(chart)
  - incidence in Denmark (1953-1972), A129(chart)
  - incidence in Puerto Rico (1955-1974), A128(chart)
  - incidence in selected countries, A70 (table)
  - mortality in the US (1955-1975), A126 (chart)
- **OVARIAN CYSTS**
  - oral contraceptives, A45(table), A46, A91
    - incidence in users and nonusers compared, A31(figure)
  - surgical procedure, F67
- **OVARIAN TUMORS**
  - animal studies, A91(table)
  - oral contraceptives, A91
- **OVARIECTOMY**
  - spontaneous tumors, A79
- **OVARY**
  - changes during menstrual cycle, pregnancy, and use of orals compared, A33(figure)
  - injury during colpotomy, C42
  - theory of sex determination, I22
- **OVERGRAZING**, J187-J189
- **OVERSTREET, E.**
  - complications following uterine aspiration, F33
- **OVER-THE-COUNTER DRUGS**, H42-H44
- **OVRAL**, A5
  - formulation and dosage, A6(table), A37 (table)
  - manufacture and marketing, A4(table), A37(table)
  - patent information, A5(table)
  - sales to USAID, A19, A23(table)
- **OVRAL 28**
  - formulation and dosage, A6(table)
- **OVRETTE**, A16
  - formulation and dosage, A6(table)
  - manufacture and marketing, A64(table)
  - USFDA approval, A55
- **OVUCAL**
  - manufacture and marketing, A4(table)
- **OVULATION**
  - cervical mucus, I7, I8
  - fertile period identification, I3(table)
  - following conception, J49
  - inhibited by oral estrogens, A31
  - injectable progestogens, K3
  - laboratory tests, I8
  - lactation, J56-J58
  - luteinizing hormone, A55
  - minipill, A55
  - prediction and identification, I4, I8
  - progesterone level, I5
  - related to menstruation, I2-I3
  - role in $\mathrm{PGF}_2\alpha$, G53-G54
  - symptomatic detection, I8
- **OVULEN**, A17
  - breast neoplasia in selected animal studies, A78(table)
  - manufacture and marketing, A4(table)
  - patent information, A5(table)
  - sales to USAID, A19, A23(table)
- **OVULEN 20**
  - formulation and dosage, A6(table)
- **OVULEN 21**
  - formulation and dosage, A6(table)
- **OVULEN 28**
  - formulation and dosage, A6(table)
- **OVUM TRANSPORT**
  - effect of postcoital estrogens, J144, J146
- **OWEN, E.**
  - vas anastomosis, D49(table), D51
- **OWN CHILD METHOD**, J214
- **OXFAM**
  - address, J283
  - funding of family planning activities, J269, J270-J271(table), J275(table)
- **OXFORD UNIVERSITY (GREAT BRITAIN)**
  - PG research, G17
- **OXORN, H.**
  - obstetrical complications with multiparity, J134(table)
- **OXYGEN**, G1
- **OXYQUINOLINE SULFATE (CHINOSOL)**, H41(table), H43(table)
- **OXYTOCIN**
  - abortion, F66, F67, F72, F74, F75(table), F76
    - urea, F79
  - calcium binding inhibition, G47
  - complication with PG infusion, G73
  - instillation-abortion interval, F69, F70, G70, G71
    - selected studies, F71(table)
  - labor induction
    - compared with PGs, G11, G50, G59
    - uterine contraction, G50
  - lactation, J51, J52(table), J59
  - level with IUD in situ, J59
  - saline abortion, F68, F71(table)
    - bleeding, F69
    - risk of coagulopathy, F70
  - use with $\mathrm{PGF}_2\alpha$ and laminaria for midtrimester abortion, F94
  - uterine aspiration, F72, F29(table)
- **OYEDIRAN, M.A.**, J104(table)

P

- **PACHECO-MENA, M.**
  - culdoscopy
    - anesthesia, C63
    - complications, C66(table), C67(table)
    - tubal occlusion, C65(table), C68(table)
- **PACIFIC ISLANDS**
  - age-specific fertility rate, J3(graph), J226 (graph)
  - birth rate, J207(table), J210(table)
  - marketing of oral contraceptives, A14 (table)
- **PADUKONE, K.**
  - sperm antibodies
    - fertility, D31
    - postvasectomy, D48
- **PAFFENBARGER, R.S., JR.**
  - orals and benign breast neoplasia, A73 (table)
  - orals and breast cancer, A76(table)
- **PAHUSKUAN**, F43
- **PAI, D.N.**
  - use-effectiveness of contraceptive jelly, H45(table)
  - use-effectiveness of foam tablets, H45 (table)
- **PAI, M.G.**
  - effectiveness of vas anastomosis, D49 (table)
- **PAI, N.**
  - psychological aspects of vasectomy, D34
- **PAIN**
  - cervical dilatation
    - laminaria and metal dilators, F92
    - PGs, G68
  - chemical tubal occlusion, C64, C88
  - clip sterilization, C46, C47, C49, C84
  - colpotomy, C42
  - copper IUDs, B5, B12
  - culdoscopy, C64, C67(table)
  - electrocoagulation of vas deferens, D5
  - intramuscular injection of PG, F76
  - IUD
    - insertion, B30
    - multiparas, B11, B14-B15
    - related to age and parity, B1
    - removal, B3(graph, table), B7 (graph), B11(table), B15(table), B21, B26, B34(figure)
    - termination rate, B12
  - menstrual regulation, F15
    - PG administration, G58, G59(table), G61
  - postcoital copper IUD, J151
  - postcoital progestogens, J148
  - uterine aspiration, F31
  - vasectomy, D9, D26
    - treatment, D26, D27
- **PAKISTAN**, D1
  - abortion, F7(table)
    - legal status, E28, E36(table)
  - age-specific fertility rate, J223(graph)
  - birth rate, J29(table), J207(table), J209 (table)
  - condom
    - distribution, H5(table), H16
    - importation costs, H5(table)
    - manufacture, J74
    - retail sale, E41, E42
    - shipments, H14(table), H15(table)
  - contraception among adolescents, J166
  - copper IUDs, B18
  - Depo-Provera
    - availability, K13(figure)
    - continuation rate, K7(table), K8(table)
    - use-effectiveness, K4(table)
  - diaphragm availability, H68(table)
  - early marriage, J158
  - estimated population, E36(table), J206
  - Expanded Population Planning Scheme, J77
  - family planning program, J206, J217
  - IUD, B21
    - acceptors, B26
    - continuation rate, B33(table)
    - insertion by nonphysicians, B28, J96
  - legal status of voluntary sterilization, CD78, CD112(table)

  mortality, J127
    maternal, J258
  new acceptors, A17, A18(table), H49 (table), J14(table)
  oral contraceptives
    marketing, A14(table)
    new acceptors, A17, A18(table)
    nonprescription, J69, J74, J77
    policy, E2, E4(table)
    supplied by USAID, A21(table)
  population, F7(table)
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population policy
    adolescents, J166
    economic incentives, E48(table), E49
    voluntary sterilization, E45(table)
  promotion of family planning
    multimedia, J306, J311(table)
    radio, J30
  religious aspects of vasectomy, D36
  subsidized community-based distribution, J75, J77
    door-to-door, J77
    foreign contributors, J77
    over-the-counter, J77
    promotion, J78
  total fertility rate, J216(table)
  unemployment, J197
  vaginal contraceptives, H48
    new acceptors, H49(table)
PAKISTAN, EAST. See **BANGLADESH**.
PAKISTAN POPULATION PLANNING COUNCIL
  directions for oral contraceptives, J73 (figure)
PAKTER, J.
  abortion mortality in New York City, F37
PALAU ISLANDS
  folk methods for sex preselection, I22
PALDI, E.
  tubal occlusion via culdoscopy, C65 (table)
    failure rate, C68(table)
PALLIEZ, R.
  laparoscopic sterilization, C2(table)
    complications, C19
    failure, C22(table)
    operative procedure, C7(table)
PALMER, R.
  laparoscopic sterilization, C3, C6, C79
    electrocoagulation with division, C8 (table)
    failure, C12
    prevention of complications, C21
PALMER UTERINE DILATOR, F89(figure)
PALPITATION
  local anesthesia, F30(table), F31
PAN AMERICAN HEALTH ORGANIZATION (PAHO)
  abortion mortality in Latin America, F37
  address, J284
  funding of family planning activities, J275(table), J277-J278
  infant mortality, J254
  Interamerican Investigation of Mortality in Childhood, J162
PANAMA
  age-specific fertility rate, J36(graph), J227(graph)
  availability of Depo-Provera, K13(figure)
  availability of diaphragm, H68(table)
  birth rate, J29(table), J207(table), J218 (figure)
  change in number of births, J219(figure), J239
  condom
    distribution, H16
    importation costs, H5(table)
  legal status of abortion, E34
  legal status of voluntary sterilization, CD70, CD112(table)
  marital status of female adolescents, J164(table)
  marketing of minipill, A64(table)
  maternal mortality, J130(table)
  new acceptors, A18(table), J18(table)
  oral contraceptives
    marketing, A14(table)
    new acceptors, A18(table)
    supplied by USAID, A21(table)
  out-of-wedlock births, J160(figure)
  training in laparoscopic sterilization, C13, C14
  training nonphysicians, J98, J106(table)
  vaginal contraceptives, H48
    price, H48(table)
PANAMA CANAL ZONE
  age-specific fertility rate, J227(graph)
  birth rate, J23(figure), J29(table), J207 (table), J210(table)
PANDYA, G.N.
  progesterone-releasing IUD, B38
PANIAGUA, M.E.
  use-effectiveness of Emko foam, H45 (table), H46
PANNUTI, C.
  sperm transport physiology, D47
PANTOPON
  culdoscopy, C63(table)
  manufacturer, C63
PAPANICOLAOU SMEAR, A80
PAPUA-NEW GUINEA
  birth rate, J29(table), J207(table), J210 (table)
  marketing of oral contraceptives, A14 (table)
PARABOLA, S.A., J171
PARACERVICAL BLOCK, C32(table), C55
  menstrual regulation, F12, F13(table), F50, F51(table)
    failure rate, F54
  uterine aspiration, F28, F29(table), F60 (table)
    perforation rate, F36
PARAFFIN OIL
  chemical tubal occlusion, C89
PARAGUAY, J194
  age-specific fertility rate, J27(graph), J227(graph)
  availability of Depo-Provera, K13(figure)
  average births per woman, J129(table)
  birth rate, J29(table), J207(table), J209 (table)
  condom shipments, H15(table)
  copper IUDs, B18
  family planning program, J26
  legal status of voluntary sterilization, CD112(table)
  marketing of minipill, A64(table)
  maternal mortality, J130(table)
  new acceptors, A18(table), J19(table)
  oral contraceptives
    marketing, A14(table)
    new acceptors, A18(table)
    supplied by USAID, A21(table)
PARALDEHYDE
  tubal occlusion, C86(table)
PARAMEDICAL PERSONNEL. See also **AUXILIARY PERSONNEL**; **MIDWIVES**; **NONPHYSICIANS**; **NURSING PERSONNEL**
  administration of injectable contraceptives, J92
  counseling, B28
  definition, J89
  diaphragm fitting, J93
  distribution of orals, J92
  health services, J195
  household distribution, J81, J83
    Philippines, J79
  IUD insertion, B26, B28, E4, J78, J93
  PG pellet administration, G37
  pregnancy termination, J96-J97
    compared with physicians, J96
  role in family planning, E2, J72, J91 (figure)
  teaching, J90
  vasectomy, J98
PARAMETRITIS
  uterine aspiration, F35
PARBHAND, C.A.
  laparoscopic sterilization in Thailand, C2, C13, C14
PARDANANI, D.S.
  postvasectomy spermatogenesis, D47
  reversible vas occlusion, D53
  vas reanastomosis, D41
    effectiveness, D49(table)
    operative procedures, D44(table)
PARDTHAISONG, T.
  attitude toward physicians, K11
  continuation rate of Depo-Provera, K7 (table), K8(table)
PARE, A.
  mechanical cervical dilatation, F88
PARIKH, M.
  training in laparoscopic sterilization in India, C14
PARISER, G.
  use-effectiveness of C-film, H45(table)
PARITY
  cervical cancer, J133(table), J135
  colpotomy, C39, C40
  failure of menstrual regulation, F55
  fertility control methods, J1
  incidence of diabetes mellitus, J132(table), J133
  IUD performance, B2, B15, B16(graph, table)
    expulsion, B34
    removal rate, B33
  maternal health, J129(figure)
  obstetrical complications, J126
  postpartum amenorrhea, J56
  use-effectiveness of diaphragm, H65, H66(table)
PARK, I.S.
  age of menarche, J162(table)
  medical complications of adolescent pregnancy, J165(table)
PARKE-DAVIS AND CO.
  low-estrogen orals, A37(table)
  marketing of norethindrone, A5
  sales to USAID, A23(table)
  worldwide marketing of orals, A13-A15 (table)
PARKES, A.S.
  age of menarche, J159, J162(table)
PARLOVECCHIO, G.
  vas anastomosis, D42
PARMENIDES OF ELEA
  sex preselection theory, I22
PARR, E.
  inflammatory response from copper IUDs, B5-B6
PARTURITION. See also **UTERINE CONTRACTION**
  endocrine changes, G45-G46
    sheep, G50(figure)
    role of PGs, G51
PATEL, V.M.
  radio promotion of family planning in India, J300
PATENTEX
  active ingredients, H41(table)
PATENTEX GmbH (WEST GERMANY), H41 (table)
PATERSON, P.J.
  laparoscopic sterilization
    failure, C22(table)
    postpartum, C22
PATHFINDER FUND, B30, C39
  address, C58, C69, J275(table)
  funding of family planning activities, J266, J268, J270-J271(table), J275(table)
  IUD conference, B25
  procurement of surgical equipment, M2
    culdoscopy, C69
    laparoscopy, C9
    menstrual regulation, F19
    uterine aspiration, F38
  research funding for copper IUD, B19
  training film on mini-laparotomy, M20
PATINO, J.F., E19
PAUERSTEIN, C.J.
  hysteroscope, C81(figure)
PAULS, F.
  medical complications of adolescent pregnancy, J165(table)
PAULSEN, C.A.
  ethynodiol diacetate minipill
    continuation rate, A62(table)
    menstrual pattern changes, A58(table)
  norgestrel minipill
    effectiveness, A56(table)
    menstrual pattern changes, A59(table)
PAXMAN, J.M.
  legal equality for children, J163
P-DIISOBUTYLPHENOXYPOLYETHOXY-ETHANOL, H42
PEARL FORMULA, C74, H46, I9, J80
  condom, H32

  diaphragm, H65
  minipill, A53, A56, A57
  rhythm method, I11(table)
    temperature method, I12(table)
PEASE, C.A.
  medicine and population growth, E19
PEEL, J.
  commercial distribution of contraceptives, J70
  condom use-effectiveness, H32, H33
PELVIC INFECTION
  menstruation disorders, K6
  stem pessaries, B24
PELVIC INFLAMMATORY DISEASE (PID)
  band sterilization, C85
  colpotomy, C39(table), C41-C42
  culdoscopy
    contraindication, C65
    diagnosis, C62
    postoperative complication, C67(table)
  diagnosis, B35
  etiology, B56
  IUD
    postcoital insertion, J151
    risk, B35-B36
    treatment, B36
  laparotomy, C57
PELVIC RELAXATION
  pregnancy complication, J137
PELVIC VARICOCELE
  complicating culdoscopy, C67
PENDELTON, E., J107(table)
PENFIELD, A.
  uterine aspiration, F28(table)
    blood loss, F34(table)
    complications, F33(table)
    equipment, F32(table), F41(table)
    local anesthesia, F29(table), F30(table)
    pressure used, F41(table)
    time required, F32(table), F34(table)
PENG, J.Y., J93(figure)
PENICILLIN
  postvasectomy, D29
PENNINGTON, M.E.
  sperm count with epididymitis, D42
PENNSYLVANIA, UNIVERSITY OF.
  19-norprogestogen synthesis, A32
PENTAZOCINE, F29(table)
PEOPLE'S REPUBLIC OF CHINA. See **CHINA, PEOPLE'S REPUBLIC OF**.
PEOPLE'S REPUBLIC TABLETS (CHINA)
  price and sales, H48(table)
PERCUTANEOUS FULGURATION, D15
PERENNIAL EDUCATION, INC., J171
PERETZ, A.
  uterine aspiration for incomplete abortion, F60
PEREZ, A.
  return of ovulation and menstruation with nursing status, J50, J56-J57, J58 (figure)
PERINEAL RETRACTOR, M25(table)
  culdoscopy, C62, C64
PERINEORRHAPHY
  colpotomy, C41
PERIODIC ABSTINENCE. See **RHYTHM METHOD**.
PERITONITIS
  colpotomy, C40(table), C42
  mortality, C42
  septic incomplete abortion, F60
  treatment, C42
  uterine aspiration, F35
PERL, S.
  family planning radio campaign, J302
PERLUTAL
  components, K2
  marketing, K2
PERRY, M.L.
  research needs in vasectomy reversibility, D57
PERU
  age-specific fertility rate, J27(graph), J36(graph), J223(graph)
  availability of Depo-Provera, K13(figure)
  average births per woman, J129(table)
  birth rate, J29(table), J207(table), J210 (table)
  diaphragm availability, H68(table)
  family planning program, J26
  fish industry, J179, J180(figure)
  legal status of abortion, E29(table)
  legal status of voluntary sterilization, CD112(table)
  marital status of female adolescents, J164(table)
  new acceptors, A18(table), J19(table)
  Norigest
    continuation rate, K7(table)
    incidence of cervical cancer, K10
    use-effectiveness, K4(table)
    withdrawal from market, K10
  oral contraceptives
    commercial supply, A9(table)
    marketing, A15(table)
    new acceptors, A18(table)
    sales, A8(table)
  out-of-wedlock births, J160(figure)
  total fertility rate, J216(table)
  tourism, J180
  training in culdoscopy, C70
  urbanization, J191
PESSARY
  abortifacient use, B24
  contraceptive use, B23
  postcoital use, J142
  therapeutic use, B23
PETAC, D.
  chemical treatment of sperm for sex preselection, I26
PETERS, H.
  duration of postpartum amenorrhea, J57(table)
PETERSON, E.P.
  complications of pneumoperitoneum
    arrhythmia, C20
    obesity, C18
  laparoscopic sterilization
    complications, C19(table), C24 (table)
    electrocoagulation with division, C8
    failure, C22(table)
PETHIDINE, C47(table), F30(table), F60(table)
  cervical dilatation with PGs, G61
  induced abortion with PGs, G35(figure), G38(figure)
  menstrual regulation, F51(table), G58
PETROLEUM, J199-J200
  US production, J199(figure)
PETROW, V., A5(table)
PETRY, J.A.
  obstetrical complications with multiparity, J134(table)
PFANNENSTIEL INCISION, C53
PFANNER, D.
  uterine aspiration, F28(table)
    anesthesia, F29(table)
    complications, F33(table)
PFARRAGO INFORMATION SYSTEMS
  maintenance of laparoscope, M31
PGE. See also **PROSTAGLANDINS**.
  autonomic effectors
    depressant effects, G27
    facilitating effects, G28
  interaction with F series, G27, G28
  levels in pregnancy and at term, G49
  neurogenic responses, G27
  postvasectomy level, D30
  uterine response, G36
PGE$_1$
  binding proteins, G54
  oviductal effects, G54
  pituitary hypothalamic effects, G54
PGE$_2$
  calcium binding inhibition, G47
  cervical dilatation, F94, F95, G68
    first trimester abortion, F95
  concentration during labor, G49
  extraovular administration, F74, F75(table)
  fetal circulatory effects, G50
  first trimester abortion, G66
    vaginal route, F95
  induction of labor, G50, G57
    advantages, G59
    compared with oxytocin, G59
    dosage, G60(table)
    effectiveness, G60(table)
    side effects, G60
    time required, G60(table)
  intravaginal administration, F76, F77(table)
    abortion, H66-H67
  menstrual regulation, G59(table)
  metabolism inhibited, G61
  midtrimester abortion, F67
    extraamniotic route, G70(table)
    intraamniotic route, G59, G72
    intramuscular administration, G59, G69
    oral administration, F95
    side effects, G69
    time required, G59, G68, G69, G70 (figure)
    vaginal route, G59, G68-G69, G70 (figure)
  oviductal effects, G54
  pituitary hypothalamic effects, G54
  reduction of cervical tissue tension, G61
  uterine contractility, G47
    mode of action, G47
PGF. See also **PROSTAGLANDINS**.
  animal studies, G27-G28
  concentration in umbilical cord, G48 (table), G49
  effect on progesterone and estradiol-17 beta levels, G36(table)
  facilitating effects on autonomic effectors, G27, G28
  influence on effector response to sympathetic nerve stimulation, G27
  interaction with E series, G27, G28
  level at term, G48(table), G49
PGF$_1\alpha$
  pituitary hypothalamic effects, G54
  urinary metabolite, G47
PGF$_1\beta$, G47
PGF$_2\alpha$
  amniotic fluid level at term, G49
  augmenting agent for abortion with urea, F76, F79
  binding proteins, G54
  calcium binding inhibition, G47
  cervical dilatation, F94-F95, G67, G68 (table)
    analogues, G67-G68
  corpus luteum, G46
  estrogen-induced release, G50
  estrous synchronization, G54
  extraovular administration
    dosage schedule, F74, F75(table)
    effectiveness, F74
    instillation-abortion interval, F75(table)
    methyl analogue, F75(table), F77(table)
    selected studies, F75(table)
  fetal circulatory effects, G50
  first trimester abortion, G66
    effectiveness, G67(figure)
    instillation-abortion interval, G70
    vaginal route, F95, F96, G66-G67
  induction of labor, G46, G51
    compared with oxytocin, G50, G59
  intraamniotic instillation
    dosage schedule, F72, F73(table)
    instillation-abortion interval, F72, F73(table), G71(table)
    mortality, F74
    selected studies, F73(table)
    side effects, F72, F73(table), F74, G72
    technique, F72
  intraarterial infusion, G46
  luteolytic effects, G46, G51
    cyclic AMP level, G60
    cyclic GMP level, G60
    LH binding capacity, G60-G61
    progesterone production, G60-G61
  management of pregnancy complications, G50
  menstrual cycle, G46
  menstrual regulation, G59(table), G66 (table)
  metabolism inhibited, G61
  midtrimester abortion
    compared with saline, G72, G73(figure)
    extraamniotic route, G70
    instillation-abortion interval, G70
    intraamniotic route, G71, G72(table)
    intramuscular route, G69
    laminaria, F94
    methyl analogue, F74
    selected studies, G70(figure)
    side effects, F67, G69
    time required, G68, G69
    USFDA approval, F67
  myometrial effects
    nonprimates, G46-G47

    - primates, G47-G48
  - oviductal effects, G54
  - parturition, G45-G46, G50, G51
    - plasma level, G46, G48
  - physiological activity, G60-G61
  - pituitary-hypothalamic effects, G54
  - pregnancy termination, G54, G57, G58, G59
    - performed by paramedical personnel, J96
  - progesterone influence, G49
  - prolactin activity, G61
  - role in ovulation, G53-G54
  - urinary metabolite, G47
  - uterine contractility, G47, G71
  - vaginal route, G66-G67, G68-G69, G69(figure), G70

- **PHADKE, A.G.**
  - effectiveness of vas anastomosis, D49 (table), D51
  - postvasectomy sperm antibodies, D48
  - postvasectomy spermatogenesis, D47
- **PHADKE, A.M.**
  - sperm antibodies and fertility, D31
- **PHADKE, G.M.**
  - postvasectomy spermatogenesis, D47
  - vas anastomosis
    - effectiveness, D49(table), D51
    - operative procedures, D45(table), D51
- **PHARRISS, B.P.**
  - use-effectiveness of Progestasert, B32 (table)
- **PHASER VALVE**, D15. See also **VALVES**
- **PHENERGAN**, C47
- **PHENOTHIAZINE**, F60(table)
- **PHENYL MERCURIC ACETATE (PMA)**, H41(table), H42, H43(table)
- **PHILIPPINES**
  - adolescent births, J159, J161(table)
  - age-specific fertility rate, J225(graph)
  - attitude towards weight gain, K6
  - birth rate, J29(table), J207(table), J209 (table), J239
  - condom
    - distribution, H5(table), H16
    - importation costs, H5(table)
    - sales, H6
    - shipments, H14(table), H15
  - continuation rates of contraceptives, I16, K8(figure)
  - contraceptive impact of breast-feeding, J50
  - contraceptive practice, A12(table), H4 (table)
  - copper IUDs, B18
  - culdoscopy, C69
  - deforestation, J192-J193
  - Depo-Provera
    - availability, K13(figure)
    - continuation rate, K7(table), K8(figure)
    - use-effectiveness, K4(table)
  - diaphragm
    - availability, H68(table)
    - training nonphysicians, H67
    - use, H60
  - distribution of contraceptives, J165
    - institutional, J78-J79, J84
    - nonphysicians, J92
    - retail sale, E41, E42
  - duration of postpartum amenorrhea, J57(table)
    - birth interval, J58
  - family planning, H11
    - incentives, E8(table)
    - programs, E2, E3(table), E11
    - promotion, J75, J290-J291, J298
  - IUD
    - continuation rate, B33(table)
    - insertion by paramedical personnel, B28
  - legal status of abortion, E28, E30
  - marketing of minipill, A64(table)
  - maternal mortality, J128(figure)
  - mini-laparotomy, C54
    - mortality, C58
    - obese women, C57
  - National Family Planning Office
    - address, J102(table)
    - training nonphysicians, J94(table), J102(table)
  - new acceptors, A17, A18(table), I2, J14 (table)
    - revisits, J20(table)
  - oral contraceptives
    - commercial supply, A9(table)
    - distribution by nonphysicians, J92
    - lactation, J60(table)
    - marketing, A15(table)
    - new acceptors, A17, A18(table)
    - nonprescription, E41, E43, E44(table), J69, J74
    - policy, E2, E4(table)
    - sales, A8(table)
    - side effects, A38
    - supplied by SIDA, A20(table)
    - supplied by USAID, A21(table)
  - out-of-wedlock births, J160(figure)
  - percentage of married female acceptors under 20, J170(table)
  - percentage of married women of reproductive age under 20, J170(table)
  - Population Education Program, J171
  - population law
    - disincentives, E47
    - family planning services, E46
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - retail sale of condoms, E41, E42
  - rhythm method, I14(table), I15(table), J74
    - use-effectiveness, I10, I12, I16
  - side effects of norlestrin, A19
  - training in culdoscopy, C70
  - training nonphysicians, J94(table), J102(table)
  - unemployment, J197
  - vaginal contraceptives, H48
    - price, H48(table)
  - voluntary sterilization, E2, E6(table)
    - legal status, CD82, CD113(table)
  - Yoon band sterilization, C85
- **PHOSPHOLIPASE A**
  - PG synthesis, G49
- **PHOTOSENSITIVITY**
  - oral contraceptives, A47
- **PHYSICIANS**
  - attitude toward fertility management, E20
  - role in health care, E13, E19
  - role in population change, E19, E22-E24
- **PIERDELT, A.**, A5(table)
- **PIEROTTI, D.J.-A.**, J105(table)
- **PILLING CO.**, C46
- **PILOVAL**
  - manufacture and marketing, A4(table)
- **PINCUS, G.**
  - oral contraceptives, A32, A34
    - protection against benign breast disease, A45
  - progestogen research, K2
- **PION, R.J.**
  - dilatation with laminaria tents, F92
    - complications, F93
  - measuring depth of uterine cavity, F12
  - menstrual regulation, F11, F13(table)
    - blood loss, F17(figure, table)
    - contraception, F18
    - counseling, F50
    - follow-up, F15
    - preceded by pregnancy test, F11
    - procedure and equipment, F14(table)
- **PIOTROW, P.T.**, author, A1-A26, A29-A51, B21-B48, C1-C16, C17-C27, C29-C44, C45-52, D1-D20, E1-E12, E13-E18, F9-F20, F25-F44, F49-F64, H21-H36, I1-I19, J69-J88
- **PITTSBURGH, UNIVERSITY OF (WESTERN PENNSYLVANIA HOSPITAL)**, C59
  - fertility management training program, J44
- **PITUITARY GLAND**
  - hormone levels, A34
- **PITUITARY GONADOTROPINS**
  - postvasectomy, D31
- **PITUITARY-HYPOTHALAMIC-OVARIAN AXIS**
  - minipill, A55
  - postcoital progestogens, J148
- **PITUITARY TUMORS**
  - estrogens, A91
  - oral contraceptives, A90
    - animal studies, A90(table)
- **PIUS XII**
  - rhythm method, I3
- **PLACE, V.A.**
  - use-effectiveness of Progestasert, B32 (table)
- **PLACENTA PREVIA**
  - definition, J136(table)
  - obstetrical complications
    - multiparas, J134-J135(table)
    - symptoms, J136(table)
- **PLACENTAL LACTOGEN**, J52(table)
- **PLACENTEX**, J116
  - cost, J118(table), J120(table)
  - diagnostic capability, J118(table)
  - HCG bonding, J118
  - mode of action, J116
  - sensitivity, J118(table), J120(table)
  - time required, J120(table)
- **PLANKTON**
  - threatened extinction, J198-J199
- **PLANNED PARENTHOOD ASSOCIATION (CHICAGO, ILLINOIS)**
  - newspaper column on family planning, J296
- **PLANNED PARENTHOOD ASSOCIATION (SIERRA LEONE)**
  - training nonphysicians, J94(table)
- **PLANNED PARENTHOOD FEDERATION OF AMERICA**
  - address, J108(table), J283
  - campaign on population growth, J301, J309
  - National Medical Committee statement on Dalkon Shield, B36-B37
  - newspaper advertising on family planning, J297
  - population program assistance, J275 (table)
  - public service advertising campaign, J301
  - television and family planning, J304
  - training nonphysicians, J108(table)
- **PLANNED PARENTHOOD FEDERATION (KOREA)**
  - sex preference campaign, I28
- **PLANNED PARENTHOOD OF METROPOLITAN WASHINGTON, D.C.**
  - diaphragm use, H59
- **PLANOR**
  - manufacture and marketing, A4(table)
  - patent information, A5(table)
- **PLANTS**
  - threatened extinction of species, J198
- **PLASTIC CLIPS**. See also **CLIPS**
  - description, C84
  - failure, C84
  - route of approach, C84
- **PLATO**
  - historical reference to the uterus, F88
- **PLUGS**
  - reversible vas occlusion, D53
- **P-METHANYLPOLYOXYETHYLENE (TS-88)**, H40, H41(table), H42, H43(table)
- **PNEUMOPERITONEUM**. See also **INSUFFLATION**
  - laparoscopic sterilization
    - alternate techniques, C5(table)
    - complications, C18, C20
  - carbon dioxide, C5, C47
  - culdoscopy, C64
  - laparoscopy, M10
  - nitrous oxide, C5, C47
- **POFFENBERGER, S.B.**
  - vasectomy in India, D36
- **POFFENBERGER, T.**
  - vasectomy in India, D36
- **POLAND**
  - adolescent births, J161(table)
  - age-specific fertility rate, J39(graph), J228(graph)
    - legalized abortion, J10(graph)
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  - change in number of births, J219(figure)
  - food policy, J241
  - incidence of cancer in women, A70(table)
  - legal status of abortion, E30(table)
  - legal status of voluntary sterilization, CD85, CD113(table)
  - marketing of oral contraceptives, A15 (table)
  - population, F7(table)
  - population policy, J239
  - postabortion IUD insertion, B29

POLIAKOFF, S.R.
  use-effectiveness of calendar rhythm method, I10, J11(table)
POLITICAL CONFLICT
  competition for resources, J193-J194
POLYETHYLENE
  cervical cap material, H71(figure), H72
  Lippes Loop, B25
  tubal occlusion, C90(table)
  vas occlusion, D53
POLYETHYLENEGLYCOL OF MONOISOCTYL PHENOL ETHER, H41(table), H43(table)
POLYOXYETHYLENENONYL PHENOL, H41(table), H43(table)
POLYPS
  contraindication for chemical tubal occlusion, C89
POLYSACCHARIDE-POLYSULFURIC ACID ESTER, H41(table), H43(table)
POLYURETHANE, H31, H32
POLYVINYL ALCOHOL, H40, H42
POMEROY, R.
  tubal ligation technique, C77
POMEROY METHOD, C75(figure), C76(table)
  advantages and disadvantages, C78
  culdoscopy, C65(table)
    failure rate, C68(table)
  failure rate, C42, C77
  mini-laparotomy, C53, C56(figure)
  procedure, C30, C77
    with anterior colpotomy, C35
  tubal ligation, C12, C33(table), C34
POPPER, A., A5(table)
POPULATION COMMISSION OF THE PHILIPPINES, H11
POPULATION COUNCIL, B29, B30
  address, B48
  condom distribution, H16
  Cooperative Statistical Program
    age and parity effects on IUD performance, B15
    establishment, B25
    IUD expulsion, pregnancy, and removal rates, B3(graph, table), B7(graph), B16(graph, table)
    Ninth Progress Report, B25
  copper IUD, B43
    expulsion, removal, and pregnancy rates, B3(graph), B7(graph), B16(graph)
    insertion technique, B8(figure), B9
  funding of family planning activities, J267, J270-J271(table), J275(table)
  International Committee for Contraception Research, B19
  international IUD conference, B24, B25
  International Postpartum Family Planning Program, B14, B29
  IUD manufacture in developing countries, B37
  IUD studies
    amount of copper and antifertility effect, B5(graph)
    pregnancy rate, B10
    termination rate, B12
  maternal mortality, J259
  oral contraceptives
    acceptors, A18(table)
    congenital abnormalities, A48
  use-effectiveness in developing countries, A36
  users of family planning services, A12(table), A17(graph)
POPULATION DENSITY
  social behavior, J189-J190
POPULATION GROWTH
  accessibility of contraception, H38-H39
  changes in number of births in selected countries, J219(figure)
  cultural aspects, I1
  dimensions, J177-J202
  economic and social aspects, J190, J246-J247
  effect of sex preselection, I21, I27
  estimated rate in China, J211(table), J213(table)
  factors affecting, E19
  food trade patterns, J185
  hypothetical model including age of marriage, years per generation, and children per family, J167(table)
  impact on food production and consumption, J237-J238, J242
  increase over five years, J239(table)
  need for action, J201
  population stability of selected countries, J241(table)
  world fertility, J212(table)
  worldwide, J238, J249(table)
POPULATION INVESTIGATION COMMITTEE (UNITED KINGDOM)
  diaphragm use, H59
POPULATION LAW
  abortion, E25-E39
  exemplary statutes
    abortion, E47
    contraceptive methods, E46
    economic incentives and disincentives, E47
    voluntary sterilization, E36-E47
  worldwide changes, E1-E11
    contraceptive methods, E42-E44
    economic incentives and disincentives, E49-E50
    family planning information and services, E42, E43(table)
    voluntary sterilization, E44-E45, E45(table), E48-E49
POPULATION PLANNING ASSOCIATES
  mail-order condoms, H13
POPULATION PROBLEMS RESEARCH COUNCIL, THE MAINICHI NEWSPAPERS
  surveys in family planning, J295
POPULATION REFERENCE BUREAU, F7(table)
POPULATION SERVICES INTERNATIONAL (PSI)
  address, J85, J283
  condom marketing, H10
    Kenya, H9, J77
    Sri Lanka, J69, J77
  family planning activities, J269, J275(table)
  mail-order condoms, H13
  social marketing, H6-H7
POPULATION TRIBUNE, E18
PORTUGAL
  age-specific fertility rate, J39(graph), J228(graph)
  birth rate, J23(figure), J29(table), J207(table), J218(figure)
  change in number of births, J219(figure)
  diaphragm availability, H68(table)
  labor force, J197
  legal status of abortion, E30
  legal status of voluntary sterilization, CD113(table)
  marketing of minipill, A64(table)
  marketing of oral contraceptives, A15(table)
  population policy, E42, E43(table)
PORTUGUESE GUINEA
  birth rate, J29(table)
  marketing of oral contraceptives, A15(table)
PORTUGUESE TIMOR
  birth rate, J29(table), J207(table), J210(table)
POSTABORTION
  clip sterilization, C48, C84
  culdoscopy, C65
  IUD insertion, B29
  rhythm method, I7
  tubal ligation, C78
POSTCOITAL CONTRACEPTION, J141-J154, J168. See also specific methods, e.g., **COPPER-T IUD, postcoital insertion; DIETHYLSTILBESTROL, postcoital use; DOUCHE, POSTCOITAL; ESTROGENS, POSTCOITAL; PROGESTOGENS, POSTCOITAL.**
  animal studies, J143, J146
  disadvantage, J141
  endometrial effects, J144, J146, J148, J150
  folk methods, J142
  research needs, J151
  timing, J141
  use in US, H59(table)
POSTGATE, J.
  sex preselection in developing countries, I28
POSTOPERATIVE PROCEDURES
  colpotomy, C35
  culdoscopy, C64-C65
  laparoscopic sterilization, C12-C13, C21, C24
  menstrual regulation, F15, F51, F58
  mini-laparotomy, C57
  uterine aspiration, F31, F33, F35
  vas anastomosis, D44-D45(table), D51, D54(chart)
  vasectomy, D9, D27
POSTPARTUM
  clip sterilization, C48
  culdoscopy, C65
  IUD displacement, B12
  IUD insertion, B29
  progestogens during lactation, K11
  rhythm method, I7
POSTPARTUM AMENORRHEA
  factors influencing, J56
  lactation, J49
    research, J50
    selected studies, J57(table)
POSTPARTUM STERILIZATION
  fimbriectomy, C78
  laparoscopic sterilization, C21-C22
    coagulation, C23
    complications, C23(table)
    contraindications, C23
    operative procedures, C22
  performed by nonphysicians, J97
POSTUNA, J147
POTTER, R.G., B25
  pregnancy rate and lactation, J57
  theoretical effectiveness of calendar rhythm method, I10
POTTS, M., author, A29-A51, J69-J88
  diaphragm use, H59
  distribution of progestogen-only pills, J64
  economic aspects of condom production, H23
  marketing of family planning programs, H16
  menstrual regulation, F13(table)
    blood loss, F17(table)
    procedure and equipment, F14(table)
    training, F20
  timing of abortion, E27
  training in colpotomy, C43
POVIDONE-IODINE
  culdoscopy, C62
  syringe cleaning, F19
  vaginal cleansing, F12, F27
POWELL, L.C.
  use-effectiveness of Depo-Provera, K4(table)
POWER, F.H.
  early description of laparoscopic sterilization, C3
  tubal occlusion via laparoscopy, C79
PRACHUABMOH, V.
  age of marriage and family size, J163
PRAMOTE, R.
  female sterilization technique, C53
  mini-laparotomy
    complication rate, C57-C58
    failure, C58
    incision closure, C56
    proctoscope, C54
PRATT DILATORS, F90(figure)
PRECEPTIN GEL
  active ingredients, H41(table)
  use-effectiveness, H45(table)
  venereal disease, H51(table)
PREDNISOLONE
  vas anastomosis, D51
PREECLAMPSIA
  adolescent pregnancy, J161-J162, J165(table)
  obstetrical complications, J126
    definition, J136(table), J137
    multiparas, J134-J135(table)
    symptoms, J136(table)
PREEMPTIVE ABORTION. See **MENSTRUAL REGULATION**.
PREETHI, H10
  marketing program, J295
  subsidized sales, J77
    program evaluation, J84(table)
PREGNA-CHEK, J116, J117(photo)

- **PREGNANCY**. See also **ADOLESCENT PREGNANCY**.
  - caloric needs, J62, J64
  - changing definition, F61
  - coital timing, I24
  - colpotomy during, C43
  - complications. See **PREGNANCY COMPLICATIONS**.
  - contraindication for postcoital IUD insertion, J151
  - corpus luteum, G35
  - culdoscopy, C65, C68(table)
  - determination by folk methods, J110
  - early diagnosis, J109
  - ectopic. See **PREGNANCY, ECTOPIC**.
  - effects of copper IUD, B17
  - endometrial changes, A33(figure)
  - failure of sterilization, C21
  - female reproductive organs, F69(figure)
  - hormone levels, A33(figure), J50, J52 (table)
    - HCG level, J110, J111(figure), J112 (figure)
  - hypertension, A42
  - incidence of abnormal pregnancy, I13
  - infection with IUD in situ, B36
  - IUD removal, B34
  - IUD surface area, B34(figure)
  - jaundice, A47
  - lactation, J57, J62
    - cultural factors, J58
  - length of amenorrhea, F52, F53(graph, table)
  - maintenance with diethylstilbestrol, J146
  - management with PGs, G2
  - maternal age, J253
  - maternal risks, J125
  - mini-laparotomy, C57, C58
  - mortality, E27(graph)
    - developed and developing countries, A35(table)
    - US, A105, A108(chart)
  - nutritional needs, J130(table)
    - iron, J130, J131(table)
  - optimal age, J126, J157-J158
  - oral contraceptives, A36
  - ovarian changes, A33(figure)
  - PG concentration at term, G49
  - physiological effects, J110
  - prevalence of anemia, J129-J130
  - progesterone requirements, G46
  - regulatory balance of uterus, G34
  - research, G39
  - sex preselection, I28
  - symptoms, J110
  - test for after uterine aspiration, F31
  - vas reanastomosis, D42-D43, D49(table), D51
- **PREGNANCY, CORNUAL**
  - hysteroscopic fulguration, C81, C82(table)
- **PREGNANCY, ECTOPIC**
  - advantage of early diagnosis, J113
  - clip sterilization, C68, C82, C83
  - HCG level, J110, J112(figure), J117
    - beta subunit test, J120
  - hysteroscopic fulguration, C82(table)
  - IUD, B17, B34
  - menstrual regulation, F15, F52
  - minipill, A53, A57, A63
    - rate compared with IUDs, A57(table)
  - postcoital estrogens, J144
  - radioreceptorassay, J121
  - symptoms, A57
- **PREGNANCY, INTERSTITIAL**
  - hysteroscopic fulguration, C81
- **PREGNANCY, UNPLANNED**
  - incidence of abnormal pregnancy, I13
  - risk of hypertension, A43
- **PREGNANCY COMPLICATIONS**, J135, J136-J137(table)
  - management, G50
  - menstrual regulation, F51, F52(table)
  - multiparas, J134-J135(table)
- **PREGNANCY RATES**
  - condom, H22, H33(table)
  - copper IUDs, B3(graph, table), B4, B5, B6(table), B7(table), B10, B11(table), B15(table), B16(graph)
    - nulliparas, B14
  - Lippes Loop A, B10
- **PREGNANCY TERMINATION**. See **ABORTION**.
- **PREGNANCY TESTS**, G33. See also specific tests.
  - cost, J118(table)
  - diagnostic capability, J109, J114, J115 (table), J118(table), J119(table)
  - false-negative, J113
  - false-positive, J113
  - folk methods, J110
  - functions, J112, J113
  - history, J110-J112
  - menstrual regulation, F11-F12, F15, F50, F53, G58
  - methods, F12
  - mice, J110
  - performed by nonphysicians, J96-J97, J98
  - rabbits, J110
  - rats, J111
  - use-effectiveness, F54(table), J112-J114
  - uterine aspiration, F31
- **PREGNANCY TESTS, BIOLOGIC**
  - diagnostic use, J114
  - disadvantages, J114
  - selected studies, J115(table)
  - sensitivity, J114
- **PREGNANCY TESTS, CAPILLARY TUBE**. See **CAPILLARY TEST**.
- **PREGNANCY TESTS, DO-IT-YOURSELF**
  - limitations in use, J112
  - reliability, J121
  - sensitivity, J122
  - USFDA, J121
- **PREGNANCY TESTS, HORMONAL-WITHDRAWAL**. See **HORMONAL-WITHDRAWAL TEST**.
- **PREGNANCY TESTS, IMMUNOLOGIC**. See also **CAPILLARY TEST**, **SLIDE TEST**; **TUBE TEST**.
  - advantages, J116
  - antibody production, J111
  - comparison, J120(table)
  - cost, J120(table)
  - current research, J122
  - diagnostic capability, J117-J118
    - trophoblastic diseases, J118
  - reliability, J117
    - early pregnancy, J117
  - selected studies, J118(table), J119 (table)
  - sensitivity, J120(table)
  - storage, J118
  - time required, J120(table)
- **PREGNANCY TESTS, RADIOIMMUNOASSAY**, J119-J121. See also **CAPILLARY TEST**.
  - beta subunit, J120-J121
  - development, J109-J110
  - measurement of HCG-LH activity, J120
  - mode of action, J112, J121
- **PREGNANCY TESTS, RADIORECEPTORASSAY**
  - diagnostic capability, J121
  - disadvantages, J121
- **PREGNANEDIOL**
  - ovulation, I8
- **PREGNOSIS**, J116
  - cost, J119(table), J120(table)
  - diagnostic capability, J119(table)
  - sensitivity, J119(table), J120(table)
  - time required, J120(table)
- **PREGNOSTICON ACCUSPHERES**, J116(photo)
  - cost, J118(table), J120(table)
  - diagnostic capability, J118(table)
  - quantifying HCG activity, J118
  - sensitivity, J118(table), J120(table)
  - storage, J118
  - time required, J120(table)
- **PREGNOSTICON DRI-DOT**, F12, F53, J120(photo)
  - cost, J119(table), J120(table)
  - diagnostic capability, J119(table)
  - laboratory procedures, J119
  - sensitivity, J119(table), J120(table)
  - storage, J119
  - time required, J120(table)
  - use-effectiveness, F54(table)
- **PREGNOSTICON PLANOTEST**
  - modifications, J119
- **PREGNOSTICON SLIDE**, J116
  - cost, J119(table), J120(table)
  - diagnostic capability, J119(table)
  - sensitivity, J119(table), J120(table)
  - time required, J120(table)
- **PREGNOSTICON TUBE**, J116
  - cost, J118(table), J120(table)
  - diagnostic capability, J118(table)
  - PG administration, G36(table), G37(table), G38(table)
  - quantifying HCG activity, J118
  - sensitivity, J118(table), J120(table)
  - time required, J120(table)
- **PREMARITAL SEX**
  - increase among adolescents, J159
- **PREMATURE BIRTH**
  - adolescent pregnancy, J165(table)
  - inhibition, G47
  - menstrual regulation, F52
- **PREMENSTRUAL TENSION**
  - oral contraceptives, A39
    - incidence in users and nonusers compared, A31(figure)
  - symptoms, A39
- **PRENCAP**, H72
- **PRENTIF CAVITY RIM**, H72
- **PREOPERATIVE PROCEDURES**
  - colpotomy, C30-C31
  - culdoscopy, C62-C63
  - laparoscopic sterilization, C4
  - menstrual regulation, F11-F12, F58
  - mini-laparotomy, C54-C55
  - uterine aspiration, F27
  - vas anastomosis, D48, D50
  - vasectomy, D3
- **PRESSER, H.B.**
  - age of marriage and family size, J163
- **PRETERM INSTITUTE**
  - address, J275(table)
  - Bentov device, F96
  - family planning activities, J269, J270-J271(table), J275(table)
  - laminaria testing, F92
- **PRIMIGRAVIDA**
  - intraamniotic PG administration, G73
- **PRIMIPARA**
  - hormonal contraceptives and breastfeeding, J58
  - maternal mortality and anemia, J131
- **PRIMOLUTIN-N**, A5
- **PRIMOVLAR**, A17
  - manufacture and marketing, A4(table)
- **PRINCETON LABORATORIES**, J121
- **PRINCETON STUDIES**, I9
- **PRITCHARD, J.A.**
  - obstetrical complications, J136-J137(table)
- **PROCAINE**, F30(table)
- **PROCAINE HYDROCHLORIDE**, C32(table), D4
  - vas contractility, D15
- **PROCAINE PENICILLIN**
  - culdoscopy, C64
- **PROCHLORPERAZINE**, G69
  - culdoscopy, C63(table)
- **PROCTOSCOPE**, M20
  - female sterilization, C53
  - mini-laparotomy, C54, C55
- **PRODUCTS OF CONCEPTION, RETENTION**
  - abortion with urea, F78(table), F79
  - extraovular instillation of PG, F74(table)
  - extrauterine administration of PG, F77 (table)
  - intraamniotic instillation of $PGF_2\alpha$, F73 (table)
  - menstrual regulation, F16(table), F51, F52(table)
    - prostaglandins, G58
  - saline abortion, F70, F72
    - selected studies, F71(table)
  - uterine aspiration, F33(table), F35, F60 (table)
- **PROFAMILIA**. See **ASSOCIACION PROBIENESTAR DE LA FAMILIA COLOMBIANA**.
- **PROGESTASERT**, B45(figure)
  - clinical testing, B38
  - description, B45
  - distribution, B45
  - expulsion rate, B29
  - use-effectiveness, B32(table)
- **PROGESTERONE**
  - breast cancer, A79

- cervical mucus, I7
- chemical structure, A31
- chemical synthesis, A32
- effect of minipill on secretion, A55
- endometrial neoplasia, A85, A87
- identification, A30-A31
- IUD, B38
- lactation, J52(table)
- menstrual cycle, A33(figure)
  - with orals, A33(table)
- myometrial activity, G47
- natural production, A34
- ovarian tumors, A91
- ovulation, I5
- $PGF_2\alpha$ inhibition, G49
- plasma level after $PGF_2\alpha$ administration, G36(table)
- postcoital estrogens, J144-J146
- pregnancy, A33(table), G34-G35, G46, G60, J50
  - prostaglandins, G60-G61
- reversal of chemical tubal occlusion, C87
- role in human reproduction, A34
- serum level, G66
- synthesis during saline abortion, F68
- tumors, A79, A80, A84, A85, A91

PROGESTIN. See **PROGESTOGEN**.

PROGESTOGEN
- 17-acetoxyprogesterone derivatives, A54, A55, A56
- analogues as contraceptive agents, A54
- blood coagulation factors, A62
- congenital defects, A62
- definition, K2
- endometrial neoplasia, A85, A87
- lactation, A63
- liver tumors, A89
- 19-norsteroids, A55, A62
- oral contraceptives
  - dosage, A6(table), A12(table), A16, A37(table), A53, A54
- protective effect for breast disease, A74-A75
- sperm capacitation, A55

PROGESTOGEN-ONLY CONTRACEPTIVES. See **MINIPILL**.

PROGESTOGENS, INJECTABLE. See **INJECTABLE PROGESTOGENS**.

PROGESTOGENS, POSTCOITAL
- menstrual pattern changes, J148
- mode of action, J148
- selected studies, J149-J150(table)
- side effects, J148

PROGRAM FOR APPLIED RESEARCH IN FERTILITY REGULATION (PARFR)
- address, C59, J283
- family planning research, J268, J271 (table), J275(table)
- research funding in vasectomy, D16
  - reversibility, D57

PROGRAM FOR INTERNATIONAL EDUCATION IN GYNECOLOGY AND OBSTETRICS (PIEGO)
- address, J283
- fertility management program, J41
- maintenance and repair of sterilization equipment, M2-M3
- training in family planning, J268-J269, J270-J271(table), J275(table), M2

PROGRAM FOR THE INTRODUCTION AND ADAPTATION OF CONTRACEPTIVE TECHNOLOGY (PIACT)
- Contraceptive Product Reference Service, M2

PROLACTIN, G54
- activity suppressed by $PGF_2\alpha$, G60
- breast cancer, A79
- lactation, J51(figure), J52(table), J59
- levels after parturition, J50
- stimulated by suckling, J62

PROLACTIN INHIBITING FACTOR, J52(table)

PROLACTIN RELEASING FACTOR, J52 (table)

PROLENE LOOP
- tubal ligation, C75

PROLONGED LABOR, J126

PROLUTIN DEPOT
- components, K2
- marketing, K2

PROMECO
- marketing of Perlutal and Topasel, K2

PROMETHAZINE, C32, F29(table), F30(table)

PROMETHAZINE HYDROCHLORIDE, F29 (table)
- culdoscopy, C63(table)

PROMOTION. See also **MARKETING**.
- mass communication for family planning
  - film, J297-J299
  - mailings, J291-J294
  - multimedia, J305-J313
  - newspapers, J294-J297
  - radio, J299-J303
  - telephone, J290-J291
  - television, J303-J305

PRO-NATALISM
- Mexico, J237
- Poland, J239

PROPANIDID
- menstrual regulation, F13(table)

PROPLAST PLUG
- tubal occlusion, C90-C91

PROSTAGLANDINS. See also **PGE**; **PGF**; **PROSTAGLANDINS, A SERIES**.
- abortifacient action, F72
- abortion. See **PROSTAGLANDINS, pregnancy termination**.
- adrenergic transmission, G26(figure), G27
- amniotic fluid, G2
- analogues, C6, C12-G13, G57, G58, G61
  - abortion, F67
  - advantages as abortifacients, F72
  - disadvantages, F95
- autonomic effects, G25, G28
  - vascular response, G27, G28
- cardiovascular effects, G25, G26
- cervical dilatation, F94
  - side effects, F95
- chemical structure, G2, G65-G66
- clinical experiments with laminaria, F94
- comparative dosage, G3, G6
- composition, G1, G2
- concentration in blood plasma, G48, G58
- concentration at term, G49
- conference, G29
- conference (summary), G53-G54, G57-G62
- current abstracts, G29-G32, G62-G64
- definition, G1
- derivation of term, G2
- differences among, G26
- discovery, G65
- effects on norepinephrine, G25, G26, G27
- estrogen-induced release, G50
- extraovular administration
  - disadvantages, F74
  - side effects, F74
  - technique, F74
- fertility control, G2, G17
  - research, G18-G21(maps)
- fetoplacental origin, G49
- impact in postconceptional therapy, G34
- induction of labor, G2, G3, G6, G17, G59, G60
  - cervical dilatation, G61
  - compared with other methods, G59
  - dosage, G10(table)
  - oral administration, G60(table)
  - side effects, G10(table), G59
  - time required, G6
  - vaginal administration, G61-G62
- inhibition, G50
- instability, F95
- lack of standardized studies, G3
- levels with IUD, B25
- luteolytic effects, G51
- mechanism of action, G37
- menstrual induction, G36(table), G37 (table)
  - administration and dosage, G35
  - mode of action, G33-G34, G37
- menstrual regulation, G57
  - comparative methods, G58
  - curettage, G58
  - dosage, G58, G59(table)
  - effectiveness, G58, G59(table)
  - side effects, G58, G59(table)
  - time required, G59(table)
  - vaginal suppository, G58
- metabolic inhibition, G61
- myometrial effects, G51
- neurogenic effects, G25, G26
  - adrenergic transmission, C26(figure)
  - mechanism of action, G25
  - physiology, G26-G27, G28
- pellet administration, G36-G37
  - applicator, G37(figure)
  - effectiveness, G37, G38(table)
- physiology, G45-G56, G60-G61
- pregnancy termination, E25, E28, G2, G54, G57
  - analogues, F67, F72
  - cervical dilatation, G11, G57, G61-G62
  - compared with other methods, G11, G12(figure)
  - curettage, G11
  - diaphragm, G59
  - dosage, G3, G6, G7(table), G8(table), G9(table), G12
  - effectiveness, G7(table), G8(table), G9(table), G59
  - first trimester, G7(table), G11, G38, G66-G67
  - laminaria, G59
  - measure of success, G3
  - midtrimester, G8(table), G9(table), G68-G72
  - saline, F68, G49
  - side effects, G7(table), G8(table), G9(table), G59
  - time required, G6, G59
  - urea, G58-G59
  - vaginal suppository, G59
- research, G2-G3, G11, G17, G20, G22, G39
  - cooperative networks, G11
  - funding in the US, G4-G5(table)
  - growth, G3, G15(figure), G17
- route of administration, G6
  - extraamniotic, G67-G68, G68(table), G69-G71
  - intraamniotic injection, G6, G8(table), G9(table), G11, G58
  - intracervical, F95, G68(table)
  - intramuscular, F76, F77(table), G58, G59, G67, G68(table), G69
  - intrauterine, G6, G7(table), G8(table), G9(table), G11, G58, G59(table), G66
  - intravenous, G6, G7(table), G8(table), G9(table), G10(table), G59(table)
  - oral, G10(table), G59, G60(table)
  - subcutaneous, G8(table), G9(table), G61
  - vaginal, F76, F77(table), G6, G7(table), G8(table), G9(table), G10(table), G11, G58, G59(table), G66-G67, G68(table), G69
- see-saw theory, G34(figure)
- side effects, G3
- synthesis, G2. See also **analogues**.
- treatment of nonpregnant women, G67
- United Kingdom, G13
  - preparations for sale, G13(figure)
- uterine response, G35, G36(table), G54
  - bleeding, G35, G36
  - contraction, G2, G58

PROSTAGLANDINS, A SERIES
- autonomic nerve transmission depressant, G26
- postvasectomy level, D30
- smooth muscle depressant, G27

PROTEIN-CALORIE MALNUTRITION, J129

PROVEST
- formulation and dosage, A6(table)
- withdrawal from market, K10

PRSIC, J.
- lynestrenol minipill
  - effectiveness, A56(table)
  - menstrual pattern changes, A58(table)

PSEUDOPREGNANCY. See also **ORAL CONTRACEPTIVES, side effects**.
- oral contraceptives, A34
- symptoms, A36

PUERPERAL INFECTION. See **SEPSIS**.

PUERPERAL STERILIZATION
- laparotomy, C74, C77
- tantalum clips, C83

PUERPERIUM
- laparoscopic sterilization, C21-C22

PUERTO RICO, A1
- abortion
  - legal status, E35(table)
  - practice, E35(table)

- age-specific fertility rate, J3(graph), J25(graph), J36, J227(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- clinical testing of orals, A32
- community-based distribution, J72
  - door-to-door, J74, J90
  - foam, J72, J74
- diaphragm availability, H68(table)
- family planning program, J24
- incidence of breast cancer among women (1955-1974), A114(chart)
- incidence of cervical cancer (1955-1974), A120(chart)
- incidence of liver cancer among women (1955-1974), A131(table)
- incidence of ovarian cancer (1955-1974), A128(chart)
- incidence of uterine cancer (1955-1974), A124(chart)
- legal status of voluntary sterilization, CD67, CD113(table)
- marital status of female adolescents, J164(table)
- new acceptors, A18(table), H49(table), J19(table)
- oral contraceptives
  - commercial supply, A9(table)
  - new acceptors, A18(table)
  - sales, A8(table)
- out-of-wedlock births, J160(figure)
- policy on voluntary sterilization, E45(table)
- use-effectiveness of condom, H32, H33 (table)
- vaginal contraceptives
  - new acceptors, H49(table)
  - use-effectiveness of Emko foam, H46

PUFFER, R.R.
- comparative infant and neonatal mortality, J166(table)

PULMONARY DISEASE
- contraindication for laparoscopic sterilization, C18

PURANDARE, B.N.
- culdoscopy complications, C67(table)
  - spinal anesthesia, C63
  - tubal occlusion, C65(table)
- sterilization by colpotomy, C31(table)
  - anesthetic, C32(table)
  - equipment, C36(table)
  - incision, C33
  - India, C29
  - procedure, C30
- tubal ligation, C34, C74
  - reversibility, C34

PURANDARE, V.N.
- medical complications of adolescent pregnancy, J165(table)

PUST, K.
- effectiveness of stem pessary, B24

PUST CERVICO-UTERINE DEVICE, B24 (figure)

PYELITIS. See **URINARY TRACT INFECTION**.

PYKE, D.A.
- diabetes mellitus and parity, J132(table)

PYREXIA. See also **FEVER**.
- laparoscopic sterilization, C23(table)
- PG administration, G3, G7(table), G8 (table), G9(table), G12, G59

Q

QATAR
- birth rate, J29(table), J207(table), J210 (table)
- marketing of oral contraceptives, A15 (table)

QUEEN VICTORIA, F88

QUEEN VICTORIA HOSPITAL (AUSTRALIA)
- diaphragm use, H59

QUENNAN, J.T.
- Rh immunization, F36

QUICKENING
- pregnancy, F61

QUILLIGAN, E.
- intramuscular injection of PGE$_2$ methyl analogue, F77(table)

QUINACRINE
- chemical sterilization, D15
- tubal occlusion, C77(table), C86(table), C87

QUINACRINE HYDROCHLORIDE
- tubal occlusion, C87
- Y-chromosome identification, I26(photo)

QUINESTROL
- administered with injectable progestogens, K6

QUINGESTANOL ACETATE, A7
- lactation, A63, J59, J63(table)
- menstrual pattern, A60(table)
- minipill
  - continuation rate, A62(table)
  - current users, A64(table)
  - effectiveness, A56(table)
  - marketing, A64(table)
- principal progestogen, A5

QUINGESTANOL ACETATE, POSTCOITAL
- administration and dosage, J147, J148, J149(table)
- menstruation disorders, J148
- use-effectiveness, J148, J149(table)
  - coital frequency, J148
  - compared with other methods, J147

QUININE
- source, J199

QUININE SULFATE, H39

QUINONES, R.
- hysteroscopic fulguration, C82(table)
- quinacrine tubal occlusion via hysteroscopy, C87

R

RABASA, E.O.
- population policy in Mexico, E2

RADEL, D.
- communication of family planning issues in Kenya, J296

RADIO
- promotion of family planning, J299-J303

RADIOIMMUNOASSAY (PREGNANCY). See **PREGNANCY TESTS, RADIOIMMUNOASSAY**.

RADIORECEPTORASSAY (PREGNANCY). See **PREGNANCY TESTS, RADIORECEPTORASSAY**.

RAGAB, M.I., B47
- evaluation of Spring Coil, B39
- use-effectiveness of Ragab Ring, B32 (table)

RAGAB RING, B47(figure)
- description, B47
- distribution, B47
- insertion, B29
- use-effectiveness, B32(table)

RAINA, B.L.
- promotion of family planning in India, J293-J294

RAINFALL
- affected by dust, J187

RAKSHIT, B.
- reversible sterilization, D41
- silastic tubal occlusion, C86(table), C88

RAMADAN, M.
- orals and lactation, J61(table)

RAMANI, P.S.
- effectiveness of vas anastomosis, D49 (table)

RAMOS, R.M., J102(table)

RAMSES, H68(table)

RAMSES BENDEX, H68(table)

RAMSES JELLY
- active ingredients, H41(table)
- venereal disease, H51(table)

RANDIC, L.
- use-effectiveness of Spring Coil, B32 (table)

RANGARAJAN, N.S.
- PGs for induction of labor, G10(table)

RAO, M.N.
- duration of postpartum amenorrhea, J57(table)

RATCLIFFE, J.W.
- sexual behavior after vasectomy, D35 (table)

RATHORE, S.H.S.
- sexual behavior after vasectomy, D35 (table)

RATNAM, S.S.
- address, C70
- culdoscopy
  - side effects of anesthesia, C62
  - training, C70

RAUH, J.L.
- medical complications of adolescent pregnancy, J165(table)

RAVENHOLT, R.T., author, A105-A132, J1-J20, J21-J39, J69-J88, J205-J234
- age of marriage and family size, J163
- compulsory sterilization, E48-E49
- demographic impact of acceptance and continuation rates, B37
- estimated population dynamics in China, J211(table), J212(table), J213(table), J250(table)
- fertility silhouette technique, J206
- funding for family planning, J267(figure)
- hypothetical model of population growth, J167(table)
- PG research and fertility control, G2
- world fertility patterns, J220-J221(map)

RAVINA, J.H.
- electrocoagulation with division and biopsy in laparoscopy, C8(table)
- operative procedure in laparoscopic sterilization, C7(table)

RAVN, J.
- lynestrenol minipill
  - effectiveness, A56(table)
  - menstrual pattern changes, A58(table)

RECALCINE LABORATORIES
- marketing of Aguria, K2

RECAMIER, J.A.
- colpotomy, C30

RECANALIZATION
- causes, D33
- culdoscopy, C68
- incidence, D28(table), D29(graph)
- postvasectomy
  - incidence, D10
  - from ligatures, D5
  - prevention, D5, D8
  - sperm granuloma, D10, D29

RECHTSWIDRIGKEIT
- sexual sterilization, CD80-CD81

RECIP
- marketing of minipill, A64(table)

RECREATION AREAS
- expanding use, J180-J181

RECTAL INJURY. See **BOWEL INJURY**.

REES, R.W.N.
- vasectomy
  - complications, D28(table)
  - technique, D28(table)

REGLOVIS
- manufacture and marketing, A4(table)

REGOVAR
- manufacture and marketing, A4(table)

REINER, E.
- use-effectiveness of calendar rhythm method, I9, I11(table)

REINGOLD, L.A., author, M1-M34

RENDELL, W.J., LTD.
- vaginal suppository, H39, H41(table)

RENDELL'S SPERMICIDE, J70
- active ingredients, H41(table)

REPETTO, R.
- son preference, I27

REPRODUCTIVE BIOLOGY RESEARCH FOUNDATION (ST. LOUIS, MISSOURI)
- diaphragm fitting, H62

RESPIRATORY INSUFFICIENCY
- culdoscopy, C66
- laparoscopic sterilization, C18, C20

RESPONSIBLE PARENTHOOD COUNCIL (PHILIPPINES), I15, I16

RESZCZNYSKI, A.
- Spiran W, B48

RETAINED PRODUCTS OF CONCEPTION. See **PRODUCTS OF CONCEPTION, RETENTION**.

RETARDIN, G58
- prostaglandins
  - abortion, G70(figure)
  - cervical dilatation, G68
  - menstrual regulation, G58

RETEX, A55
RETRACTOR, M20
    colpotomy, C36, C37(figure)
    culdoscopy, C69
RETROPROGESTAGEN, POSTCOITAL
    administration and dosage, J150(table)
    use-effectiveness, J150(table)
REUNION
    age-specific fertility rate, J3(graph), J25(graph), J34(graph), J224(graph)
    birth rate, J23(figure), J29(table), J207 (table), J218(figure)
    change in number of births, J219(figure)
    family planning program, J24
    marketing of oral contraceptives, A15 (table)
REVERSIBILITY, D41-D59
    clip sterilization, C45, C46, C50
    Depo-Provera, K8-K9
        factors influencing, K9
    female sterilization, C8
        clips, C12
    injectable progestogens, K1
    intravas device, D14
    intravasal thread, D14
    sperm antibodies, D31-D32
    tubal fulguration, C74
    tubal ligation, C34, C74, C75
    tubal occlusion, C73
        chemical, C87, C88
        clips, C82, C83
    vasectomy. See **VASECTOMY REVERSIBILITY**.
REVERSIBLE INTRAVAS DEVICE
    effectiveness, D14
    insertion, D14
REVERSIBLE INTRAVASAL OCCLUSIVE DEVICE (RIOD), D57(figure, photo)
    advantages, D56
    animal studies, D56-D57
    complications, D56
    description, D56
R.G. KAR MEDICAL COLLEGE (INDIA)
    reversible sterilization, D41
RH-ANTIBODY SCREENING
    before menstrual regulation, F11
RH IMMUNIZATION, F36
    menstrual regulation, F11
RHODE, W.
    sperm separation by centrifugation, I25
RHODES, P., A33(figure)
RHODESIA
    availability of Depo Provera, K13(figure), K14
    birth rate, J29(table)
    copper IUDs, B18
    cost of injectable progestogens, K14
    diaphragm availability, H68(table)
    marketing of oral contraceptives, A15 (table)
    training nonphysicians, J94(table), J104(table)
RHYTHM CENTER (RHODE ISLAND)
    fertile period identification, I3(table)
RHYTHM METHOD
    acceptability, I2, I13, I14-I16
    Australia, I14(table), I15(table)
    Belgium, I14(table)
    Catholics, I2, I9, I14, I15, J81
    Colombia, I14(table)
    complications, I12-I14
    continuation rate
        Mauritius, I16
        Philippines, I16
    contraindications, I7
        adolescents, J167
        lactation, J59
    costs, I16
    counseling, I16
    derivation of term, I3
    developing countries, I2, I14(table), I15
    disadvantages, I16-I17
    family planning programs, J74
        France, I14(table)
        Mauritius, J81, J82(table)
    history, I1, I2-I4
    India, I14(table)
    Italy, I14(table)
    Japan, H11, I14(table)
    motivation, I9
    ovulation detection, I8
    Philippines, I2, I14(table), I15(table), I16, J20(table)
    psychological factors, I13
    research, I17
    selected developed and developing countries, H4(table)
    South Korea, I15
    techniques, I4-I8
    theoretical effectiveness, I8-I9
    training programs for nonphysicians in selected countries, J94-J95(table)
    United Kindgon, I14(table)
    US, H59(table), I14(table), I15(table)
    use-effectiveness, H37, H39(figure), I8-I9
    West Germany, I14(table)
RHYTHM METHOD, CALENDAR, I9
    basis, I4-I5
    Colombia, I15
    combined with temperature rhythm method, I6
    menstrual cycle irregularity, I5
    ovulation calendar, I4(table)
    theoretical effectiveness, I10
    use-effectiveness, I9, I10, I11(table)
RHYTHM METHOD, CERVICAL MUCUS, I7-I8
    chart, I7(figure)
    reliability, I7-I8
    safe days, I7
    use-effectiveness, I11(table), I12
RHYTHM METHOD, OVULATION. See **RHYTHM METHOD, CERVICAL MUCUS**.
RHYTHM METHOD, SYMPTO-THERMAL, I7
RHYTHM METHOD, TEMPERATURE, I5
    BBT level, I5, I6(table)
    combined with calendar rhythm method, I6
    disadvantages, I5-I6
    formula, I6
    history of development, I5
    individual variations, I6
    temperature charts, I6(figure)
    use-effectiveness, I1-I2, I10, I11(table), I12
RICE, F.J.
    use-effectiveness of temperature rhythm method I10, I11(table), I12(table)
RICE, F.M.
    psychosocial aspects of rhythm method, I13
RICE-WRAY, E.
    continuation of contraceptives, K8
    d-norgestrel minipill
        effectiveness, A56(table)
        menstrual pattern changes, A59(table)
    orals and lactation, J61(table)
    use-effectiveness of Norigest, K4(table)
RICHART, R.M.
    tubal occlusion with silver nitrate, C86 (table), C87-C88
RICHTER IUD, B24(figure)
RIECHE, K.
    orals and breast neoplasia in animals, A78(table)
RIFAMPICIN
    decreased effectiveness of orals, A48
RIGLOVIS
    manufacture and marketing, A4(table)
    patent information, A5(table)
RIKSFORBUNDET FOR SEXUELL UPPLYSING (RFSU). See **ASSOCIATION FOR SEX EDUCATION**.
RIMBACHER GUMMINWAREN FABRIC GmbH, H19
RINEHART, W., author, A53-A67, A69-A100, A105-A132, I21-I32, J141-J154, K1-K16
RING PATTERN
    hemagglutination inhibition tube test, J112, J113(figure), J116
RINGER BATH, G61
RIO GRANDE DO NORTE (BRAZIL)
    contraceptive distribution by village leaders, J80-J81
RIOD. See **REVERSIBLE INTRAVASAL OCCLUSIVE DEVICE**.
RITCO. See **ROYAL INDUSTRIES OF THAILAND CO., LTD.**
RITTER CO.
    address, M33
    electrosurgical generator, M15(table)
    guarantee and service of sterilization equipment, M30(table)
    vasectomy equipment, M27(table)
ROBERTS, G.
    PGs for induction of labor, G10(table)
    PGs for pregnancy termination, G7(table)
ROBINS, A.H. AND CO., B37
    Dalkon Shield, B42
        distribution, B36
ROBINS, J.
    intraamniotic instillation of $PGF_2\alpha$ for abortion, F73(table)
ROBINSON, R.R.
    Saf-T-Coil, B42
ROCHE DIAGNOSTICS, J116, J118(table), J119(table)
ROCHE LABORATORIES
    address, C63
ROCK, J.
    oral contraceptives
        Catholic acceptance, A34
        research, A32, A34
    role of hormones in ovulation, A31
    use-effectiveness of calendar rhythm method, I10, I11(table)
ROCKEFELLER FOUNDATION
    address, J283
    funding of family planning activities, J268, J271(table), J275(table), J278(table)
ROCKEFELLER UNIVERSITY (NEW YORK, NEW YORK)
    reversible vas occlusion, D53
ROCKET OF LONDON, D11, F19
    address, M33
    aspiration equipment system, F43(figure)
    cannula adaptors, F41(figure)
    dilators, F90(figure)
    guarantee and service of sterilization equipment, M30(table)
    laparoscopy equipment
        fiberoptic projectors, M9(table)
        tubal occlusion, M19(table)
    menstrual regulation kit, F19(figure), F57(figure)
    metal cannula, F40(figure)
    uterine manipulation devices, M22(table)
    vasectomy equipment, M25(table)
RODGERS, D.A.
    sexual behavior and fertility control, D35-D36
RODRIGUEZ-ARGUELLES, J.
    menstrual pattern changes with d-norgestrel minipill, A60(table)
ROE, R.E.
    sterilization by colpotomy, C31(table)
        anesthesia, C32(table), C33
        complications, C40(table)
        failure, C39(table), C43(table)
        fimbriectomy, C33(table)
        tubal ligation, C34
ROE v. WADE, E36, E47, F5
ROLAND, M.
    complications of culdoscopy, C66(table)
    progestogens and sperm capacitation, A55
ROLAND, S.I.
    operative procedures for vas anastomosis, D45(table)
ROLNICK, H.C.
    vas recanalization, D33
ROMANIA
    abortion, J257
        legal status, E30(table), E36, E38
        maternal mortality, E36, E37(table)
    age-specific fertility rate, J3(graph), J39(graph), J228(graph)
        with legalized abortion, J10(graph)
    birth rate, J23(figure), J29(table), J207 (table), J218(figure)
    change in number of births, J219(figure)
    effect of abortion law repeal on fertility, J4
    incidence of cancer in women, A70(table)
    legal status of voluntary sterilization, CD113(table)
    marketing of oral contraceptives, A14 (table)
    oil reserves, J200
    population, F7(table)
ROOPNARINESINGH, S.S.
    medical complications of adolescent pregnancy, J165(table)
ROSA, F.W.
    contraceptive impact of breast-feeding in Philippines, J50

- couple-years protection due to breast-feeding, J58
  - developing countries, J59(table)
- duration of postpartum amenorrhea, J57(table)
  - birth interval, J58
- progestogens for lactating women, K11

ROSACEA
- oral contraceptives, A47

ROSALES, V.
- rhythm method, I16

ROSE, N.
- postvasectomy antibody formation, D32

ROSEN, A.D.
- laparoscopic sterilization
  - electrocoagulation with division and biopsy, C8(table)
  - operative procedures, C7(table)
  - preoperative medication and anesthesia, C3(table)
  - technique for pneumoperitoneum, C5(table)

ROSENBLOOM, D.
- vas anastomosis effectiveness, D43

ROSENFELD, D.L.
- postcoital diethylstilbestrol
  - side effects, J148(table)
  - use-effectiveness, J145(table)

ROSENFIELD, A.G.
- nonphysicians
  - screening IUD candidates, J96(figure)
  - screening oral contraceptive candidates, J91
  - training in IUD insertion, J93
  - training in sexual sterilization, J97

ROSENKRANZ, G., A5(table)

ROSS, C., author, I1-I19

ROSS, C.T.
- measurement of HCG, F53

ROTH-BRANDEL, U.
- PGs for induction of labor, G10(table)
- PGs for pregnancy termination, G8(table), G9(table)

ROTKIN, I.D.
- factors influencing cervical cancer, J133 (table)

ROTZER, J.
- use-effectiveness of temperature rhythm method, I11(table)

ROUSSEL CO.
- oral contraceptives, A4(table), A5(table), A7
  - worldwide marketing, A13-A15(tables)
- synthesis of norgestrienone, A32

ROVINSKY, J.J.
- IUD insertion after abortion, F33
- use-effectiveness of contraceptive creams, H45(table)

ROYAL COLLEGE OF GENERAL PRACTITIONERS (U.K.)
- oral contraceptives
  - beneficial and adverse conditions in users and nonusers compared, A31(graph)
  - benign breast neoplasia, A73(table), A74
  - blood pressure, A42
  - breast cancer, A76(table)
  - breast disease, A44(table), A46(figure)
  - cervical neoplasia, A44(table), A46
  - discontinuation, A39
  - gallbladder disease, A47
  - interval of nonuse, A43
  - iron deficiency anemia, J132
  - menstrual blood loss, A38
  - ovarian neoplasia, A45(table)
  - prospective study, A40
  - risk, A30
  - skin disorders, A47
  - thromboembolic disease, A41(table)
  - uterine fibroids, A88

ROYAL INDUSTRIES OF THAILAND CO., LTD. (RITCO)
- condom marketing experiment, H9
- condom production and sale, H9, H19

RUBBER
- production, H22
- valves, D15
- vulcanization, H22

RUBIO, B.
- quingestanol acetate minipill
  - effectiveness, A56(table)
  - menstrual pattern changes, A60(table)
  - postcoital, J149(table)

RUBION GmbH HKG, H19

RUDALI, G., A78(table)
- orals and breast neoplasia in animals, A78(table)

RUDEL, A.W.
- IUD removal after perforation, B31

RUDEL, H.M.
- minipill
  - development, A54
  - mode of action, A56

RUMKE, P.
- sperm antibodies
  - fertility, D31
  - infertility, D48
  - postvasectomy, D48

RURAL BANK OF SAN LUIS (PHILIPPINES)
- agricultural extension workers, J79
- distribution of contraceptives, J79

RURAL POPULATION
- access to health services, J125
- availability of IUDs, B26
- breast-feeding, J54-J55
  - duration of postpartum amenorrhea, J56, J57(table)
- distribution of orals, J91, J92

RUTGERS, J.
- diaphragm sizes, H58

RUTTNER, B.T.
- transcervical technique for saline abortion, F69

RWANDA
- birth rate, J29, J207(table), J210(table)
- duration of postpartum amenorrhea, J57 (table)
- infant mortality, J255, J258
- marketing of oral contraceptives, A15 (table)

RYDER, N.B.
- birth spacing, I9
- contraception and motivation, H46
  - condom, H33
- contraceptive effectiveness, H39(figure), I9
  - diaphragm, H65
- discontinuation of orals, A39

RYUKYU ISLANDS
- birth rate, J29(table)

S

S-382
- chemical tubal occlusion, C88

S-521
- chemical tubal occlusion, C88

SADIK, N.
- training for menstrual regulation, F62

SAF-T-COIL, B42(photo)
- description, B42
- distribution, B42
  - USAID, B37
- insertion, B29
  - technique, B30
- menstrual flow, B11, B35
  - mortality, B36(table)
  - US, B37
  - use-effectiveness, B32(table)

SAGALL, E.L.
- sterilization with consent, CD84

SAGAMI RUBBER INDUSTRIES, H11, H19
- plastic condom, H32

SAI, F.T., E21(photo)
- contraception among adolescents in Africa, J166, J168
- family planning, E19
  - for childless couples, J164

SALAS, R., E16(figure)

SALBER, E.J.
- postpartum amenorrhea and lactation, J56

SALDANA, L.
- intraamniotic instillation of PGF$_2\alpha$ for abortion, F73(table)

SALINE
- abortion. See **ABORTION, SALINE.**
- instillation before chemical tubal occlusion, C89

SALPINGECTOMY, C34
- advantages and disadvantages, C77
- combined with cautery, C77
- effectiveness, C76(table), C77
- Netherlands, C77
- procedure, C75
- reversibility, C75
- route of approach, C77

SALPINGITIS
- colpotomy, C42

SALPINGO-OOPHORECTOMY
- colpotomy to treat abscesses, C42
- uterine aspiration, F35

SALT
- spermicidal solution, H38

SALUM, R.
- menstrual pattern changes with norethindrone minipill, A59(table)

SAMUELSSON, B.
- PGF$_2\alpha$ level at term, G48

SAN MARINO
- birth rate, J29(table), J207(table), J218 (figure)
- change in number of births, J219(figure)

SAN SALVADOR
- Yoon band sterilization, C85

SANDER, F.J.
- spermicidal potency, H44

SANDHOLM, L.
- orals and lactation, J61(table)

SANDMEYER, M.W.
- obstetrical complications with multiparity, J134(table)

SANDMIRE, H.F.
- orals and cervical neoplasia, A82(table)

SANDOZ PHARMACEUTICALS
- Syntocinon, G49

SANGER, M., A32, H58

SANTAS, A., E21(photo)

SANTOS, V.A.
- voluntary sterilization, E6

SAO TOME AND PRINCIPE
- birth rate, J23(table), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)

SAPIRE, K.E., J104(table)

SARAWAK FAMILY PLANNING ASSOCIATION COUNCIL (MALAYSIA)
- address, J102(table)
- training nonphysicians, J94(table), J102(table)

SARRIA, C.
- use-effectiveness of postcoital norgestrel, J149(table)

SARTWELL, P.E.
- oral contraceptives
  - benign breast neoplasia, A44(table), A73(table)
  - thromboembolic disease, A41(table)

SASTRAWINATA, S.
- menstrual regulation in family planning, F61

SAUDI ARABIA
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- diaphragm availability, H68(table)
- legal status of abortion, E29, E30
- legal status of voluntary sterilization, CD113(table)
  - Islamic law, CD87
- marketing of minipill, A64(table)
- oral contraceptives
  - ban for family planning E42, E44 (table)
  - marketing, A15(table)

SAUNDERS, W.G.
- mini-laparotomy, C54

SAVAGE, P.M.
- sexual behavior after vasectomy, D35 (table)

SAWHNEY, Y.L.
- general health after vasectomy, D34(table)

SAXENA, B.
- pregnancy testing, F53
- radioreceptorassay, J109, J121

SCHAEFER, G.
- cervical dilatation technique, F91(figure)

SCHAEFER, O.
- birth rate among Eskimos, J56

SCHALK, J.
  sex ratio affected by spleen removal, I26
SCHARDEIN, J.L.
  animal studies with orals
    breast neoplasia, A78(table)
    cervical tumors, A85(table)
    endometrial tumors, A87(table)
    liver tumors, A89(table)
    ovarian tumors, A91(table)
    pituitary tumors, A90(table)
SCHARFF, H.J.
  effectiveness of d-norgestrel minipill, A56(table)
SCHENK, L.
  age of ovum and sex, I22
SCHENK, M., A5(table)
SCHERING AG
  distribution of minipill, A63, A64(table)
  manufacture of hydroxyprogesterone caproate, K2
  manufacture of norgestrel, A5
  marketing of norethindrone, A5
  Norigest, K1
    withdrawal from market, K10
  oral contraceptives, A4(table), A5, A7
    commercial sales, A7
    worldwide marketing, A13-A14(tables)
  postcoital norgestrel, J147
    manufacture, J147
    use-effectiveness, J149(table)
  studies on norethindrone enanthate, K2
SCHILLING, E.
  chemical treatment of sperm for sex preselection, I26
SCHINER, W.B., J107(table)
SCHISTOSOMIASIS, J183
SCHLEGEL, W.
  estrogen-induced PG release, G50
SCHMID, JULIUS, CO., INC., B37, H19
SCHMID LABORATORIES, H41(table)
  address, H68(table)
  diaphragm manufacture, H68(table)
  Saf-T-Coil, B42
SCHMIDT, S.S.
  danger of sclerosing agents, D15
  postvasectomy epididymitis, D47
  recanalization and sperm granuloma, D10
  sperm antibodies, D48
  vas anastomosis
    causes of failure, D46
    effectiveness, D49(table), D51
    equipment, D46
    experimental, D46
    operative procedures, D45(table), D50
    patient follow-up, D48
    preoperative procedures, D48
    splinting material, D50
    suture material, D51
  vasectomy
    complications, D28(table), D47
    kit, M26(table)
    sperm granulomas, D29, D30
    technique, D5, D7(table), D28(table), D30, D33
SCHOFIELD, M.
  contraception among adolescents, J166
SCHRODER, S.
  Antigon-F, B46
SCHRODER, V.N.
  sperm separation by electrophoresis, I25
SCHROEDER, C.
  hysteroscopic fulguration, C81
SCHULMAN, H.
  diaphragm administration of PGs, H66-H67
  intravaginal administration of PGE$_2$, F76, F77(table)
  PG for pregnancy termination, G59
SCHUMACHER, P.C.
  use-effectiveness of postcoital diethylstilbestrol, J145(table)
SCHWALLIE, P.C.
  Depo-Provera
    conception rates after discontinuation compared with IUD, K9(graph)
    continuation rate, K7(table)
    use-effectiveness, K4(table), K5(table)
  side effects of injectable and oral contraceptives, K7
SCIENCE COUNCIL OF CANADA
  population growth, J246
SCOMMEGNA, A.
  progesterone-releasing IUD, B38
SCOPOLAMINE, F29(table)
  culdoscopy, C63(table)
SCORED DILATING PROBE, D14
SCOTLAND
  diabetes mellitus and parity, J132(table)
  family planning campaign, J307-J308, J311(table)
  incidence of cancer in women, A70(table)
SCOTT, L.S.
  edema after electrocoagulation of vas, D5
  vasectomy technique, D7(table)
SCOTT, R.
  mortality with copper IUD, B17
SCOTTI, R.J.
  menstrual regulation, F51(table)
    complications, F52(table)
SCROTUM
  conditions contraindicating vasectomy, D26
SCUTCHFIELD, F.D.
  comparative contraceptive continuation rates, K8(graph)
  Depo-Provera
    continuation rate, K7(table), K8(table)
    side effects compared with IUDs, K7
    use-effectiveness, K4(table)
SEARLE, G.D., AND CO.
  copper-7 IUD, B43
    insertion technique, B9(figure)
    manufacturer, B4
  manufacture of low-estrogen orals, A37 (table)
  marketing of minipill, A64(table)
  oral contraceptives, A4(table), A5(table), A7
    marketing, A3, A13-A15(tables)
    sales to USAID, A23(table)
  recommended IUD withdrawal technique, B7
  synthesis of norethynodrel, A32
SEBACEOUS CYSTS
  oral contraceptives, A47
SECURITAS
  Spiran W, B48
SEE-SAW THEORY
  prostaglandins, G34(figure)
SEGUY, B.
  effectiveness of coital timing method of sex preselection, I24
SEGUY, J.
  cervical mucus, I7
SEIN, M.
  cervical cap
    manufacture, H71(figure)
    use-effectiveness, H72
SELF HELP HEALTH PROJECT FOR RURAL COMMUNITY DEVELOPMENT (BANGLADESH), J97
SELYE, H.
  stress-related problems, J190
SEMINAL VESICLES
  release of PGs, G26
SEMINOMA
  diagnosis, J114
SEMM, K.
  electrocoagulation in laparoscopic sterilization, C8(table), C80
  orals and lactation, J61(table)
SEMORI
  active ingredients, H41(table)
SENEGAL
  age-specific fertility rate, J224(graph)
  average births per woman, J129(table)
  birth rate, J29(table), J207(table), J210 (table)
  condom sales, H6
  copper IUDs, B18
  drought and famine, J244-J245
  duration of postpartum amenorrhea, J57(table)
  marketing of oral contraceptives, A15 (table)
  paramedical personnel for IUD insertion, B28
  training nonphysicians, J98, J104(table)
SEOUL NATIONAL UNIVERSITY (SOUTH KOREA)
  vas anastomosis, D48
SEPPALA, M.
  PGF$_2\alpha$ for midtrimester abortion, G71(table)
SEPSIS
  clip sterilization, C49
  mortality associated with IUD, B36(table)
  predisposing factors, J137(table)
  symptoms, J137(table)
SEPTICEMIA
  uterine aspiration, F35
SEQUENTIAL ORAL CONTRACEPTIVES
  endometrial cancer, A70, A84
    animal studies, A87(table)
  liver tumors in animal studies, A89(table)
  pituitary tumors in animal studies, A90 (table), A91(table)
  recommended for adolescents, J168
  withdrawn from US market, J168
SERRANO, C.V.
  comparative infant and neonatal mortality, J166(table)
SEVIGNE, MME. DE, H21, H32
SEX CHROMOSOMES, I23(figure)
  sex determination, I22-I23(figure)
  X-chromosome, I23, I25-I26
  Y-chromosome, I23, I25-I27
SEX EDUCATION
  available films, J171
  Jamaica, J309
  nonschool programs, J171
  obstacles to in-school programs, J171
  recommendations, J170
SEX PREFERENCE
  attitude and behavior surveys, I27
  Bangladesh, I27
  contraceptive behavior, I27
  fertility behavior, I27
  India, I27
  Korea, I27
  Morocco, I27
  regional differences, I28
  role of family planning programs, I22
SEX PRESELECTION, I21-I32. See also **FETAL SEX IDENTIFICATION; SPERM SEPARATION METHOD**
  acceptance of methods, I28
  amniocentesis, I26
  blastocyst identification, I27
  chemical treatment of sperm, I26
  coital timing methods, I22, I24
  current research, I23-I27
  developing countries, I28
  early theories, I22
  folk methods, I22
  immunization, I26
  planned pregnancy, I28
  postcoital douche. See **DOUCHE, POSTCOITAL**.
  potential demographic effects, I21, I27
  potential social effects, I21
  selective abortion, I21, I26
  sex ratio, I28
  sperm separation, I25-I26
SEX RATIO
  BBT shifts, I24
  Europe, I23
  Gambia, I23
  Israel, I24
  Montserrat, I23
  probability theory, I23
  sex preselection, I28
  US, I23
  variables, I23
SEYCHELLES
  age-specific fertility rate, J225(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J28(table), J207(table), J209 (table)
SEYMOUR, R.J.
  use-effectiveness of Depo-Provera, K4 (table)
SHALITA, R., author, G57-G64
SHAMROCK, B47(figure)
  description, B47
  distribution, B47
  use-effectiveness, B32(table)
SHAPIRO, A.
  extraovular instillation of PGF$_2\alpha$, F75 (table)
SHAPIRO, S.
  breast disease, A45

SHARP, H.
  voluntary vasectomy, D2
SHAW, S.T.
  anemia associated with IUD use, B35
SHEBAB, R.U.
  sterilization and Islamic law, CD86
SHERMAN, J.K.
  clinical use of frozen semen, D52
SHETH, S.S.
  colpotomy, C31(table)
    anesthesia, C32(table)
    combined with abortion, C35, C43
    complications, C40(table)
    Madlener method, C33(table)
SHETTLES, L.B.
  coital timing method, I24
  precoital douches, I25
SHOCK
  culdoscopy, C66(table)
  PG administration, G3, G7(table)
SHULMAN, S.
  postvasectomy antibodies, D31(table), D48
SHUTE, W.B.
  colpotomy
    complications, C40(table)
    electrocautery, C34
    equipment, C36(table), C37(figures)
    failure, C39(table)
    muscle relaxant, C34
SHUTIKA, J256
SICKLE CELL ANEMIA, F68, F70
SIEGLER, A.M.
  laparoscopic sterilization
    electrocoagulation with division and biopsy, C8(table)
    operative procedure, C7(table)
    preoperative medication and anesthesia, C3(table)
    training, C2, C13
    two-incision technique with single-handed biopsy instrument, C11 (figure)
  laparoscopy procedure, C6
  uterine position for colpotomy, C40
SIERRA LEONE
  availability of Depo-Provera, K13(figure)
  birth rate, J29(table), J207(table), J210 (table)
  contraception among adolescents, J166
  legal status of abortion, E29(table)
  marketing of oral contraceptives, A15 (table)
  new acceptors of vaginal contraceptives, H49(table)
  population, F7(table)
  population per hospital bed, J71(table)
  population per physician, J71(table)
  training nonphysicians, J94(table)
SIKKIM
  birth rate, J29(table), J210(table)
SILASTIC
  chemical tubal occlusion, C86(table), C88
  clip material, C83
  implant devices, D30
SILASTIC PLUG
  tubal occlusion, C77(table), C88(figure), C90(photo, table)
  vas occlusive device, D53
SILBER, S.J.
  vas anastomosis
    effectiveness, D49(table), D51
    microsurgery, D51(photo)
    operative procedures, D45(table)
    sutures, D51
SILESIA LABORATORIES
  marketing of Unalones, K2
SILICONE
  condom lubrication, H23
  intravaginal disk for PG release, F76
  tubal occlusion, C88
  valves, D15
  vas occlusion, D53
SILK
  incision closure, C58
  tubal ligation, C74, C78
  vas ligation, D5, D6
  vas occlusion, D27, D28(table)
    infection, D27
SILVER NITRATE
  chemical sterilization, D15
  treatment for granuloma, C68
  tubal occlusion, C77(table), C86(table), C87-C88
SILVER NITRATE HYDROPHILIC OINTMENT
  effectiveness, C64
  tubal occlusion via culdoscopy, C64
    complications, C64
SILVERSTEIN, I.
  sperm motility of frozen semen, D52
SIMMONDS, J.
  testicular function after vasectomy, D30
SIMON POPULATION TRUST
  tantalum clip design, C83
  vasectomy
    attitude, D36
    complications, D28(table)
    general health, D34(table)
    sexual behavior, D35(table)
    technique, D28(table)
SIMONNET, H.
  cervical mucus, I7
SIMPSON, J.Y.
  cervical dilatation, F88
  leeches as precursor of uterine aspiration, F26
  syringe suction of uterus, F26
  technique for cervical dilatation, F26-F27
SIMS SPECULUM, M5
  culdoscopy, C64
SIMS UTERINE DILATOR, F89(figure)
SIN, H.W.
  continuation rate with Depo-Provera, K7(table), K8(table)
SINGAPORE
  abortion
    compared with PGs, saline solution, and hysterotomy, G12
    impact on population growth, E38
    legal status, E29, E30(table), E32, E33(table)
  age-specific fertility rate, J3(graph), J5(graph), J25(graph), J37(graph), J222(graph)
  birth rate, J21, J23(figure), J29(table), J207(table), J218(figure), J239
  change in number of births, J219(figure)
  condom shipments, H14(table)
  contraceptive practice, A12(table)
  culdoscopy, C61
    complications, C66(table), C67(table)
    training, C62, C69, C70
    tubal occlusion, C65(table), C68(table)
  diaphragm availability, H68(table)
  estimated population, E30(table)
  family planning, J2, J24
    preference for oral contraceptives, J2
  hormonal-withdrawal test, J115
  incentive programs, E8(table), E48(table), E49
  IUD
    acceptability, B26
    acceptors, B27(table)
    continuation rate, B33(table)
    perforation, B30
    use, J2
  legal status of voluntary sterilization, CD70, CD73, CD78, CD114(table), CD126-CD127
    medical conditions, CD69
    minimum age, CD69
    minimum number of children, CD70
    prescribed waiting period, CD69
  marital status of female adolescents, J164(table)
  marketing of minipill, A64(table)
  menstrual regulation, F20, F51
  new acceptors, A17, A18(table), J15(table)
  oral contraceptives, B26
    marketing, A15(table)
    new acceptors, A17, A18(table)
    supplied by SIDA, A20(table)
    supplied by USAID, A21(table)
  percentage of legal abortions to women under 20, J171(table)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  population, F7(table)
  population law, J200, J247
    incentives and disincentives, E47
    voluntary sterilization, E42, E45(table), E47, E48
  total fertility rate, J215(table), J216, J217(table)
  training in laparoscopic sterilization, C14
  uterine aspiration, F27
  vaginal contraceptives, H48(table)
  Yoon band sterilization, C85
SINGH, B.
  vaginal contraceptives
    prophylactic quality, H50
    venereal disease, H51(tables)
SINGH, K.B.
  compulsory sterilization in India, E48
  intraamniotic saline abortion, F71(table)
SINGLE-TOOTH TENACULUM
  menstrual regulation, F12
  uterine aspiration, F38
SINNATHURAY, T.A.
  age of menarche, J162(table)
  attitude toward out-of-wedlock pregnancy in Malaysia, J163
SIVIN, I.
  analysis of IUD continuation rates in Asia, B14
  copper IUDs
    expulsion, pregnancy, removal, and continuation rates, B6(table)
    pregnancy rate, B10
    replacement, B2
  expulsion rates of IUDs, B10
  International Postpartum Family Planning Program, B14
  Lippes Loop preferred in multiparas, B15
SKLAR, J., MFG. CO.
  address, M33
  guarantee and service of sterilization equipment, M30(table)
  vasectomy equipment, M25(table)
SLIDE TEST. See also **PREGNANCY TESTS, IMMUNOLOGIC**.
  advantages, J109, J118
  direct agglutination test, J116
  latex agglutination inhibition, J116
  mode of action, J116-J117
  modifications, J119
  reliability, J117
  sensitivity, J117
SLIPPERY ELM BARK, F89
SLIPPERY ELM TENTS, F88(figure)
SLOAN-KETTERING CANCER CENTER (NEW YORK, NEW YORK)
  immunologic control of sex ratio, I26
SMITH, D.C.
  estrogen use and endometrial cancer in postmenopause, A86(table)
SMITH, K.D.
  plasma hormone levels after vasectomy, D31
  sperm motility of frozen semen, D52
SMITH, M.
  ectopic pregnancy rate with minipill, A57(table)
SMITH, R.A.
  colpotomy, C31(table)
    complications, C40(table)
    equipment, C36(table)
    failure, C39(table)
    fimbriectomy, C33(table)
  menstrual regulation, F13(table)
    procedure and equipment, F14(table)
SMITH, W.T.
  cervical mucus, I7
SMITH-HODGE REVERSED DIAPHRAGM. See **MATRISALUS DIAPHRAGM**.
SMITHSONIAN INSTITUTION (US)
  threatened extinction of plants in US, J198
SMOKING
  breast-feeding, J54
  oral contraceptives and stroke, A42
  thromboembolic disease, A42
SNIDVONGS, W.
  training in laparoscopic sterilization in Thailand, C14
SNOWDEN, R.
  use-effectiveness of Dalkon Shield, B32 (table)
SOBRERO, A.J.
  vasectomy
    complications, D28(table)
    failure, D28(table), D33
    technique, D28(table)

SOCIAL MARKETING. See **COMMUNITY-BASED DISTRIBUTION**.
SOCIAL RESEARCH CENTER OF THE AMERICAN UNIVERSITY IN CAIRO (AUC)
  household distribution of contraceptives, J82
SOCIEDADE CIVIL DE BEM ESTAR FAMILIAR NO BRASIL (BEMFAM)
  address, J105(table)
  distribution of orals, J92
  family planning program, J80-J81
  training nonphysicians, J95(table), J105 (table)
SOCIETE PRIMAGUM (FRANCE), H19
SODERSTROM, R.M.
  laparoscopic sterilization
    complications, C19(table)
    operative procedure, C7(table)
    rectal polyp snare, C12
    technique for pneumoperitoneum, C5(table)
  needles for insufflation, M10
  recommendations for laparoscopic fulguration, C80
SODIUM CARBOXYMETHYL CELLULOSE, H42
SODIUM DICHLOROSULPHAMIDOBENZOATE, H41(table), H43(table)
SODIUM HYDROXIDE, I26
SODIUM METHOHEXITAL, C55
  menstrual regulation, F13(table)
SODIUM MORRHUATE
  chemical sterilization, D15
SODIUM PENTOBARBITAL, C32(table)
SODIUM PENTOTHAL
  menstrual regulation, F51(table)
SODIUM TETRADECYL SULFATE
  chemical sterilization, D15
SOEMARWOTO, O.
  soil erosion in Indonesia, J192
SOGOLOW, S.
  sterilization by colpotomy, C31(table)
    complications, C40
    fimbriectomy and Pomeroy method, C33(table)
    postoperative morbidity rate, C41
SOICHET, S.
  use-effectiveness of Depo-Provera, K4 (table)
  Ypsilon, B45
    use-effectiveness, B39
SOIL EROSION, J188
  deforestation, J192, J193
SOLBERG, N.
  midtrimester abortion with urea, F78(table)
SOLID PLUG TUBAL OCCLUSION. See also **TUBAL OCCLUSION**.
  aloplastic, C90(table)
  ceramic, C90
  dacron, C91
  polyethylene, C90
  Proplast
    insertion procedure, C90
    results, C90-C91
  selected studies, C90(table)
  silastic, C88(figure), C90(photo)
    advantages and disadvantages, C90
    effectiveness, C90
    route of application, C90
    sizes, C90
  site of insertion in selected studies, C90(table)
  suggested criteria, C89
  Teflon
    insertion procedure, C91
    reversibility, C91
  US, C90, C91
SOLLINS, A.D.
  commercial distribution of contraceptives, J70
    condom, H5
SOLLMAN, P., A5(table)
SOLUBLE FILM, H42. See also **C-FILM**.
  active ingredients, H41(table), H43(table)
  duration of spermicidal effect, H43(table)
  mode of action, H43(table)
  packaging, H43(table)
  use-effectiveness, H45(table)
SOMALIA
  birth rate, J29(table), J207(table), J210 (table)
  famine, J245
  marketing of oral contraceptives, A15 (table)
SOMBOONSUK, A.
  IUD reinsertion after expulsion, B34
  use-effectiveness of Lippes Loop, B32 (table)
SOOD, S.V.
  uterine aspiration, F28(table)
SOONAWALA, R.P.
  aspiration apparatus, F28(figure)
  IUD acceptability, B26
  sterilization by colpotomy, C31(table)
    abortion, C43
    complications, C40(table), C41, C42
    equipment, C36(table), C37(figure)
    failure, C39(table), C43(table)
    fimbriectomy and Pomeroy method, C33(table)
    incision, C33, C35
    India, C29, C42, C43
    mortality, C42
    postoperative care, C35
    preoperative medication, C32(table)
    surgical sterility, C31, C42
  tubal ligation technique, C34
SORANOS
  fertile period identification, I3(table)
  fertility and menstruation, I2
  postcoital contraception, J142
  vaginal contraceptives, H38
SORENSON VACUUM APPARATUS
  menstrual regulation, F51(table)
SOUTH AFRICA
  birth rate, J29(table), J207(table), J209 (table)
  copper IUDs, B18
    legal restriction, B18
  Depo-Provera
    availability, K13(figure), K14
    use-effectiveness, K4(table)
  diabetes mellitus and parity, J132(table)
  diaphragm availability, H68(table)
  legal status of abortion, E29(table), E32, E33(table)
  legal status of voluntary sterilization, CD114(table)
  marketing of minipill, A64(table)
  oral contraceptives
    marketing, A15(table)
    prescription, E44
  price and sales of vaginal contraceptives, H48(table)
SOUTH AMERICA
  adolescent births, J161(table)
  cervical cancer, J135
  folate deficiency anemia, J130
  marital status of female adolescents, J164(table)
  maternal mortality and anemia, J131
  population per hospital bed and per physician, J71(table)
  postcoital estrogens, J141, J147
  postcoital progestogens, J147
    norgestrel, J141, J147
    quingestanol acetate, J147
SOUTH SEA ISLANDS
  folk methods of postcoital contraception, J142
SOUTH WEST AFRICA. See **NAMIBIA**.
SOUTHERN CALIFORNIA, UNIVERSITY OF
  training nonphysicians, J98
SOUTHERN RHODESIA
  birth rate, J207(table), J210(table)
SOVIET UNION. See **UNION OF SOVIET SOCIALIST REPUBLICS**.
SOYBEANS
  supply v. demand, J182-J183
SPADONI, L.
  pregnancy tests
    biologic, J115(table)
    immunologic, J119(table)
SPAIN, J194
  adolescent births, J161(table)
  age-specific fertility rate, J39(graph), J228(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  change in number of births, J219(figure)
  injectable contraceptives, K2
  labor force, J197
  legal status of abortion, E28, F61
  legal status of voluntary sterilization, CD114(table)
  oral contraceptives
    commercial supply, A9(table)
    marketing, A15(table)
    sales, A8(table)
  population per hospital bed, J71(table)
  population per physician, J71(table)
SPANISH SAHARA
  birth rate, J207(table), J210(table)
SPARK-GAP GENERATOR, M17, M27(table), M28(figures)
SPARKS, R.M., author, G1-G15, G17-G24
SPARROW, M.J.
  use-effectiveness of postcoital diethylstilbestrol, J145(table)
SPECULUM
  colpotomy, C33, C35, C36, C37(figure)
  culdoscopy, C69
  menstrual regulation, F12
  types, F38
  uterine aspiration, F31
SPEIDEL, J.J.
  demographic impact of acceptance and continuation rates, B37
  PG research and fertility control, G2
  reversibility, D57
  vasectomy research, D15-D16
SPELLACY, W.N.
  carbohydrate metabolism, A62
  orals and blood pressure, A42
SPERM ANTIBODIES. See also **AUTOIMMUNE RESPONSE**.
  fertility, D31-D32, D48
  occurrence, D48
  postvasectomy, D31-D32, D48
    incidence, D31(table)
    timing, D32(table)
  prevasectomy, D48
  types, D48
  vasectomy reversibility failure, D42
SPERM BANK, D55(chart)
  advantages and disadvantages, D52
  freezing techniques, D52
  sperm motility, D52
SPERM CAPACITATION
  frozen semen storage, D52
  progestogens, A55
SPERM COUNT
  epididymitis, D42
  method, D10
  postvasectomy, D9-D10
    causes of sperm appearance, D10
    reduction by irrigation, D10
    reduction by preoperative ejaculation, D10
  prevasectomy, D48
  vasectomy reversal
    vas anastomosis, D42, D43, D47, D49(table)
    vaso-epididymal anastomosis, D42
SPERM CRYOFREEZER
  frozen semen storage, D52
SPERM GRANULOMA
  postvasectomy, D5, M27
    prevention, D9
    recanalization, D10
SPERM MOTILITY
  following vas anastomosis, D49(table)
SPERM SEPARATION METHOD, I21. See also **SEX PRESELECTION**.
  accuracy, I25
  centrifugation, I25
  electrophoresis, I25
  froth flotation, I26
  in vitro technique, I25
  quinacrine staining, I75
  sedimentation, I25
  sperm motility, I25
  X-chromosome, I25-I26
  Y-chromosome, I25-I26
SPERM TRANSPORT, J142
  following vas anastomosis, D47, D48
  injectable progestogens, K3
  minipill, A55
  physiology, D47-D48
  postcoital progestogens, J148

SPERMATOGENESIS
  postvasectomy, D30, D47
  sex chromosomes, I22-I23
SPERMATOZOA
  aging and chromosomal abnormalities, I12
  life span, I3
SPERMEX VAS ELEVATOR, D12(figure)
SPERMICIDES. See **VAGINAL CONTRACEPTIVES**.
SPEROFF, L.
  PGs for pregnancy termination, G7(table)
SPETON
  active ingredients, H41(table)
SPHYGMOMANOMETER
  insufflation equipment, M10
SPILMAN, C.H.
  oviductal effects of PGs, G54
SPIRA RING, B44(figure)
  description, B44
  distribution, B44
  Japan, B44
  use-effectiveness, B44
SPIRAN W, B48(figure)
  description, B48
  distribution, B48
  use-effectiveness, B48
SPLEEN
  prostaglandins, G25, G26, G27
SPONGE TENTS, F89
SPONTANEOUS REANASTOMOSIS
  vasectomy, M27
SPOTTING, F51, F52
  minipill, A57
    selected studies, A58-A60(tables)
  postcoital quingestanol acetate, J148
SPRING COIL, B38, B45(figure)
  description, B45
  distribution, B45
  evaluation, B39
  insertion technique, B30
  performance, B33
  surface area related to pregnancy and removal rates, B34(figure)
  termination rate, B22(table)
  use-effectiveness, B32(table)
SPRING-LOADED CLIPS. See also **CLIPS**.
  advantages and disadvantages, C84
  compared with fulguration, C85(table)
  compared with Yoon band, C85(table)
  description, C83-C84
  failure rate, C83(table), C84
  laparoscopic application, C84(photo)
  reversal procedure, C84
  side effects, C84
  timing, C84
SQUAMOUS METAPLASIA
  oral contraceptives, A83, A84(table)
SQUIBB, E.R., AND SONS
  injectable contraceptives, K2
  marketing of chlormadinone acetate, A55
  marketing of Delalutin, K2
SQUIRE, W.
  BBT and menstrual cycle, I5
SRI LANKA
  age-specific fertility rate, J37(graph), J222(graph)
  birth rate, J23(figure), J29(table), J207(table), J218(figure), J239
  change in number of births, J219(figure)
  communication of family planning, J311(table)
  condom
    distribution, H10, H13
    importation costs, H5(table)
    promotion, H10
    shipments, H14(table), H15(table)
  Depo-Provera
    availability, K13(figure)
    IPPF distribution, K14
    use-effectiveness, K4
  diaphragm
    availability, H68(table)
    failure rate, H65(table), H66(table)
    use, H60
  distribution of contraceptives, J70(photo)
    evaluation, J84(table)
    newspaper advertising, J295-J296
    subsidized sale, J69, J75, J77
  factors influencing cervical cancer, J133(table)
  food supply, J244
  IUD acceptors, B27(table)
  legal status of abortion, E30, E34
  legal status of voluntary sterilization, CD78, CD79, CD89, CD114(table)
  marketing of contraceptives, A15(table), H48
  mortality rate, J244
  oral contraceptives
    lactation, J60(table)
    marketing, A15(table)
    new acceptors, A18(table)
    supplied by SIDA, A20(table)
    supplied by USAID, A21(table)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  population education, E42, E43(table)
  rubber plantations, H22
  total fertility rate, J214(table), J217(table)
  unemployment, J197
  use-effectiveness of Norigest, K4(table)
ST. CHRISTOPHER-NEVIS-ANGUILLA
  birth rate, J29(table)
ST. HELENA
  birth rate, J29(table), J207(table), J210(table)
ST. KITTS
  availability of Depo-Provera, K13(figure)
ST. KITTS-NEVIS
  age-specific fertility rate, J227(graph)
  birth rate, J21, J23(figure), J207(table), J218(figure)
  change in number of births, J219(figure)
ST. LUCIA
  age-specific fertility rate, J227(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J23(figure), J29(table), J207(table), J218(figure)
  change in number of births, J219(figure)
  new acceptors of vaginal contraceptives, H49(table)
ST. PIERRE AND MIQUELON
  age-specific fertility rate, J227(graph)
  birth rate, J29(table), J207(table)
ST. VINCENT
  age-specific fertility rate, J227(graph)
  availability of Depo-Provera, K13(figure)
  birth rate, J23(figure), J29(table), J207(table), J218(figure)
  change in number of births, J219(figure)
  condom shipments, H15(table)
STAINLESS STEEL RING, B44(figure)
  description, B44
  use-effectiveness, B44
  vas ligation, D5, D6(table)
STALLWORTHY, J.
  cervical dilatation
    degree, F86
    technique, F91(figure)
  perforation of retroverted gravid uterus, F90(figure)
  uterine aspiration, F28(table)
    complications, F33(table)
    equipment, F32(table)
    incidence and management of perforation, F35(table)
STANLEY, M.A.
  orals and cervical neoplasia, A81(table)
STANNOUS OCTOATE
  tubal occlusion, C88
STANSFIELD, M., A5(table)
STAPLES
  vasectomy, D7
STATE TEXTILE RESEARCH INSTITUTE (CZECHOSLOVAKIA), B47
STATZER, D.E.
  menstrual pattern changes with norgestrel minipill, A60(table)
STEDIRIL
  manufacture and marketing, A4(table)
STEINACH, E.
  vasectomy for rejuvenation, D2
STEINBERGER, E.
  chemical male sterilization, D15
  comparison of fresh and frozen semen, D52
  sperm motility of frozen semen, D52
STEPAN, J., author, CD57-CD132
STEPHENSON, B., E21(photo)
STEPTOE, P.C.
  equipment for laparoscopy, C6
  laparoscopic sterilization, C2(table)
    coagulation, C6, C8, C21
    complications, C19(table), C24
    electrocoagulation with division, C8(table)
    failure, C22(table)
    local anesthetic, C4(table)
    modification of Palmer technique, C6
    operative procedure, C7(table)
    postabortion, C23-C24
    postpartum, C21-C22, C23
    silastic plug for tubal occlusion, C90(photo, table)
    technique for pneumoperitoneum, C5(table)
    timing, C21-C22
STERILETTE, B24
STERILIZATION, COMPULSORY
  India, E48-E49, J237, J247
STERILIZATION, FEMALE, C1-C44, C73-C96. See also specific methods: **BAND STERILIZATION**, **CLIP STERILIZATION**, **FULGURATION**, **STERILIZATION, SEXUAL**, **TUBAL LIGATION**, **TUBAL OCCLUSION**, etc.
  defined, C1
  developing countries, D2
  equipment
    colpotomy, M23-M24(table)
    culdoscopy, M1, M24(table), M25(figure, table)
    laparoscopy, M1, M4(table), M5(figure, table), M6(figure, table), M7(figure), M8-M9(table), M10(figure), M11-M12(tables), M13(figures), M14-M15(tables), M16(table), M17(figure), M18-M19(figures, table), M20(figure)
    laparotomy, M23
    mini-laparotomy, M1, M20, M21(table), M22(table), M23(figure)
  experimental techniques, C45
  fibrosis, M20
  hemostasis, M20
  history, C1
  mortality, J258
  new acceptors
    Barbados, J16(table)
    Hong Kong, J13(table)
    India, J13(table)
    Indonesia, J13(table)
    Jamaica, J18(table)
    Malaysia, J14(table)
    Nepal, J14(table)
    Pakistan, J14(table)
    Singapore, J15(table)
    South Korea, J14(table)
    Sri Lanka, J15(table)
    Thailand, J15(table)
    Tunisia, J12(table)
    Venezuela, J19(table)
  nonphysicians, J97
  outpatient clinic, J72
  postabortion, F66
  reversibility, C8
  sources of funding, J270-J271(table), J274-J276(table)
  timing. See **INTERVAL STERILIZATION**
  US, H59(table)
STERILIZATION, MALE, D1-D20. See also **STERILIZATION, SEXUAL**; **VASECTOMY**.
  chemical occlusion, D15
  equipment
    vasectomy, M25(table), M26(table), M27(figure, table)
  outpatient clinic, J72
  sources of funding, J270(table), J274-J276(table)
  US, H59(table)
STERILIZATION, SEXUAL, CD1-CD132. See also **STERILIZATION, FEMALE**; **STERILIZATION, MALE**.
  attitudes, CD89, CD94
  bibliography, CD1-CD55
  China, F2
  consent, CD81, CD82, CD85, CD93-CD94
  demographic considerations, CD70
  effect on sexuality, CD63
  Egypt, A12(table)
  emergency provisions, M32

- equipment
  - addresses of selected manufacturers and distributors, M32
  - cleaning techniques, M28-M29
  - donor agencies, M2-M3
  - manufacturers, M3-M5
- family planning, CD64, CD76, CD90, CD93, J1
- Fiji, A12(table)
- Hong Kong, A12(table)
- human right, CD64, CD79, CD90, CD94
- international conference (1973), C25-C26
- legal aspects
  - Afghanistan, CD103(table)
  - Albania, CD103(table)
  - Algeria, CD103(table)
  - Argentina, CD103(table)
  - Australia, CD83, CD103(table)
  - Austria, CD80, CD81, CD103(table)
  - Barbados, CD103(table)
  - Belgium, CD80, CD104(table)
  - Bolivia, CD104(table)
  - Brazil, CD104(table)
  - Bulgaria, CD104(table)
  - Burma, CD78, CD104(table)
  - Burundi, CD104(table)
  - California, CD84, CD130-CD131
  - Cameroon, CD104(table)
  - Canada, CD82, CD83, CD105(table)
  - Canon Law, CD87
  - Central African Republic, CD105(table)
  - Ceylon. See **STERILIZATION, SEXUAL, legal aspects, Sri Lanka**
  - Chile, CD70, CD81, CD105(table)
  - Colombia, CD75, CD105(table)
  - Colombo, CD79
  - Connecticut, CD74
  - Costa Rica, CD77, CD105(table)
  - Czechoslovakia, CD68, CD69, CD70, CD85, CD105(table), CD126
  - Denmark, CD69, CD70, CD71, CD72, CD106(table)
  - Dominican Republic, CD106(table)
  - East Germany, CD70, CD107(table)
  - Eastern Europe, CD84-CD85
  - Ecuador, CD106(table)
  - Egypt, CD115(table)
  - Eire, CD106(table)
  - El Salvador, CD113(table)
  - Ethiopia, CD78, CD106(table)
  - Europe, CD75, CD82
  - Finland, CD70, CD106(table)
  - France, CD75, CD80, CD106(table)
  - Germany, CD73, CD78, CD81
  - Ghana, CD79, CD107(table)
  - Great Britain. See **STERILIZATION, SEXUAL, legal aspects, United Kingdom**
  - Greece, CD78, CD106(table)
  - Guatemala, CD77, CD107(table)
  - Haiti, CD107(table)
  - Honduras, CD70, CD78, CD79, CD89, CD93
  - Hungary, CD108(table)
  - Iceland, CD70, CD108(table)
  - India, CD70, CD78, CD79, CD89, CD93
  - Indonesia, CD82, CD108(table)
  - Iran, CD67, CD108(table)
  - Islamic law, CD86-CD87
  - Israel, CD108(table)
  - Italy, CD73, CD109(table)
  - Ivory Coast, CD109(table)
  - Jamaica, CD83, CD93, CD109(table)
  - Japan, CD69, CD70, CD89, CD91, CD109(table)
  - Jewish law, CD87
  - Jordan, CD109(table)
  - Kansas, CD74
  - Latin America, CD75, CD76, CD77, CD89
  - Lebanon, CD110(table)
  - Liberia, CD110(table)
  - Luxembourg, CD110(table)
  - Malagasy Republic, CD110(table)
  - Malawi, CD110(table)
  - Malaysia, CD78, CD79
  - Malta, CD110(table)
  - Mexico, CD80, CD111(table)
  - minimum age, CD91
  - Morocco, CD111(table)
  - Nepal, CD111(table)
  - Netherlands, CD111(table)
  - New Zealand, CD111(table)
  - Nicaragua, CD74, CD77, CD111(table)
  - Niger, CD111(table)
  - Nigeria, CD79, CD112(table)
  - North Carolina, CD68, CD71, CD89
  - Norway, CD70, CD112(table)
  - Pakistan, CD78, CD112(table)
  - Panama, CD70, CD112(table)
  - Paraguay, CD112(table)
  - Peru, CD112(table)
  - Philippines, CD82, CD113(table)
  - Poland, CD85, CD113(table)
  - Portugal, CD113(table)
  - Puerto Rico, CD67, CD113(table)
  - religious law, CD86-CD87
  - Romania, CD113(table)
  - Russia. See **STERILIZATION, SEXUAL, legal aspects, Union of Soviet Socialist Republics**
  - Saudi Arabia, CD113(table)
  - Scandinavia, CD89
  - Singapore, CD69, CD70, CD73, CD78, CD89, CD114(table), CD126-CD127
  - South Africa, CD114(table)
  - South Korea, CD70, CD77, CD89, CD93, CD109(table)
  - South Vietnam, CD74, CD116(table)
  - Spain, CD114(table)
  - Sri Lanka, CD78, CD79, CD89, CD93, CD114(table)
  - Sweden, CD70, CD71, CD81, CD114 (table)
  - Switzerland, CD81, CD114(table)
  - Tanzania, CD79, CD114(table)
  - Thailand, CD70, CD115(table)
  - Tunisia, CD115(table)
  - Turkey, CD73, CD115(table)
  - Union of Soviet Socialist Republics, CD76, CD115(table)
  - United Arab Republic. See **STERILIZATION, SEXUAL, legal aspects, Egypt**
  - United Kingdom, CD68, CD70, CD71, CD82, CD83, CD89, CD93, CD94, CD107(table), CD128, CD130
  - Uruguay, CD77, CD115(table)
  - US, CD115(table)
  - Utah, CD74
  - Venezuela, CD116(table)
  - Virginia, CD68, CD71, CD89, CD125
  - West Germany, CD67, CD69, CD70, CD71, CD72, CD78, CD89, CD93, CD94, CD107(table), CD128-CD130
  - Western Europe, CD84
  - Wisconsin, CD84
  - Yugoslavia, CD116(table)
  - Zaire, CD79(table)
  - Zambia, CD79, CD116(table)
- Mauritius, A12(table)
- Mexico, A12(table)
- Morocco, A12(table)
- new acceptors, A17(graph)
- Philippines, A12(table)
- prevalence in Japan, CD91
- Singapore, A12(table)
- sources of funding for equipment and projects, J270-J271(table)
- Taiwan, A12(table)
- Thailand, A12(table)
- therapeutic, CD63, CD64, CD90

STERILIZATION, VOLUNTARY, C61
- availability, E6
- Great Britain. Committee on the Working of the Abortion Act, E45
- international conference, E45, E48
- legal aspects, E6
  - Austria, E6(table)
  - Denmark, E6(table)
  - Iran, E6(table)
  - Philippines, E6(table)
  - selected countries, E44-E45, E48
  - Tunisia, E6(table)
- policy changes, E2
- Singapore, E42
- Sweden, E42

STERN, E.
- cervical dysplasia and diaphragm, H64-H65

STEVENSON, T.C.
- chemical tubal occlusion
  - contraindications, C89
  - methyl-2-cyanoacrylate, C86(table), C89
- proctoscope for mini-laparotomy, C54

STEWART, G.
- complication rate with colpotomy and vacuum aspiration, C41
- uterine aspiration, F28(table)
  - complications, F33(table)
  - incidence and management of perforation, F35(table)

STILBESTROL
- estrogenic activity, G47
- ovarian tumors, A91

STILBESTROL DIPHOSPHATE
- postcoital administration, J145(table)

STIM, E.M.
- menstrual regulation, F13(table), F51 (table)
  - bleeding, F15
  - complications, F52(table)
  - pregnancy tests, F12, F54(table)
  - procedure and equipment, F14(table)

STOKES, B., author, J177-J202

STONE, A.
- rhythm method in developing countries, I15

STOOT, J.E.G.M.
- tubal ligation, C77

STORZ, KARL, KG, C9
- address, M33
- culdoscopy equipment, M24(table)
- guarantee and service of sterilization equipment, M30(table)
- laparoscopy equipment
  - electrosurgical generators, M15(table)
  - fiberoptic projectors, M9(table)
  - laparoscopes, M4(table), M5(table), H6(photo)
  - teaching attachments, M6(table), M10 (photo)
- uterine manipulation devices, M22(table)

STRAUSZ, I.K.
- uterine aspiration, F28(table)
  - complications, F33(table)
  - equipment, F32(table)
  - incidence and management of perforation, F35(table)
  - local anesthesia, F29(table), F30(table)
  - postoperative medication, F29(table)
  - preoperative medication, F29(table)

STRESS
- physiological effects, J190

STRITTMATTER, I.P.
- diagnostic curettage, F11

STRODE, J.E.
- unilateral vas anastomosis, D42, D45 (table)

STROKE
- oral contraceptives, A2

STRYCHNINE, A30

STUART-WEBB, I., A5(table)

STUBBLEFIELD, P.G.
- midtrimester abortions with laminaria, F94
- pregnancy termination with laminaria and PGs, G59

STUBBS, F.
- mini-laparotomy
  - analgesia, C55
  - bladder injury, C58
  - electrocoagulation, C56
  - incision closure, C56
  - local anesthesia, C54
  - operative procedures, C55

STYCOS, J.
- radio campaign in Colombia, J302

SUCCINYLCHOLINE, C3(table), C32(table)
- laparoscopic sterilization, C4

SUCKLING. See also **LACTATION**
- factor in lactation continuation, J55, J59
- prolactin serum level, J62

SUDAN, J194
- age-specific fertility rate, J225(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J210 (table)
- condom shipments, H15(table)
- legal status of abortion, E29(table)
- marketing, A15(table)
- orals supplied by SIDA, A20(table)
- population growth, J188

SUDOMO, S., J101(table)
SUGIMOTO, O.
- hysteroscopic fulguration, C82(table)

SULFUR
- latex condoms, H23

SUMATRA
- folk barrier methods, H58

SUN, T.H.
- duration of postpartum amenorrhea, J57(table)

SUNDARAM, C.
- general health after vasectomy, D34(table)

SUNNEN, J.
- contraceptive foam, H40

SUPPOSITORY. See also **VAGINAL CONTRACEPTIVES**
- active ingredients, H41(table), H43(table)
- duration of spermicidal effectiveness, H43(table)
- mechanism of action, H40
- mode of application, H43(table)
- packaging, H43(table)
- price and sales of selected products, H48(table)
- use-effectiveness, H44, H45(table)

SURFACE ACTIVE AGENTS
- mode of action, H42
- vaginal contraceptives, H41(table)

SURGICAL ERROR
- vasectomy, D28(table), D29(graph)

SURINAM
- availability of Depo-Provera, K13(figure)
- birth rate, J23(figure), J29(table), J207(table), J210(table)
- condom shipments, H15(table)
- marketing of oral contraceptives, A15(table)

SUSSEX, UNIVERSITY OF (ENGLAND)
- measuring force of cervical dilatation instruments, F87

SUTTON, P.M.
- orals and breast disease, A45, A46

SVENNERUD, S.
- laparoscopic sterilization, C2(table)
  - electrocoagulation with division and biopsy, C8(table)
  - equipment, C11-C12
  - operative procedure, C7(table)
  - postabortion, C24

SWARTWOUT, J.R.
- sperm diversion device, D57

SWAZILAND
- age-specific fertility rate, J225(graph)
- birth rate, J29(table), J207(table), J210(table)
- diaphragm availability, H68(table)
- legal status of abortion, E29(table)
- marketing of oral contraceptives, A15(table)

SWEDEN
- abortion
  - among adolescents, J169
  - incidence in midtrimester, F66
  - legal status, E2, E7, E29, E30(table), E47
  - mortality, F37(table)
  - women under 20, J171(table)
- adolescent births, J161(table)
- advertisement for contraceptives, H11
- age-specific fertility rate, J3(graph), J32 (graph), J39(graph), J228 (graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- condom
  - distribution to developing countries, H13
  - promotion, H2
  - standards, H25, H26(table), H27, H29(table)
  - use, H4
- contraceptive usage, H4(table)
- Depo-Provera
  - availability, K13(figure)
  - continuation rate, K8(table)
- diaphragm
  - availability, H68(table)
  - quality control, H68
  - standards, H67
  - testing, H68(photo), H69(photo,table)
- fertility decline, J22
- IUD
  - expulsion and removal rates, B8
  - legal restriction of copper IUD, B18
  - postabortion insertion, B8, B29
  - use, B19
- marketing of minipill, A64(table)
- National Board of Health and Welfare, H68
- oral contraceptives
  - lactation, J61(table)
  - marketing, A15(table)
  - withdrawal bleeding, A38
- out-of-wedlock births, J160(figure)
- PG research, G11, G18, G19, G20, G21, G22
- population, F7(table)
- population assistance funds. See **SWEDISH INTERNATIONAL DEVELOPMENT AUTHORITY**
- premarital sex among adolescents, J159
- sales of vaginal contraceptives, H48
- sex education, J171
- Swedish Standards Committee, H30
- training nonphysicians, J95(table), J105(table)
- venereal disease rate, H32
- voluntary sterilization, E6
  - legal status, CD70, CD71, CD81, CD114(table), E42, E45(table), E46-E47, E48

SWEDISH INTERNATIONAL DEVELOPMENT AUTHORITY (SIDA)
- address, J284
- condom distribution to developing countries, H2, H14(table), H24
- Depo-Provera, K14
- funding of family planning activities, J266, J270-J271(table), J272, J275(table)
- supply of orals, A17, A63
  - selected countries, A20(table)

SWEDISH MEDICAL ASSOCIATION
- conference host, E19

SWEENEY, W.O., author, J289-J317
SWELLING
- vasectomy, D26

SWITZERLAND
- age-specific fertility rate, J39(graph), J229(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- diaphragm availability, H68(table)
- legal restriction of copper IUDs, B18
- legal status of abortion, E29(table), E30, E34
- legal status of voluntary sterilization, CD81, CD114(table)
- marital status of female adolescents, J164(table)
- marketing of minipill, A64(table)
- marketing of oral contraceptives, A15 (table)
- migration, J197
- PG research, G20, G23
- population trends, J240
- uterine aspiration equipment, F41

SWYER, G.I.M.
- potency of progestogens in women, A37
  - with estrogen, A37

SYMPATHETIC NERVOUS SYSTEM
- injured by vasectomy, D47-D48

SYMPOSIUM ON LAW AND POPULATION, TUNIS, 1974
- statement on family planning education, J171

SYN-A-GEN
- active ingredients, H41
- price and sales, H48(table)
- use-effectiveness, H45

SYNCOPE
- IUD insertion, B30
- laminaria tent insertion, F39(table)

SYNTEX CORP., B38
- manufacture of Norinyl, A38
- marketing of minipill, A54-A55, A64(table)
- norethindrone marketing, A5
- oral contraceptives, A4(table), A5(table)
  - estrogen-free, A16
  - low-estrogen, A37(table)
  - sales to USAID, A23(table)
  - worldwide marketing, A13-A15(tables)
- progesterone production, A32
- use-effectiveness of Ypsilon, B32(table)

SYNTHETASE, G26(figure), G27
SYNTOCINON, F29(table), G49
SYPHILIS. See **VENEREAL DISEASE**.
SYRIA
- age-specific fertility rate, J27(graph), J223(graph)
- birth rate, J29(table), J207(table), J210 (table)
- family planning program, J26
- legal status of abortion, E29(table)
- marketing of oral contraceptives, A15 (table)
- population growth, J189
- total fertility rate, J216(table)

SYRINGE, F55(figure), F59(figure)
- menstrual regulation, F51(table)
  - advantages and disadvantages, F55
  - failure rate, F54

SZONTAGH, F.E., B45
- postcoital dienestrol, J144

SZONTAGH, B38, B45(figure)
- description, B45
- Hungary, B45
- use-effectiveness, B45

T

TS-88. See **P-METHANYLPHENYL-POLYOXYETHYLENE**
TACHYCARDIA
- local anesthesia, F31
- PG administration, G3

TACHYPHLAXIS
- PG administration, G60

TAIT'S UTERINE DILATOR, F88(figure)
TAIWAN
- abortion
  - impact on fertility, E38
  - legal status, E34, E35(table)
  - practice, E33, E35(table)
  - unmarried women, J165
- acceptors, B26, J15(table)
  - client revisits, J20(table)
  - IUD, B27(table)
  - orals, A18(table)
- adolescent births, J159, J161(table)
- age-specific fertility rate, J3(graph), J5(graph), J25(graph), J37(graph), J222(graph)
  - cumulative fertility, J33(graph)
- birth rate, J21, J32(figure), J29(table), J207(table), J218(figure), J239
- breast-feeding, J54
- change in number of births, J219(figure)
- condom shipments, H15(table)
- continuation rates
  - condom, J82
  - IUD, B26, B33(table)
  - orals, J82
- contraceptive practice, A12(table), B21, B37
- copper-T
  - expulsion rate, B10
  - pregnancy rate, B10
- culdoscopy, C61
  - training, C62
- distribution of contraceptives, J70, J83 (figure), J165
  - evaluation, J84(table)
  - household, J82
- duration of postpartum amenorrhea, J56, J57(table)
- experimental study of copper IUD, B18
- family planning, J2
  - emphasis on IUDs, J2
  - mass communication techniques, J291, J292-J293(table), J296, J298, J300-J301, J304, J306, J312(table)
  - program, B28, E2, J24, J324
- fertility rate, J28
- incentive programs, E8(table)
- oral contraceptives
  - marketing, A13(table)
  - new acceptors, A18(table)
  - supplied by USAID, A21(table)
- out-of-wedlock births, J160(figure)

  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  training
    colpotomy, C43
    culdoscopy, C62
    nonphysicians, J94(table), J103(table)
  tubal ligation, C75
  voluntary sterilization, E6, E48
TAMADA, T.
  IUD mode of action, B25
TAMASKAR, K.P.
  sterilization by colpotomy, C31(table)
    equipment, C36(table)
    postpartum, C43
TANGANYIKA. See **TANZANIA**.
TANN, G.
  slide test modifications, J119
TANTALUM HEMOCLIP (WECK). See **HEMOCLIP**.
TANZANIA
  age-specific fertility rate, J34(graph), J225(graph)
  availability of Depo-Provera, K13(figure)
  average births per woman, J192(table)
  birth rate, J29(table), J207(table), J210 (table)
  condom shipments, H15(table)
  diaphragm availability, H68(table)
  early marriage, J158
  legal status of abortion, E32
  legal status of voluntary sterilization, CD79, CD114(table)
  oral contraceptives
    marketing, A15(table)
    supplied by SIDA, A20(table)
    supplied by USAID, A21(table)
  overgrazing, J188
  training nonphysicians, J94(table), J104(table)
TAPPAN, J.G.
  sterilization by colpotomy, C31(table)
    complications, C40(table)
    failure, C39(table)
    fimbriectomy, C33(table)
    preoperative medication and anesthetic, C32(table)
TARTARIC ACID, H41(table)
TATUM, H.J.
  copper IUD
    human toxicity, B17
    postcoital insertion, J150
    pregnancy rate, B10
    "sleeve" technique, B4
  copper-T IUD, B43
    development, B4
    expulsion, pregnancy, removal, and continuation rates, B6(table), B11(table)
TAUBER, A.S.
  vasectomy
    complications, D28(table)
    technique, D7(table), D28(table)
TAYLOR, C., author, E19–E24, E21(photo)
  maternal health services, E20
  technology and culture, E20
  use-effectiveness of contraceptive foam, H45(table)
  use-effectiveness of contraceptive jelly, H45(table)
TAYLOR, G.S., E21(photo)
TAYLOR, H.C., JR.
  silastic tubal occlusion, C88
TE LINDE, R., J41
TEACHERS COUNCIL OF THAILAND
  contraceptive distribution, J81
TEALE FORCEPS
  menstrual regulation, F12
TEFLON PLUG
  tubal occlusion, C91
TEJUJA, S.
  norgestrel minipill
    continuation, A62(table)
    menstrual pattern changes, A60(table)
  use-effectiveness of copper-7 IUD, B32 (table)
TELEPHONE
  family planning communication, J289
    Philippines, J291
    South Korea, J290
    Taiwan, J291
    US, J291
TELEVISION
  promotion of family planning, J303-J305
TEMMLER-WERK, H41(table)
TENACULUM
  cervical injuries, F85, F86, F90
  colpotomy, C33, C35
  uterine aspiration, F31
    controversy, F38
TENNESSEE
  heart disease and air pollution, J183-J184
  recordkeeping for client identification, J325
TERRORISM, J193
TESTIS
  diagnosis of malignancy by HCG level, J113-J114
  postvasectomy, D30
  sex preselection theory, I22
  sperm production and chromosomes, I23
TESTOSTERONE
  postvasectomy implants, D30
  postvasectomy level, D31
TETANUS
  vasectomy, D28
TETER, J.
  estrogen use in postmenopause
    breast cancer, A77(table)
    endometrial cancer, A86(table)
TEXAS, UNIVERSITY OF
  PG research, G54
  training nonphysicians, J98
THAILAND
  abortion
    adolescents, J169
    legal status, E29(table), E34, E35(table)
    practice, E35(table)
  age-specific fertility rate, J222(graph)
  attitude toward physicians, K11
  average births per woman, J129(table)
  birth rate, J29(table), J207(table), J209 (table), J239
  clip sterilization, C47(table)
  condom
    distribution, H5(table), H9, H13, H16
    importation costs, H5(table)
    manufacture, H5, H23, H74
    shipments, H15(table)
    standards, H25
    use, H9
  continuation rates for IUDs, orals, and Depo-Provera compared, K8(graph)
  contraceptive practice, A12(table)
  contraceptive usage, H4(table)
  copper-T
    expulsion rate, B10
    pregnancy rate, B10
    termination rate, B22(table)
  culdoscopy, C61
    complications, C66(table), C67(table)
    training, C70
    tubal occlusion, C65(table), C68(table)
  deforestation, J193
  Depo-Provera
    availability, K13(figure), K14
    continuation rate, K7(table), K8(graph, table)
    distribution, K14
    requirements for acceptors, K12, K13
    restricted use, K12
    use-effectiveness, K4(table), K5(table)
  diaphragm
    availability, H68(table)
    training nonphysicians, H67
  distribution of contraceptives, J70, J81, J92
  experimental study of copper IUD, B18
  family planning communication, J296
  folklore about amenorrhea, K8
  health services, J195
  infant mortality, J259
  injectable progestogens
    administered by nonphysicians, J92
    cost, K14
  IUD
    acceptors, B27(table)
    continuation rate, K8(table)
    insertion by nonphysicians, J96
  lactation
    effect of combined orals, J60(table)
    effect of progestogen-only contraceptives, J63(table)
  laparoscopic sterilization, C2, C14
    training, C2, C13, C14
  legal status of voluntary sterilization, CD70, CD115(table)
  marketing of minipill, A64(table)
  maternal mortality, J128(figure), J130 (table), J254(table), J255(table)
  mini-laparotomy, C53
    complication rate, C57
    training, C59
  Ministry of Health
    address, J103(table)
    training nonphysicians, J94(table), J103(table)
  new acceptors, A17, A18(table), J15(table)
  oral contraceptives
    continuation rate, K8(graph)
    distribution, J92
    marketing, A15(table)
    new acceptors, A17, A18(table)
    supplied by SIDA, A20(table)
    supplied by USAID, A21(table)
  percentage of married female acceptors under 20, J170(table)
  percentage of married women of reproductive age under 20, J170(table)
  PG research, G20, G23
  population growth rate, J193
  population per hospital bed, J71(table)
  population per physician, J71(table)
  population policy, E41, E42, E43(table), E46
  side effects of norlestrin, A19
  total fertility rate, J215(table), J216, J217(table)
  training in colpotomy, C43
  training nonphysicians, J94(table), J98, J103(table)
  use-effectiveness of Norigest, K4(table)
  vaginal contraceptives, H48
    price, H48(table)
  vasectomy
    general health, D34(table)
    sexual behavior, D35(table)
  water supply, J196–J197
  World Fertility Survey data, J216
  Yoon band sterilization, C85
THALAMONAL. See **DROPERIDOL**.
THAMBU, J.A.M.
  culdoscopy
    operative medication, C63(table)
    postoperative complications, C67 (table)
    preoperative medication, C63(table)
    tubal occlusion, C65(table)
THEORETICAL EFFECTIVENESS, H32, H44, H46
  calendar rhythm method, I10
    defined, I8–I9
  minipill, A56(table)
  oral contraceptives, A35
THERMAL POLLUTION
  climatic effects, J187
THEMOCOAGULATION, M16, M27(table)
THIOPENTAL SODIUM, C3(table), C32(table)
THOMAS, D.B.
  orals and cervical neoplasia, A44(table), A82(table)
THOMPSON, B.
  laparoscopic sterilization
    complications, C19(table)
    failure, C22(table)
    training, C13
THORSTEINNSON, V.T.
  equipment for colpotomy, C36(table)
THREE-BURN TECHNIQUE
  laparoscopic fulguration, C80
THROMBOEMBOLISM
  colpotomy, C42
  diethylstilbestrol, J147
  minipill, A54, A61–A62
  oral contraceptives, A2, A12, A41, A42, A62
    incidence among users and nonusers, A31(table)
    selected studies, A41(table)
THROMBOPHLEBITIS
  induced by sepsis, J137(table)
  laparoscopic sterilization, C23(table)
  vasectomy, D31

THYROTROPIN RELEASING HORMONE, J52(table)
- anovulatory effect, J62
- postpartum amenorrhea and breast-feeding, J50
- prolactin serum level and lactation, J62

THYROXINE
- lactation, J52(table)

TIETZ, N.W.
- pregnancy tests
  - biologic, J115(table)
  - immunologic, J118(table), J119(table)
- reliability of hemagglutination tube tests, J117

TIETZE, C.
- abortion
  - adolescents in midtrimester, J170
  - complication rates, F31
  - maternal mortality, E28, F37, J138
- calendar rhythm method, I10, I11(table)
- cervical cap, H70, H71
  - discontinuation, H71(table)
- colpotomy preferred to laparotomy after abortion, C41
- condom
  - manufacturing machine, H23
  - use-effectiveness, H29, H32, H33(table)
- diaphragm
  - failure, H65(table), H66(table)
  - theoretical effectiveness, H65
- IUD
  - comparison of types, B25
  - continuation rates, B14
  - copper, B5
  - reinsertion after expulsion, B34
  - use-effectiveness, B32(table)
- use-effectiveness
  - condom, H29, H32, H33(table)
  - foam, H45(table), H46
  - jelly, H45(table)
  - Lippes Loop, B32(table)
  - Saf-T-Coil, B32(table)
- uterine aspiration, F28(table)
  - complications, F33(table)
  - incidence and management of perforation, F35(table)

TIETZE-POTTER LIFE TABLE METHOD. See **LIFE TABLE ANALYSIS**.

TIMONEN, H.
- hysterographic studies of IUD embedding, B12

TINCKLER VASECTOMY CLAMP, D11(figure)

TODA (INDIA)
- folk methods for sex preselection, I22

TOGO
- age-specific fertility rate, J225(graph)
- birth rate, J29(table), J207(table), J210 (table)
- marketing of oral contraceptives, A15 (table)

TOLOR, A.
- psychosocial aspects of rhythm method, I13

TONGA
- average births per woman, J129(table)
- birth rate, J29(table), J207(table), J210 (table)
- use-effectiveness of cervical mucus method, I11(table), I12

TONSILLECTOMY
- mortality, E27(graph)

TOPASEL
- ingredients, K2
- marketing, K2

TOPICAL CONTRACEPTIVES. See **VAGINAL CONTRACEPTIVES**.

TOPPOZADA, M.
- cervical dilatation with PGF$_2\alpha$ analogue, G68(table)
- PGs for pregnancy termination, G8(table)

TOTAL FERTILITY RATE (TFR). See **FERTILITY RATE**.

TOXEMIA (PREGNANCY). See **ECLAMPSIA**; **PREECLAMPSIA**.
- contraindication for laparoscopic sterilization, C23

TRADITIONAL BIRTH ATTENDANTS. See also **INDIGENOUS MEDICAL PRACTITIONERS**.
- distribution of orals, J92
- seminar, J92

TRADITIONAL WORKERS. See also **INDIGENOUS MEDICAL PRACTITIONERS**.
- definition, J89
- distribution of orals, J92
- training in vasectomy, J97, J98

TRAINING
- colpotomy, C43
- culdoscopy, C70
- fertility control, C2, C13, J41-J45
  - USAID, F20
- film on mini-laparotomy, M20
- laparoscopic sterilization, C2-C3, C25
  - Costa Rica, C14
  - El Salvador, C13
  - Ghana, C2, C13
  - Hong Kong, C14
  - India, C2, C14
  - Malaysia, C14
  - Nepal, C13
  - Panama, C13, C14
  - schools in the US, C2, C13
  - Singapore, C14
  - Thailand, C2, C13, C14
- menstrual regulation, F20, F61-F62
- mini-laparotomy, C59
- nonphysicians
  - diaphragm fitting, H67, J92-J93
  - distribution of contraceptives, J72-J73, J90-J92
  - family planning, J89-J108
  - injectable contraceptives
    - administration, J92
  - IUD insertion, B28, J93, J96
  - pregnancy termination, J96-J97
  - programs, J94-J95(table), J98, J101-J108(table)
  - tubal ligation, J97
  - vasectomy, J97-J98
- outpatient female sterilization, C26-C27
- physicians in family planning, B26
  - culdoscopy, C69-C70
- sources of funding assistance, J274-J276(table)

TRAISSAC, R.
- use-effectiveness of temperature rhythm method, I11(table)

TRALL, R.T.
- fertile period identification, I3(table)

TRAUMA
- induration, C49
- menstrual regulation, F16, F17

TREDWAY, D.R.
- menstrual regulation with PGs, G59(table)

TRELOAR, A.E.
- menstrual cycle variations, I10
- menstrual intervals, I10(graph)

TRENDELENBURG POSITION
- advantages in laparoscopy, C6
- colpotomy, C34
- disadvantages in pneumoperitoneum, C18
  - hiatal hernia, C18
- general anesthesia administration, C4, C33
- mini-laparotomy, C54

TRICOMONIASIS
- menstruation disorders, K6

TRIFLUPROMAZINE, C32(table)

TRIFLUPROMAZINE HYDROCHLORIDE, C35

TRINIDAD AND TOBAGO
- adolescent births, J161(table)
- age-specific fertility rate, J3(graph), J6(graph), J25(graph), J36(graph), J222(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- condom shipments, H14(table), H15(table)
- family planning program, J24
- fertility, J4
- marketing of minipill, A64(table)
- new acceptors, A18(table), J19(table)
- oral contraceptives
  - marketing, A15(table)
  - new acceptors, A18(table)
  - supplied by SIDA, A20(table)
- total fertility rate, J215(table), J216, J217(table)
- training in culdoscopy, C70
- training nonphysicians, J94(table), J107(table)
  - diaphragm fitting, H67

TROCAR
- laparoscopy, M7-M9, M10(figure)
- maintenance and repair, M29

TROCAR SLEEVE, M7-M9, M10(figure)
- maintenance and repair, M29

TROPHOBLASTIC DISEASES. See also **HYDATIDIFORM MOLE**.
- diagnosis, J118
  - HCG level, J113
- radioreceptorassay, J121
- tumor, A88

TROWBRIDGE, J.W.
- mass media campaign in Jamaica, J297

TRUAX'S MODIFIED ELLINGER DILATOR, F89(figure)

TRYPSINCHYMOTRYPSIN
- therapeutic use, D27

TSAI, J.
- family planning promotion in Taiwan
  - radio, J300
  - television, J304

T'SAI, K.T.
- suction with curettage, F27

TUBAL HOOKS, M20

TUBAL LIGATION
- abortion, C43
- advantages and disadvantages, C74
- culdoscopy, C64, C65(table)
- definition, C74
- equipment, J281(photo), J282, M24
- failure rate, C74
- history, C74
- India, C74
- Jamaica, CD83
- mortality, C17, E27(graph)
- Netherlands, C74
- performed by nonphysicians, J97
  - training programs, J94(table)
- reversibility, C74
- techniques, C33(table), C34, C74-C78, C75(figure), C76(table)
  - ligation and crushing, C74-C75
  - ligation, division, and burial, C75
  - ligation and resection, C75-C77
  - ligation, resection, and burial, C78
- US, C74

TUBAL OCCLUSION. See also **FIMBRIOTEXY**; **SOLID PLUG TUBAL OCCLUSION**; **TUBAL OCCLUSION, CHEMICAL**.
- clips, M18-M19(photo, table), M20
- complications, C73
- culdoscopy, C64, C65(table)
  - failure rate, C68(table)
- electrocoagulation, C56, M16-M20
- laser, C91
  - advantages and disadvantages, C91
  - Colombia, C91
- reversibility, C73
- route of approach, C73
- technique, C73, M18-M19(table)
- thermocoagulation, M16(table)

TUBAL OCCLUSION, CHEMICAL, C76(table), C86-C89. See also **TUBAL OCCLUSION**.
- administration, C86
- advantages and disadvantages, C87
- Chile, C87
- gelatin-resorcinol-formaldehyde effectiveness, C89
  - mode of action, C89
  - reversibility, C89
- India, C87
- methyl-2-cyanoacrylate
  - advantages and disadvantages, C89
  - complications, C89
  - contraindications, C89
  - dosage, C89
  - effectiveness, C89
- Mexico, C87
- mode of action, C86
- quinacrine
  - advantages and disadvantages, C87
  - complications, C87
  - dosage, C87
  - effectiveness, C87
  - reversibility, C87
  - route of administration, C87, C88 (figure)
- silastic
  - advantages and disadvantages, C88
  - dosage, C88
  - effectiveness, C88

    - reversibility, C88
  - silver nitrate
    - disadvantages, C88
    - effectiveness, C88
    - history, C87–C88
  - suggested criteria, C87
  - US, C87, C88, C89
  - use-effectiveness in selected studies, C86(table)
  - West Germany, C89
- **TUBAL PATENCY**
  - test by culdoscopy, C62
- **TUBAL RING APPLICATORS**, M20
- **TUBE TEST**. See also **PREGNANCY TESTS, IMMUNOLOGIC**.
  - availability, J116
  - effects of vibration, J118
  - hemagglutination inhibition, J112–J113
    - available types, J116
    - do-it-yourself test, J121
    - mode of action, J116
  - latex agglutination inhibition, J113, J116
  - mode of action, J111–J112, J116
  - reliability, J117
  - sensitivity, J117
  - storage, J118
- **TUNISIA**
  - abortion
    - impact on population growth, E38
    - legal status, E11, E29, E30, E32
    - need for trained personnel, E38
    - women under 20, J171(table)
  - adolescent births, J161(table)
  - age-specific fertility rate, J3(graph), J34(graph), J225(graph)
  - availability of Depo-Provera, K13(figure)
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure), J239
  - change in number of births, J219(figure)
  - colpotomy, C31(table)
  - condom shipments, H14(table), H15(table)
  - estimated population, E30(table)
  - family planning, E2, E3(table), J206
  - National Office for Family Planning and Population, E46
    - address, J105(table)
    - training nonphysicians, J94(table), J105(table)
  - new acceptors, A18(table), J12(table)
  - oral contraceptives
    - marketing, A15(table)
    - new acceptors, A18(table)
    - nonprescription refills, E43
    - supplied by USAID, A21(table)
  - out-of-wedlock births, J160(figure)
  - percentage of married female acceptors under 20, J170(table)
  - percentage of married women of reproductive age under 20, J170(table)
  - population, F7(table)
  - population policy, E46
    - training nonphysicians, J94(table), J105(table)
      - diaphragm fitting, H67
    - voluntary sterilization, E2, E6(table)
      - legal status, C[illegible] CD115(table)
- **TUOHY NEEDLE**, C52
  - instillation of urea, F76
- **TUPELO**, F88(figure), F89
- **TURKEY**
  - age-specific fertility rate, J37(graph), J225(graph)
  - birth rate, J29(table), J207(table), J209 (table)
  - condom
    - distribution, H5(table), H16
    - importation costs, H5(table)
    - shipments, H14(table)
  - experimental study of copper IUD, B18
  - IUD acceptors, B27(table)
  - IUD continuation rate, B33(table)
  - labor force, J197
  - legal status of abortion, E29(table), J164, J165
  - legal status of voluntary sterilization, CD73, CD115(table)
    - grounds, CD73
  - marital status of female adolescents, J164(table)
  - new acceptors, A18(table), J15(table)
  - oral contraceptives
    - commercial supply, A9(table)
    - marketing, A15(table)
    - new acceptors, A18(table)
    - sales, A8(table)
    - supplied by SIDA, A20(table)
  - percentage of married female acceptors under 20, J170(table)
  - percentage of married women of reproductive age under 20, J170(table)
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - vaginal contraceptives, H48
- **TURKS AND CAICOS ISLANDS**
  - birth rate, J29(table), J207(table), J210 (table)
- **TURNBULL, A.C.**
  - PGE in labor, G49
  - physician attitude toward fertility management, E20
- **TWYMAN, E.J.**
  - vas anastomosis, D42
- **TYLER, E.T.**
  - early clinical testing of orals, A32
  - frozen semen storage, D52
  - menstrual pattern changes with norgestrel minipill, A60(table)
  - use-effectiveness
    - Depo-Provera, K4(table)
    - vaginal contraceptives, H45(table)
- **TYPHOID**
  - water pollution, J184
- **TYRER, L.**
  - IUD mortality, B17
- **TYROSINE**, G26
- **TYSON, J.E.**
  - postpartum amenorrhea and breastfeeding, J50

U

- **U.C.G.**
  - cost, J118(table)
  - diagnostic capability, J118(table)
  - sensitivity, J118(table)
- **U.C.G. LYPHOTEST TUBE**, J116
  - cost, J120(table)
  - sensitivity, J120(table)
  - storage, J118
  - time required, J120(table)
- **U.C.G. SLIDE**, J116, J117(photo)
  - cost, J120(table)
  - sensitivity, J120(table)
  - time required, J120(table)
- **U.C.G. TITRATION**
  - quantifying HCG activity, J118
- **U.C.G. TUBE**, J116(photo)
  - quantifying HCG activity, J118
- **UCHIDA, H.**
  - laparotomy, C54
  - tubal ligation technique, C78
- **UCHIDA TECHNIQUE**, C75(figure), C76 (table), C78
  - advantages and disadvantages, C78
  - effectiveness, C78
  - Japan, C78
  - US, C78
- **UELAND, K.**
  - cervical dilatation with PGs, F95
- **UGANDA**
  - age-specific fertility rate, J223(graph)
  - birth rate, J29(table), J207(table), J210 (table)
  - condom
    - importation costs, H5(table)
    - shipments, H15(table)
  - cost of injectable progestogens, K14
  - Depo-Provera
    - availability, K13(figure), K14
    - IPPF distribution, K14
  - legal status of abortion, E29(table)
  - marital status of female adolescents, J164(table)
  - oral contraceptives
    - marketing, A15(table)
    - new acceptors, A18(table)
    - supplied by SIDA, A20(table)
  - paramedical personnel for IUD insertion, B28
  - PG research, G19, G20, G21, G23
  - population, F7(table)
  - total fertility rate, J216(table)
  - vaginal contraceptives, H49
- **ULCERS**
  - prostaglandins, G1
- **UNALMES**
  - ingredients, K2
  - marketing, K2
- **UNEMPLOYMENT**. See also **LABOR FORCE**.
  - economic growth, J197–J198
  - psychological aspects, J198
- **UNILEVER**
  - PG synthesis, G2
- **UNION OF SOVIET SOCIALIST REPUBLICS (USSR)**
  - abortion
    - legal status, E30(table), E36(table), F1, F2, F4–F5
    - methods, F66
  - adolescent births, J159, J161(table)
  - age-specific fertility rate, J39(graph), J229(graph)
    - legalized abortion, J10(graph)
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  - change in number of births, J219(figure)
  - early marriage, J158
  - estimated population, E36(table)
  - housing shortage, J186
  - legal status of voluntary sterilization, CD76, CD115(table)
    - socialist criminal law, CD84–CD85
  - marital status of female adolescents, J164(table)
  - oral contraceptives
    - availability, A2
    - marketing, A15(table)
  - percentage of population under 20, J168(figure)
  - population, F7(table)
  - population growth, J240–J241
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - population policy, J241
  - premarital sex among adolescents, J159
  - uterine aspiration equipment, F41
  - wheat supplies, J244
- **UNITED ARAB EMIRATES**
  - birth rate, J29(table), J207(table), J210 (table)
  - marketing of oral contraceptives, A15 (table)
- **UNITED ARAB REPUBLIC**. See **EGYPT**.
- **UNITED HUNGARIAN RUBBER FACTORIES**, H19
- **UNITED KINGDOM**
  - abortion, F7(table)
    - adolescents, J169
    - legal status, E29, E30(table), E34, E36(table)
    - maternal mortality, E36, E37, F37 (table)
    - methods, F66
    - midtrimester, F66
    - morbidity, E37
  - adolescents
    - abortion, J169
    - contraception, J166
    - premarital sex, J159
  - age-specific fertility rate, J3(graph) J38(graph), J229(graph)
  - availability of Depo-Provera, K13(figure)
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  - change in number of births, J219(figure)
  - clip sterilization, C47(table)
  - cod war, J194
  - colpotomy training, C43
  - Committee on Safety of Medicines. See **BRITISH COMMITTEE ON SAFETY OF MEDICINES**.
  - condom
    - distribution, H5, H13
    - manufacture, H5, H23
    - standards, H25, H26(table), H27, H28, H29(table)
    - use-effectiveness, H33(table)
  - contraceptive usage, H4(table), H47
  - copper IUDs, B18

  - diabetes mellitus and parity, J132 (table)
  - diaphragm
    - availability, H68(table)
    - distribution, H67
    - manufacture, H68(table), H72
    - standards, H67
    - testing, H67(photo)
    - use, H58, H59
    - use-effectiveness, H65(table), H66(table)
  - estimated population, E36(table)
  - factors influencing cervical cancer, J133(table)
  - Family Planning Amendment Act (1972), CD89, CD128
  - family planning policy, E1, E3(table), E4 (table)
  - housing needs in London, J186
  - imported minerals, J194
  - legal rights of unwed mothers, J163
  - legal status of voluntary sterilization, CD63, CD82-CD83, CD89, CD107 (table)
  - manufacturers of sterilization equipment, M2
  - marketing of minipill, A55, A64(table)
  - maternal mortality, E36, E37, F37 (table), J128(figure)
  - menstrual regulation, F20, F51
  - Ministry of Overseas Development
    - address, J284
    - funding of population activities, J270-J271(table), J273, J275 (table), J278(table)
  - oral contraceptives, A1, A7
    - beneficial and adverse conditions in users and nonusers compared, A31(graph)
    - breast cancer, A43, A44(table)
    - commercial supply, A9(table), A10(graph)
    - discontinuation, A11, A39
    - distribution by nonphysicians, E43
    - marketing, A15(table)
    - nonprescription, J74
    - sales, A8(table), A11(graph)
    - selected studies on carcinogenic effects, A44-A45(table)
    - selected studies on thromboembolic disease, A41(table)
    - side effects, J74
    - withdrawal bleeding, A38
  - oral PGs for induction of labor, G59
  - percentage of legal abortions to women under 20, J171(table)
  - PG research, G11, G13, G18, G19, G20, G21, G23
  - population, F7(table)
  - population estimates, J240, J241(table), J245
  - population per hospital bed, J71(table)
  - population per physicians, J71(table)
  - population policy
    - voluntary sterilization, E45(table)
  - rhythm method, I14(table)
    - sympto-thermal method, I7
    - temperature method, I11(table)
  - subsidy for foreign community-based distribution, J77
  - training nonphysicians, J95(table), J105(table)
  - tubal occlusion
    - plugs, C90
    - tantalum clips, C83
  - uterine aspiration, F27
  - vaginal contraceptives, H48(table)
  - vasectomy, CD68
    - complications, D28(table)
    - general health, D34(table)
    - reversal, D41
    - sexual behavior, D35(table)
    - technique, D28(table)
  - Vasectomy Act, CD70

- **UNITED KINGDOM. COMMITTEE ON THE WORKING OF THE ABORTION ACT (LANE COMMITTEE).**
  - report on abortion seekers, E34
  - voluntary sterilization, E45
- **UNITED NATIONS (UN)**
  - adolescents
    - birth rate, J159
    - early marriage, J160(figure)
  - family planning, E48, J125
  - involvement in population matters, E29, E30
  - out-of-wedlock births in selected countries, J160(figure)
  - subsidy for community-based distribution, J77
  - supply of contraceptives, J74
  - urbanization estimates, J161
- **UN CHILDREN'S FUND (UNICEF)**
  - address, J284
  - colpotomy kit, M24
  - condom distribution, H30
  - condom purchase, H24
  - cost of foam tablets, H49
  - laparotomy equipment, M23
  - maintenance and repair of sterilization equipment, M3
  - mini-laparotomy kits, M21(table)
  - oral contraceptives, A1, A17
  - population program assistance, J270 (table), J275(table)
- **UN CONFERENCE ON HUMAN RIGHTS, TEHERAN, 1968**, E4
  - resolution, E29
- **UN CONFERENCE ON POPULATION AT BUCHAREST, 1974**, J247
- **UN DECLARATION OF THE RIGHTS OF THE CHILD, 1959**, J163
- **UN DECLARATION ON SOCIAL PROGRESS AND DEVELOPMENT, 1969**, CD90, F2
- **UN DEMOGRAPHIC YEARBOOKS**
  - trends in percentage of total births to adolescents in selected countries, J161(table)
- **UN EDUCATIONAL, SCIENTIFIC, AND CULTURAL ORGANIZATION (UNESCO)**
  - address, J284
  - population program assistance, J271 (table), J275(table), J278
- **UN FOOD AND AGRICULTURE ORGANIZATION**
  - desertification in Africa, J188
  - supply v. demand for haddock, J183 (figure)
- **UN FUND FOR POPULATION ACTIVITIES (UNFPA)**, E1, J201
  - address, J284
  - condom purchase, H30
  - distribution of Depo-Provera, K14
  - funding of family planning activities, J266, J270-J271(table), J275(table), J277
  - population programs, E16, E18
  - symposium in Tunis, E1, E2
  - Working Party on Youth and Population, J166
- **UN INTERNATIONAL DEVELOPMENT ORGANIZATION (UNIDO)**
  - recommendations for contraceptive marketing, H17
- **UN STATISTICAL YEARBOOK, 1971**, J71
- **UN STUDY ON THE INTERRELATIONSHIP OF THE STATUS OF WOMEN AND FAMILY PLANNING**, J160(figure)
  - socioeconomic aspects of early pregnancy, J163
- **UNITED STATES (US)**, J194. See also individual states.
  - abortion
    - adolescents, J169, J171(table)
    - controversy, E36
    - curettage, F66
    - foreign assistance, E36
    - incidence in midtrimester, F66
    - legal status, E2, E7(table), E29, E30 (table), E32, E36(table), E47
    - maternal mortality, E36, E37, F37 (table), F65, F67(figure)
    - saline solution, F67, F68
    - Supreme Court, F1, F5, F6
  - adolescents
    - abortion, J169, J171(table)
    - access to family planning, J165
    - birth trends, J161(table), J254
    - contraception, J166
    - female marital status, J164(table)
    - pregnancy complications, J165(table)
    - premarital sex, J159
  - age of marriage, J160
  - age of menarche, J159, J162(table)
  - age-specific fertility rate, J3(graph), J4, J9(graph), J36(graph), J227(graph)
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure), J237, J240
  - births to unwed mothers, J254
  - breast cancer, A43(figure)
  - cervical cancer, J133(table)
  - change in number of births, J219(figure)
  - clip sterilization, C46, C47(table)
  - colpotomy, C31(table)
    - morbidity rate, C40
  - condom
    - distribution, H12, H13, J169
    - manufacture, H5, H23
    - standards, H25, H26(table), H27, H29(table)
    - use, H17
    - use-effectiveness, H32, H33(table)
  - continuation rates compared among IUDs, orals, and Depo-Provera, K8(graph)
  - contraceptive usage, H4(table), H47, H59(table)
  - copper IUD
    - legal aspects, B18
    - postcoital insertion, J141
  - culdoscopy, C61, C69
    - complications, C66(table), C67(table)
    - training, C69, C70
    - tubal occlusion, C65(table), C68(table)
  - Depo-Provera
    - availability, K13(figure)
    - continuation rate, K7(table), K8(graph)
    - use-effectiveness, K4(table), K5(table)
  - diaphragm
    - availability, H58
    - manufacture, H68(table)
    - use, H60(table)
    - use-effectiveness, H65(table), H66 (table)
  - duration of postpartum amenorrhea among Eskimos, J57(table)
  - estimated population, E36(table)
  - fertility surveys, I9
  - folk methods for sex preselection, I22
  - foreign assistance in family planning, J1, J266, J278(table). See also **US AGENCY FOR INTERNATIONAL DEVELOPMENT**
  - hormonal-withdrawal test, J115
  - illegal immigrants, J197, J198
  - incidence of cancer in women, A43(figure)
    - Connecticut, A70(table)
  - incidence of liver tumors in women, A88, A89
  - infant mortality, A36, J166(table)
    - adolescent mothers, J162
    - maternal age, J254(table)
  - IUD, B21
    - continuation, B35, K8(graph)
    - insertion by nonphysicians, B28, J93
    - mortality, B36(table)
    - sales, B37(table)
  - labor force, J237
  - legal rights of unwed mothers, J163
  - legal status of voluntary sterilization, CD68, CD74, CD83-CD84, CD89, CD115(table), E45(table), E48
    - case law in California, CD130-CD131
    - Virginia statute, CD125
  - manufacturers of sterilization equipment, M2
  - marketing of minipill, A64(table)
  - mass communication of family planning, J291, J293, J296-J297, J301, J304-J305, J309, J312(table)
  - maternal mortality, A36, J126, J254, J255(table)
    - abortion, E36, E37, F37(table), F65, F67(figure)
  - menstrual regulation, F50, F51
  - mineral resources, J194
  - mortality
    - breast cancer, A112(chart)
    - broad ligament cancer, A126(chart)
    - cervical cancer, A116(chart)
    - fallopian tube cancer, A126(chart)
    - liver cancer, A130(chart)
    - malignant neoplasia, A109(chart), A110(chart), A111(chart)

  - selected operative procedures, E27(graph)
  - uterine cancer, A122(chart)
- national park attendance, J180
- obstetrical complications with multiparity, J134-J135(table)
- oral contraceptives, A1, A9(table), A36
  - breast cancer, A43, A44(table)
  - commercial supply, A10(graph)
  - continuation rate, K8(graph)
  - distribution, J92
  - estimated use (1964-1976), A107(chart), H12
  - liver tumors, A89
  - marketing, A15(table)
  - sales, A8(table)
  - selected studies on carcinogenic effects, A44-A45(table)
  - selected studies on thromboembolic disease, A41(table)
  - side effects, J74
  - use-effectiveness, A36
  - withdrawal bleeding, A38
- out-of-wedlock births, J160(figure)
- over-the-counter drugs, H42-H44
- petroleum production, J199(figure)
- PG research, G11, G19, G20, G21, G23-G24
  - funding, F4-F5(table)
  - status, G13
- population, F7(table)
- population density and crime rate, J190
- population per hospital bed, J71(table)
- population per physician, J71(table)
- postcoital estrogens, J141
- pregnancy rate with copper-T, B10
- premature marriage and divorce, J163-J164
- rhythm method, I2, I14, I15(table), J74
  - calendar method, I10, I11 (table)
  - declining practice, I14
  - sympto-thermal method, I7
- sex ratio, I23
- survey on contraceptive effectiveness, H37
- training midwives in IUD insertion, B28
- training nonphysicians, J95(table), J98, J107-J108(table)
- tubal ligation, C74, C77, C78
- tubal occlusion
  - band, C85
  - chemical, C87, C88, C89
  - clips, C82, C83
  - fimbriotexy, C91
  - fulguration, C78, C79, C80
  - plugs, C90, C91
- uterine aspiration, F26, F27
- vaginal contraceptives
  - new acceptors, H49(table)
  - price and sales, H48(table)
  - use-effectiveness of foam, H46
- vasectomy
  - complications, D25, D28(table)
  - racial aspects, D36
  - sexual behavior, D35(table)
  - technique, D28(table)
- water consumption, J196

US AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID), J186(photo), J189(photo), J197(photo), J201
- address, J85, J284(table)
- age-specific fertility rate by country, J3(graph), J5-J7(graphs), J9-J10(graphs)
- birth rate data, J21
- colpotomy instrument kit, C36, C38 (figure), C39, M24(table)
  - availability, C39
- condom
  - cost, H49
  - distribution to developing countries, H2, H15(table)
  - prices, H24
  - shipments to Jamaica, H10
  - standards, H29
- copper IUD research, B19
- Dalkon Shield, B37
- distribution programs
  - condom, H2, H15(table)
  - copper IUD, B18
  - Depo-Provera, K14
  - IUD, B37, B38(table)
  - low-dose orals, A38, A63
  - orals, A1-A2, A17, A19(figure), A21 (table), A23
  - vaginal contraceptives, H49(table), H50
- equipment for IUD insertion, B30, B31 (figure)
- family planning programs, J266, J267 (figure), J269, J270-J271(table), J272, J274(table)
  - fertility data, J1
- laparoscopic sterilization training and equipment, C3, C9
- menstrual regulation equipment, F19
- mini-laparotomy kits, C58(figure), M21 (table)
- oral contraceptives
  - cost, H49
  - iron supplements, J131-J132
  - side effects related to dosage, A48
  - study, J257
  - supplies, A1-A2, A17, A19(figure), A21(table), A22, A23
- PG research, G2-G3, G5(table)
- pregnancy test research, J110, J122
- sterilization equipment, M2
- subsidies for community-based distribution
  - contraceptive supplies, J74
  - household systems, J81, J82
  - Indonesia, J78
  - institutional systems, J78
  - Sri Lanka, J77
- training in fertility control, F20
- training nonphysicians, J98
  - nurse-midwives, J91(figure)
- vasectomy equipment, D12-D13, M26 (table)

US BUREAU OF THE CENSUS
- address, J284
- age-specific fertility rate by country, J3(graph), J5-J7(graphs), J10(graph)
- family planning programs and fertility data, J1
- funding of family planning activities, J271(table), J272, J275(table)
- International Statistical Programs Center, J1, J21
- new acceptors, A17(graph)
- world fertility pattern (1972), J30-J31(figure)

US BUREAU OF MINES
- mineral consumption, J194
- petroleum production, J199(figure)

US CENTER FOR DISEASE CONTROL
- abortion mortality
  - by week of gestation, F67(figure)
  - saline, F70
- address, J284
- funding of family planning activities, J272, J276(table)

US CENTER FOR POPULATION RESEARCH, J272, J276(table)
- address, J284

US COMMISSION ON POPULATION GROWTH AND THE AMERICAN FUTURE, J161

US DEPARTMENT OF AGRICULTURE
- Peruvian anchovy catch, J180(figure)
- supply v. demand of cereals, J182(figure)
- world grain consumption, J184(figure)

US DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
- incidence of types of cancer in US women, A43(figure)

US ENVIRONMENTAL PROTECTION AGENCY
- water carcinogens, J184

US FOOD AND DRUG ADMINISTRATION, H29
- approval of copper IUD, B4, B18
- condom
  - safety, H23
  - standards, H25
  - testing, H29
- Dalkon Shield configuration and sepsis, B36
- Depo-Provera
  - regulation, K1, K2, K10, K13
  - use for endometrial cancer, K2
- evaluation of contraceptives, K11
- evaluation of vaginal douches, J143
- hormonal-withdrawal test, J115, J116
- IUD safety, B36
- minipill
  - approved brands, A55
  - labeling, A62
  - tests with chlormadinone acetate, A55
- oral contraceptives, A5, A33, A37(table)
  - approved, A6(table)
  - dosage, A12, A37
  - standards for distribution, A24
  - use-effectiveness, A36
- over-the-counter pregnancy tests, J121
- postcoital diethylstilbestrol, J144
- prostaglandins, G13
  - abortion, F72
  - induction of labor, G59
- regulation of medical devices, M8
- therapeutic use of progestogens, A32-A33
- vaginal contraceptives, H42

US GOVERNMENT SERVICES ADMINISTRATION
- condom standards, H25

US IMMIGRATION AND NATURALIZATION SERVICE
- illegal immigrants, J197

US NATIONAL CENTER FOR HEALTH STATISTICS
- address, J284
- contraceptive practice, H59(table)
- diaphragm use, H60(table)
- family planning activities, J271(table), J272, J276(table)

US NATIONAL FERTILITY SURVEY, I9
- changes in diaphragm use, H59
- oral contraceptive use, A7, A39
- rhythm method, I15(table)

US NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD)
- postcoital estrogen research, J144

US NATIONAL INSTITUTES OF HEALTH
- PG research, G2, G4-G5(table)

US NATIONAL PARK SERVICE
- regulations, J180-J181

US SUPREME COURT
- abortion, E6, E7(table)
- definition of pregnancy, F61
- *Doe v. Bolton*, F5
- *Griswold v. Connecticut*, F5
- *Roe v. Wade*, F5-F6
- safety of early abortion, F37

US SURGICAL CORP., D12

US VIRGIN ISLANDS
- age-specific fertility rate, J227(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)

UNOVIS
- manufacture and marketing, A4(table)
- patent information, A5(table)

UNTERBERGER, F.
- sperm capacitation, I25

UPJOHN CO., A5, A32, J92, K14
- Depo-Provera, K1, K7
  - advertising, K3(photo)
  - causes of discontinuation, K8
  - sales, K14
- marketing of PGs
  - United Kingdom, G13(figure)
  - US, G13
- medroxyprogesterone acetate, K2
- prostaglandins
  - administration, G36
  - analogues, G2, G13
  - induction of labor, G59-G80
  - marketing, G13
  - research, G2, G17, G54
- Provest withdrawn from market, K10

UPPER VOLTA
- age-specific fertility rate, J34(graph), J225(graph)
- birth rate, J29(table), J207(table), J209 (table)
- drought and famine, J244-J245
- marketing of oral contraceptives, A15 (table)

URBAN POPULATION
- breast-feeding, J54-J55
  - duration of postpartum amenorrhea, J56, J57(table)

URBANIZATION, J191-J192
- influence on adolescent sexuality, J160-J161
- side effects, J192

UREA
- abortifacient agent, F67, F76
- compared with PGs for abortion, F76, G58-G59
- midtrimester abortion
  - complications and side effects, F78 (table), F79
  - effectiveness, F76, F79
  - instillation-abortion interval, F76
  - selected studies, F78(table)
  - technique, F76

URINALYSIS
- performed by nonphysicians, J98

URINARY TRACT INFECTION
- colpotomy, C40(table)
- oral contraceptives, A47
  - incidence in users and nonusers compared, A31(figure)

URQUHART-HAY, D.
- irrigation after vasectomy, D10

URTICARIA
- local anesthesia, F13, F30(table)

URUGUAY
- abortion
  - impact on population growth, E38
  - legal status, E30(table), E32
- age-specific fertility rate, J36(graph), J227(graph)
- birth rate, J23(figure), J29(table), J207 (table), J218(figure)
- change in number of births, J219(figure)
- legal status of voluntary sterilization, CD115(table)
  - consent, CD77-CD78
- marketing of minipill, A64(table)
- marketing of oral contraceptives, A15 (table)
- population, F7(table)
- population per hospital bed, J71(table)
- population per physician, J71(table)

USE-EFFECTIVENESS, H46
- clip sterilization, C50
- condom, H22, H32, H33(table), I9
  - douche, I9
  - IUD, I9
- contraceptive methods, H37, H39(figure)
- Depo-Provera, K4(table)
- diaphragm, H65, H66(table), I9
- foam, H46
- life table analysis, H46
- measurement variables, I9
- methods of determination, I9
- minipill, A56(table)
- Norigest, K4(table)
- oral contraceptives, A35-A36, I9
  - Philippines, I16
- Pearl formula, H46
- postcoital contraception
  - copper IUD, J150
  - dienestrol, J144
  - diethylstilbestrol, J144, J145(table), J147
  - douche, J143
  - estrogen-progestin combination, J150
  - estrogens, J144, J145(table)
  - progestogens, J147, J148, J149(table)
- rhythm methods, I8-I12, I11(table), I12 (table)
- vaginal contraceptives, H46
  - selected studies, H45(table)

USV PHARMACEUTICAL CORP., H40, H41(table)

UTERINE ASPIRATION. See also **MENSTRUAL REGULATION**; **VACUUM ASPIRATION**.
- anesthesia, F27-F31
- comparative preoperative and postoperative medication and anesthesia, F29 (table)
- compared with curettage, F42, F57, F59, F60
- compared with dilatation and curettage, F26
  - perforation rate, F36
- compared with PGs for pregnancy termination, G11
- complications, F33, F35-F36
  - incidence and management of perforation, F35(table), F36
- cost, F62
- current use, F27
- diagnostic use, F57, F59
- ectopic pregnancy, F36
- equipment, F27, F32(table), F38-F44, F55-F57
- histological exam, F31
- history, F26-F27
- incomplete abortion, F59-F60
- Lebanon, J45
- local anesthesia, F29(table), F30(table)
- menstrual disorder, F36
- midtrimester, F67-F68
- mortality rate, F38
- operative procedure, F31
  - blood loss, F34(table)
  - inpatient or outpatient, F33
  - time required, F32(table), F34(table)
- outpatient procedure, F57
- postoperative procedures, F31, F33, F35
- preoperative procedures, F27
- secondary sterility, F36
- spontaneous abortion, F36
- studies, F28(table)
- therapeutic uses, F59-F60
- training programs for nonphysicians in selected countries, J94-J95(table)
- US, F26
- Yugoslavia, F26

UTERINE CANCER
- incidence in Connecticut (1955-1975), A123(chart)
- incidence in Denmark (1953-1972), A125(chart)
- incidence in Puerto Rico (1955-1974), A124(chart)
- incidence in selected countries, A70(table)
- mortality in the US, A122(chart)
- oral contraceptives, A46

UTERINE CONTRACTION. See also **PARTURITION**.
- estradiol-17β, G49
- PG mode of action, G46-G48

UTERINE CRAMPS
- menstrual regulation, F51, F52(table)
- PG administration, F95, G66

UTERINE FIBROIDS. See **FIBROIDS**.

UTERINE MANIPULATION
- equipment, M22(table), M23

UTERINE PERFORATION
- abortion, F36
- cervical dilatation, F90(figure), F91, G67
- IUD, B8, B12-B13
  - configuration, B29
  - detection, F36
  - insertion, B30-B31
  - Lippes Loop, B26
  - removal, B31
  - Ypsilon, B38-B39
- laparoscopic sterilization, C18, C19(table)
- menstrual regulation, F52(table)
- mini-laparotomy, C57
- prevention during surgery, C20
- risk with plastic cannula, F15
- uterine aspiration, F35(table), F60 (table)

UTERINE RETROVERTER, ATRAUMATIC
- colpotomy, C36, C37(figure)

UTERUS
- effect of semen, G1, G2
- manipulation for mini-laparotomy, C55
- perforation. See **UTERINE PERFORATION**.
- position for colpotomy, C39-C40
- pregnancy, G34
- prostaglandins, G2, G35
  - bleeding, G35, G36
  - pellets, G37
- retroversion for posterior colpotomy, C34, C36

UTERUS, RETROVERTED
- clip sterilization, C48

UTERUS, RUPTURED
- obstetrical complications in multiparas, J134-J135
- PGF$_2$α, F74

UTIDJIAN, H.M.D.
- vaginal contraceptives and venereal disease, H51(tables)

UTUS PASTE, F67

V

VABRA ASPIRATOR
- evaluation, F59

VACTEL
- multiple congenital abnormalities, J116

VACUUM ASPIRATION. See also **MENSTRUAL REGULATION**; **UTERINE ASPIRATION**.
- abortion, F66
  - midtrimester, F67
- cervical dilatation with PGs, G68(table)
- colpotomy, C41
- complication rate, F52
  - length of amenorrhea, F66(figure)
- culdoscopy, C65
- disadvantage, G38
- incomplete abortion, F60
- performed by paramedical personnel, J96, J97
- types of pumps, F26

VACUUM BOTTLE, F56(figure)
- advantages, F56
- uterine aspiration, F41(table), F43(figure), F44(figures)
  - advantages, F44

VACUUM PUMP
- uterine aspiration, F32(table), F41(table), F43(figure), F60(table)

VACUUM PUMP, ELECTRICAL, F42(figures)
- menstrual regulation failure rate, F54
- requirements, F42

VACUUM PUMP, HAND-OPERATED, F56 (figure)
- description, F56
- use-effectiveness, F56

VACUUM PUMP, NONELECTRICAL, F56 (figure)
- advantages, F43, F56
- menstrual regulation failure rate, F54

VACUUM SUCTION
- menstrual regulation, F14(table)
  - equipment, F18-F19

VAGAL REFLEX
- postcoital copper IUD insertion, J151

VAGINAL CANCER
- diethylstilbestrol use in pregnancy, J146

VAGINAL CONTRACEPTIVES. See also **CREAM**; **FOAM**; **JELLY**; **SUPPOSITORY**.
- acceptors in selected countries, H49(table)
- active ingredients, H41(table), H43(table)
- advantages and disadvantages, H37, H38
- application and insertion, H40
- characteristics, H43(table)
- cost, H37
- distribution, H37, H50
  - IPPF, H50(table)
  - USAID, H49(table)
- early agents, H38
- fetal abnormalities, H42
- history, H38-H40
- inconsistent use, H37
- indications, H47
- IPPF testing standards, H47
- laboratory testing, H44
- marketing, H47-H48
  - commercial sector, H48-H49
  - directory, H47
- mode of action, H37, H40, H42
- packaging, H40
- prevalence of use, H47, H48
- price, H49
  - selected countries, H48(table)
- prophylactic quality, H38, H64
- quality control, H42
- role in family planning, H38
- sales, H48-H49
  - selected countries, H48(table)
- sources of funding, J270(table), J274-J276(table)
- testing samples, H69(table)
- use-effectiveness, H37, H44-H47
  - point scoring method, H44(table)
  - selected studies, H45(table)
- used with diaphragm, H62-H63
- venereal disease, H50-H51(table)

VAGINAL DIAPHRAGM. See **DIAPHRAGM**.
VAGINAL FOAM. See **FOAM**.
VAGINAL STERILIZATION. See **COLPOTOMY**.
VAGINITIS
- quinacrine tubal occlusion, C87

VAGUS NERVE
- clip sterilization, C49

VAILLANT, H.W.
- use-effectiveness of contraceptive foam, H45(table)

VAITUKAITIS, J.L.
- beta subunit of HCG assay, J120
- measurement of HCG, F53

VAKHARIYA, V.R.
- PGs for induction of labor, G10(table)

VAKILZADEH, J.
- uterine aspiration, F28(table)
  - anesthesia, F29(table)
  - complications, F33(table)

VALIUM. See **DIAZEPAM**.
VALLEYLAB, INC.
- address, M33
- electrosurgical generators, M15(table)
- guarantee and service of sterilization equipment, M30(table)

VALVES. See also **PHASER VALVE**.
- advantage and disadvantage in vas occlusion, D15
- flexible-end device, D56(photo)
- materials tested, D15
- problems, D56
- reversible vas occlusion, D56-D57
- rigid-end device, D56

VAN DE VELDE, T.H.
- BBT and ovulation, I5

VAN DER VLUGT, T., author, A29-A51, F9-F20, F25-F44, F49-F64
VAN GORP, P.
- extraovular instillation of PGF$_{2}\alpha$, F75 (table)

VAN PRAAGH, I.G.L.
- local anesthesia for uterine aspiration, F30(table)

VAN WAGENEN, G.
- postcoital estrogens, J143
  - side effects, J148(table)
  - use-effectiveness, J145(table)

VAN ZILE HYDE, H., author, E19-E24
VARAKAMIN, S., J103(table)
VARICOCELE
- contraindication to vasectomy, D26

VARICOSITIES
- pregnancy complication, J137

VAS ANASTOMOSIS. See also **VASECTOMY REVERSIBILITY**.
- definition, D48
- effectiveness, D49(table), D51, D54(chart)
  - pregnancy, D42, D43, D49(table), D51
  - sperm count, D42, D43, D49(table), D51
  - sperm motility, D42, D43, D49(table)
  - technique, D51
- equipment, D42, D43, D50
- history, D42, D43, D46
- operative procedures, D42, D43, D48, D50-D51, D54(chart)
  - action on vas ends, D44-D45(table)
  - incision closure, D44-D45(table)
  - microsurgery, D51(photo)
  - scrotal incision, D44-D45(table), D48, D50
  - splinting, D44-D45(table)
  - suturing, D44-D45(table)
  - testing vas patency, D44-D45(table), D50
- postoperative procedures, D44-D45 (table), D51, D54(chart)
- splinting materials, D50
- suture material, D50-D51
- techniques, D42-D43, D44-D45(table), D49(table)
  - end-to-end anastomosis, D43, D50 (figure)
  - mucosa-to-mucosa, D42, D46, D51 (photo)
  - side-to-side anastomosis, D42, D50, D51
  - vaso-epididymal anastomosis, D42, D50, D51
- time interval since vasectomy, D49(table)

VAS DEFERENS, M26
- anatomy, D43(figure)
- artificial, D56
- electrocoagulation, D5
- ligation, D5, D6-D7(table)
- location and identification, D4
  - palpation, D4
- prostaglandins, G25, G27
  - release, G26

VAS LIGATION. See also **VASECTOMY**.
- material, D5, D6-D7(table)
- side effects, D5

VAS OBSTRUCTION
- vasectomy reversal failure, D46

VAS OCCLUSION. See also **VASECTOMY**.
- techniques, D27, D28(table)

VAS OCCLUSIVE DEVICES
- advantages, D42
- history, D52
- reasons for failure, D57
- research, D33, D56-D57
- suggested criteria, D53
- types, D53, D56-D57
  - clips, D53
  - intravas devices, D53
  - plugs, D53
  - valves, D56-D57

VASECTOMY. See also **VAS LIGATION**; **VAS OCCLUSION**.
- acceptance in India, J313
- advantages, D1, D25
- antibody formation, D31(table), D32(table)
  - cell-mediated immunity, D32
  - humoral immunity, D31
- clips, D7
- Colombia, CD77
- complications, D25, D28(table), D29 (graph), D46, D47-D48
  - hematoma, D27, D28(table)
  - infection, D27-D28(table)
  - sperm granuloma, D28(table), D29-D30
- Costa Rica, CD77
- differentiated from castration, D2
- disadvantages, D1-D2, D9
- electrocoagulation, D5, D6-D7(table)
- enzymatic effects, D30
- equipment, D11-D13, J282, M25(table), M26-M28
  - kit, J282
  - sources of funding, J270(table), J274-J276(table)
- eugenic reasons, D2
- experimental methods, D14-D15
- family planning programs, D3
  - incentive payments, D9
- female response, D36
- focus of research, D2, D15-D16
- general anesthetic, D4, D7(table)
- general health status, D34(table)
- hematological effects, D30
- history, D2-D3, D25
- ligation, D5, D6-D7(table)
- local anesthetic, D3, D6-D7(table)
- morbidity, D1
- mortality, D1, D28, J258
- motivation, D35
- nonphysicians
  - Australia, J98
  - China, J98
  - Indonesia, J98
  - Malaysia, J98
  - Netherlands, J98
  - training programs in selected countries, J94-J95(table)
- operative procedure, D1, D8(figure), D25, D28(table), D54-D55(chart)
  - equipment, D6-D7(table), D11-D13, J282, M25(table), M26-M28
  - scrotal incision, D4-D5, D6-D7(table), D8
- physical contraindications, D26
- popularity, D25
- postoperative care, D9
- preoperative procedure, D3
- prevalence
  - Latin America and Asia, D1
  - US and Europe, D3
- psychological aspects, D33-D34, D34-D36
- religious aspects, D36
- reversibility. See **VASECTOMY REVERSIBILITY**.
- safety, J258
- seminal plasma effects, D30
- side effects, D26-D27, D35
  - selected studies, D35(table)
  - sexual, D35-D36
- sperm count, D9-D10
- spermatic granulomas, M27
- staples, D7
- surgical error, D10
- techniques. See **VASECTOMY, operative procedure**.
- testicular effects, D30-D31
- theory of rejuvenation, D2
- United Kingdom, C68
  - government subsidy, C70
- US, CD84, J239
- use of contraceptives after, D11
- use-effectiveness, D10-D11, D28(table), D32-D33

VASECTOMY REVERSIBILITY, D7, D8, D36, D41. See also **VAS ANASTOMOSIS**.
- anatomical failure, D42, D46-D47
  - misalignment, D46
  - obstruction, D46
  - segment size removed, D47
  - spermatic granuloma, D46
  - vasectomy in convoluted vas, D46
- demand for, D41
- effectiveness, D36
  - anatomical, D41, D46
  - factors affecting, D41, D46
  - functional, D41, D46
- evaluation criteria, D41, D46, D48
- functional failure, D42, D47-D48
  - epididymal changes, D47
  - fertility of partner, D48
  - prevasectomy semen quality, D48
  - sperm agglutinating antibodies, D48
  - sperm immobilizing antibodies, D48
  - sympathetic nervous system injury, D47-D48
- guide for physicians, D54-D55(chart)
- history, D42-D43, D46
- India, D41
- indications, D41
- Korea, D41
- motivation for vasectomy, D41
- research needs, D57
- techniques, D41-D57
- United Kingdom, D41

VASOCLIPS. See **CLIPS, TANTALUM**.
VASOVASOSTOMY. See **VAS ANASTOMOSIS**.
VAULT CAP, H70(figure)
- description, H72
- disadvantage, H72
- fitting, H72
- indications, H72

VEHASKARI, A.
- obstetrical complications with multiparity, J135(table)

VELAROE, N.
- promotion of family planning in El Salvador, J297, J302-J303

VELLUZ, L.
- synthesis of norgestrienone, A32

VELOSO, I.
- menstrual pattern changes with norgestrel minipill, A57, A59(table)

VENEREAL DISEASE
- condoms, H13, H29, H32
- contraindication for postcoital IUD insertion, J151
- prevention, H38
- screening prior to IUD insertion, B36
- vaginal contraceptives, H50-H51(table)

VENEZUELA
- adolescent births, J161(table)
- age-specific fertility rate, J3(graph), J27(graph), J36(graph), J227(graph)
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J209 (table)
- condom
  - distribution, H5(table), H6, H16
  - importation costs, H5(table)
  - sales, H6
  - shipments, H15(table)
- contraceptive usage, H4(table)
- diaphragm availability, H68(table)
- family planning program, J26

- IUD acceptors, B27(table)
- legal status of abortion, E28
- legal status of voluntary sterilization, CD116(table)
- maternal mortality, J130(table)
  - septic abortion, E27
- medical complications of adolescent pregnancy, J165(table)
- new acceptors, A17, A18(table), J19(table)
- oral contraceptives
  - commercial supply, A9(table)
  - marketing, A15(table)
  - new acceptors, A17, A18(table)
  - sales, A8(table)
  - supplied by USAID, A21(table)
- out-of-wedlock births, J160(figure)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- training in culdoscopy, C70
- vaginal contraceptives, H48

VENGADASALAM, D.
- effectiveness of hormonal-withdrawal tests, J114

VENTURA, W.P.
- sperm transport physiology, D47

VERNITRON MEDICAL PRODUCTS, F41 (table)

VERRES NEEDLE, C5(table)

VERTIGO
- local anesthesia, F30(table), F31

VERTON
- marketing, A55

VESSEY, M.P.
- diaphragm
  - failure, H65(table), H66(table)
  - use-effectiveness, H66(table)
- IUDs and spontaneous abortion, B34
- menstrual changes with norgestrel minipill, A60(table)
- oral contraceptives
  - benign breast neoplasia, A45, A46, A73(table)
  - breast cancer, A44(table), A45, A76 (table)
  - cervical neoplasia, A82(table)
  - thromboembolic disease, A41(table)

VETERANS ADMINISTRATION HOSPITAL (SAN FRANCISCO, CALIFORNIA)
- vas anastomosis, D51

VIETNAM, NORTH
- birth rate, J29(table)
- condom shipments, H14(table)
- oral contraceptives
  - marketing, A15(table)
  - supplied by SIDA, A20(table)
- population, F7(table)

VIETNAM, SOUTH
- availability of Depo-Provera, K13(figure)
- birth rate, J29(table), J207(table), J208, J210(table)
- condom shipments, H15(table)
- estimated population, E30(table)
- family planning policy, E2
- incentive programs, E8(table)
- legal status of abortion, E30(table)
- Ministry of Health, National Population Council
  - address, J103(table)
  - training nonphysicians, J94(table), J103(table)
- oral contraceptives
  - marketing, A15(table)
  - supplied by USAID, A21(table)
- penal code on pregnancy prevention, CD74
- price of vaginal contraceptives, H48(table)
- training in culdoscopy, C70
- training nonphysicians, J94(table), J103(table)
- voluntary sterilization, E6
  - legal status, CD116(table)

VILLAGE DISTRIBUTION. See **COMMUNITY-BASED DISTRIBUTION, village distribution**

VILLARREAL, J., E20, E21(photo)

VIMEUX, J.
- cervical mucus, I7

VIMULE, H70(figure)
- description, H72
- indications, H72

VINCENT, B.
- use-effectiveness of temperature rhythm method, I11(table)

VINEGAR
- postcoital douching agent, J142

VINKE, B.
- diabetes mellitus and parity, J132(table)

VIRKAR, K.D.
- continuation rate of chlormadinone acetate minipill, A62(table)
- lactation
  - effects of orals, J60(table)
  - effect of progestogen-only contraceptives, J63(table)

VIS, H.L.
- age of menarche, J162(table)

VISMARA SPA, A5(table)

VISTER
- oral contraceptives, A4(table), A7

VITOON, O.
- female sterilization technique, C53
- mini-laparotomy
  - local anesthesia, C54, C55
  - operative procedure, C55, C56
  - performed by nurses, J97
  - preoperative procedure, C54
  - surgical kits, M21(table)

VLADOV, E.
- uterine aspiration, F28(table)
  - anesthesia, F29(table)
  - blood loss, F34(table)
  - complications, F33(table)
  - equipment, F32(table), F41(table)
  - postoperative medication, F29(table)
  - preoperative medication, F29(table)
  - pressure used, F41(table)
  - time required, F32(table), F34(table)

VOERMAN, J.
- lynestrenol minipill
  - effectiveness, A56(table)
  - menstrual pattern changes, A58(table)

VOJTA, M.
- uterine aspiration, F28(table)
  - complications, F33(table)
  - equipment, F32(table), F41(table)
  - pressure used, F41(table)

VOLDYS
- manufacture and marketing, A4(table)

VOLIDAN
- manufacture and marketing, A4(table)
- patent information, F5(table)

VOLLMAN, R.F.
- menstrual cycle length, A60(table)

VOLPLAN
- manufacture and marketing, A4(table)

VOMITING, F1, F52
- abortion
  - PGE_2, F77(table), G70(figure), G72
  - PGE_2 analogue, F95
  - $PGF_{2}\alpha$, F72, F73(table), F74, F75(table)
  - $PGF_{2}\alpha$ methyl analogue, F74, F75 (table), F77(table), G66, G67, G68, G69, G70(figure), G71
  - saline, F71(table), F72, G72
  - urea, F78(table), F79
- analgesia, C66
- minipill, A61
- PG administration, G3
  - abortion, G7(table), G8(table), G9 (table), G12, G59
  - cervical dilatation, G61
  - induction of labor, G10(table)
  - menstrual regulation, G38, G59(table)
- postcoital estrogens, J141, J148(table)
  - diethylstilbestrol, J147
  - prevention, J147
- postcoital progestogens, J148
- pseudopregnancy, A34, A36

VON BAER, C.E., I2

VON BLUNDELL, C1

VON EULER, U.S., G65

VON FRIESEN, B.
- irrigation after vasectomy, D10

VULSELLUM FORCEPS
- culdoscopy, C64
- menstrual regulation, F12
- uterine aspiration, F38

VUMBACO, B.J., author, E41-E51

W

WADHWA, R.
- complications of laparoscopic sterilization, C19(table)
- mortality associated with laparoscopy, C21

WAGATSUMA, T.
- morbidity with saline abortion, F68

WAHI, P.N.
- cervical cancer, J133(table)

WALES. See **UNITED KINGDOM**

WALLE, E. VAN DE
- estimated Chinese fertility levels, J208, J211(table)

WALNUT CREEK STUDY. See **KAISER PERMANENTE MEDICAL CENTER**

WAMPOLE LABORATORIES, J116, J118 (table), J119(table)
- tube tests, J116

WARNER-LAMBERT
- oral contraceptives, A4(table)

WASHINGTON UNIVERSITY (ST. LOUIS, MISSOURI), C59
- fertility management training program, J45, J268

WATER
- interrelated with other resources, J196
- pollution, J181, J184
- supply v. demand, J196-J197

WATERHOUSE, J.
- incidence of cancer of selected sites in women in selected countries, A70 (table)

WATERS INSTRUMENTS, INC.
- address, M33
- guarantee and service of sterilization equipment, M30(table)
- laparoscopy equipment
  - insufflator, M12(table), M13(photo)
  - thermocoagulation device, M16(table)

WAZETER, F.X.
- orals and breast neoplasia in animals, A78, A79(table)
- orals and liver tumors in animals, A89 (table)

WEATHER. See **CLIMATE**

WEBER, T.
- orals and cervical neoplasia, A81(table)

WEBSTER, R.L.
- pain with IUD insertion, B30

WECK, EDWARD, AND CO. INC., C45, D12
- address, C84, M33
- culdoscopy equipment
  - culdoscope, M24(table), M25(figure)
  - perineal retractors, M25(table)
- fiberoptic projector, M9(table)
- guarantee and service of sterilization equipment, M30(table)
- hemoclips, C84(photo)
- uterine sound with single tooth tenaculum C6(figure)

WEIDEGER, P.
- diaphragm use in US, H59

WEINBERG, P.C.
- midtrimester abortion with urea, F78(table)

WEISS, F.
- vasectomy technique, D7(table)
  - use of staples, D7

WEISS (JOHN) AND SON (LONDON, ENGLAND)
- self-acting douche, J143(figure)

WEISSMAN, M.C.
- use-effectiveness of cervical mucus rhythm method, I11(table)

WENTZ, A.C.
- side effect of intraamniotic administration of $PGF_{2}\alpha$, G71-G72

WERU, C., H9

WEST BENGAL
- folk methods for sex preselection, I22

WEST GERMANY. See **GERMANY, WEST**

WEST INDIES
- culdoscopy, C61
  - postoperative complications, C67 (table)
  - training, C70

WEST INDIES, UNIVERSITY OF (JAMAICA)
- training program in culdoscopy, C70

WEST VIRGINIA
- use-effectiveness of condom, H32, H33 (table)

WESTERN ONTARIO, UNIVERSITY OF (CANADA)
- PG research, G53

WESTERN PENNSYLVANIA HOSPITAL (PITTSBURGH, PENNSYLVANIA)
- fertility management training program, J44

WESTERN SAMOA
- age-specific fertility rate, J226(graph)
- average births per woman, J129(table)
- birth rate, J29(table), J207(table), J209 (table)
- marketing of oral contraceptives, A15 (table)
- population per hospital bed, J71(table)
- population per physician, J71(table)
- training in culdoscopy, C70

WESTINGHOUSE POPULATION CENTER
- condom distribution, H5(table), H16
- condom use, H34
- contraceptive usage, H4(table)
- survey in Antigua, H10
- survey on contraceptive distribution, H48

WESTOFF, C.F.
- discontinuation of orals, A39

WHEELESS, C.R., J41(photo)
- clip sterilization, C45, C83(table)
- laparoscopic sterilization, C2(table)
  - complications, C19(table)
  - electrocoagulation, C8(table), C79 (table), C80
  - failure, C22(table), C69
  - local anesthetic, C4(table)
  - one-incision method, C11
  - operative procedure, C7(table)
  - training, C2, C13, C14, C26-C27
- technique for pneumoperitoneum, C5 (table)
- vaginal instruments used in laparoscopy, C6

WHITELY, P.F.
- complications of postpartum laparoscopic sterilization, C23(table)

WHITES
- sex ratio, I23

WIDE, L.
- tube test, J111

WIDHOLM, O.
- age of menarche, J162(table)
- contraception among adolescents, J166

WIED, G.L.
- orals and cervical neoplasia, A44(table)

WIEST, F.M.
- thermoprobe, C82

WIG, N.N.
- psychological aspects of vasectomy, D34
- sexual behavior after vasectomy, D35 (table)

WIGGINS, P.
- use-effectiveness of diaphragm, H65, H66(table)

WILDE, F.A.
- cervical cap, H70

WILDER, F., J290

WILDLIFE, ENDANGERED. See **ENDANGERED WILDLIFE**

WILHOITE, R.
- diagnosis of endometrial cancer, F59

WILKS, J.W., G29, G53

WILLIAMS, J.A.
- Dexon suture after scrotal incision, D8

WILLIAMS, P.P.
- operative procedure in laparoscopic sterilization, C7(table)

WILLIAMS, W., J41

WILLSON, J.R.
- IUD removal and patient attitude, B35

WILSON, K.H.
- intravaginal administration of PGs, H66-H67
- midtrimester abortion with PGF$_2\alpha$, G69, G72(table)

WILSON, L.
- sperm antibodies and infertility, D48

WILSON, R.A.
- estrogen use and breast cancer in postmenopause, A77(table)

WILTBERGER, P.B.
- male toad pregnancy test, J111

WINER, J.
- operative procedures for vas anastomosis, D45(table), D51

WINTER, J., author K1-K16

WINTER, J.N.
- research needs in vasectomy reversibility, D57

WINTER AND IBE
- address, M33
- culdoscopy equipment, M24(table)
- guarantee and service of sterilization equipment, M30(table)
- laparoscopy equipment
  - fiberoptic projectors, M9(table)
  - laparoscopes, M4(table), M5(table)
  - teaching attachments, M6(table)
- uterine manipulation devices, M22(table)

WINTON, R.R., E21(photo)

WIQVIST, N.
- extraovular instillation of PGF$_2\alpha$, methyl analogue, F75(table)
- PG research, G17
- PGs for pregnancy termination, G7(table), G8(table)
  - intraamniotic administration of analogues, G13
  - midtrimester with PGF$_2\alpha$, G72(table)
  - preferred route of administration and timing, G11

WISAP MEDICAL EQUIPMENT CORP.
- address, M33
- guarantee and service of sterilization equipment, M30(table)
- laparoscopy equipment
  - combination units, M11(table)
  - insufflators, M12(table)
  - thermocoagulation device, M16(table), M18(photo)
- uterine manipulation devices, M22(table)

WOLF, RICHARD, GmbH, C9

WOLF, RICHARD, MEDICAL INSTRUMENTS CORP.
- address, C9, M33
- culdoscopy equipment, M24(table)
- guarantee and service of sterilization equipment, M30(table)
- laparoscopy equipment
  - combination units, M11(table)
  - electrosurgical generator, M15(table), M17(photo)
  - fiberoptic projector, M9(table)
  - insufflator, M12(table)
  - laparoscopes, M4(table), M5(table), M6(figure)
  - teaching attachments, M6(table)
  - thermocoagulation unit, M16(table)
- tubal occlusion devices, M19(table)
- uterine manipulation devices, M22(table)

WOLFERS, H.
- vasectomy
  - counseling, D36
  - psychological aspects, D34
  - sexual behavior, D35(table)

WOMEN
- status, E16
- worldwide literacy rate, J178

WONG, V.
- reversibility of clip sterilization, C82

WOOD, C.
- negative attitudes toward diaphragm use, H59
- surface active agents, H42
- tubal ligation technique, C75

WOOD TECHNIQUE, C76(table)
- advantages and disadvantages, C75
- Australia, C75
- procedure, C75
- reversibility, C75

WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY
- oral contraceptive research, A32
- PG research, G2, G17

WORK, B.A.
- tubal ligation, C34

WORKSHOP IN ADVANCES IN IUD CONTRACEPTION FOR DEVELOPING COUNTRIES, SEATTLE, 1973, B18

WORKSHOP ON CONTROL OF MALE FERTILITY
- hormone levels after vasectomy, D31

WORLD BANK
- address, J284
- funding of family planning activities, J270-J271(table), J276(table), J278-J279
- policy paper on housing, J186

WORLD CONGRESS ON FERTILITY AND STERILITY, 8th, BUENOS AIRES, 1974.
- drug therapy with IUDs, B39
- IUD evaluation, B33

WORLD EDUCATION, J284
- population program assistance, J276 (table)

WORLD FEDERATION FOR MEDICAL EDUCATION
- conference sponsorship, E13, E19

WORLD FERTILITY SURVEY. See **INTERNATIONAL STATISTICAL INSTITUTE**.

WORLD FOOD CONFERENCE, ROME, 1974, J243

WORLD HEALTH ORGANIZATION (WHO)
- abortion-related mortality in Romania, E37(table)
- address, J284
- conference sponsorship, E13, E19
- Expanded Program of Research Development and Research Training in Human Reproduction, G11
- Expert Committee on Nutrition in Pregnancy and Lactation, J54
- funding of family planning activities, J270-J271(table), J276(table), J277-J278
- hemoglobin level and anemia, J130
- Human Reproduction Unit, B48
- IUD Conference, Cairo, B25
- maintenance and repair of sterilization equipment, M3
- Meeting on Pregnancy and Abortion in Adolescence, Geneva (1974), J163
  - definition of adolescence, J157
  - selected recommendations, J172
- oral contraceptives
  - side effects related to dosage, A48
- pilot program of laparoscopic sterilization, C2
- restricted use of Depo-Provera, K12
- Scientific Group
  - rhythm method, I6
- standards for contraceptives, H30
- studies of the long-term effects of cervical dilatation, F87
- study of oral contraceptives, J257
- support for PG research, G2
  - clinical research, G11
- Task Force on the Use of Prostaglandins for the Regulation of Fertility
  - incidence of endometritis, F74
  - PGF$_2\alpha$ v. saline for abortion, G72, G73(figure)
- testing of Progestasert, B38

WORLD HEALTH STATISTICS ANNUAL
- maternal mortality in selected countries, J128(table)

WORLD MEDICAL ASSOCIATION
- conference sponsorship, E13, E19

WORLD NEIGHBORS
- address, J85, J284
- funding of family planning activities, J269, J270(table), J276(table)
- subsidy for community-based distribution
- Indonesia, J78
  - Philippines, J79

WORLD POPULATION CONFERENCE, BUCHAREST, 1974, E13, J212, J260
- achievements, E14
- attendance, E13, E14
- committee topics, E18
- issues
  - population policy, E14
  - right of choice, E14, E16
  - socioeconomic development, E14
  - status of women, E16
- newspaper, E18(photo)
- Plan of Action, E14, E16, E17, E18
  - summary, E17
- World Plan of Action, E29-E30

WORLDWATCH INSTITUTE (WASHINGTON, D.C.)
- population estimates, J239(table)

    - China, J250(table)
  - world fertility patterns, J220-J221(map)

WORM INFESTATION
  - anemia, J131

WORTH, A.J.
  - orals and cervical neoplasia, A44(table), A83(table)

WORTMAN, J., author, C1-C16, C17-C27, C29-C44, C45-C52, C53-C59, C61-C72, C73-C95, D1-D20, D25-D39, F65-F83, H57-H75, J89-J108

WRIGHT, N.H.
  - maternal mortality, J259
  - pelvic inflammatory disease
    - diagnosis, B36
    - increased risk with IUD, B36

WU, H.C.
  - suction with curettage, F27

WU, P.C.
  - uterine aspiration, F28(table)
    - blood loss, F34(table)
    - equipment, F32(table), F41(table)
    - pressure used, F41(table)
    - time required, F32(table), F34(table)
    - vacuum bottles, F43

WU, Y.T.
  - suction with curettage, F27

WY-4355
  - breast neoplasia in dogs, A78(table), A79(table)
  - liver tumors in dogs, A89(table)

WYETH LABORATORIES
  - development of norgestrel, A5
  - estrogen-free product, A16
  - manufacture of low-estrogen orals, A37 (table)
  - marketing of minipill, A64(table)
  - oral contraceptives, A4(table), A5(table), A7
    - sales to USAID, A23(table)
  - synthesis of norgestrel, A32

WYNDER, E.L.
  - cervical cancer, J133(table)

WYNN, R.
  - IUD mode of action, B25

WYNN, V.
  - orals and carbohydrate metabolism, A47

WYNTER, H.H.
  - address, C70
  - culdoscopy
    - postoperative complications, C67 (table)
    - preoperative medication, C63(table)
    - training program, C70
    - tubal occlusion, C65(table)

X

XEROPHTHALMIA, J129

XOMED, D12

X-RAY
  - hysteroscopic fulguration, C81
  - IUD perforation, B31

XYLOCAINE, F30(table). See also **LIDOCAINE**.
  - clip application, C48, C49
  - combined with quinacrine for tubal occlusion, C87

Y

YAHIA, C.
  - biologic test for pregnancy, J115(table)

YALE UNIVERSITY (CONNECTICUT)
  - orals and breast disease, A45
  - postcoital estrogen research, J143

YAMANOUCHI PHARMACEUTICAL CO., LTD., H19, H41(table)

YAYASAN INDONESIA SEJAHTERA (PROSPEROUS INDONESIA FOUNDATION)
  - subsidized community-based distribution, J78

Y-CHROMOSOME
  - function in sex determination, I23
  - identification by karyotyping, I26
  - identification by quinacrine staining, I25, I26(photo)

Y-CHROMOSOME BEARING SPERM
  - immunization against, I26
  - separation methods, I25

Y-DEVICE, B38

YEMEN
  - birth rate, J29(table), J207(table), J210 (table)
  - oral contraceptives
    - marketing, A15(table)
    - supplied by SIDA, A20(table)

YEN, C.H.
  - menstrual regulation in family planning, F61

YERMONIL
  - manufacture and marketing, A4(table)

YLIKORKALA, O.
  - menstrual regulation with PGs, G59(table)

YOON, I.B.
  - clip sterilization and silicone bands, C45
  - Yoon band design, C85

YOON BAND, C46(figure), C55, C56. See also **BAND STERILIZATION**.
  - advantages and disadvantages, C86
  - application procedure, C85(photo)
    - route, C85
    - side effects, C85
    - training, C85
  - compared with fulguration, C85(table)
  - compared with spring-loaded clip, C85 (table)
  - complications, C85(table)
  - contraindications, C85
  - description, C85
  - Egypt, C85
  - failure rate, C85
  - India, C85
  - Iran, C85
  - Korea, C85
  - Mexico, C85
  - mode of action, C85
  - Philippines, C85
  - San Salvador, C85
  - Singapore, C85
  - Thailand, C85
  - US, C85
  - use, C85
  - vas occlusion, D53

YOUNG, I.S.
  - vasectomy failure, D33

YOUNGS DRUG PRODUCTS, Inc., H19

YPSILON, B45(figure)
  - description, B45
  - distribution, B45
  - nulliparas, B38-B39
  - use-effectiveness, B32(table), B39

YUGOSLAVIA
  - abortion
    - legal status, E30(table)
    - morbidity following legalization, E37
    - mortality, F37(table)
    - women under 20, J171(table)
  - adolescent births, J161(table)
  - age-specific fertility rate, J39(graph), J229(graph)
    - legalized abortion, J10(graph)
  - anesthesia for menstrual regulation, F51
  - birth rate, J23(figure), J29(table), J207 (table), J218(figure)
  - change in number of births, J219(figure)
  - copper IUDs, B18
  - diaphragm availability, H68(table)
  - family planning policy, E2, E3(table)
  - incidence of cancer in women, A70(table)
  - labor force, J197
  - legal status of voluntary sterilization, CD116(table)
  - marital status of female adolescents, J164(table)
  - oral contraceptives
    - commercial supply, A9(table)
    - marketing, A15(table)
    - sales, A8(table)
  - PG research, G11, G20, G24
  - population, F7(table)
  - population per hospital bed, J71(table)
  - population per physician, J71(table)
  - termination rate with IUDs in selected studies, B23(table)
    - M-device, B22(table)
  - uterine aspiration, F26, F27

YUSEI RING, B42(figure)
  - description, B42
  - distribution, B42
  - Japan, B42, E41, E43
  - use-effectiveness, B42

YUSEIRING SOGOKENKYUSHO
  - Ota ring, B43
  - Yusei ring, B42

YUSSMAN, M.A.
  - use-effectiveness of postcoital conjugated estrogens, J145(table)

YUZPE, A.A.
  - laparoscopic fulguration, C79(table)
    - bipolar instruments, C80
  - laparoscopic sterilization
    - failure, C22(table)
    - preoperative medication and anesthesia, C3(table)
  - postcoital estrogen-progestin combination, J150
  - sterilization by colpotomy, C31(table)
    - combined anesthesia, C32(table), C33
    - failure, C39(table), C43(table)
    - morbidity, C41
    - preoperative medication, C32(table)

Y-VALVE
  - sperm diversion device, D57

Z

ZACHARIAS, L.
  - age of menarche, J162(table)

ZAIRE
  - age-specific fertility rate, J3(graph), J224(graph), J225(graph)
  - birth rate, J29(table), J207(table), J210 (table)
  - legal status of voluntary sterilization, CD116(table)
  - marketing of oral contraceptives, A13 (table), A15(table)
  - medical complications of adolescent pregnancy, J165(table)
  - nutrition, J255

ZAMBIA
  - abortion
    - legal status, E30(table), E32
    - need for trained personnel, E38
  - age-specific fertility rate, J225(graph)
  - birth rate, J29(table), J207(table), J210 (table)
  - diaphragm availability, H68(table)
  - estimated population, E30(table)
  - legal status of voluntary sterilization, CD79, CD116(table)
  - marketing of oral contraceptives, A15 (table)
  - medical complications of adolescent pregnancy, J165(table)
  - Ministry of Health
    - address, J105(table)
    - training nonphysicians, J105(table)
  - population, F7(table)
  - training nonphysicians, J105(table)

ZANARTU, J.
  - Depo-Provera
    - use-effectiveness, K4(table), K5(table)
  - Norigest
    - reversibility, K9
    - use-effectiveness, K4(table)
  - postpartum amenorrhea and breastfeeding, J50
  - progestogen-only contraceptives and lactation, J63(table)
  - use-effectiveness of postcoital progestogens, J150(table)

ZANEVELD, L.J.D.
  - sperm diversion device, D57

ZARTMAN, E.R.
  - Depo-Provera
    - continuation rate, K7(table), K8(table)
    - use-effectiveness, K4(table)

ZEIL, H.K.
  - estrogen use and endometrial cancer in postmenopause, A87(table)

ZELNIK, M.
contraception among adolescents, J166, J167
urbanization and premarital coitus, J161
ZIEGLER, F.J.
psychclogical aspects of vasectomy, D34
sexual behavior and fertility control, D35-D36
ZIEL, H.A.
obstetrical complications with multiparity, J135(table)
ZIMBARDO, P.
stress and social behavior, J190
ZIMMERMAN, M., author, E25-E40
ZINC
world consumption, J194
ZINC OXIDE
latex condoms, H23
ZIPPER, J.
copper-7 IUD, B43
copper-T IUD, B43
development of copper IUD, B2, B4, B5
expulsion, pregnancy, removal, and continuation rates of copper-T and -7, B6(table)
IUD termination, B12
preference for IUD in Chile, B28
pregnancy after copper IUD removal, B17
tubal occlusion with quinacrine, C86(table)
reversibility, C87
ZONDEK, B.
biologic pregnancy test, J110
hormone therapy for amenorrhea, J111
ZORANE, A12
ZORANE 1/20
formulation and dosage, A6(table), A37 (table)
manufacturer, A37(table)
ZORANE 1/50
formulation and dosage, A6(table), A36 (table)
manufacturer, A36(table)
ZORANE 1.5/30
formulation and dosage, A6(table), A37 (table)
manufacturer, A37(table)
ZUCK, T.T., I5
ZUCKERMAN, H.
sperm cryofreezer, D52

This **CUMULATIVE INDEX** covers only English-language issues. The references and pagination are applicable only to English-language **Reports.**